Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
Lung Cancer Biomarkers and Uses Thereof
[0001]
FIELD OF THE INVENTION
[0002] The present application relates generally to the detection
of biomarkers
and the diagnosis of cancer in an individual and, more specifically, to one or
more
biomarkers, methods, devices, reagents, systems, and kits for diagnosing
cancer, more
particularly lung cancer, in an individual.
BACKGROUND
[0003] The following description provides a summary of information
relevant
to the present application and is not an admission that any of the information
provided
or publications referenced herein is prior art to the present application.
[0004] More people die from lung cancer than any other type of
cancer. This
is true for both men and women. In 2005 in the United States (the most recent
year
for which statistics are currently available), lung cancer accounted for more
deaths
than breast cancer, prostate cancer, and colon cancer combined. In that year,
107,416
men and 89,271 women were diagnosed with lung cancer, and 90,139 men and
69,078 women died from lung cancer. Among men in the United States, lung
cancer
is the second most common cancer among white, black, Asian/Pacific Islander,
American Indian/Alaska Native, and Hispanic men. Among women in the United
States, lung cancer is the second most common cancer among white, black, and
American Indian/Alaska Native women, and the third most common cancer among
Asian/Pacific Islander and Hispanic women. For those who do not quit smoking,
the
probability of death from lung cancer is 15% and remains above 5% even for
those
who quit at age 50-59. The annual healthcare cost of lung cancer in the U.S.
alone is
$95 billion,
CA 3011730 2018-07-18
[0005] Ninety-one percent of lung cancer caused by smoking is non-
small cell
lung cancer (NSCLC), which represents approximately 87% of all lung cancers.
The
remaining 13% of all lung cancers are small cell lung cancers, although mixed-
cell
lung cancers do occur. Because small cell lung cancer is rare and rapidly
fatal, the
opportunity for early detection is small.
[0006] There are three main types of NSCLC: squamous cell carcinoma,
large
cell carcinoma, and adenocarcinoma. Adenocarcinoma is the most common form of
lung cancer (30% - 40% and reported to be as high as 50%) and is the lung
cancer
most frequently found in both smokers and non-smokers. Squamous cell carcinoma
accounts for 25-30% of all lung cancers and is generally found in a proximal
bronchus. Early stage NSCLC tends to be localized, and if detected early it
can often
be treated by surgery with a favorable outcome and improved survival. Other
treatment options include radiation treatment, drug therapy, and a combination
of
these methods.
[0007] NSCLC is staged by the size of the tumor and its presence in
other
tissues including lymph nodes. In the occult stage, cancer cells are found in
sputum
samples or lay age samples and no tumor is detectable in the lungs. In stage
0, only
the innermost lining of the lungs exhibit cancer cells and the tumor has not
grown
through the lining. In stage IA, the cancer is considered invasive and has
grown deep
into the lung tissue but the tumor is less than 3 cm across. In this stage,
the tumor is
not found in the bronchus or lymph nodes. In stage IB, the tumor is either
larger than
3 cm across or has grown into the bronchus or pleura, but has not grown into
the
lymph nodes. In stage IIA, the tumor is more than 3 cm across and has grown
into the
lymph nodes. In stage IIB, the tumor has either been found in the lymph nodes
and is
greater than 3 cm across or grown into the bronchus or pleura; or the cancer
is not in
the lymph nodes but is found in the chest wall, diaphragm, pleura, bronchus,
or tissue
that surrounds the heart. In stage IIIA, cancer cells are found in the lymph
nodes near
the lung and bronchi and in those between the lungs but on the side of the
chest where
the tumor is located. Stage IIIB. cancer cells are located on the opposite
side of the
chest from the tumor and in the neck. Other organs near the lungs may also
have
cancer cells and multiple tumors may be found in one lobe of the lungs. In
stage IV,
tumors are found in more than one lobe of the same lung or both lungs and
cancer
cells are found in other parts of the body.
2
CA 3011730 2018-07-18
[0008] Current methods of diagnosis for lung cancer include testing
sputum
for cancerous cells, chest x-ray, fiber optic evaluation of airways, and low
dose spiral
computed tomography (CT). Sputum cytology has a very low sensitivity. Chest X-
ray is also relatively insensitive, requiring lesions to be greater than 1 cm
in size to be
visible. Bronchoscopy requires that the tumor is visible inside airways
accessible to
the bronchoscope. The most widely recognized diagnostic method is CT, but in
common with X-ray, the use of CT involves ionizing radiation, which itself can
cause
cancer. CT also has significant limitations: the scans require a high level of
technical
skill to interpret and many of the observed abnormalities are not in fact lung
cancer
and substantial healthcare costs are incurred in following up CT findings. The
most
common incidental finding is a benign lung nodule.
[0009] Lung nodules are relatively round lesions, or areas of
abnormal tissue,
located within the lung and may vary in size. Lung nodules may be benign or
cancerous, but most are benign. lf a nodule is below 4 mm the prevalence is
only
1.5%, if 4-8 mm the prevalence is approximately 6%, and if above 20 mm the
incidence is approximately 20%. For small and medium-sized nodules, the
patient is
advised to undergo a repeat scan within three months to a year. For many large
nodules, the patient receives a biopsy (which is invasive and may lead to
complications) even though most of these are benign.
[0010] Therefore, diagnostic methods that can replace or complement
CT are
needed to reduce the number of surgical procedures conducted and minimize the
risk
of surgical complications, in addition, even when lung nodules are absent or
unknown, methods are needed to detect lung cancer at its early stages to
improve
patient outcomes. Only 16% of lung cancer cases are diagnosed as localized,
early
stage cancer, where the 5-year survival rate is 46%, compared to 84% of those
diagnosed at late stage, where the 5-year survival rate is only 13%. This
demonstrates
that relying on symptoms for diagnosis is not useful because many of them are
common to other lung disease. These symptoms include a persistent cough,
bloody
sputum, chest pain, and recurring bronchitis or pneumonia.
[0011] Where methods of early diagnosis in cancer exist, the benefits
are
generally accepted by the medical community. Cancers that have widely utilized
screening protocols have the highest 5-year survival rates, such as breast
cancer
(88%) and colon cancer (65%) versus 16% for lung cancer. However, 88% of lung
cancer patients survive ten years or longer if the cancer is diagnosed at
Stage 1
3
CA 3011730 2018-07-18
through screening. This demonstrates the clear need for diagnostic methods
that can
reliably detect early-stage NSCLC.
[0012] Biomarker selection for a specific disease state involves
first the
identification of markers that have a measurable and statistically significant
difference
in a disease population compared to a control population for a specific
medical
application. Biomarkers can include secreted or shed molecules that parallel
disease
development or progression and readily diffuse into the blood stream from lung
tissue
or from distal tissues in response to a lesion. The biomarker or set of
biomarkers
identified are generally clinically validated or shown to be a reliable
indicator for the
original intended use for which it was selected. Biomarkers can include small
molecules, peptides, proteins, and nucleic acids. Some of the key issues that
affect
the identification of biomarkers include over-fitting of the available data
and bias in
the data.
[0013] A variety of methods have been utilized in an attempt to
identify
biomarkers and diagnose disease. For protein-based markers, these include two-
dimensional electrophoresis, mass spectrometry, and immunoassay methods. For
nucleic acid markers, these include mRNA expression profiles, microRNA
profiles,
FISH, serial analysis of gene expression (SAGE), and large scale gene
expression
arrays.
[0014] The utility of two- dimensional electrophoresis is limited by
low
detection sensitivity; issues with protein solubility, charge, and
hydrophobicity; gel
reproducibility; and the possibility of a single spot representing multiple
proteins. For
mass spectrometry, depending on the format used, limitations revolve around
the
sample processing and separation, sensitivity to low abundance proteins,
signal to
noise considerations, and inability to immediately identify the detected
protein.
Limitations in immunoassay approaches to biomarker discovery are centered on
the
inability of antibody-based multiplex assays to measure a large number of
analytes.
One might simply print an array of high-quality antibodies and, without
sandwiches,
measure the analytes bound to those antibodies. (This would be the formal
equivalent
of using a whole genome of nucleic acid sequences to measure by hybridization
all
DNA or RNA sequences in an organism or a cell. The hybridization experiment
works because hybridization can be a stringent test for identity. Even very
good
antibodies are not stringent enough in selecting their binding partners to
work in the
context of blood or even cell extracts because the protein ensemble in those
matrices
4
CA 3011730 2018-07-18
have extremely different abundances.) Thus, one must use a different approach
with
immunoassay-based approaches to biomarker discovery ¨ one would need to use
multiplexed ELISA assays (that is, sandwiches) to get sufficient stringency to
measure many analytes simultaneously to decide which analytes are indeed
biomarkers. Sandwich immunoassays do not scale to high content, and thus
biomarker discovery using stringent sandwich immunoassays is not possible
using
standard array formats. Lastly, antibody reagents are subject to substantial
lot
variability and reagent instability. The instant platfoim for protein
biomarker
discovery overcomes this problem.
[0015] Many of these methods rely on or require some type of sample
fractionation prior to the analysis. Thus the sample preparation required to
run a
sufficiently powered study designed to identify/discover statistically
relevant
biomarkers in a series of well-defined sample populations is extremely
difficult,
costly, and time consuming. During fractionation, a wide range of variability
can be
introduced into the various samples. For example, a potential marker could be
unstable to the process, the concentration of the marker could be changed,
inappropriate aggregation or disaggregation could occur, and inadvertent
sample
contamination could occur and thus obscure the subtle changes anticipated in
early
disease.
[0016] It is widely accepted that biomarker discovery and detection
methods
using these technologies have serious limitations for the identification of
diagnostic
biomarkers. These limitations include an inability to detect low-abundance
biomarkers, an inability to consistently cover the entire dynamic range of the
proteome, irreproducibility in sample processing and fractionation, and
overall
irreproducibility and lack of robustness of the method. Further, these studies
have
introduced biases into the data and not adequately addressed the complexity of
the
sample populations, including appropriate controls, in terms of the
distribution and
randomization required to identify and validate biomarkers within a target
disease
population.
[0017] Although efforts aimed at the discoveiy of new and effective
biomarkers have gone on for several decades, the efforts have been largely
unsuccessful. Biomarkers for various diseases typically have been identified
in
academic laboratories, usually through an accidental discovery while doing
basic
research on some disease process. Based on the discovery and with small
amounts of
CA 3011730 2018-07-18
clinical data, papers were published that suggested the identification of a
new
biomarker. Most of these proposed biomarkers, however, have not been confirmed
as
real or useful biomarkers, primarily because the small number of clinical
samples
tested provide only weak statistical proof that an effective biomarker has in
fact been
found. That is, the initial identification was not rigorous with respect to
the basic
elements of statistics. In each of the years 1994 through 2003, a search of
the
scientific literature shows that thousands of references directed to
biomarkers were
published. During that same time frame, however, the FDA approved for
diagnostic
use, at most, three new protein biomarkers a year, and in several years no new
protein
biomarkers were approved.
[0018] Based on the history of failed biomarker discovery efforts,
mathematical theories have been proposed that further promote the general
understanding that biomarkers for disease are rare and difficult to find.
Biomarker
research based on 2D gels or mass spectrometry supports these notions. Very
few
useful biomarkers have been identified through these approaches. However, it
is
usually overlooked that 2D gel and mass spectrometry measure proteins that are
present in blood at approximately 1 nM concentrations and higher, and that
this
ensemble of proteins may well be the least likely to change with disease.
Other than
the instant biomarker discovery platform, proteomic biomarker discovery
platforms
that are able to accurately measure protein expression levels at much lower
concentrations do not exist.
[0019] Much is known about biochemical pathways for complex human
biology. Many biochemical pathways culminate in or are started by secreted
proteins
that work locally within the pathology, for example growth factors are
secreted to
stimulate the replication of other cells in the pathology, and other factors
are secreted
to ward off the immune system, and so on. While many of these secreted
proteins
work in a paracrine fashion, some operate distally in the body. One skilled in
the art
with a basic understanding of biochemical pathways would understand that many
pathology-specific proteins ought to exist in blood at concentrations below
(even far
below) the detection limits of 2D gels and mass spectrometry. What must
precede the
identification of this relatively abundant number of disease biomarkers is a
proteomic
platform that can analyze proteins at concentrations below those detectable by
2D gels
or mass spectrometry.
6
CA 3011730 2018-07-18
[0020] Accordingly, a need exists for biomarkers, methods, devices,
reagents,
systems, and kits that enable (a) the differentiation of benign pulmonary
nodules from
malignant pulmonary nodules; (b) the detection of lung cancer biomarkers; and
(c) the
diagnosis of lung cancer.
SUMMARY
[0021] The present application includes biomarkers, methods,
reagents,
devices, systems, and kits for the detection and diagnosis of cancer and more
particularly, lung cancer. The biomarkers of the present application were
identified
using a multiplex aptamer-based assay which is described in detail in Example
1. By
using the aptamer-based biomarker identification method described herein, this
application describes a surprisingly large number of lung cancer biomarkers
that are
useful for the detection and diagnosis of lung cancer. In identifying these
biomarkers,
over 800 proteins from hundreds of individual samples were measured, some of
which at concentrations in the low femtomolar range. This is about four orders
of
magnitude lower than biomarker discovery experiments done with 2D gels and/or
mass spectrometry.
[0022] While certain of the described lung cancer biomarkers are
useful alone
for detecting and diagnosing lung cancer, methods are described herein for the
grouping of multiple subsets of the lung cancer biomarkers that are useful as
a panel
of biomarkers. Once an individual biomarker or subset of biomarkers has been
identified, the detection or diagnosis of lung cancer in an individual can be
accomplished using any assay platform or format that is capable of measuring
differences in the levels of the selected biomarker or biomarkers in a
biological
sample.
[0023] However, it was only by using the aptamer-based biomarker
identification method described herein, wherein over 800 separate potential
biomarker
values were individually screened from a large number of individuals having
previously been diagnosed either as having or not having lung cancer that it
was
possible to identify the lung cancer biomarkers disclosed herein. This
discovery
approach is in stark contrast to biomarker discovery from conditioned media or
lysed
cells as it queries a more patient-relevant system that requires no
translation to human
pathology.
7
CA 3011730 2018-07-18
[0024] Thus, in one aspect of the instant application, one or more
biomarkers
are provided for use either alone or in various combinations to diagnose lung
cancer
or permit the differential diagnosis of pulmonary nodules as benign or
malignant.
Exemplary embodiments include the biomarkers provided in Table 1, Col. 2,
which as
noted above, were identified using a multiplex aptamer-based assay, as
described in
Example 2. The markers provided in Table 1, Col. 5 are useful in
distinguishing
benign nodules from cancerous nodules. The markers provided in Table 1, Col. 6
are
useful in distinguishing asymptomatic smokers from smokers having lung cancer.
[0025] While certain of the described lung cancer biomarkers are
useful alone
for detecting and diagnosing lung cancer, methods are also described herein
for the
grouping of multiple subsets of the lung cancer biomarkers that are each
useful as a
panel of three or more biomarkers. Thus, various embodiments of the instant
application provide combinations comprising N biomarkers, wherein N is at
least two
biomarkers. In other embodiments. N is selected to be any number from 2-61
biomarkers.
[0026] In yet other embodiments, N is selected to be any number from
2-7, 2-
10, 2-15, 2-20, 2-25, 2-30, 2-35, 2-40, 2-45, 2-50, 2-55, or 2-61. In other
embodiments, N is selected to be any number from 3-7, 3-10, 3-15, 3-20, 3-25,
3-30,
3-35, 3-40, 3-45, 3-50, 3-55, or 3-61. In other embodiments, N is selected to
be any
number from 4-7, 4-10, 4-15, 4-20, 4-25, 4-30, 4-35, 4-40, 4-45, 4-50, 4-55,
or 4-61.
In other embodiments, N is selected to be any number from 5-7, 5-10, 5-15, 5-
20, 5-
25, 5-30, 5-35, 5-40, 5-45, 5-50, 5-55, or 5-61. In other embodiments, N is
selected to
be any number from 6-10, 6-15, 6-20, 6-25, 6-30, 6-35, 6-40, 6-45, 6-50, 6-55,
or 6-
61. In other embodiments, N is selected to be any number from 7-10, 7-15, 7-
20, 7-
25, 7-30, 7-35, 7-40, 7-45, 7-50, 7-55, or 7-61. In other embodiments, N is
selected to
be any number from 8-10, 8-15, 8-20, 8-25, 8-30, 8-35, 8-40, 8-45, 8-50, 8-55,
or 8-
61. In other embodiments, N is selected to be any number from 9-15, 9-20, 9-
25, 9-
30, 9-35, 9-40, 9-45, 9-50, 9-55, or 9-61. In other embodiments, N is selected
to be
any number from 10-15, 10-20, 10-25, 10-30, 10-35, 10-40, 10-45, 10-50, 10-55,
or
10-61. It will be appreciated that N can be selected to encompass similar, but
higher
order, ranges.
[0027] In another aspect, a method is provided for diagnosing lung
cancer in
an individual, the method including detecting, in a biological sample from an
individual, at least one biomarker value corresponding to at least one
biomarker
8
CA 3011730 2018-07-18
selected from the group of biomarkers provided in Table 1, Col. 2, wherein the
individual is classified as having lung cancer based on the at least one
biomarker
value.
[0028] In another aspect, a method is provided for diagnosing lung
cancer in
an individual, the method including detecting, in a biological sample from an
individual, biomarker values that each correspond to one of at least N
biomarkers
selected from the group of biomarkers set forth in Table 1, Col. 2, wherein
the
likelihood of the individual having lung cancer is determined based on the
biomarker
values.
[0029] In another aspect, a method is provided for diagnosing lung
cancer in
an individual, the method including detecting, in a biological sample from an
individual, biomarker values that each correspond to one of at least N
biomarkers
selected from the group of biomarkers set forth in Table 1, Col. 2, wherein
the
individual is classified as having lung cancer based on the biomarker values,
and
wherein N = 2-10.
[0030] In another aspect, a method is provided for diagnosing lung
cancer in
an individual, the method including detecting, in a biological sample from an
individual, biomarker values that each correspond to one of at least N
biomarkers
selected from the group of biomarkers set forth in Table 1, Col. 2, wherein
the
likelihood of the individual having lung cancer is determined based on the
biomarker
values, and wherein N = 2-10.
[0031] In another aspect, a method is provided for differentiating an
individual having a benign nodule from an individual having a malignant
nodule, the
method including detecting, in a biological sample from an individual, at
least one
biomarker value corresponding to at least one biomarker selected from the
group of
biomarkers set forth in Table I, Col. 5, wherein the individual is classified
as having a
malignant nodule, or the likelihood of the individual having a malignant
nodule is
determined, based on the at least one biomarker value.
[0032] In another aspect, a method is provided for differentiating an
individual having a benign nodule from an individual having a malignant
nodule, the
method including detecting, in a biological sample from an individual,
biomarker
values that each correspond to one of at least N biomarkers selected from the
group of
biomarkers set forth in Table 1, Col. 5, wherein the individual is classified
as having a
9
CA 3011730 2018-07-18
malignant nodule, or the likelihood of the individual having a malignant
nodule is
determined, based on said biomarker values, wherein N = 2-10.
[0033] In another aspect, a method is provided for screening smokers
for lung
cancer, the method including detecting, in a biological sample from an
individual who
is a smoker, at least one biomarker value corresponding to at least one
biomarker
selected from the group of biomarkers set forth in Table 1, Col. 6, wherein
the
individual is classified as having lung cancer, or the likelihood of the
individual
having lung cancer is determined, based on the at least one biomarker value.
[0034] In another aspect, a method is provided for screening smokers
for lung
cancer, the method including detecting, in a biological sample from an
individual who
is a smoker, biomarker values that each correspond to one of at least N
biomarkers
selected from the group of biomarkers set forth in Table 1, Col. 6, wherein
the
individual is classified as having lung cancer, or the likelihood of the
individual
having lung cancer is determined, based on said biomarker values, wherein N =
2-10.
[0035] In another aspect, a method is provided for diagnosing that an
individual does not have lung cancer, the method including detecting, in a
biological
sample from an individual, at least one biomarker value corresponding to at
least one
biomarker selected from the group of biomarkers set forth in Table 1, Col. 2,
wherein
the individual is classified as not having lung cancer. based on the at least
one
biomarker value.
[0036] In another aspect, a method is provided for diagnosing that an
individual does not have lung cancer, the method including detecting, in a
biological
sample fiom an individual, biomarker values that each corresponding to one of
at least
N biomarkers selected from the group of biomarkers set forth in Table 1, Col.
2,
wherein the individual is classified as not having lung cancer based on the
biomarker
values, and wherein N = 2-10.
[0037] In another aspect, a method is provided for diagnosing lung
cancer, the
method including detecting, in a biological sample from an individual,
biomarker
values that each correspond to a biomarker on a panel of N biomarkers, wherein
the
biomarkers are selected from the group of biomarkers set forth in Table 1,
Col. 2,
wherein a classification of the biomarker values indicates that the individual
has lung
cancer, and wherein N = 3-10.
[0038] In another aspect, a method is provided for diagnosing lung
cancer, the
method including detecting, in a biological sample from an individual,
biomarker
CA 3011730 2018-07-18
values that each correspond to a biomarker on a panel of N biomarkers, wherein
the
biomarkers are selected from the group of biomarkers set forth in Table 1,
Col. 2,
wherein a classification of the biomarker values indicates that the individual
has lung
cancer, and wherein N = 3-15.
[0039] In another aspect, a method is provided for diagnosing lung
cancer, the
method including detecting, in a biological sample from an individual,
biomarker
values that each correspond to a biomarker on a panel of biomarkers selected
from the
group of panels set forth in Tables 2-27, wherein a classification of the
biomarker
values indicates that the individual has lung cancer.
[0040] In another aspect, a method is provided for differentiating
an
individual having a benign nodule from an individual having a malignant
nodule, the
method including detecting, in a biological sample from an individual,
biomarker
values that each correspond to a biomarker on a panel of N biomarkers, wherein
the
biomarkers are selected from the group of biomarkers set forth in Table 1,
Col. 5,
wherein the individual is classified as having a malignant nodule, or the
likelihood of
the individual having a malignant nodule is determined, based on the biomarker
values, and wherein N = 3-10.
[0041] In another aspect, a method is provided for differentiating
an
individual having a benign nodule from an individual having a malignant
nodule, the
method including detecting, in a biological sample from an individual,
biomarker
values that each correspond to a biomarker on a panel of N biomarkers, wherein
the
biomarkers are selected from the group of biomarkers set forth in Table 1,
Col. 5,
wherein the individual is classified as having a malignant nodule, or the
likelihood of
the individual having a malignant nodule is determined, based on the biomarker
values, and wherein N = 3-15.
[0042] In another aspect, a method is provided for screening smokers
for lung
cancer, the method including detecting, in a biological sample from an
individual who
is a smoker, biomarker values that each correspond to a biomarker on a panel
of N
biomarkers. wherein the biomarkers are selected from the group of biomarkers
set
forth in Table 1, Col. 6, wherein the individual is classified as having lung
cancer, or
the likelihood of the individual having lung cancer is determined, based on
the
biomarker values, and wherein N = 3-10.
[0043] In another aspect, a method is provided for screening smokers
for lung
cancer, the method including detecting, in a biological sample from an
individual who
11
CA 3011730 2018-07-18
is a smoker, biomarker values that each correspond to a biomarker on a panel
of N
biomarkers. wherein the biomarkers are selected from the group of biomarkers
set
forth in Table 1, Col. 6, wherein the individual is classified as having lung
cancer, or
the likelihood of the individual having lung cancer is determined, based on
the
biomarker values, wherein N = 3-15.
[0044] In another aspect, a method is provided for diagnosing an
absence of
lung cancer, the method including detecting, in a biological sample from an
individual, biomarker values that each correspond to a biomarker on a panel of
N
biomarkers. wherein the biomarkers are selected from the group of biomarkers
set
forth in Table 1, Col. 2, wherein a classification of the biomarker values
indicates that
the individual has lung cancer, and wherein N = 3-10.
[0045] In another aspect, a method is provided for diagnosing an
absence of
lung cancer, the method including detecting, in a biological sample from an
individual, biomarker values that each correspond to a biomarker on a panel of
N
biomarkers, wherein the biomarkers are selected from the group of biomarkers
set
forth in Table 1, Col. 2, wherein a classification of the biomarker values
indicates that
the individual has lung cancer, and wherein N = 3-15.
[0046] In another aspect, a method is provided for diagnosing an
absence of
lung cancer, the method including detecting, in a biological sample from an
individual, biomarker values that each correspond to a biomarker on a panel of
biomarkers selected from the group of panels provided in Tables 2-27, wherein
a
classification of the biomarker values indicates an absence of lung cancer in
the
individual.
[0047] In another aspect, a method is provided for diagnosing lung
cancer in
an individual, the method including detecting, in a biological sample from an
individual, biomarker values that correspond to one of at least N biomarkers
selected
from the group of biomarkers set forth in Table 1, Col. 2, wherein the
individual is
classified as having lung cancer based on a classification score that deviates
from a
predetermined threshold, and wherein N=2-10.
[0048] In another aspect, a method is provided for differentiating
an
individual having a benign nodule from an individual having a malignant
nodule, the
method including detecting, in a biological sample from an individual,
biomarker
values that each correspond to a biomarker on a panel of N biomarkers, wherein
the
biomarkers are selected from the group of biomarkers set forth in Table 1,
Col. 5,
12
CA 3011730 2018-07-18
wherein the individual is classified as having a malignant nodule, or the
likelihood of
the individual having a malignant nodule is determined, based on a
classification
score that deviates from a predetermined threshold, and wherein N = 3-10.
[0049] In another aspect, a method is provided for differentiating an
individual having a benign nodule from an individual having a malignant
nodule, the
method including detecting, in a biological sample from an individual,
biomarker
values that each correspond to a biomarker on a panel of N biomarkers, wherein
the
biomarkers are selected from the group of biomarkers set forth in Table 1,
Col. 5,
wherein the individual is classified as having a malignant nodule, or the
likelihood of
the individual having a malignant nodule is determined, based on a
classification
score that deviates from a predetermined threshold, wherein N = 3-15.
[0050] In another aspect, a method is provided for screening smokers
for lung
cancer, the method including detecting, in a biological sample from an
individual who
is a smoker, biomarker values that each correspond to a biomarker on a panel
of N
biomarkers. wherein the biomarkers are selected from the group of biomarkers
set
forth in Table I, Col. 6, wherein the individual is classified as having lung
cancer, or
the likelihood of the individual having lung cancer is determined, based on a
classification score that deviates from a predetermined threshold, wherein N =
3-10.
[0051] In another aspect, a method is provided for screening smokers
for lung
cancer, the method including detecting, in a biological sample from an
individual who
is a smoker, biomarker values that each correspond to a biomarker on a panel
of N
biomarkers, wherein the biomarkers are selected from the group of biomarkers
set
forth in Table 1, Col, 6, wherein the individual is classified as having lung
cancer, or
the likelihood of the individual having lung cancer is determined, based on a
classification score that deviates from a predetermined threshold, wherein N =
3-15.
[0052] In another aspect, a method is provided for diagnosing an
absence of
lung cancer in an individual, the method including detecting, in a biological
sample
from an individual, biomarker values that correspond to one of at least N
biomarkers
selected from the group of biomarkers set forth in Table 1, Col. 2, wherein
said
individual is classified as not having lung cancer based on a classification
score that
deviates from a predetermined threshold, and wherein N=2-10.
[0053] In another aspect, a computer-implemented method is provided
for
indicating a likelihood of lung cancer. The method comprises: retrieving on a
computer biomarker information for an individual, wherein the biomarker
information
13
CA 3011730 2018-07-18
comprises biomarker values that each correspond to one of at least N
biomarkers,
wherein N is as defined above, selected from the group of biomarkers set forth
in
Table 1, Col. 2; performing with the computer a classification of each of the
biornarker values; and indicating a likelihood that the individual has lung
cancer
based upon a plurality of classifications.
[0054] In another aspect, a computer-implemented method is provided
for
classifying an individual as either having or not having lung cancer. The
method
comprises: retrieving on a computer biomarker information for an individual,
wherein
the biomarker information comprises biomarker values that each correspond to
one of
at least N biomarkers selected from the group of biomarkers provided in Table
1, Col.
2; performing with the computer a classification of each of the biomarker
values; and
indicating whether the individual has lung cancer based upon a plurality of
classifications.
[0055] In another aspect, a computer program product is provided for
indicating a likelihood of lung cancer. The computer program product includes
a
computer readable medium embodying program code executable by a processor of a
computing device or system, the program code comprising: code that retrieves
data
attributed to a biological sample from an individual, wherein the data
comprises
biomarker values that each coffespond to one of at least N biomarkers, wherein
N is
as defined above, in the biological sample selected from the group of
biomarkers set
forth in Table 1, Col. 2; and code that executes a classification method that
indicates a
likelihood that the individual has lung cancer as a function of the biomarker
values.
[0056] In another aspect, a computer program product is provided for
indicating a lung cancer status of an individual. The computer program product
includes a computer readable medium embodying program code executable by a
processor of a computing device or system, the program code comprising: code
that
retrieves data attributed to a biological sample from an individual, wherein
the data
comprises biomarker values that each correspond to one of at least N
biomarkers in
the biological sample selected from the group of biomarkers provided in Table
1, Col.
2; and code that executes a classification method that indicates a lung cancer
status of
the individual as a function of the biomarker values.
[0057] In another aspect, a computer-implemented method is provided
for
indicating a likelihood of lung cancer, The method comprises retrieving on a
computer biomarker information for an individual, wherein the biomarker
information
14
CA 3011730 2018-07-18
comprises a biomarker value corresponding to a biomarker selected from the
group of
biomarkers set forth in Table 1, Col. 2; performing with the computer a
classification
of the biomarker value; and indicating a likelihood that the individual has
lung cancer
based upon the classification.
[0058] In another aspect, a computer-implemented method is provided
for
classifying an individual as either having or not having lung cancer. The
method
comprises retrieving from a computer biomarker information for an individual,
wherein the biomarker information comprises a biomarker value corresponding to
a
biomarker selected from the group of biomarkers provided in Table 1, Col. 2;
performing with the computer a classification of the biomarker value; and
indicating
whether the individual has lung cancer based upon the classification.
[0059] In still another aspect, a computer program product is
provided for
indicating a likelihood of lung cancer. The computer program product includes
a
computer readable medium embodying program code executable by a processor of a
computing device or system, the program code comprising: code that retrieves
data
attributed to a biological sample from an individual, wherein the data
comprises a
biomarker value corresponding to a biomarker in the biological sample selected
from
the group of biomarkers set forth in Table 1, Col. 2; and code that executes a
classification method that indicates a likelihood that the individual has lung
cancer as
a function of the biomarker value.
[0060] In still another aspect, a computer program product is
provided for
indicating a lung cancer status of an individual. The computer program product
includes a computer readable medium embodying program code executable by a
processor of a computing device or system, the program code compiising: code
that
retrieves data attributed to a biological sample from an individual, wherein
the data
comprises a biomarker value corresponding to a bioniarker in the biological
sample
selected from the group of biomarkers provided in Table 1, Col. 2; and code
that
executes a classification method that indicates a lung cancer status of the
individual as
a function of the biomarker value.
BRIEF DESCRIPTION OF THE DRAWINGS
[0061] Figure lA is a flowchart for an exemplary method for detecting
lung
cancer in a biological sample.
CA 3011730 2018-07-18
[0062] Figure 1B is a flowchart for an exemplary method for detecting
lung
cancer in a biological sample using a naïve Bayes classification method.
[0063] Figure 2 shows a ROC curve for a single biomarker. SCFsR,
using a
naïve Bayes classifier for a test that detects lung cancer in asymptomatic
smokers.
[0064] Figure 3 shows ROC curves for biomarker panels of from one to
tell
biomarkers using naïve Bayes classifiers for a test that detects lung cancer
in
asymptomatic smokers.
[0065] = Figure 4 illustrates the increase in the classification
score (specificity +
sensitivity) as the number of biomarkers is increased from one to ten using
naïve
Bayes classification for a benign nodule-lung cancer panel.
[0066] Figure 5 shows the measured biomarker distributions for SCFsR
as a
cumulative distribution function (cdf) in log-transformed RFU for the benign
nodule
control group (solid line) and the lung cancer disease group (dotted line)
along with
their curve fits to a normal cdf (dashed lines) used to train the naïve Bayes
classifiers.
[0067] Figure 6 illustrates an exemplary computer system for use with
various
computer-implemented methods described herein.
[0068] Figure 7 is a flowchart for a method of indicating the
likelihood that an
individual has lung cancer in accordance with one embodiment.
[0069] Figure 8 is a flowchart for a method of indicating the
likelihood that an
individual has lung cancer in accordance with one embodiment.
[0070] - Figure 9 illustrates an exemplary aptamer assay that can be
used to
detect one or more lung cancer biomarkers in a biological sample.
[0071] Figure 10 shows a histogram of frequencies for which
biomarkers were
used in building classifiers to distinguish between NSCLC and benign nodules
from
an aggregated set of potential biomarkers.
[0072] Figure 11 shows a histogram of frequencies for which
biomarkers were
used in building classifiers to distinguish between NSCLC and asymptomatic
smokers
from an aggregated set of potential biomarkers.
[0073] Figure 12 shows a histogram of frequencies for which
biomarkers were
used in building classifiers to distinguish between NSCLC and benign nodules
from a
site-consistent set of potential biomarkers.
[0074] Figure 13 shows a histogram of frequencies for which
biomarkers were
used in building classifiers to distinguish between NSCLC and asymptomatic
smokers
from a site-consistent set of potential biomarkers.
16
CA 3011730 2018-07-18
[0075] Figure 14 shows a histogram of frequencies for which
biomarkers were
used in building classifiers to distinguish between NSCLC and benign nodules
from a
set of potential biomarkers resulting from a combination of aggregated and
site-
consistent markers.
[0076] Figure 15 shows a histogram of frequencies for which
biomarkers were
used in building classifiers to distinguish between NSCLC and asymptomatic
smokers
from a set of potential biomarkers resulting from a combination of aggregated
and
site-consistent markers.
[0077] Figure 16 shows gel images resulting from pull-down
experiments that
illustrate the specificity of aptamers as capture reagents for the proteins
LBP, C9 and
IgM. For each gel, lane 1 is the eluate from the Streptavidin-agarose beads,
lane 2 is
the final eluate, and lane is a MW marker lane (major bands are at 110, 50,
30, 15,
and 3.5 kDa from top to bottom).
[0078] Figure 17A shows a pair of histograms summarizing all possible
single
protein naïve Bayes classifier scores (sensitivity + specificity) using the
biomarkers
set forth in Table 1, Col 5 (solid) and a set of random markers (dotted).
[0079] Figure 17B shows a pair of histograms summarizing all possible
two-
protein protein naïve Bayes classifier scores (sensitivity + specificity)
using the
biomarkers set forth in Table 1, Col 5 (solid) and a set of random markers
(dotted).
[0080] Figure 17C shows a pair of histograms summarizing all possible
three-
protein naïve Bayes classifier scores (sensitivity + specificity) using the
biomarkers
set forth in Table 1, Col 5 (solid) and a set of random markers (dotted).
[0081] Figure 18A shows a pair of histograms summarizing all possible
single
protein naïve Bayes classifier scores (sensitivity + specificity) using the
biomarkers
set forth in Table 1, Col 6 (solid) and a set of random markers (dotted).
[0082] Figure 18B shows a pair of histograms summarizing all possible
two-
protein protein naïve Bayes classifier scores (sensitivity + specificity)
using the
biomarkers set forth in Table 1, Col 6 (solid) and a set of random markers
(dotted).
[0083] Figure 18C shows a pair of histograms summarizing all possible
three-
protein naïve Bayes classifier scores (sensitivity + specificity) using the
biomarkers
set forth in Table 1, Col 6 (solid) and a set of random markers (dotted).
[0084] Figure 19A shows the sensitivity + specificity score for naïve
Bayes
classifiers using from 2-10 markers selected from the full panel (*) and the
scores
17
CA 3011730 2018-07-18
obtained by dropping the best 5 (a), 10 ( ) and 15 (x) markers during
classifier
generation for the benign nodule control group.
[0085] Figure] 9B shows the sensitivity + specificity score for
nave Bayes
classifiers using from 2-10 markers selected from the full panel (+) and the
scores
obtained by dropping the best 5 (a), 10 ( A) and 15 (x) markers during
classifier
generation for the smoker control group.
[0086] Figure 20A shows a set of ROC curves modeled from the data
in
Tables 38 and 39 for panels of from one to five markers.
[0087] Figure 20B shows a set of ROC curves computed from the
training
data for panels of from one to five markers as in Figure 19A.
DETAILED DESCRIPTION
[0088] Reference will now be made in detail to representative
embodiments of
the invention. While thc invention will be described in conjunction with the
enumerated embodiments, it will be understood that the invention is not
intended to
be limited to those embodiments. On the contrary, the invention is intended to
cover
all alternatives, modifications, and equivalents that may be included within
the scope
of the present invention as defined by the claims.
[0089] One skilled in the art will recognize many methods and
materials
similar or equivalent to those described herein, which could be used in and
are within
the scope of the practice of the present invention. The present invention is
in no way
limited to the methods and materials described.
[0090] Unless defined otherwise, technical and scientific terms
used herein
have the same meaning as commonly understood by one of ordinary skill in the
art to
which this invention belongs. Although any methods, devices, and materials
similar
or equivalent to those described herein can be used in the practice or testing
of the
invention, the preferred methods, devices and materials are now described.
[0091] All publications, published patent documents, and patent
applications
cited in this application are indicative of the level of skill in the art(s)
to which the
application pertains.
18
CA 3011730 2018-07-18
[0092] As used in this application, including the appended claims,
the singular
forms "a," "an," and "the" include plural references, unless the content
clearly dictates
otherwise, and are used interchangeably with "at least one" and "one or more."
Thus,
reference to "an aptamer" includes mixtures of aptamers, reference to "a
probe"
includes mixtures of probes, and the like.
[0093] As used herein, the term "about" represents an insignificant
modification or variation of the numerical value such that the basic function
of the
item to which the numerical value relates is unchanged.
[0094] As used herein, the terms "comprises," "comprising,"
"includes,"
"including," "contains," "containing," and any variations thereof, are
intended to cover
a non-exclusive inclusion, such that a process, method, product-by-process, or
composition of matter that comprises, includes, or contains an element or list
of
elements does not include only those elements but may include other elements
not
expressly listed or inherent to such process, method, product-by-process, or
composition of matter.
[0095] The present application includes biomarkers, methods,
devices,
reagents, systems, and kits for the detection and diagnosis of lung cancer.
[0096] In one aspect, one or more biomarkers are provided for use
either alone
or in various combinations to diagnose lung cancer, permit the differential
diagnosis
of pulmonary nodules as benign or malignant, monitor lung cancer recurrence,
or
address other clinical indications. As described in detail below, exemplary
embodiments include the biomarkers provided in Table 1, Col. 2, which were
identified using a multiplex aptamer-based assay that is described generally
in
Example 1 and more specifically in Example 2.
[0097] Table 1, Col. 2 sets forth the findings obtained from
analyzing
hundreds of individual blood samples from NSCLC cancer cases, and hundreds of
equivalent individual blood samples from smokers and from individuals
diagnosed
with benign lung nodules. The smoker and benign nodule groups were designed to
match the populations with which a lung cancer test can have the most benefit.
(These cases and controls were obtained from multiple clinical sites to mimic
the
range of real world conditions under which such a test can be applied). The
potential
biomarkers were measured in individual samples rather than pooling the disease
and
control blood; this allowed a better understanding of the individual and group
variations in the phenotypes associated with the presence and absence of
disease (in
19
CA 3011730 2018-07-18
this case lung cancer). Since over 800 protein measurements were made on each
sample, and several hundred samples from each of the disease and the control
populations were individually measured, Table 1, Col. 2 resulted from an
analysis of
an uncommonly large set of data. The measurements were analyzed using the
methods described in the section, "Classification of Biomarkers and
Calculation of
Disease Scores" herein.
[0098] Table 1, Col. 2 lists the biomarkers found to be useful in
distinguishing
samples obtained from individuals with NSCLC from "control" samples obtained
from smokers and individuals with benign lung nodules. Using a multiplex
aptamer
assay as described herein, thirty-eight biomarkers were discovered that
distinguished
the samples obtained from individuals who had lung cancer from the samples
obtained from individuals in the smoker control group (see Table 1, Col. 6).
Similarly, using a multiplex aptamer assay, forty biomarkers were discovered
that
distinguished samples obtained from individuals with NSCLC from samples
obtained
from people who had benign lung nodules (see Table 1, Col. 5). Together, the
two
lists of 38 and 40 biomarkers are comprised of 61 unique biomarkers, because
there is
considerable overlap between the list of biomarkers for distinguishing NSCLC
from
benign nodules and the list for distinguishing NSCLC from smokers who do not
have
lung cancer.
[0099] While certain of the described lung cancer biomarkers are
useful alone
for detecting and diagnosing lung cancer, methods are also described herein
for the
grouping of multiple subsets of the lung cancer biomarkers, where each
grouping or
subset selection is useful as a panel of three or more biomarkers,
interchangeably
referred to herein as a "biomarker panel" and a panel. Thus, various
embodiments of
the instant application provide combinations compising N biomarkers, wherein N
is
at least two biomarkers. In other embodiments, N is selected from 2-61
biomarkers.
[00100] In yet other embodiments, N is selected to be any number from
2-7, 2-
10, 2-15, 2-20, 2-25, 2-30, 2-35, 2-40, 2-45, 2-50, 2-55, or 2-61. In other
embodiments, N is selected to be any number from 3-7, 3-10, 3-15, 3-20, 3-25,
3-30,
3-35, 3-40, 3-45, 3-50, 3-55, or 3-61. In other embodiments. N is selected to
be any
number from 4-7, 4-10, 4-15, 4-20, 4-25, 4-30, 4-35, 4-40, 4-45, 4-50, 4-55,
or 4-61.
In other embodiments, N is selected to be any number from 5-7, 5-10, 5-15, 5-
20, 5-
25, 5-30, 5-35, 5-40, 5-45, 5-50, 5-55, or 5-61. In other embodiments. N is
selected to
be any number from 6-10, 6-15. 6-20, 6-25, 6-30, 6-35, 6-40, 6-45, 6-50, 6-55,
or 6-
CA 3011730 2018-07-18
61. Tn other embodiments, N is selected to be any number from 7-10, 7-15, 7-
20, 7-
25, 7-30, 7-35, 7-40, 7-45, 7-50, 7-55, or 7-61. In other embodiments, N is
selected to
be any number from 8-10, 8-15, 8-20, 8-25, 8-30, 8-35, 8-40, 8-45, 8-50, 8-55,
or 8-
61. In other embodiments, N is selected to be any number from 9-15, 9-20, 9-
25, 9-
30, 9-35, 9-40, 9-45, 9-50, 9-55, or 9-61. In other embodiments, N is selected
to be
any number from 10-15, 10-20, 10-25, 10-30, 10-35, 10-40, 10-45, 10-50, 10-55,
or
10-61. It will be appreciated that N can be selected to encompass similar, but
higher
order, ranges.
[00101] In one embodiment, the number of biomarkers useful for a
biomarker
subset or panel is based on the sensitivity and specificity value for the
particular
combination of biomarker values. The terms "sensitivity" and "specificity" are
used
herein with respect to the ability to correctly classify an individual, based
on one or
more biomarker values detected in their biological sample, as having lung
cancer or
not having lung cancer. "Sensitivity" indicates the performance of the
biomarker(s)
with respect to correctly classifying individuals that have lung cancer.
"Specificity"
indicates the performance of the biomarker(s) with respect to correctly
classifying
individuals who do not have lung cancer. For example, 85% specificity and 90%
sensitivity for a panel of markers used to test a set of control samples and
lung cancer
samples indicates that 85% of the control samples were correctly classified as
control
samples by the panel, and 90% of the lung cancer samples were correctly
classified as
lung cancer samples by the panel. The desired or preferred minimum value can
be
determined as described in Example 3. Representative panels are set forth in
Tables
2-27, which set forth a series of 100 different panels of 3-15 biomarkers,
which have
the indicated levels of specificity and sensitivity for each panel. The total
number of
occurrences of each marker in each of these panels is indicated at the bottom
of each
Table.
[00102] In one aspect, lung cancer is detected or diagnosed in an
individual by
conducting an assay on a biological sample from the individual and detecting
biomarker values that each correspond to at least one of the biomarkers ERBB
I,
LRIG3 or SCFsR and at least N additional biomarkers selected from the list of
=
biomarkers in Table 1, Col. 2, wherein N equals 2, 3, 4, 5. 6, 7, 8, 9, 10,
11, 12, 13, 14
or 15. In a further aspect, lung cancer is detected or diagnosed in an
individual by
conducting an assay on a biological sample from the individual and detecting
biomarker values that each correspond to the biomarkers ERBB I, LRIG3 and
SCFsR
21
CA 3011730 2018-07-18
and one of at least N additional biomarkers selected from the list of
biomarkers in
Table 1, Col. 2, wherein N equals 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13.
In a further
aspect, lung cancer is detected or diagnosed in an individual by conducting an
assay
on a biological sample from the individual and detecting biomarker values that
each
correspond to the biomarker ERBB1 and one of at least N additional biomarkers
selected from the list of biomarkers in Table I, Col. 2, wherein N equals 2,
3, 4, 5, 6,
7, 8, 9, 10, 11, 12, 13, 14 or 15. In a further aspect, lung cancer is
detected or
diagnosed in an individual by conducting an assay on a biological sample from
the
individual and detecting biomarker values that each correspond to the
biomarker
LRIG3 and one of at least N additional biomarkers selected from the list of
biomarkers in Table I, Col. 2, wherein N equals 2, 3, 4, 5,6, 7, 8, 9, 10, 11,
12, 13, 14
or 15. In a further aspect, lung cancer is detected or diagnosed in an
individual by
conducting an assay on a biological sample from the individual and detecting
biomarker values that each correspond to the biomarker SCFsR and one of at
least N
additional biomarkers selected from the list of biomarkers in Table 1, Col. 2,
wherein
N equals 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15.
[00103] The lung cancer biomarkers identified herein represent a
relatively
large number of choices for subsets or panels of biomarkers that can be used
to
effectively detect or diagnose lung cancer. Selection of the desired number of
such
biomarkers depends on the specific combination of biomarkers chosen. It is
important to remember that panels of biomarkers for detecting or diagnosing
lung
cancer may also include biomarkers not found in Table 1, Col. 2, and that the
inclusion of additional biomarkers not found in Table 1, Col. 2 may reduce the
number of biomarkers in the particular subset or panel that is selected from
Table 1,
Col. 2. The number of biomarkers from Table 1, Col. 2 used in a subset or
panel may
also be reduced if additional biomedical information is used in conjunction
with the
biomarker values to establish acceptable sensitivity and specificity values
for a given
assay.
[00104] Another factor that can affect the number of biomarkers to be
used in a
subset or panel of biomarkers is the procedures used to obtain biological
samples
from individuals who are being diagnosed for lung cancer. In a carefully
controlled
sample procurement environment, the number of biomarkers necessary to meet
desired sensitivity and specificity values will be lower than in a situation
where there
can be more variation in sample collection, handling and storage. In
developing the
22
CA 3011730 2018-07-18
list of biomarkers set forth in Table I, Col. 2, multiple sample collection
sites were
utilized to collect data for classifier training. This provides for more
robust
biomarkers that are less sensitive to variations in sample collection,
handling and
storage, but can also require that the number of biomarkers in a subset or
panel be
larger than if the training data were all obtained under very similar
conditions.
[00105] One aspect of the instant application can be described
generally with
reference to Figures IA and B. A biological sample is obtained from an
individual or
individuals of interest. The biological sample is then assayed to detect the
presence of
one or more (N) biomarkers of interest and to determine a biomarker value for
each of
said N biomarkers (referred to in Figure 1B as marker RFU). Once a biomarker
has
been detected and a biomarker value assigned each marker is scored or
classified as
described in detail herein. The marker scores are then combined to provide a
total
diagnostic score, which indicates the likelihood that the individual from whom
the
sample was obtained has lung cancer.
[00106] As used herein, "lung" may be interchangeably referred to as
"pulmonary".
[00107] As used herein, "smoker" refers to an individual who has a
history of
tobacco smoke inhalation.
[00108] "Biological sample", "sample", and "test sample" are used
interchangeably herein to refer to any material, biological fluid, tissue, or
cell
obtained or otherwise derived from an individual. This includes blood
(including
whole blood, leukocytes, peripheral blood mononuclear cells, buffy coat,
plasma, and
serum), sputum, tears, mucus, nasal washes, nasal aspirate, breath, urine,
semen,
saliva, meningeal fluid, amniotic fluid, glandular fluid, lymph fluid, nipple
aspirate,
bronchial aspirate, synovial fluid, joint aspirate, cells, a cellular extract,
and
cerebrospinal fluid. This also includes experimentally separated fractions of
all of the
preceding. For example, a blood sample can be fractionated into serum or into
fractions containing particular types of blood cells, such as red blood cells
or white
blood cells (leukocytes). If desired, a sample can be a combination of samples
from
an individual, such as a combination of a tissue and fluid sample. The term
"biological sample" also includes materials containing homogenized solid
material,
such as from a stool sample, a tissue sample, or a tissue biopsy, for example.
The
term "biological sample" also includes materials derived from a tissue culture
or a cell
culture. Any suitable methods for obtaining a biological sample can be
employed;
23
CA 3011730 2018-07-18
exemplary methods include, e.g., phlebotomy, swab (e.g., buccal swab), and a
fine
needle aspirate biopsy procedure. Exemplary tissues susceptible to fine needle
aspiration include lymph node, lung, lung washes, BAL (bronchoalveolar
lavage),
thyroid, breast, and liver. Samples can also be collected, e.g., by micro
dissection
(e.g., laser capture micro dissection (LCM) or laser micro dissection (LMD)),
bladder
wash, smear (e.g., a PAP smear), or ductal lavage. A "biological sample"
obtained or
derived from an individual includes any such sample that has been processed in
any
suitable manner after being obtained from the individual.
[00109] Further, it should be realized that a biological sample can
be derived
by taking biological samples from a number of individuals and pooling them or
pooling an aliquot of each individual's biological sample. The pooled sample
can be
treated as a sample from a single individual and if the presence of cancer is
established in the pooled sample, then each individual biological sample can
be re-
tested to determine which individual/s have lung cancer.
[00110] For purposes of this specification, the phrase "data
attributed to a
biological sample from an individual" is intended to mean that the data in
some form
derived from, or were generated using, the biological sample of the
individual. The
data may have been reformatted, revised, or mathematically altered to some
degree
after having been generated, such as by conversion from units in one
measurement
system to units in another measurement system; but, the data are understood to
have
been derived from, or were generated using, the biological sample.
[00111] "Target", "target molecule", and "analyte" are used
interchangeably
herein to refer to any molecule of interest that may be present in a
biological sample.
A "molecule of interest" includes any minor variation of a particular
molecule, such
as, in the case of a protein, for example, minor variations in amino acid
sequence,
disulfide bond formation, oycosylation, lipidation, acetylation,
phosphorylation, or
any other manipulation or modification, such as conjugation with a labeling
component, which does not substantially alter the identity of the molecule. A
"target
molecule", "target", or "analyte" is a set of copies of one type or species of
molecule
or multi-molecular structure. "Target molecules", "targets", and "analytes"
refer to
more than one such set of molecules. Exemplary target molecules include
proteins,
polypeptides, nucleic acids, carbohydrates, lipids, polysaccharides,
glycoproteins,
hormones, receptors, antigens, antibodies, affybodies, antibody mimics,
viruses,
pathogens, toxic substances, substrates, metabolites, transition state
analogs,
24
CA 3011730 2018-07-18
cofactors, inhibitors, drugs, dyes, nutrients, growth factors, cells, tissues,
and any
fragment or portion of any of the foregoing.
[00112] As used herein, ''polypeptide," "peptide," and "protein" are
used
interchangeably herein to refer to polymers of amino acids of any length. The
polymer may be linear or branched, it may comprise modified amino acids, and
it may
be interrupted by non-amino acids. The terms also encompass an amino acid
polymer
that has been modified naturally or by intervention; for example, disulfide
bond
formation, elycosylation, lipidation, acetylation, phosphorylation, or any
other
manipulation or modification, such as conjugation with a labeling component.
Also
included within the definition are, for example, polypeptides containing one
or more
analogs of an amino acid (including, for example, unnatural amino acids,
etc.), as well
as other modifications known in the art. Polypeptides can be single chains or
associated chains. Also included within the definition are preproteins and
intact
mature proteins; peptides or polypeptides derived from a mature protein;
fragments of
a protein; splice variants; recombinant forms of a protein; protein variants
with amino
acid modifications, deletions, or substitutions; digests; and post-
translational
modifications, such as glycosylation, acetylation, phosphorylation, and the
like.
[00113] As used herein, "marker" and "biomarker" are used
interchangeably to
refer to a target molecule that indicates or is a sign of a normal or abnormal
process in
an individual or of a disease or other condition in an individual. More
specifically, a
"marker'' or ''biomarker" is an anatomic, physiologic, biochemical, or
molecular
parameter associated with the presence of a specific physiological state or
process,
whether normal or abnormal, and, if abnormal, whether chronic or acute.
Biomarkers
are detectable and measurable by a variety of methods including laboratory
assays and
medical imaging. When a biomarker is a protein, it is also possible to use the
expression of the corresponding as a surrogate measure of the amount or
presence or
absence of the corresponding protein biomarker in a biological sample or
methylation
state of the gene encoding the biomarker or proteins that control expression
of the
biomarker.
[00114] As used herein, "biomarker value", "value", "biomarker
level", and
"level" are used interchangeably to refer to a measurement that is made using
any
analytical method for detecting the biomarker in a biological sample and that
indicates
the presence, absence, absolute amount or concentration, relative amount or
concentration, titer, a level, an expression level, a ratio of measured
levels, or the like,
CA 3011730 2018-07-18
of, for, or corresponding to the biomarker in the biological sample. The exact
nature
of the "value" or "level" depends on the specific design and components of the
particular analytical method employed to detect the biomarker.
[00115] When a biomarker indicates or is a sign of an abnormal process
or a
disease or other condition in an individual, that biomarker is generally
described as
being either over-expressed or under expressed as compared to an expression
level or
value of the biomarker that indicates or is a sign of a normal process or an
absence of
a disease or other condition in an individual. "Up-regulation", "up-
regulated", "over-
expression", "over-expressed", and any variations thereof are used
interchangeably to
refer to a value or level of a biomarker in a biological sample that is
greater than a
value or level (or range of values or levels) of the biomarker that is
typically detected
in similar biological samples from healthy or normal individuals. The terms
may also
refer to a value or level of a biomarker in a biological sample that is
greater than a
value or level (or range of values or levels) of the biomarker that may be
detected at a
different stage of a particular disease.
[00116] "Down-regulation", "down-regulated", "under-expression",
"under-
expressed", and any variations thereof are used interchangeably to refer to a
value or
level of a biomarker in a biological sample that is less than a value or level
(or range
of values or levels) of the biomarker that is typically detected in similar
biological
samples from healthy or normal individuals. The terms may also refer to a
value or
level of a biomarker in a biological sample that is less than a value or level
(or range
of values or levels) of the biomarker that may be detected at a different
stage of a
particular disease.
[00117] Further, a biomarker that is either over-expressed or under-
expressed
can also be referred to as being "differentially expressed" or as having a
"differential
level" or "differential value" as compared to a "normal" expression level or
value of
the biomarker that indicates or is a sign of a normal process or an absence of
a disease
or other condition in an individual. Thus, "differential expression" of a
biomarker can
also be referred to as a variation from a "normal" expression level of the
biomarker.
[00118] The term "differential gene expression" and "differential
expression"
are used interchangeably to refer to a gene (or its corresponding protein
expression
product) whose expression is activated to a higher or lower level in a subject
suffering
from a specific disease, relative to its expression in a normal or control
subject. The
terms also include genes (or the corresponding protein expression products)
whose
26
CA 3011730 2018-07-18
expression is activated to a higher or lower level at different stages of the
same
disease. It is also understood that a differentially expressed gene may be
either
activated or inhibited at the nucleic acid level or protein level, or may be
subject to
alternative splicing to result in a different polypeptide product. Such
differences may
be evidenced by a variety of changes including mRNA levels, surface
expression,
secretion or other partitioning of a polypeptide. Differential gene expression
may
include a comparison of expression between two or more genes or their gene
products; or a comparison of the ratios of the expression between two or more
genes
or their gene products; or even a comparison of two differently processed
products of
the same gene, which differ between normal subjects and subjects suffering
from a
disease; or between various stages of the same disease. Differential
expression
includes both quantitative, as well as qualitative, differences in the
temporal or
cellular expression pattern in a gene or its expression products among, for
example,
normal and diseased cells, or among cells which have undergone different
disease
events or disease stages.
[00119] As used herein, "individual" refers to a test subject or
patient. The
individual can be a mammal or a non-mammal. In various embodiments, the
individual is a mammal. A mammalian individual can be a human or non-human. In
various embodiments, the individual is a human. A healthy or normal individual
is an
individual in which the disease or condition of interest (including, for
example, lung
diseases, lung-associated diseases, or other lung conditions) is not
detectable by
conventional diagnostic methods.
[00120] "Diagnose", "diagnosing", "diagnosis", and variations thereof
refer to
the detection, determination, or recognition of a health status or condition
of an
individual on the basis of one or more signs, symptoms, data, or other
information
pertaining to that individual. The health status of an individual can be
diagnosed as
healthy / normal (i.e., a diagnosis of the absence of a disease or condition)
or
diagnosed as ill / abnoiTrial (i.e., a diagnosis of the presence, or an
assessment of the
characteristics, of a disease or condition). The terms "diagnose",
"diagnosing",
"diagnosis", etc., encompass, with respect to a particular disease or
condition, the
initial detection of the disease; the characterization or classification of
the disease; the
detection of the progression, remission, or recurrence of the disease; and the
detection
of disease response after the administration of a treatment or therapy to the
individual.
The diagnosis of lung cancer includes distinguishing individuals, including
smokers
27
CA 3011730 2018-07-18
and nonsmokers, who have cancer from individuals who do not. It further
includes
distinguishing benign pulmonary nodules from cancerous pulmonary nodules.
[00121] "Prognose", "prognosing", "prognosis", and variations thereof
refer to
the prediction of a future course of a disease or condition in an individual
who has the
disease or condition (e.g., predicting patient survival), and such terms
encompass the
evaluation of disease response after the administration of a treatment or
therapy to the
individual.
[00122] "Evaluate", "evaluating", "evaluation", and variations thereof
encompass both "diagnose" and "prognose" and also encompass determinations or
predictions about the future course of a disease or condition in an individual
who does
not have the disease as well as determinations or predictions regarding the
likelihood
that a disease or condition will recur in an individual who apparently has
been cured
of the disease. The term "evaluate" also encompasses assessing an individual's
response to a therapy, such as, for example, predicting whether an individual
is likely
to respond favorably to a therapeutic agent or is unlikely to respond to a
therapeutic
agent (or will experience toxic or other undesirable side effects, for
example),
selecting a therapeutic agent for administration to an individual, or
monitoring or
determining an individual's response to a therapy that has been administered
to the
individual. Thus, "evaluating" lung cancer can include, for example, any of
the
following: prognosing the future course of lung cancer in an individual;
predicting
the recurrence of lung cancer in an individual who apparently has been cured
of lung
cancer; or determining or predicting an individual's response to a lung cancer
treatment or selecting a lung cancer treatment to administer to an individual
based
upon a determination of the biomarker values derived from the individual's
biological
sample.
[00123] Any of the following examples may be referred to as either
"diagnosing" or "evaluating" lung cancer: initially detecting the presence or
absence
of lung cancer; determining a specific stage, type or sub-type, or other
classification
or characteristic of lung cancer; determining whether a pulmonary nodule is a
benign
lesion or a malignant lung tumor; or detecting/monitoring lung cancer
progression
(e.g., monitoring lung tumor growth or metastatic spread), remission, or
recurrence.
[00124] As used herein, "additional biomedical information" refers to
one or
more evaluations of an individual, other than using any of the biomarkers
described
herein, that are associated with lung cancer risk. "Additional biomedical
information"
28
CA 3011730 2018-07-18
includes any of the following: physical descriptors of an individual, physical
descriptors of a pulmonary nodule observed by CT imaging, the height and/or
weight
of an individual, the gender of an individual, the ethnicity of an individual,
smoking
history, occupational history, exposure to known carcinogens (e.g., exposure
to any of
asbestos, radon gas, chemicals, smoke from fires, and air pollution, which can
include
emissions from stationary or mobile sources such as industrial/factory or
auto/marine/aircraft emissions), exposure to second-hand smoke, family history
of
lung cancer (or other cancer), the presence of pulmonary nodules, size of
nodules,
location of nodules, morphology of nodules (e.g., as observed through CT
imaging,
ground glass opacity (GGO), solid, non-solid), edge characteristics of the
nodule (e.g.,
smooth, lobulated, sharp and smooth, spiculated, infiltrating), and the like.
Smoking
history is usually quantified in terms of "pack years", which refers to the
number of
years a person has smoked multiplied by the average number of packs smoked per
day. For example, a person who has smoked, on average, one pack of cigarettes
per
day for 35 years is referred to as having 35 pack years of smoking history.
Additional
biomedical information can be obtained from an individual using routine
techniques
known in the art, such as from the individual themselves by use of a routine
patient
questionnaire or health history questionnaire, etc., or from a medical
practitioner, etc.
Alternately, additional biomedical information can be obtained from routine
imaging
techniques, including CT imaging (e.g., low-dose CT imaging) and X-ray.
Testing of
biomarker levels in combination with an evaluation of any additional
biomedical
information may, for example, improve sensitivity, specificity, and/or AUC for
detecting lung cancer (or other lung cancer-related uses) as compared to
biomarker
testing alone or evaluating any particular item of additional biomedical
information
alone (e.g., CT imaging alone).
[00125] The term "area
under the curve" or "AUC" refers to the area under the
curve of a receiver operating characteristic (ROC) curve, both of which are
well
known in the art. AUC measures are useful for comparing the accuracy of a
classifier
across the complete data ranee. Classifiers with a greater AUC have a greater
capacity to classify unknowns correctly between two groups of interest (e.g.,
lung
cancer samples and normal or control samples). ROC curves are useful for
plotting
the performance of a particular feature (e.g., any of the biomarkers described
herein
and/or any item of additional biomedical information) in distinguishing
between two
populations (e.g., cases having lung cancer and controls without lung cancer).
29
CA 3011730 2018-07-18
Typically, the feature data across the entire population (e.g., the cases and
controls)
are sorted in ascending order based on the value of a single feature. Then,
for each
value for that feature, the true positive and false positive rates for the
data are
calculated. The true positive rate is determined by counting the number of
cases above
the value for that feature and then dividing by the total number of cases. The
false
positive rate is determined by counting the number of controls above the value
for that
feature and then dividing by the total number of controls. Although this
definition
refers to scenarios in which a feature is elevated in cases compared to
controls, this
definition also applies to scenarios in which a feature is lower in cases
compared to
the controls (in such a scenario, samples below the value for that feature
would be
counted). ROC curves can be generated for a single feature as well as for
other single
outputs, for example, a combination of two or more features can be
mathematically
combined (e.g., added, subtracted, multiplied, etc.) to provide a single sum
value, and
this single sum value can be plotted in a ROC curve. Additionally, any
combination
of multiple features, in which the combination derives a single output value,
can be
plotted in a ROC curve. These combinations of features may comprise a test.
The
ROC curve is the plot of the true positive rate (sensitivity) of a test
against the false
positive rate (1-specificity) of the test.
[00126] As used herein, "detecting" or "determining" with respect to a
biomarker value includes the use of both the instrument required to observe
and
record a signal corresponding to a biomarker value and the material/s required
to
generate that signal. In various embodiments, the biomarker value is detected
using
any suitable method, including fluorescence, chemiluminescence, surface
plasmon
resonance, surface acoustic waves, mass spectrometry, infrared spectroscopy,
Raman
spectroscopy, atomic force microscopy, scanning tunneling microscopy,
electrochemical detection methods, nuclear magnetic resonance, quantum dots,
and
the like.
[00127] "Solid support" refers herein to any substrate having a
surface to which
molecules may be attached, directly or indirectly, through either covalent or
non-
covalent bonds. A "solid support" can have a variety of physical formats,
which can
include, for example, a membrane; a chip (e.g., a protein chip); a slide
(e.g., a glass
slide or coverslip); a column; a hollow, solid, semi-solid, pore- or cavity-
containing
particle, such as, for example, a bead; a gel; a fiber, including a fiber
optic material; a
matrix; and a sample receptacle. Exemplary sample receptacles include sample
wells,
CA 3011730 2018-07-18
tubes, capillaries, vials, and any other vessel, groove or indentation capable
of holding
a sample. A sample receptacle can be contained on a multi-sample platform,
such as
a microtiter plate, slide, microfluidics device, and the like. A support can
be
composed of a natural or synthetic material, an organic or inorganic material.
The
composition of the solid support on which capture reagents are attached
generally
depends on the method of attachment (e.g., covalent attachment). Other
exemplary
receptacles include microdroplets and microfluidic controlled or bulk
oil/aqueous
emulsions within which assays and related manipulations can occur. Suitable
solid
supports include, for example, plastics, resins, polysaccharides, silica or
silica-based
materials, functionalized glass, modified silicon, carbon, metals, inorganic
glasses,
membranes, nylon, natural fibers (such as, for example, silk, wool and
cotton),
polymers, and the like. The material composing the solid support can include
reactive
groups such as, for example, carboxy, amino, or hydroxyl groups, which are
used for
attachment of the capture reagents. Polymeric solid supports can include,
e.g.,
polystyrene, polyethylene glycol tetraphthalate, polyvinyl acetate, polyvinyl
chloride,
polyvinyl pyrrolidone, polyacrylonitrile, polymethyl methacryl ate,
polytetrafluoroethylene, butyl rubber, styrenebutadiene rubber, natural
rubber,
polyethylene, polypropylene, (poly)tetrafluoroethylene,
(poly)vinylidenefluoride,
polycarbonate, and polymethylpentene. Suitable solid support particles that
can be
used include, e.g., encoded particles, such as Luminee-type encoded particles,
magnetic particles, and glass particles.
Exemplary Uses of Biomarkers
[00128] In various exemplary embodiments, methods are provided for
diagnosing lung cancer in an individual by detecting one or more biomarker
values
corresponding to one or more biornarkers that are present in the circulation
of an
individual, such as in serum or plasma, by any number of analytical methods,
including any of the analytical methods described herein. These biomarkers
are, for
example, differentially expressed in individuals with lung cancer as compared
to
individuals without lung cancer. Detection of the differential expression of a
biomarker in an individual can be used, for example, to permit the early
diagnosis of
lung cancer, to distinguish between a benign and malignant pulmonary nodule
(such
as, for example, a nodule observed on a computed tomography (CT) scan), to
monitor
lung cancer recurrence, or for other clinical indications.
31
CA 3011730 2018-07-18
[00129] Any of the biomarkers described herein may be used in a
variety of
clinical indications for lung cancer, including any of the following:
detection of lung
cancer (such as in a high-risk individual or population); characterizing lung
cancer
(e.g., determining lung cancer type, sub-type, or stage), such as by
distinguishing
between non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)
and/or between adenocarcinoma and squamous cell carcinoma (or otherwise
facilitating histopathology); determining whether a lung nodule is a benign
nodule or
a malignant lung tumor; determining lung cancer prognosis; monitoring lung
cancer
progression or remission; monitoring for lung cancer recurrence; monitoring
metastasis; treatment selection; monitoring response to a therapeutic agent or
other
treatment; stratification of individuals for computed tomography (CT)
screening (e.g.,
identifying those individuals at greater risk of lung cancer and thereby most
likely to
benefit from spiral-CT screening, thus increasing the positive predictive
value of CT);
combining biomarker testing with additional biomedical information, such as
smoking
history, etc., or with nodule size, morphology, etc. (such as to provide an
assay with
increased diagnostic performance compared to CT testing or biomarker testing
alone);
facilitating the diagnosis of a pulmonary nodule as malignant or benign;
facilitating
clinical decision making once a lung cancer nodule is observed on CT (e.g.,
ordering
repeat CT scans if the nodule is deemed to be low risk, such as if a biomarker-
based
test is negative, with or without categorization of nodule size, or
considering biopsy if
the nodule is deemed medium to high risk, such as if a biomarker-based test is
positive, with or without categorization of nodule size); and facilitating
decisions
regarding clinical follow-up (e.g., whether to implement repeat CT scans, fine
needle
biopsy, or thoracotomy after observing a non-calcified nodule on CT).
Biomarker
testing may improve positive predictive value (PPV) over CT screening alone.
In
addition to their utilities in conjunction with CT screening, the biomarkers
described
herein can also be used in conjunction with any other imaging modalities used
for
lung cancer, such as chest X-ray. Furthermore, the described biomarkers may
also be
useful in permitting certain of these uses before indications of lung cancer
are
detected by imaging modalities or other clinical correlates, or before
symptoms
appear.
[00130] As an example of the manner in which any of the biomarkers
described
herein can be used to diagnose lung cancer, differential expression of one or
more of
the described biornarkers in an individual who is not known to have lung
cancer may
32
CA 3011730 2018-07-18
indicate that the individual has lung cancer, thereby enabling detection of
lung cancer
at an early stage of the disease when treatment is most effective, perhaps
before the
lung cancer is detected by other means or before symptoms appear. Over-
expression
of one or more of the biomarkers during the course of lung cancer may be
indicative
of lung cancer progression, e.g., a lung tumor is growing and/or metastasizing
(and
thus indicate a poor prognosis), whereas a decrease in the degree to which one
or
more of the biomarkers is differentially expressed (i.e., in subsequent
biomarker tests,
the expression level in the individual is moving toward or approaching a
"normal"
expression level) may be indicative of lung cancer remission, e.g., a lung
tumor is
shrinking (and thus indicate a good or better prognosis). Similarly, an
increase in the
degree to which of one or more of the biomarkers is differentially expressed
(i.e., in
subsequent biomarker tests, the expression level in the individual is moving
further
away from a "normal" expression level) during the course of lung cancer
treatment
may indicate that the lung cancer is progressing and therefore indicate that
the
treatment is ineffective, whereas a decrease in differential expression of one
or more
of the biornarkers during the course of lung cancer treatment may be
indicative of
lung cancer remission and therefore indicate that the treatment is working
successfully. Additionally, an increase or decrease in the differential
expression of
one or more of the biomarkers after an individual has apparently been cured of
lung
cancer may be indicative of lung cancer recurrence. In a situation such as
this, for
example, the individual can be re-started on therapy (or the therapeutic
regimen
modified such as to increase dosage amount and/or frequency, if the individual
has
maintained therapy) at an earlier stage than if the recurrence of lung cancer
was not
detected until later. Furthermore, a differential expression level of one or
more of the
biomarkers in an individual may be predictive of the individual's response to
a
particular therapeutic agent. In monitoring for lung cancer recurrence or
progression,
changes in the biomarker expression levels may indicate the need for repeat
imaging
(e.g., repeat CT scanning), such as to determine lung cancer activity or to
determine
the need for changes in treatment.
[00131] Detection of any of the biomarkers described herein may be
particularly useful following, or in conjunction with, lung cancer treatment,
such as to
evaluate the success of the treatment or to monitor lung cancer remission,
recurrence,
and/or progression (including metastasis) following treatment. Lung cancer
treatment
may include, for example, administration of a therapeutic agent to the
individual,
33
CA 3011730 2018-07-18
peiforrnance of surgery (e.g., surgical resection of at least a portion of a
lung tumor),
administration of radiation therapy, or any other type of lung cancer
treatment used in
the art, and any combination of these treatments. For example, any of the
biomarkers
may be detected at least once after treatment or may be detected multiple
times after
treatment (such as at periodic intervals), or may be detected both before and
after
treatment. Differential expression levels of any of the biomarkers in an
individual
over time may be indicative of lung cancer progression, remission, or
recurrence,
examples of which include any of the following: an increase or decrease in the
expression level of the biomarkers after treatment compared with the
expression level
of the biomarker before treatment; an increase or decrease in the expression
level of
the biomarker at a later time point after treatment compared with the
expression level
of the biomarker at an earlier time point after treatment; and a differential
expression
level of the biomarker at a single time point after treatment compared with
normal
levels of the biomarker.
[00132] As a specific example, the biomarker levels for any of the
biomarkers
described herein can be determined in pre-surgery and post-surgery (e.g., 2-4
weeks
after surgery) serum samples. An increase in the biomarker expression level(s)
in the
post-surgery sample compared with the pre-surgery sample can indicate
progression
of lung cancer (e.g., unsuccessful surgery), whereas a decrease in the
biomarker
expression level(s) in the post-surgery sample compared with the pre-surgery
sample
can indicate regression of lung cancer (e.g., the surgery successfully removed
the lung
tumor). Similar analyses of the biomarker levels can be carried out before and
after
other forms of treatment, such as before and after radiation therapy or
administration
of a therapeutic agent or cancer vaccine.
[00133] In addition to testing biomarker levels as a stand-alone
diagnostic test,
biomarker levels can also be done in conjunction with determination of SNPs or
other
genetic lesions or variability that are indicative of increased risk of
susceptibility of
disease. (See, e.g., Amos et al., Nature Genetics 40, 616-622 (2009)).
[00134] In addition to testing biomarker levels as a stand-alone
diagnostic test,
biomarker levels can also be done in conjunction with CT screening. For
example,
the biomarkers may facilitate the medical and economic justification for
implementing CT screening, such as for screening large asymptomatic
populations at
risk for lung cancer (e.g., smokers). For example, a "pre-CT" test of
biomarker levels
could be used to stratify high-risk individuals for CT screening, such as for
34
CA 3011730 2018-07-18
identifying those who are at highest risk for lung cancer based on their
biomarker
levels and who should be prioritized for CT screening. If a CT test is
implemented,
biomarker levels (e.g., as determined by an aptamer assay of serum or plasma
samples) of one or more biomarkers can be measured and the diagnostic score
could
be evaluated in conjunction with additional biomedical information (e.g.,
tumor
parameters determined by CT testing) to enhance positive predictive value
(PPV) over
CT or biomarker testing alone. A "post-CT" aptamer panel for determining
biomarker
levels can be used to determine the likelihood that a pulmonary nodule
observed by
CT (or other imaging modality) is malignant or benign.
[00135] Detection of any of the biomarkers described herein may be
useful for
post-CT testing. For example, biomarker testing may eliminate or reduce a
significant
number of false positive tests over CT alone. Further, biomarker testing may
facilitate treatment of patients. By way of example, if a lung nodule is less
than 5 mm
in size, results of biomarker testing may advance patients from "watch and
wait" to
biopsy at an earlier time; if a lung nodule is 5-9 mm, biomarker testing may
eliminate
the use of a biopsy or thoracotorny on false positive scans; and if a lung
nodule is
larger than 10 mm, biomarker testing may eliminate surgery for a sub-
population of
these patients with benign nodules. Eliminating the need for biopsy in some
patients
based on biomarker testing would be beneficial because there is significant
morbidity
associated with nodule biopsy and difficulty in obtaining nodule tissue
depending on
the location of nodule. Similarly, eliminating the need for surgery in some
patients,
such as those whose nodules are actually benign, would avoid unnecessary risks
and
costs associated with surgery.
[00136] In addition to testing biomarker levels in conjunction with
CT
screening (e.g., assessing biomarker levels in conjunction with size or other
characteristics of a lung nodule observed on a CT scan), information regarding
the
biomarkers can also be evaluated in conjunction with other types of data,
particularly
data that indicates an individual's risk for lung cancer (e.g., patient
clinical history,
symptoms, family history of cancer, risk factors such as whether or not the
individual
is a smoker, and/or status of other biomarkers, etc.). These various data can
be
assessed by automated methods, such as a computer program/software, which can
be
embodied in a computer or other apparatus/device.
[00137] Any of the described biomarkers may also be used in imaging
tests.
For example, an imaging agent can be coupled to any of the described
biomarkers,
CA 3011730 2018-07-18
which can be used to aid in lung cancer diagnosis, to monitor disease
progression/remission or metastasis, to monitor for disease recurrence, or to
monitor
response to therapy, among other uses.
Detection and Determination of Biomarkers and Biomarker Values
[00138] A biomarker value for the biomarkers described herein can be
detected
using any of a variety of known analytical methods. In one embodiment, a
biomarker
value is detected using a capture reagent. As used herein, a "capture agent'
or
"capture reagent" refers to a molecule that is capable of binding specifically
to a
biomarker. In various embodiments, the capture reagent can be exposed to the
biomarker in solution or can be exposed to the biomarker while the capture
reagent is
immobilized on a solid support. In other embodiments, the capture reagent
contains a
feature that is reactive with a secondary feature on a solid support. In these
embodiments, the capture reagent can be exposed to the biomarker in solution,
and
then the feature on the capture reagent can be used in conjunction with the
secondary
feature on the solid support to immobilize the biomarker on the solid support.
The
capture reagent is selected based on the type of analysis to be conducted.
Capture
reagents include but are not limited to aptamers, antibodies, adnectins,
ankyrins, other
antibody mimetics and other protein scaffolds, autoantibodies, chimeras, small
molecules, an F(ab).) fragment, a single chain antibody fragment, an Fv
fragment, a
single chain Fv fragment, a nucleic acid, a lectin, a ligand-binding receptor,
affybodies, nanobodies, imprinted polymers, avimers, peptidomimetics, a
hormone
receptor, a cytokine receptor, and synthetic receptors, and modifications and
fragments of these.
[00139] In some embodiments, a biomarker value is detected using a
biomarker/capture reagent complex.
[00140] In other embodiments, the biomarker value is derived from the
biomarker/capture reagent complex and is detected indirectly, such as, for
example, as
a result of a reaction that is subsequent to the biomarker/capture reagent
interaction,
but is dependent on the formation of the biomarker/capture reagent complex.
[00141] In some embodiments, the biomarker value is detected directly
from
the biomarker in a biological sample.
[00142] In one embodiment, the biomarkers are detected using a
multiplexed
format that allows for the simultaneous detection of two or more biomarkers in
a
36
CA 3011730 2018-07-18
biological sample. In one embodiment of the multiplexed format, capture
reagents are
immobilized, directly or indirectly, covalently or non-covalently, in discrete
locations
on a solid support. In another embodiment, a multiplexed format uses discrete
solid
supports where each solid support has a unique capture reagent associated with
that
solid support, such as, for example quantum dots. In another embodiment, an
individual device is used for the detection of each one of multiple biomarkers
to be
detected in a biological sample. Individual devices can be configured to
permit each
biomarker in the biological sample to be processed simultaneously. For
example, a
microtiter plate can be used such that each well in the plate is used to
uniquely
analyze one of multiple biomarkers to be detected in a biological sample.
[00143] In one or more of the foregoing embodiments, a fluorescent
tag can be
used to label a component of the biomarker/capture complex to enable the
detection
of the biomarker value. In various embodiments, the fluorescent label can be
conjugated to a capture reagent specific to any of the biomarkers described
herein
using known techniques, and the fluorescent label can then be used to detect
the
corresponding biomarker value. Suitable fluorescent labels include rare earth
chelates, fluorescein and its derivatives, rhodamine and its derivatives,
dansyl,
allophycocyanin, PBXL-3, Qdot 605, Lissamine, phycoerythrin, Texas Red, and
other
such compounds.
[00144] In one embodiment, the fluorescent label is a fluorescent dye
molecule.
In some embodiments, the fluorescent dye molecule includes at least one
substituted
indolium ring system in which the substituent on the 3-carbon of the indolium
ring
contains a chemically reactive group or a conjugated substance. In some
embodiments, the dye molecule includes an AlexFluor molecule, such as, for
example, AlexaFluor 488, AlexaFluor 532, AlexaFluor 647, AlexaFluor 680, or
AlexaFluor 700. In other embodiments, the dye molecule includes a first type
and a
second type of dye molecule, such as, e.g., two different AlexaFluor
molecules. In
other embodiments, the dye molecule includes a first type and a second type of
dye
molecule, and the two dye molecules have different emission spectra.
[00145] Fluorescence can be measured with a variety of
instrumentation
compatible with a wide range of assay formats. For example,
spectrofluorimeters
have been designed to analyze microtiter plates, microscope slides, printed
arrays,
cuvettes, etc. See Principles of Fluorescence Spectroscopy, by J.R. Lakowicz,
Springer Science + Business Media, Inc., 2004. See Bioluminescence &
37
CA 3011730 2018-07-18
Chemiluminescence: Progress & Current Applications; Philip E. Stanley and
Larry J.
Kricka editors, World Scientific Publishing Company, January 2002.
[00146] In one or more of the foregoing embodiments, a
chemiluminescence
tag can optionally be used to label a component of the biomarker/capture
complex to
enable the detection of a biomarker value. Suitable chemiluminescent materials
include any of oxalyl chloride, Rodamin 6G, Ru(bipy)32+ , TMAE
(tetrakis(dimethylamino)ethylene), Pyrogallol (1,2,3-trihydroxibenzene),
Lucigenin,
peroxyoxalates, Aryl oxalates, Acridinium esters, dioxetanes, and others.
[00147] In yet other embodiments, the detection method includes an
enzyme/substrate combination that generates a detectable signal that
corresponds to
the biomarker value. Generally, the enzyme catalyzes a chemical alteration of
the
chromogenic substrate which can be measured using various techniques,
including
spectrophotometry, fluorescence, and chemiluminescence. Suitable enzymes
include,
for example, luciferases, luciferin, malate dehydrogenase, urease, horseradish
peroxidase (HRPO), alkaline phosphatase, beta-galactosidase, glucoamylase,
lysozyme, glucose oxidase, galactose oxidase, and glucose-6-phosphate
dehydroeenase, uricase, xanthine oxidase, lactoperoxidase, microperoxidase,
and the
like.
[00148] In yet other embodiments, the detection method can be a
combination
of fluorescence, chemiluminescence, radionuclide or enzyme/substrate
combinations
that generate a measurable signal. Multimodal signaling could have unique and
advantageous characteristics in biomarker assay formats.
[00149] More specifically, the biomarker values for the biomarkers
described
herein can be detected using known analytical methods including, singleplex
aptamer
assays, multiplexed aptamer assays, singleplex or multiplexed immunoassays,
mRNA
expression profiling, miRNA expression profiling, mass spectrometric analysis,
histological/cytological methods, etc. as detailed below.
Determination of Biomarker Values using Aptamer-Based Assays
[00150] Assays directed to the detection and quantification of
physiologically
significant molecules in biological samples and other samples are important
tools in
scientific research and in the health care field. One class of such assays
involves the
use of a microarray that includes one or more aptamers immobilized on a solid
support. The aptamers are each capable of binding to a target molecule in a
highly
38
CA 3011730 2018-07-18
specific manner and with very high affinity. See, e.g., U.S. Patent No.
5,475,096
entitled ''Nucleic Acid Ligands"; see also, e.g., U.S. Patent No. 6,242,246,
U.S. Patent
= No. 6,458,543, and U.S. Patent No. 6,503,715, each of which is entitled
"Nucleic
Acid Ligand Diagnostic Biochip". Once the microarray is contacted with a
sample,
the aptamers bind to their respective target molecules present in the sample
and
thereby enable a determination of a biomarker value corresponding to a
biomarker.
[00151] As used herein, an "aptamer" refers to a nucleic acid that
has a specific
binding affinity for a target molecule. It is recognized that affinity
interactions are a
matter of degree; however, in this context, the "specific binding affinity" of
an
aptamer for its target means that the aptamer binds to its target generally
with a much
higher degree of affinity than it binds to other components in a test sample.
An
''aptamer" is a set of copies of one type or species of nucleic acid molecule
that has a
particular nucleotide sequence. An aptamer can include any suitable number of
nucleotides, including any number of chemically modified nucleotides.
"Aptamers"
refers to more than one such set of molecules. Different aptamers can have
either the
same or different numbers of nucleotides. Aptamers can be DNA or RNA or
chemically modified nucleic acids and can be single stranded, double stranded,
or
contain double stranded regions, and can include higher ordered structures. An
aptamer can also be a photoaptamer, where a photoreactive or chemically
reactive
functional group is included in the aptamer to allow it to be covalently
linked to its
corresponding target. Any of the aptamer methods disclosed herein can include
the
use of two or more aptamers that specifically bind the same target molecule.
As
further described below, an aptamer may include a tag. If an aptamer includes
a tag,
all copies of the aptamer need not have the same tag. Moreover, if different
aptamers
each include a tag, these different aptamers can have either the same tag or a
different
tag.
[00152] An aptamer can be identified using any known method,
including the
SELEX process. Once identified, an aptamer can be prepared or synthesized in
accordance with any known method, including chemical synthetic methods and
enzymatic synthetic methods.
[00153] The terms "SELEX" and "SELEX process" are used
interchangeably
herein to refer generally to a combination of (1) the selection of aptamers
that interact
with a target molecule in a desirable manner, for example binding with high
affinity
to a protein, with (2) the amplification of those selected nucleic acids. The
SELEX
39
CA 3011730 2018-07-18
process can be used to identify aptamers with high affinity to a specific
target or
biomarker.
[00154] SELEX generally includes preparing a candidate mixture of
nucleic
acids, binding of the candidate mixture to the desired target molecule to form
an
affinity complex, separating the affinity complexes from the unbound candidate
nucleic acids, separating and isolating the nucleic acid from the affinity
complex,
purifying the nucleic acid, and identifying a specific aptamer sequence. The
process
may include multiple rounds to further refine the affinity of the selected
aptamer. The
process can include amplification steps at one or more points in the process.
See, e.g.,
U.S. Patent No. 5,475,096, entitled "Nucleic Acid Ligands". The SELEX process
can
be used to generate an aptamer that covalently binds its target as well as an
aptamer
that non-covalently binds its target. See, e.g., U.S. Patent No. 5,705,337
entitled
"Systematic Evolution of Nucleic Acid Ligands by Exponential Enrichment: Chemi-
SELEX."
[00155] The SELEX process can be used to identify high-affinity
aptamers
containing modified nucleotides that confer improved characteristics on the
aptamer,
such as, for example, improved in vivo stability or improved delivery
characteristics.
Examples of such modifications include chemical substitutions at the ribose
and/or
phosphate and/or base positions. SELEX process-identified aptamers containing
modified nucleotides are described in U.S. Patent No. 5,660,985, entitled
"High
Affinity Nucleic Acid Ligands Containing Modified Nucleotides", which
describes
oligonucleotides containing nucleotide derivatives chemically modified at the
5'- and
2'-positions of pyrimidines. U.S. Patent No. 5,580,737, see supra, describes
highly
specific aptamers containing one or more nucleotides modified with 2'-amino
(2'-
NH2), 2'-fluoro (2'-F), and/or 2'-0-methyl (2'-0Me). See also, U.S. Patent
Application Publication 20090098549, entitled "SELEX and PHOTOSELEX", which
describes nucleic acid libraries having expanded physical and chemical
properties and
their use in SELEX and photoSELEX.
[00156] SELEX can also be used to identify aptamers that have
desirable off-
rate characteristics. See U.S. Patent Application Publication 20090004667,
entitled
"Method for Generating Aptamers with Improved Off-Rates", which describes
improved SELEX methods for generating aptamers that can bind to target
molecules.
Methods for producing aptamers and photoaptamers having slower rates of
dissociation from their respective target molecules are described. The methods
CA 3011730 2018-07-18
involve contacting the candidate mixture with the target molecule, allowing
the
formation of nucleic acid-target complexes to occur, and performing a slow off-
rate
enrichment process wherein nucleic acid-target complexes with fast
dissociation rates
will dissociate and not reform, while complexes with slow dissociation rates
will
remain intact. Additionally, the methods include the use of modified
nucleotides in
the production of candidate nucleic acid mixtures to generate aptamers with
improved
off-rate performance.
[00157] A variation of this assay employs aptamers that include
photoreactive
functional groups that enable the aptamers to covalently bind or
"photocrosslink" their
target molecules. See, e.g., U.S. Patent No. 6,544,776 entitled "Nucleic Acid
Ligand
Diagnostic Biochip". These photoreactive aptamers are also referred to as
photoaptamers. See, e.g., U.S. Patent No. 5,763,177, U.S. Patent No.
6,001,577, and
U.S. Patent No. 6,291,184, each of which is entitled "Systematic Evolution of
Nucleic
Acid Ligands by Exponential Enrichment: Photoselection of Nucleic Acid Ligands
and Solution SELEX"; see also, e.g., U.S. Patent No. 6,458,539, entitled
"Photoselection of Nucleic Acid Ligands". After the microarray is contacted
with the
sample and the photoaptamers have had an opportunity to bind to their target
molecules, the photoaptamers are photoactivated, and the solid support is
washed to
remove any non-specifically bound molecules. Harsh wash conditions may be
used,
since target molecules that are bound to the photoaptamers are generally not
removed,
due to the covalent bonds created by the photoactivated functional group(s) on
the
photoaptamers. In this manner, the assay enables the detection of a biomarker
value
corresponding to a biomarker in the test sample.
[00158] In both of these assay formats, the aptamers are immobilized
on the
solid support prior to being contacted with the sample. Under certain
circumstances,
however, immobilization of the aptamers prior to contact with the sample may
not
provide an optimal assay. For example, pre-immobilization of the aptamers may
result in inefficient mixing of the aptamers with the target molecules on the
suiface of
the solid support, perhaps leading to lengthy reaction times and, therefore,
extended
incubation periods to permit efficient binding of the aptamers to their target
molecules. Further, when photoaptamers are employed in the assay and depending
upon the material utilized as a solid support, the solid support may tend to
scatter or
absorb the light used to effect the formation of covalent bonds between the
photoaptamers and their target molecules. Moreover, depending upon the method
41
CA 3011730 2018-07-18
employed, detection of target molecules bound to their aptamers can be subject
to
imprecision, since the surface of the solid support may also be exposed to and
affected by any labeling agents that are used. Finally, immobilization of the
aptamers
on the solid support generally involves an aptamer-preparation step (i.e., the
immobilization) prior to exposure of the aptamers to the sample, and this
preparation
step may affect the activity or functionality of the aptamers.
[00159] Aptamer assays that permit an aptamer to capture its target in
solution
and then employ separation steps that are designed to remove specific
components of
the aptamer-target mixture prior to detection have also been described (see
U.S.
Patent Application Publication 20090042206, entitled "Multiplexed Analyses of
Test
Samples"). The described aptamer assay methods enable the detection and
quantification of a non-nucleic acid target (e.g., a protein target) in a test
sample by
detecting and quantifying a nucleic acid (i.e., an aptamer). The described
methods
create a nucleic acid surrogate (i.e, the aptamer) for detecting and
quantifying a non-
nucleic acid target, thus allowing the wide variety of nucleic acid
technologies,
including amplification, to be applied to a broader range of desired targets,
including
protein targets.
[00160] Aptamers can be constructed to facilitate the separation of
the assay
components from an aptamer biomarker complex (or photoaptamer biomarker
covalent complex) and permit isolation of the aptamer for detection and/or
quantification. In one embodiment, these constructs can include a cleavable or
releasable element within the aptamer sequence. In other embodiments,
additional
functionality can be introduced into the aptamer, for example, a labeled or
detectable
component, a spacer component, or a specific binding tag or immobilization
element.
For example, the aptamer can include a tag connected to the aptamer via a
cleavable
moiety, a label, a spacer component separating the label, and the cleavable
moiety. In
one embodiment, a cleavable element is a photocleavable linker. The
photocleavable
linker can be attached to a biotin moiety and a spacer section, can include an
NHS
group for derivatization of amines, and can be used to introduce a biotin
group to an
aptamer, thereby allowing for the release of the aptamer later in an assay
method.
[00161] Homogenous assays, done with all assay components in solution,
do
not require separation of sample and reagents prior to the detection of
signal. These
methods are rapid and easy to use. These methods generate signal based on a
molecular capture or binding reagent that reacts with its specific target. For
lung
42
CA 3011730 2018-07-18
cancer, the molecular capture reagents would be an aptamer or an antibody or
the like
and the specific target would be a lung cancer biomarker of Table 1, Col. 2.
[00162] In one embodiment, a method for signal generation takes
advantage of
anisotropy signal change due to the interaction of a fluorophore-labeled
capture
reagent with its specific biomarker target. When the labeled capture reacts
with its
target, the increased molecular weight causes the rotational motion of the
fluorophore
attached to the complex to become much slower changing the anisotropy value.
By
monitoring the anisotropy change, binding events may be used to quantitatively
measure the biomarkers in solutions. Other methods include fluorescence
polarization assays, molecular beacon methods, time resolved fluorescence
quenching, chemiluminescence, fluorescence resonance energy transfer, and the
like.
[00163] An exemplary solution-based aptamer assay that can be used to
detect
a biomarker value corresponding to a biomarker in a biological sample includes
the
following: (a) preparing a mixture by contacting the biological sample with an
aptamer that includes a first tag and has a specific affinity for the
biomarker, wherein
an aptamer affinity complex is formed when the biomarker is present in the
sample;
(b) exposing the mixture to a first solid support including a first capture
element, and
allowing the first tag to associate with the first capture element; (c)
removing any
components of the mixture not associated with the first solid support; (d)
attaching a
second tag to the biomarker component of the aptamer affinity complex; (e)
releasing
the aptamer affinity complex from the first solid support; (1) exposing the
released
aptamer affinity complex to a second solid support that includes a second
capture
element and allowing the second tag to associate with the second capture
element; (g)
removing any non-complexed aptamer from the mixture by partitioning the non-
complexed aptamer from the aptamer affinity complex; (h) eluting the aptamer
from
the solid support; and (i) detecting the biomarker by detecting the aptamer
component
of the aptamer affinity complex.
Determination of Biomarker Values using Immunoassays
[00164] Immunoassay methods are based on the reaction of an antibody
to its
corresponding target or analyte and can detect the analyte in a sample
depending on
the specific assay format. To improve specificity and sensitivity of an assay
method
based on immuno-reactivity, monoclonal antibodies are often used because of
their
specific epitope recognition. Polyclonal antibodies have also been
successfully used
43
CA 3011730 2018-07-18
in various immunoassays because of their increased affinity for the target as
compared
to monoclonal antibodies. Immunoassays have been designed for use with a wide
range of biological sample matrices. Immunoassay formats have been designed to
provide qualitative, semi-quantitative, and quantitative results.
[00165] Quantitative results are generated through the use of a
standard curve
created with known concentrations of the specific analyte to be detected. The
response or signal from an unknown sample is plotted onto the standard curve,
and a
quantity or value corresponding to the target in the unknown sample is
established.
[00166] Numerous immunoassay formats have been designed. ELISA or EIA
can be quantitative for the detection of an analyte. This method relies on
attachment
of a label to either the analyte or the antibody and the label component
includes, either
directly or indirectly, an enzyme. EL1SA tests may be formatted for direct,
indirect,
competitive, or sandwich detection of the analyte. Other methods rely on
labels such
as, for example, radioisotopes (1125) or fluorescence. Additional techniques
include,
for example, agglutination, nephelometry, turbidimetry, Western blot,
immunoprecipitation, immunocytochemistry, immunohistochemistry, flow
cytometry,
Luminex assay, and others (see IinmunoAssay: A Practical Guide, edited by
Brian
Law, published by Taylor & Francis, Ltd., 2005 edition).
[00167] Exemplary assay formats include enzyme-linked immunosorbent
assay
(ELISA), radioimmunoassay, fluorescent, chemiluminescence, and fluorescence
resonance energy transfer (FRET) or time resolved-FRET (TR-FRET) immunoassays.
Examples of procedures for detecting biomarkers include biomarker
immunoprecipitation followed by quantitative methods that allow size and
peptide
level discrimination, such as gel electrophoresis, capillary electrophoresis,
planar
electrochromatogyaphy, and the like.
[00168] Methods of detecting and/or for quantifying a detectable label
or signal
generating material depend on the nature of the label. The products of
reactions
catalyzed by appropriate enzymes (where the detectable label is an enzyme; see
above) can be, without limitation, fluorescent, luminescent, or radioactive or
they may
absorb visible or ultraviolet light. Examples of detectors suitable for
detecting such
detectable labels include, without limitation, x-ray film, radioactivity
counters,
scintillation counters, spectrophotometers, colorimeters, tluorometers,
luminometers,
and densitometers.
44
CA 3011730 2018-07-18
[00169] Any of the methods for detection can be performed in any
format that
allows for any suitable preparation, processing, and analysis of the
reactions. This can
be, for example, in multi-well assay plates (e.g., 96 wells or 386 wells) or
using any
suitable array or micromay. Stock solutions for various agents can be made
manually
or robotically, and all subsequent pipetting, diluting, mixing, distribution,
washing,
incubating, sample readout, data collection and analysis can be done
robotically using
commercially available analysis software, robotics, and detection
instrumentation
capable of detecting a detectable label.
Determination of Biomarker Values using Gene Expression Profiling
[00170] Measuring mRNA in a biological sample may be used as a
surrogate
for detection of the level of the corresponding protein in the biological
sample. Thus,
any of the biomarkers or biomarker panels described herein can also be
detected by
detecting the appropriate RNA.
[00171] mRNA expression levels are measured by reverse transcription
quantitative polymerase chain reaction (RT-PCR followed with qPCR). RT-PCR is
used to create a cDNA from the mRNA. The cDNA may be used in a qPCR assay to
produce fluorescence as the DNA amplification process progresses. By
comparison
to a standard curve, qPCR can produce an absolute measurement such as number
of
copies of mRNA per cell. Northern blots, mieroarrays, Invader assays, and RT-
PCR
combined with capillary electrophoresis have all been used to measure
expression
levels of mRNA in a sample. See Gene Expression Profiling: Methods and
Protocols,
Richard A. Shimkets, editor, Humana Press, 2004.
[00172] miRNA molecules are small RNAs that are non-coding but may
regulate gene expression. Any of the methods suited to the measurement of mRNA
expression levels can also be used for the corresponding miRNA. Recently many
laboratories have investigated the use of miRNAs as biomarkers for disease.
Many
diseases involve wide-spread transcriptional regulation, and it is not
surprising that
miRNAs might find a role as biomarkers. The connection between miRNA
concentrations and disease is often even less clear than the connections
between
protein levels and disease, yet the value of miRNA biomarkers might be
substantial.
Of course, as with any RNA expressed differentially during disease, the
problems
facing the development of an in vitro diagnostic product will include the
requirement
that the miRNAs survive in the diseased cell and are easily extracted for
analysis, or
CA 3011730 2018-07-18
that the miRNAs are released into blood or other matrices where they must
survive
long enough to be measured. Protein biomarkers have similar requirements,
although
many potential protein biomarkers are secreted intentionally at the site of
pathology
and function, during disease, in a paraciine fashion. Many potential protein
biomarkers are designed to function outside the cells within which those
proteins are
synthesized.
Detection of Biomarkers Using In Vivo Molecular Imaging Technologies
[00173] Any of the described biomarkers (see Table 1, Col. 2) may also
be
used in molecular imaging tests. For example, an imaging agent can be coupled
to
any of the described biomarkers, which can be used to aid in lung cancer
diagnosis, to
monitor disease progression/remission or metastasis, to monitor for disease
recurrence, or to monitor response to therapy, among other uses.
[00174] In vivo imaging technologies provide non-invasive methods for
determining the state of a particular disease in the body of an individual.
For
example, entire portions of the body, or even the entire body, may be viewed
as a
three dimensional image, thereby providing valuable information concerning
morphology and structures in the body. Such technologies may be combined with
the
detection of the biomarkers described herein to provide information concerning
the
cancer status, in particular the lung cancer status, of an individual.
[00175] The use of in vivo molecular imaging technologies is expanding
due to
various advances in technology. These advances include the development of new
contrast agents or labels, such as radiolabels and/or fluorescent labels,
which can
provide strong signals within the body; and the development of powerful new
imaging
technology, which can detect and analyze these signals from outside the body,
with
sufficient sensitivity and accuracy to provide useful information. The
contrast agent
can be visualized in an appropriate imaging system, thereby providing an image
of the
portion or portions of the body in which the contrast agent is located. The
contrast
agent may be bound to or associated with a capture reagent, such as an aptamer
or an
antibody, for example, and/or with a peptide or protein, or an oligonucleotide
(for
example, for the detection of gene expression), or a complex containing any of
these
with one or more macromolecules and/or other particulate forms.
[00176] The contrast agent may also feature a radioactive atom that is
useful in
imaging. Suitable radioactive atoms include technetium-99m or iodine-123 for
46
CA 3011730 2018-07-18
scintigraphic studies. Other readily detectable moieties include, for example,
spin
labels for magnetic resonance imaging (MRI) such as, for example, iodine-123
again,
iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17,
gadolinium,
manganese or iron. Such labels are well known in the art and could easily be
selected
by one of ordinary skill in the art.
[00177] Standard imaging techniques include but are not limited to
magnetic
resonance imaging, computed tomography scanning, positron emission tomography
(PET), single photon emission computed tomography (SPECT), and the like. For
diagnostic in vivo imaging, the type of detection instrument available is a
major factor
in selectin.g, a given contrast agent, such as a given radionuclide and the
particular
biomarker that it is used to target (protein, mRNA, and the like). The
radionuclide
chosen typically has a type of decay that is detectable by a given type of
instrument.
Also, when selecting a radionuclide for in vivo diagnosis, its half-life
should be long
enough to enable detection at the time of maximum uptake by the target tissue
but
short enough that deleterious radiation of the host is minimized.
[00178] Exemplary imaging techniques include but are not limited to
PET and
SPECT, which are imaging techniques in which a radionuclide is synthetically
or
locally administered to an individual. The subsequent uptake of the
radiotracer is
measured over time and used to obtain information about the targeted tissue
and the
biomarker. Because of the high-energy (gamma-ray) emissions of the specific
isotopes employed and the sensitivity and sophistication of the instruments
used to
detect them, the two-dimensional distribution of radioactivity may be inferred
from
outside of the body.
[00179] Commonly used positron-emitting nuclides in PET include, for
example, carbon-11, nitrogen-13, oxygen-15, and fluorine-18. Isotopes that
decay by
electron capture and/or gamma-emission are used in SPECT and include, for
example
iodine-123 and technetium-99m. An exemplary method for labeling amino acids
with
technetium-99m is the reduction of pertechnetate ion in the presence of a
chelating
precursor to form the labile technetium-99m-precursor complex, which, in turn,
reacts
with the metal binding group of a bifunctionally modified chemotactic peptide
to form
a technetium-99m-chemotactic peptide conjugate.
[00180] Antibodies are frequently used for such in vivo imaging
diagnostic
methods. The preparation and use of antibodies for in vivo diagnosis is well
known in
the art. Labeled antibodies which specifically bind any of the biomarkers in
Table 1,
47
CA 3011730 2018-07-18
Col. 2 can be injected into an individual suspected of having a certain type
of cancer
(e.g., lung cancer), detectable according to the particular biomarker used,
for the
purpose of diagnosing or evaluating the disease status of the individual. The
label
used will be selected in accordance with the imaging modality to be used, as
previously described. Localization of the label permits determination of the
spread of
the cancer. The amount of label within an organ or tissue also allows
determination
of the presence or absence of cancer in that organ or tissue.
[00181] Similarly, aptamers may be used for such in vivo imaging
diagnostic
methods. For example, an aptamer that was used to identify a particular
biomarker
described in Table 1, Col. 2 (and therefore binds specifically to that
particular
biomarker) may be appropriately labeled and injected into an individual
suspected of
having lung cancer, detectable according to the particular biomarker, for the
purpose
of diagnosing or evaluating the lung cancer status of the individual. The
label used
will be selected in accordance with the imaging modality to be used, as
previously
described. Localization of the label permits determination of the spread of
the cancer.
The amount of label within an organ or tissue also allows determination of the
presence or absence of cancer in that organ or tissue. Aptamer-directed
imaging
agents could have unique and advantageous characteristics relating to tissue
penetration, tissue distribution, kinetics, elimination, potency, and
selectivity as
compared to other imaging agents.
[00182] Such techniques may also optionally be performed with labeled
oligonucleotides, for example, for detection of gene expression through
imaging with
antisense oligonucleotides. These methods are used for in situ hybridization,
for
example, with fluorescent molecules or radionuclides as the label. Other
methods for
detection of gene expression include, for example, detection of the activity
of a
reporter gene.
[00183] Another general type of imaging technology is optical imaging,
in
which fluorescent signals within the subject are detected by an optical device
that is
external to the subject. These signals may be due to actual fluorescence
and/or to
bioluminescence. Improvements in the sensitivity of optical detection devices
have
increased the usefulness of optical imaging for in vivo diagnostic assays.
[00184] The use of in vivo molecular biomarker imaging is increasing,
including for clinical trials, for example, to more rapidly measure clinical
efficacy in
trials for new cancer therapies and/or to avoid prolonged treatment with a
placebo for
48
CA 3011730 2018-07-18
those diseases, such as multiple sclerosis, in which such prolonged treatment
may be
considered to be ethically questionable.
[00185] For a review of other techniques, see N. Blow, Nature Methods,
6,
465-469, 2009.
Determination of Biomarker Values using Histology/Cytology Methods
[00186] For evaluation of lung cancer, a variety of tissue samples may
be used
in histological or cytological methods. Sample selection depends on the
primary
tumor location and sites of metastases. For example, endo- and trans-bronchial
biopsies, fine needle aspirates, cutting needles, and core biopsies can be
used for
histology. Bronchial washing and brushing, pleural aspiration, and sputum, can
be
used for cyotology. While cytological analysis is still used in the diagnosis
of lung
cancer, histological methods are known to provide better sensitivity for the
detection
of cancer. Any of the biomarkers identified herein that were shown to be up-
regulated (see Table 37) in the individuals with lung cancer can be used to
stain a
histological specimen as an indication of disease.
[00187] In one embodiment, one or more capture reagent/s specific to
the
corresponding biomarker/s are used in a cytological evaluation of a lung cell
sample
and may include one or more of the following: collecting a cell sample, fixing
the cell
sample, dehydrating, clearing, immobilizing the cell sample on a microscope
slide,
permeabilizing the cell sample, treating for analyte retrieval, staining,
destaining,
washing, blocking, and reacting with one or more capture reagent/s in a
buffered
solution. In another embodiment, the cell sample is produced from a cell
block.
[00188] In another embodiment, one or more capture reagent/s specific
to the
corresponding biomarkers are used in a histological evaluation of a lung
tissue sample
and may include one or more of the following: collecting a tissue specimen,
fixing the
tissue sample, dehydrating, clearing, immobilizing the tissue sample on a
microscope
slide, permeabilizine the tissue sample, treating for analyte retrieval,
staining,
destaining, washing, blocking, rehydrating, and reacting with capture
reagent/s in a
buffered solution. In another embodiment, fixing and dehydrating are replaced
with
freezing.
[00189] In another embodiment, the one or more aptamer/s specific to
the
corresponding biomarker/s are reacted with the histological or cytological
sample and
can serve as the nucleic acid target in a nucleic acid amplification method.
Suitable
49
CA 3011730 2018-07-18
nucleic acid amplification methods include, for example, PCR, q-beta
replicase,
rolling circle amplification, strand displacement, helicase dependent
amplification,
loop mediated isothermal amplification, ligase chain reaction, and restriction
and
circularization aided rolling circle amplification.
[00190] In one embodiment, the one or more capture reagent/s specific
to the
corresponding biomarkers for use in the histological or cytological evaluation
are
mixed in a buffered solution that can include any of the following: blocking
materials,
competitors, detergents, stabilizers, carrier nucleic acid, polyanionic
materials, etc. -
[00191] A "cytology protocol" generally includes sample collection,
sample
fixation, sample immobilization, and staining. "Cell preparation" can include
several
processing steps after sample collection, including the use of one or more
slow off-
rate aptamers for the staining of the prepared cells.
[00192] Sample collection can include directly placing the sample in
an
untreated transport container, placing the sample in a transport container
containing
some type of media, or placing the sample directly onto a slide
(immobilization)
without any treatment or fixation.
[00193] Sample immobilization can be improved by applying a portion of
the
collected specimen to a ems slide that is treated with polylysine, gelatin, or
a silane.
Slides can be prepared by smearing a thin and even layer of cells across the
slide.
Care is generally taken to minimize mechanical distortion and drying
artifacts. Liquid
specimens can be processed in a cell block method. Or, alternatively, liquid
specimens can be mixed 1:1 with the fixative solution for about 10 minutes at
room
temperature.
[00194] Cell blocks can be prepared from residual effusions, sputum,
urine
sediments, gastrointestinal fluids, cell scraping, or fine needle aspirates.
Cells are
concentrated or packed by centrifugation or membrane filtration. A number of
methods for cell block preparation have been developed. Representative
procedures
include the fixed sediment, bacterial agar, or membrane filtration methods. In
the
fixed sediment method, the cell sediment is mixed with a fixative like Bouins,
picric
acid, or buffered formalin and then the mixture is centrifuged to pellet the
fixed cells.
The supernatant is removed, drying the cell pellet as completely as possible.
The
pellet is collected and wrapped in lens paper and then placed in a tissue
cassette. The
tissue cassette is placed in a jar with additional fixative and processed as a
tissue
sample. Agar method is very similar but the pellet is removed and dried on
paper
CA 3011730 2018-07-18
towel and then cut in half. The cut side is placed in a drop of melted agar on
a glass
slide and then the pellet is covered with agar making sure that no bubbles
form in the
agar. The agar is allowed to harden and then any excess agar is trimmed away.
This
is placed in a tissue cassette and the tissue process completed.
Alternatively, the
pellet may be directly suspended in 2% liquid agar at 65 C and the sample
centrifuged. The agar cell pellet is allowed to solidify for an hour at 4 C.
The solid
agar may be removed from the centrifuge tube and sliced in half. The agar is
wrapped
in filter paper and then the tissue cassette. Processing from this point
forward is as
described above. Centrifugation can be replaced in any these procedures with
membrane filtration. Any of these processes may be used to generate a "cell
block
sample".
[00195] Cell blocks can be prepared using specialized resin including
Lowicryl
resins, LR White, LR Gold, Unicryl, and MonoStep. These resins have low
viscosity
and can be polymerized at low temperatures and with ultra violet (UV) light.
The
embedding process relies on progressively cooling the sample during
dehydration,
transferring the sample to the resin, and polymerizing a block at the final
low
temperature at the appropriate UV wavelength.
[00196] Cell block sections can be stained with hematoxylin-eosin for
cytomorphological examination while additional sections are used for
examination for
specific markers.
[00197] Whether the process is cytologoical or histological, the
sample may be
fixed prior to additional processing to prevent sample degradation. This
process is
called "fixation" and describes a wide range of materials and procedures that
may be
used interchangeably. The sample fixation protocol and reagents are best
selected
empirically based on the targets to be detected and the specific cell/tissue
type to be
analyzed. Sample fixation relies on reagents such as ethanol, polyethylene
glycol,
methanol, formalin, or isopropanol. The samples should be fixed as soon after
collection and affixation to the slide as possible. However, the fixative
selected can
introduce structural changes into various molecular targets making their
subsequent
detection more difficult. The fixation and immobilization processes and their
sequence can modify the appearance of the cell and these changes must be
anticipated
and recognized by the cytotechnologist. Fixatives can cause shrinkage of
certain cell
types and cause the cytoplasm to appear granular or reticular. Many fixatives
51
CA 3011730 2018-07-18
function by crosslinlcing cellular components. This can damage or modify
specific
epitopes, generate new epitopes, cause molecular associations, and reduce
membrane
permeability. Formalin fixation is one of the most common
cytological/histological
approaches. Fon-nalin forms methyl bridges between neighboring proteins or
within
proteins. Precipitation or coagulation is also used for fixation and ethanol
is
frequently used in this type of fixation. A combination of crosslinking and
precipitation can also be used for fixation. A strong fixation process is best
at
preserving morphological information while a weaker fixation process is best
for the
preservation of molecular targets.
[00198] A representative fixative is 50% absolute ethanol, 2 mM
polyethylene
glycol (PEG), 1.85% formaldehyde. Variations on this formulation include
ethanol
(50% to 95%), methanol (20% - 50%), and formalin (fon-naldehyde) only. Another
common fixative is 2% PEG 1500, 50% ethanol, and 3% methanol. Slides are place
in the fixative for about 10 to 15 minutes at room temperature and then
removed and
allowed to dry. Once slides are fixed they can be rinsed with a buffered
solution like
PBS.
[00199] A wide range of dyes can be used to differentially highlight
and
contrast or "stain" cellular, sub-cellular, and tissue features or
morphological
structures. Hematoylin is used to stain nuclei a blue or black color. Orange G-
6 and
Eosin Azure both stain the cell's cytoplasm. Orange G stains keratin and
glycogen
containing cells yellow. Eosin Y is used to stain nucleoli, cilia, red blood
cells, and
superficial epithelial squamous cells. Romanowsky stains are used for air
dried slides
and are useful in enhancing pleomorphism and distinguishing extracellular from
intracytoplasmic material.
[00200] The staining process can include a treatment to increase the
permeability of the cells to the stain. Treatment of the cells with a
detergent can be
used to increase permeability. To increase cell and tissue permeability, fixed
samples
can be further treated with solvents, saponins, or non-ionic detergents.
Enzymatic
digestion can also improve the accessibility of specific targets in a tissue
sample.
[00201] After staining, the sample is dehydrated using a succession
of alcohol
rinses with increasing alcohol concentration. The final wash is done with
xylene or a
xylene substitute, such as a citrus terpene, that has a refractive index close
to that of
the coverslip to be applied to the slide. This final step is referred to as
clearing. Once
the sample is dehydrated and cleared, a mounting medium is applied. The
mounting
52
CA 3011730 2018-07-18
medium is selected to have a refractive index close to the glass and is
capable of
bonding the coverslip to the slide. It will also inhibit the additional
drying, shrinking,
or fading of the cell sample.
[00202] Regardless of the stains or processing used, the final
evaluation of the
lung cytological specimen is made by some type of microscopy to permit a
visual
inspection of the morphology and a determination of the marker's presence or
absence. Exemplary microscopic methods include brightfield, phase contract,
fluorescence, and differential interference contrast.
[00203] If secondary tests are required on the sample after
examination, the
coverslip may be removed and the slide destained. Destaining involves using
the
original solvent systems used in staining the slide originally without the
added dye
and in a reverse order to the original staining procedure. Destaining may also
be
completed by soaking the slide in an acid alcohol until the cells are
colorless. Once
colorless the slides are rinsed well in a water bath and the second staining
procedure
applied.
[00204] In addition, specific molecular differentiation may be
possible in
conjunction with the cellular morphological analysis through the use of
specific
molecular reagents such as antibodies or nucleic acid probes or aptamers. This
improves the accuracy of diagnostic cytology. Micro-dissection can be used to
isolate
a subset of cells for additional evaluation, in particular, for genetic
evaluation of
abnormal chromosomes, gene expression, or mutations.
[002051 Preparation of a tissue sample for histological evaluation
involves
fixation, dehydration, infiltration, embedding, and sectioning. The fixation
reagents
used in histology are very similar or identical to those used in cytology and
have the
same issues of preserving morphological features at the expense of molecular
ones
such as individual proteins. Time can be saved if the tissue sample is not
fixed and
dehydrated but instead is frozen and then sectioned while frozen. This is a
more
gentle processing procedure and can preserve more individual markers. However,
freezing is not acceptable for long term storage of a tissue sample as
subcellular
information is lost due to the introduction of ice crystals. Ice in the frozen
tissue
sample also prevents the sectioning process from producing a very thin slice
and thus
some microscopic resolution and imaging of subcellular structures can be lost.
In
addition to formalin fixation, osmium tetroxide is used to fix and stain
phospholipids
(membranes).
53
CA 3011730 2018-07-18
[00206] Dehydration of tissues is accomplished with successive washes
of
increasing alcohol concentration. Clearing employs a material that is miscible
with
alcohol and the embedding material and involves a stepwise process starting at
50:50
alcohol:dealing reagent and then 100% clearing agent (xylene or xylene
substitute).
Infiltration involves incubating the tissue with a liquid form of the
embedding agent
(warm wax, nitrocellulose solution) first at 50:50 embedding agent: clearing
agent and
the 100% embedding_ agent. Embedding is completed by placing the tissue in a
mold
or cassette and filling with melted embedding agent such as wax, agar, or
gelatin. The
embedding agent is allowed to harden. The hardened tissue sample may then be
sliced into thin section for staining and subsequent examination.
[00207] Prior to staining, the tissue section is dewaxed and
rehydrated. Xylene
is used to dewax the section, one or more changes of xylene may be used, and
the
tissue is rehydrated by successive washes in alcohol of decreasing
concentration.
Prior to dewax, the tissue section may be heat immobilized to a glass slide at
about
80 C for about 20 minutes.
[00208] Laser capture micro-dissection allows the isolation of a
subset of cells
for further analysis from a tissue section.
[00209] As in cytology, to enhance the visualization of the
microscopic
features, the tissue section or slice can be stained with a variety of stains.
A large
menu of commercially available stains can be used to enhance or identify
specific
features.
[00210] To further increase the interaction of molecular reagents
with
cytological/histological samples, a number of techniques for "analyte
retrieval" have
been developed. The first such technique uses high temperature heating of a
fixed
sample. This method is also referred to as heat-induced epitope retrieval or
HIER. A
variety of heating techniques have been used, including steam heating,
microwaving,
autoclaving, water baths, and pressure cooking or a combination of these
methods of
heating. Analyte retrieval solutions include, for example, water, citrate, and
normal
saline buffers. The key to analyte retrieval is the time at high temperature
but lower
temperatures for longer times have also been successfully used. Another key to
analyte retrieval is the pH of the heating solution. Low pH has been found to
provide
the best immunostaining but also gives rise to backgrounds that frequently
require the
use of a second tissue section as a negative control. The most consistent
benefit
54
CA 3011730 2018-07-18
(increased immunostaining without increase in background) is generally
obtained
with a high pH solution regardless of the buffer composition. The analyte
retrieval
process for a specific target is empirically optimized for the target using
heat, time,
pH, and buffer composition as variables for process optimization. Using the
microwave analyte retrieval method allows for sequential staining of different
targets
with antibody reagents. But the time required to achieve antibody and enzyme
complexes between staining steps has also been shown to degrade cell membrane
analytes. Microwave heating methods have improved in situ hybridization
methods
as well.
[00211] To initiate the analyte retrieval process, the section is
first dewaxed
and hydrated. The slide is then placed in 10mM sodium citrate buffer pH 6.0 in
a dish
or jar. A representative procedure uses an 1100W microwave and microwaves the
slide at 100% power for 2 minutes followed by microwaving the slides using 20%
power for 18 minutes after checking to be sure the slide remains covered in
liquid.
The slide is then allowed to cool in the uncovered container and then rinsed
with
distilled water. HIER may be used in combination with an enzymatic digestion
to
improve the reactivity of the target to immunochemical reagents.
[00212] One such enzymatic digestion protocol uses proteinase K. A
20pg/m1
concentration of proteinase K is prepared in 50 mM Tris Base, 1mM EDTA, 0.5%
Triton X-100, pH 8.0 buffer. The process first involves dewaxing sections in 2
changes of xylene, 5 minutes each. Then the sample is hydrated in 2 changes of
100% ethanol for 3 minutes each, 95% and 80% ethanol for 1 minute each, and
then
rinsed in distilled water. Sections are covered with Proteinase K working
solution and
incubate 10-20 minutes at 37 C in humidified chamber (optimal incubation time
may
vary depending on tissue type and degree of fixation). The sections are cooled
at
room temperature for 10 minutes and then rinsed in PBS Tween 20 for 2x2 min.
If
desired, sections can be blocked to eliminate potential interference from
endogenous
compounds and enzymes. The section is then incubated with primary antibody at
appropriate dilution in primary antibody dilution buffer for 1 hour at room
temperature or overnight at 4 C. The section is then rinsed with PBS Tween 20
for
2x2 min. Additional blocking can be performed, if required for the specific
application, followed by additional rinsing with PBS Tween 20 for 3x2 min and
then
finally the immunostaining protocol completed.
CA 3011730 2018-07-18
[00213] A simple treatment with 1% SDS at room temperature has also
been
demonstrated to improve immunohistochemical staining. Analyte retrieval
methods
have been applied to slide mounted sections as well as free floating sections.
Another
treatment option is to place the slide in ajar containing citric acid and 0.1
Nonident
P40 at pH 6.0 and heating to 95 C. The slide is then washed with a buffer
solution
like PBS.
[00214] For immunological staining of tissues it may be useful to
block non ¨
specific association of the antibody with tissue proteins by soaking the
section in a
protein solution like serum or non-fat dry milk.
[00215] Blocking reactions may include the need to reduce the level
of
endogenous biotin; eliminate endogenous charge effects; inactivate endogenous
nucleases; and/ or inactivate endogenous enzymes like peroxidase and alkaline
phosphatase. Endogenous nucleases may be inactivated by degradation with
proteinase K, by heat treatment, use of a chelating agent such as EDTA or
EGTA, the
introduction of carrier DNA or RNA, treatment with a chaotrope such as urea,
thiourea, guanidine hydrochloride, guanidine thiocyanate, lithium perchlorate,
etc, or
diethyl pyrocarbonate. Alkaline phosphatase may be inactivated by treated with
0.1N
HC1 for 5 minutes at room temperature or treatment with 1 mM levamisole.
Peroxidase activity may be eliminated by treatment with 0.03% hydrogen
peroxide.
Endogenous biotin may be blocked by soaking the slide or section in an avidin
(streptavidin, neutravidin may be substituted) solution for at least 15
minutes at room
temperature. The slide or section is then washed for at least 10 minutes in
buffer.
This may be repeated at least three times. Then the slide or section is soaked
in a
biotin solution for 10 minutes. This may be repeated at least three times with
a fresh
biotin solution each time. The buffer wash procedure is repeated. Blocking
protocols
should be minimized to prevent damaging either the cell or tissue structure or
the
target or targets of interest but one or more of these protocols could be
combined to
"block" a slide or section prior to reaction with one or more slow off-rate
aptamers.
See Basic Medical Histology: the Biology of Cells, Tissues and Organs,
authored by
Richard G. Kessel, Oxford University Press, 1998.
56
CA 3011730 2018-07-18
=
Determination of Biomarker Values using Mass Spectrometry Methods
[00216] A variety of configurations of mass spectrometers can be used
to detect
biomarker values. Several types of mass spectrometers are available or can be
produced with various configurations. In general, a mass spectrometer has the
following major components: a sample inlet, an ion source, a mass analyzer, a
detector, a vacuum system, and instrument-control system, and a data system.
Difference in the sample inlet, ion source, and mass analyzer generally define
the type
of instrument and its capabilities. For example, an inlet can be a capillary-
column
liquid chromatography source or can be a direct probe or stage such as used in
matrix-
assisted laser desorption. Common ion sources are, for example, electrospray,
including nanospray and microspray or matrix-assisted laser desorption. Common
mass analyzers include a quadrupole mass filter, ion trap mass analyzer and
time-of-
flight mass analyzer. Additional mass spectrometry methods are well known in
the
art (see Burlingame et al. Anal. Chem. 70:647 R-716R (1998); Kinter and
Sherman,
New York (2000)).
[00217] Protein biomarkers and biomarker values can be detected and
measured by any of the following: electrospray ionization mass spectrometry
(ESI-
MS), ESI-MS/MS, ESI-MS/(MS)n, matrix-assisted laser desorption ionization time-
of-flight mass spectrometry (MALDI-TOF-MS), surface-enhanced laser
desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS),
desorption/ionization on silicon (DIOS), secondary ion mass spectrometry
(SIMS),
quadrupole time-of-flight (Q-TOF), tandem time-of-flight (TOF/TOF) technology,
called ultraflex 111 TOF/TOF, atmospheric pressure chemical ionization mass
spectrometry (APCI-MS), APCI-MS/MS, APCI-(MS)N, atmospheric pressure
photoionization mass spectrometry (APPI-MS), APPI-MS/MS, and APPI-(MS)N,
quadrupole mass spectrometry, Fourier transform mass spectrometry (FTMS),
quantitative mass spectrometry, and ion trap mass spectrometry.
[00218] Sample preparation strategies are used to label and enrich
samples
before mass spectroscopic characterization of protein biomarkers and
determination
biomarker values. Labeling methods include but are not limited to isobaric tag
for
relative and absolute quantitation (iTRAQ) and stable isotope labeling with
amino
acids in cell culture (SILAC). Capture reagents used to selectively enrich
samples for
candidate biomarker proteins prior to mass spectroscopic analysis include but
are not
limited to aptamers, antibodies, nucleic acid probes, chimeras, small
molecules, an
57
CA 3011730 2018-07-18
F(ab')., fragment, a single chain antibody fragment, an Fv fragment, a single
chain Fv
fragment, a nucleic acid, a lectin, a lieand-binding receptor, affybodies,
nanobodies,
ankyrins, domain antibodies, alternative antibody scaffolds (e.g. diabodies
etc)
imprinted polymers. avimers, peptidomimetics, peptoids, peptide nucleic acids,
threose nucleic acid, a hormone receptor, a cytokine receptor, and synthetic
receptors,
and modifications and fragments of these.
[00219] The foregoing assays enable the detection of biomarker values
that are
useful in methods for diagnosing lung cancer, where the methods comprise
detecting,
in a biological sample from an individual, at least N biomarker values that
each
correspond to a biomarker selected from the group consisting of the biomarkers
provided in Table 1. Col. 2, wherein a classification, as described in detail
below,
using the biomarker values indicates whether the individual has lung cancer.
While
certain of the described lung cancer biomarkers are useful alone for detecting
and
diagnosing lung cancer, methods are also described herein for the grouping of
multiple subsets of the lung cancer biomarkers that are each useful as a panel
of three
or more biomarkers. Thus, various embodiments of the instant application
provide
combinations comprising N biomarkers, wherein N is at least three biomarkers.
In
other embodiments, N is selected to be any number from 2-61 biomarkers. It
will be
appreciated that N can be selected to be any number from any of the above
described
ranges, as well as similar, but higher order, ranges. In accordance with any
of the
methods described herein, biomarker values can be detected and classified
individually or they can be detected and classified collectively, as for
example in a
multiplex assay format.
[00220] In another aspect, methods are provided for detecting an
absence of
lung cancer, the methods comprising detecting, in a biological sample from an
individual, at least N biomarker values that each correspond to a biomarker
selected
from the group consisting of the biomarkers provided in Table 1, Col. 2,
wherein a
classification, as described in detail below, of the biomarker values
indicates an
absence of lung cancer in the individual. While certain of the described lung
cancer
biomarkers are useful alone for detecting and diagnosing the absence of lung
cancer,
methods are also described herein for the grouping of multiple subsets of the
lung
cancer biomarkers that are each useful as a panel of three or more biomarkers.
Thus,
various embodiments of the instant application provide combinations comprising
N
biomarkers, wherein N is at least three biomarkers. In other embodiments, N is
58
CA 3011730 2018-07-18
selected to be any number from 2-61 biomarkers. It will be appreciated that N
can be
selected to be any number from any of the above described ranges, as well as
similar,
but higher order, ranges. In accordance with any of the methods described
herein,
biomarker values can be detected and classified individually or they can be
detected
and classified collectively, as for example in a multiplex assay format.
Classification of Biomarkers and Calculation of Disease Scores
[00221] A biomarker "signature" for a given diagnostic test contains
a set of
markers, each marker having different levels in the populations of interest.
Different
levels, in this context, may refer to different means of the marker levels for
the
individuals in two or more groups, or different variances in the two or more
groups, or
a combination of both. For the simplest form of a diagnostic test, these
markers can
be used to assign an unknown sample from an individual into one of two groups,
either diseased or not diseased. The assignment of a sample into one of two or
more
groups is known as classification, and the procedure used to accomplish this
assignment is known as a classifier or a classification method. Classification
methods
may also be referred to as scoring methods. There are many classification
methods
that can be used to construct a diagnostic classifier from a set of biomarker
values. In
general, classification methods are most easily performed using supervised
learning
techniques where a data set is collected using samples obtained from
individuals
within two (or more, for multiple classification states) distinct groups one
wishes to
distinguish. Since the class (group or population) to which each sample
belongs is
known in advance for each sample, the classification method can be trained to
give
the desired classification response. It is also possible to use unsupervised
learning
techniques to produce a diagnostic classifier.
[00222] Common approaches for developing diagnostic classifiers
include
decision trees; bagging + boosting + forests; rule inference based learning;
Parzen
Windows; linear models; logistic; neural network methods; unsupervised
clustering;
K-means; hierarchical ascending/ descending; semi-supervised learning;
prototype
methods; nearest neighbor; kernel density estimation; support vector machines;
hidden Markov models; Boltzmann Learning; and classifiers may be combined
either
simply or in ways which minimize particular objective functions. For a review,
see,
e.g., Pattern Classification, R.O. Duda, et al., editors, John Wiley & Sons,
2nd edition,
2001; see also, The Elements of Statistical Learning - Data Mining, Inference,
and
59
CA 3011730 2018-07-18
Prediction, T. Mastic., et al., editors, Springer Science+Business Media, LLC,
2nd
edition, 2009.
[00223] To produce a classifier using supervised learning
techniques, a set of
samples called training data are obtained. In the context of diagnostic tests,
training
data includes samples from the distinct groups (classes) to which unknown
samples
will later be assigned. For example, samples collected from individuals in a
control
population and individuals in a particular disease population can constitute
training
data to develop a classifier that can classify unknown samples (or, more
particularly,
the individuals from whom the samples were obtained) as either having the
disease or
being free from the disease. The development of the classifier from the
training data
is known as training the classifier. Specific details on classifier training
depend on
the nature of the supervised learning technique. For purposes of illustration,
an
example of training a naive Bayesian classifier will be described below (see,
e.g.,
Pattern Classification, R.O. Duda, et al., editors, John Wiley & Sons, 2nd
edition,
2001; see also, The Elements of Statistical Learning - Data Mining, Inference,
and
Prediction, T. Hastie, et al., editors, Springer Science+Business Media, LLC,
2nd
edition, 2009).
[00224] Since typically there are many more potential biomarker
values than
samples in a training set, care must be used to avoid over-fitting. Over-
fitting occurs
when a statistical model describes random error or noise instead of the
underlying
relationship. Over-fitting can be avoided in a variety of way, including, for
example,
by limiting the number of markers used in developing the classifier, by
assuming that
the marker responses are independent of one another, by limiting the
complexity of
the underlying statistical model employed, and by ensuring that the underlying
statistical model conforms to the data.
[00225] An illustrative example of the development of a diagnostic
test using a
set of biomarkers includes the application of a naïve Bayes classifier, a
simple
probabilistic classifier based on Bayes theorem with strict independent
treatment of
the biomarkers. Each biornarker is described by a class-dependent probability
density
function (pdf) for the measured RFU values or log RFU (relative fluorescence
units)
values in each class. The joint pdfs for the set of markers in one class is
assumed to
be the product of the individual class-dependent pdfs for each biomarker.
Training a
naive Bayes classifier in this context amounts to assigning parameters
("parameterization") to characterize the class dependent pdfs. Any underlying
model
CA 3011730 2018-07-18
for the class-dependent pdfs may be used, but the model should generally
conform to
the data observed in the training set.
[00226] Specifically, the class-dependent probability of measuring a
value x;
for biomarker i in the disease class is written as p(x, I d) and the overall
naïve Bayes
probability of observing n markers with values x = (x, õr. ,...xn) is written
as
p(x I d) = f[ p(x I d) where the individual x; s are the measured biomarker
levels in
RFU or log RFU. The classification assignment for an unknown is facilitated by
calculating the probability of being diseased p(d I x) having measured x
compared
to the probability of being disease free (control) p(c I x) for the same
measured
values. The ratio of these probabilities is computed from the class-dependent
pdfs by
p(c I x) p(x I c)(1¨ P(d))
application of Bayes theorem, i.e., __ _ _
where P(d) is the
p(d I x) p(x I d)P(d)
prevalence of the disease in the population appropriate to the test. 'I'aking
the
logarithm of both sides of this ratio and substituting the naive Bayes class-
dependent
p(c I x) n (I
m ¨ P(d)) . This form
probabilities from above gives In __ = p(x c in
p(d I x) j1 ptx,I el ) P(d)
is known as the log likelihood ratio and simply states that the log likelihood
of being
free of the particular disease versus having the disease and is primarily
composed of
the sum of individual log likelihood ratios of the 12 individual biomarkers.
In its
simplest form, an unknown sample (or, more particularly, the individual from
whom
the sample was obtained) is classified as being free of the disease if the
above ratio is
greater than zero and having the disease if the ratio is less than zero.
[00227] In one exemplary embodiment, the class-dependent biomarker
pdfs
Mx; I c) and p(x, I d) are assumed to be normal or log-normal distributions in
the
24,
measured RFU values x1, i.e. p(x,. I c)= 1 e with a
similar expression
for p(x, I d) with pd., and o . Parameterization of the model requires
estimation of
two parameters for each class-dependent pdf, a mean la and a variance G2, from
the
training data. This may be accomplished in a number of ways, including, for
61
CA 3011730 2018-07-18
example, by maximum likelihood estimates, by least-squares, and by any other
methods known to one skilled in the art. Substitutine the normal distributions
for
N2
p(x, I c) and p(x. I d) into the log-likelihood ratio defined above gives the
following
p(r1 x) 1 " ¨P.
+ln (1¨ _______________________________________________________
expression: In _____ - ¨ Eln
p(d I ô 2 ,, (To j Pfd)
Once a set of [is and 02s have been defined for each pdf in each class from
the
training data and the disease prevalence in the population is specified, the
Bayes
classifier is fully determined and may be used to classify unknown samples
with
measured values x.
[00228] The performance of the naive Bayes classifier is dependent
upon the
number and quality of the biomarkers used to construct and train the
classifier. A
single biomarker will perform in accordance with its KS-distance (Kolmogorov-
Smirnov), as defined in Example 3, below. If a classifier performance metric
is
defined as the sum of the sensitivity (fraction of true positives, f,) and
specificity
(one minus the fraction of false positives, 1¨ fõ), a perfect classifier will
have a
score of two and a random classifier, on average, will have a score of one.
Using the
definition of the KS-distance, that value x* which maximizes the difference in
the cdf
afa a(c114(x)¨relf,,(x))
functions can be found by solving = 0 for x
which leads
ax ax
to p(x* I (:)= p(X' 1 d), Le, the KS distance occurs where the class-dependent
pdfs
cross. Substituting this value of x* into the expression for the KS-distance
yields the
following definition for KS
KS = cdfc(x* )¨ cdf,(x* )= p(x I c)dx¨ p(x I d)clx =1¨ f p(x I c)dx ¨ f p(x I
d)dx =1_ ¨ fõ FN
, the KS distance is one minus the total fraction of errors using a test with
a cut-off at
x*, essentially a single analyte Bayesian classifier. Since we define a score
of
sensitivily + specificity = 2¨ fFp ¨f, , combining the above definition of
the KS-
distance we see that sensitivity+ specificity =1+ KS. We select biomarkers
with a
statistic that is inherently suited for building naïve Bayes classifiers.
[00229] The addition of subsequent markers with good KS distances
(>0.3, for
example) will, in general, improve the classification performance if the
subsequently
added markers are independent of the first marker. Using the sensitivity plus
62
CA 3011730 2018-07-18
specificity as a classifier score, it is straightforward to generate many high
scoring
classifiers with a variation of a greedy algorithm. (A greedy algorithm is any
algorithm that follows the problem solving metaheuristic of making the locally
optimal choice at each stage with the hope of finding the global optimum.)
[00230] The algorithm approach used here is described in detail in
Example 4.
Briefly, all single analyte classifiers are generated from a table of
potential
biomarkers and added to a list. Next, all possible additions of a second
analyte to
each of the stored single analyte classifiers is then performed, saving a
predetermined
number of the best scoring pairs, say, for example, a thousand, on a new list.
All
possible three marker classifiers are explored using this new list of the best
two-
marker classifiers, again saving the best thousand of these. This process
continues
until the score either plateaus or begins to deteriorate as additional markers
are added.
Those high scoring classifiers that remain after convergence can be evaluated
for the
desired performance for an intended use. For example, in one diagnostic
application,
classifiers with a high sensitivity and modest specificity may be more
desirable than
modest sensitivity and high specificity. In another diagnostic application,
classifiers
with a high specificity and a modest sensitivity may be more desirable. The
desired
level of performance is generally selected based upon a trade-off that must be
made
between the number of false positives and false negatives that can each be
tolerated
for the particular diagnostic application. Such trade-offs generally depend on
the
medical consequences of an error, either false positive or false negative.
[002311 Various other techniques are known in the art and may be
employed to
generate many potential classifiers from a list of biomarkers using a naïve
Bayes
classifier. In one embodiment, what is referred to as a genetic algorithm can
be used
to combine different markers using the fitness score as defined above. Genetic
algorithms are particularly well suited to exploring a large diverse
population of
potential classifiers. In another embodiment, so-called ant colony
optimization can be
used to generate sets of classifiers. Other strategies that are known in the
art can also
be employed, including, for example, other evolutionary strategies as well as
simulated annealing and other stochastic search methods. Metaheuristic
methods,
such as, for example, harmony search may also be employed.
[00232] Exemplary embodiments use any number of the lung cancer
biomarkers listed in Table 1, Col. 2 in various combinations to produce
diagnostic
tests for detecting lung cancer (see Example 2 for a detailed description of
how these
63
CA 3011730 2018-07-18
biomarkers were identified). In one embodiment, a method for diagnosing lung
cancer uses a naïve Bayes classification method in conjunction with any number
of
the lung cancer biomarkers listed in Table 1, Col. 2. In an illustrative
example
(Example 3), the simplest test for detecting lung cancer from a population of
asymptomatic smokers can be constructed using a single biomarker, for example,
SCFsR which is down-regulated in lung cancer with a KS-distance of 0.37
(1+ KS =1.37 ). Using the parameters , acd, pd., and ad., for SCFsR from
Table
41 and the equation for the log-likelihood described above, a diagnostic test
with a
sensitivity of 63% and specificity of 73% ( sensitivity + specificity =1.36)
can he
produced, see Table 40. The ROC curve for this test is displayed in Figure 2
and has
an AUC of 0.75.
[00233] Addition of biomarker I-ISP90a, for example. with a KS-
distance of
0.5, significantly improves the classifier performance to a sensitivity of 76%
and
specificity of 0.75% (sensitivity + specificity =1.51) and an AUC = 0.84. Note
that
the score for a classifier constructed of two biomarkers is not a simple sum
of the KS-
distances; KS-distances are not additive when combining biomarkers and it
takes
many more weak markers to achieve the same level of performance as a strong
marker. Adding a third marker, ERBB1, for example, boosts the classifier
performance to 78% sensitivity and 83% specificity and AUC = 0.87. Adding
additional biomarkers, such as, for example, PTN, BTK, CD30, Kallikrcin 7,
LR1G3,
LDI-I-1-11, and PARC, produces a series of lung cancer tests summarized in
Table 40
and displayed as a series of ROC curves in Figure 3. The score of the
classifiers as a
function of the number of analytes used in classifier construction is
displayed in
Figure 4. The sensitivity and specificity of this exemplary ten-marker
classifier is
>87% and the AUC is 0.91.
[00234] The markers listed in Table 1, Col. 2 can be combined in many
ways to
produce classifiers for diagnosing lung cancer. In some embodiments, panels of
biomarkers are comprised of different numbers of analytes depending on a
specific
diagnostic performance criterion that is selected. For example, certain
combinations
of biomarkers will produce tests that are more sensitive (or more specific)
than other
combinations.
[00235] Once a panel is defined to include a particular set of
biomarkers from
Table 1. Col. 2 and a classifier is constructed from a set of training data,
the definition
64
CA 3011730 2018-07-18
of the diagnostic test is complete. In one embodiment, the procedure used to
classify
an unknown sample is outlined in Figure 1A. In another embodiment the
procedure
used to classify an unknown sample is outlined in Figure 113. The biological
sample
is appropriately diluted and then run in one or more assays to produce the
relevant
quantitative biomarker levels used for classification. The measured biomarker
levels
are used as input for the classification method that outputs a classification
and an
optional score for the sample that reflects the confidence of the class
assignment.
[00236] Table 1 identifies 61 biomarkers that are useful for
diagnosing lung
cancer. This is a surprisingly larger number than expected when compared to
what is
typically found during biomarker discovery efforts and may be attributable to
the
scale of the described study, which encompassed over 800 proteins measured in
hundreds of individual samples, in some cases at concentrations in the low
femtomolar range. Presumably, the large number of discovered biomarkers
reflects
the diverse biochemical pathways implicated in both tumor biology and the
body's
response to the tumor's presence; each pathway and process involves many
proteins.
The results show that no single protein of a small group of proteins is
uniquely
informative about such complex processes; rather, that multiple proteins are
involved
in relevant processes, such as apoptosis or extracellular Matrix repair, for
example.
[00237] Given the numerous biomarkers identified during the described
study,
one would expect to be able to derive large numbers of high-performing
classifiers
that can be used in various diagnostic methods. To test this notion, tens of
thousands
of classifiers were evaluated using the biomarkers in Table 1. As described in
Example 4, many subsets of the biomarkers presented in Table I can be combined
to
generate useful classifiers. By way of example, descriptions are provided for
classifiers containing 1, 2, and 3 biomarkers for each of two uses: lung
cancer
screening of smokers at high risk and diagnosis of individuals that have
pulmonary
nodules that are detectable by CT. As described in Example 4, all classifiers
that
were built using the biomarkers in Table 1 perform distinctly better than
classifiers
that were built usina "non-markers".
[00238] The performance of classifiers obtained by randomly excluding
some
of the markers in Table 1, which resulted in smaller subsets from which to
build the
classifiers, was also tested. As described in Example 4, Part 3, the
classifiers that
were built from random subsets of the markers in Table 1 performed similarly
to
optimal classifiers that were built using the full list of markers in Table I.
CA 3011730 2018-07-18
[00239] The performance of ten-marker classifiers obtained by
excluding the
"best" individual markers from the ten-marker aggregation was also tested. As
described in Example 4, Part 3, classifiers constructed without the "best"
markers in
Table I also performed well. Many subsets of the biomarkers listed in Table I
performed close to optimally, even after removing the top 15 of the markers
listed in
the Table. This implies that the performance characteristics of any particular
classifier are likely not due to some small core group of biomarkers and that
the
disease process likely impacts numerous biochemical pathways, which alters the
expression level of many proteins.
[00240] The results from Example 4 suggest certain possible
conclusions:
First, the identification of a large number of biomarkers enables their
aggregation into
a vast number of classifiers that offer similarly high performance. Second,
classifiers
can be constructed such that particular biomarkers may be substituted for
other
biomarkers in a manner that reflects the redundancies that, undoubtedly
pervade the
complexities of the underlying disease processes. That is to say, the
information
about the disease contributed by any individual biomarker identified in Table
1
overlaps with the information contributed by other biomarkers, such that it
may be
that no particular biomarker or small group of biomarkers in Table I must be
included
in any classifier.
[00241] Exemplary embodiments use naïve Baycs classifiers constructed
from
thc data in Tables 38 and 39 to classify an unknown sample. The procedure is
outlined in Figures lA and B. In one embodiment, the biological sample is
optionally
diluted and run in a multiplexed aptamer assay. The data from the assay are
normalized and calibrated as outlined in Example 3, and the resulting
biomarker
levels are used as input to a Bayes classification scheme. The log-likelihood
ratio is
computed for each measured biomarker individually and then summed to produce a
final classification score, which is also referred to as a diagnostic score.
The resulting
assignment as well as the overall classification score can be reported.
Optionally, the
individual log-likelihood risk factors computed for each biomarkcr level can
be
reported as well. The details of the classification score calculation are
presented in
Example 3.
66
CA 3011730 2018-07-18
Kits
[00242] Any combination of the biomarkers of Table 1, Col. 2 (as well
as
additional biomedical information) can be detected using a suitable kit, such
as for use
in performing the methods disclosed herein. Furthermore, any kit can contain
one or
more detectable labels as described herein, such as a fluorescent moiety, etc.
[00243] In one embodiment, a kit includes (a) one or more capture
reagents
(such as, for example, at least one aptamer or antibody) for detecting one or
more
biomarkers in a biological sample, wherein the biomarkers include any of the
biomarkers set forth in Table 1, Col. 2, and optionally (b) one or more
software or
computer program products for classifying the individual from whom the
biological
sample was obtained as either having or not having lung cancer or for
determining the
likelihood that the individual has lung cancer, as further described herein.
Alternatively, rather than one or more computer program products, one or more
instructions for manually performing the above steps by a human can be
provided.
[00244] The combination of a solid support with a corresponding
capture
reagent and a signal generating material is referred to herein as a "detection
device" or
"kit". The kit can also include instructions for using the devices and
reagents,
handling the sample, and analyzing the data. Further the kit may be used with
a
computer system or software to analyze and report the result of the analysis
of the
biological sample.
[00245] The kits can also contain one or more reagents (e.g.,
solubilization
buffers, detergents, washes, or buffers) for processing a biological sample.
Any of the
kits described herein can also include, e.g., buffers, blocking agents, mass
spectrometry matrix materials, antibody capture agents, positive control
samples,
negative control samples, software and information such as protocols, guidance
and
reference data.
[00246] In one aspect, the invention provides kits for the analysis
of lung
cancer status. The kits include PCR primers for one or more biomarkers
selected
from Table 1, Col. 2. The kit may further include instructions for usc and
correlation
of the biomarkers with lung cancer. The kit may also include a DNA array
containing
the complement of one or more of the biomarkers selected from Table 1, Col. 2,
reagents, and/or enzymes for amplifying or isolating sample DNA. The kits may
include reagents for real-time PCR, for example. TagMan probes and/or primers,
and
enzymes.
67
CA 3011730 2018-07-18
[00247] For example, a kit can comprise (a) reagents comprising at
least
capture reagent for quantifying one or more biomarkers in a test sample,
wherein said
biomarkers comprise the biomarkers set forth in 'fable 1, Col. 2, or any other
biomarkers or biomarkers panels described herein, and optionally (b) one or
more
algorithms or computer programs for performing the steps of comparing the
amount
of each biomarker quantified in the test sample to one or more predetermined
cutoffs
and assigning a score for each biomarker quantified based on said comparison,
combining the assigned scores for each biomarker quantified to obtain a total
score,
comparing the total score with a predetermined score, and using said
comparison to
determine whether an individual has lung cancer. Alternatively, rather than
one or
more algorithms or computer programs, one or more instructions for manually
performing the above steps by a human can be provided.
Computer Methods and Software
[00248] Once a biomarker or biomarker panel is selected, a method for
diagnosing an individual can comprise the following: 1) collect or otherwise
obtain a
biological sample; 2) perform an analytical method to detect and measure the
biomarker or biomarkers in the panel in the biological sample; 3) perform any
data
normalization or standardization required for the mcthod used to collect
biomarkcr
values; 4) calculate the marker score; 5) combine the marker scores to obtain
a total
diagnostic score; and 6) report the individual's diagnostic score. In this
approach, the
diagnostic score may be a single number determined from the sum of all the
marker
calculations that is compared to a pre ¨ set threshold value that is an
indication of the.
presence or absence of disease. Or the diagnostic score may be a series of
bars that
each represent a biomarker value and the pattern of the responses may be
compared to
a pre-set pattern for determination of the presence or absence of disease.
[00249] At least some embodiments of the methods described herein can
be
implemented with the usc of a computer. An example of a computer system 100 is
shown in Figure 6. With reference to Figure 6, system 100 is shown comprised
of
hardware elements that arc electrically coupled via bus 108, including a
processor
101, input device 102, output device 103, storage device 104, computer-
readable
storage media reader 105a, communications system 106 processing acceleration
(e.g.,
DSP or special-purpose processors) 107 and memory 109. Computer-readable
storage media reader 105a is further coupled to computer-readable storage
media
68
CA 3011730 2018-07-18
105b, the combination comprehensively representing remote, local, fixed and/or
removable storage devices plus storage media, memory, etc. for temporarily
and/or
more permanently containing computer-readable information, which can include
storage device 104, memory 109 and/or any other such accessible system 100
resource. System 100 also comprises software elements (shown as being
currently
located within working memory 191) including an operating system 192 and other
code 193, such as programs, data and the like.
[00250] With respect to Figure 6, system 100 has extensive flexibility
and
configurability. Thus, for example, a single architecture might be utilized to
implement one or more servers that can be further configured in accordance
with
currently desirable protocols, protocol variations, extensions, etc. However,
it will be
apparent to those skilled in the art that embodiments may well be utilized in
accordance with more specific application requirements. For example, one or
more
system elements might be implemented as sub-elements within a system 100
component (e.g., within communications system 106). Customized hardware might
also he utilized and/or particular elements might be implemented in hardware,
software or both. Further, while connection to other computing devices such as
network input/output devices (not shown) may be employed, it is to be
understood
that wired, wireless, modem, and/or other connection or connections to other
computing devices might also be utilized.
[00251] In one aspect, the system can comprise a database containing
features
of biomarkers characteristic of lung cancer. The biomarker data (or biomarker
information) can be utilized as an input to the computer for use as part of a
computer
implemented method. The biomarker data can include the data as described
herein.
[00252] In one aspect, the system further comprises one or more
devices for
providing input data to the one or more processors.
[00253] The system further comprises a memory for storing a data set
of ranked
data elements.
[00254] In another aspect, the device for providing input data
comprises a
detector for detecting the characteristic of the data clement, e.g., such as a
mass
spectrometer or gene chip reader.
[00255] The system additionally may comprise a database management
system.
User requests or queries can be formatted in an appropriate language
understood by
69
CA 3011730 2018-07-18
the database management system that processes the query to extract the
relevant
information from the database of training, sets.
100256] "[he system may be connectable to a network to which a
network
server and one or more clients are connected. The network may be a local area
network (LAN) or a wide area network (WAN), as is known in the art.
Preferably, the
server includes the hardware necessary for running computer program products
(e.g.,
software) to access database data for processing user requests.
[00257] The system may include an operating system (e.g., UNIX or
Linux) for
executing instructions from a database management system. In one aspect, the
operating system can operate on a global communications network, such as the
Internet, and utilize a global communications network server to connect to
such a
network.
[00258] The system may include one or more devices that comprise a
graphical
display interface comprising interface elements such as buttons, pull down
menus,
scroll bars, fields for entering text, and the like as are routinely found in
graphical
user interfaces known in the an. Requests entered on a user interface can be
transmitted to an application program in the system for formatting to search
for
relevant information in one or more of the system databases. Requests or
queries
entered by a user may be constructed in any suitable databasc language.
[00259] The graphical user interface may be generated by a graphical
user
interface code as part of the operating system and can be used to input data
and/or to
display inputted data. The result of processed data can be displayed in the
interface,
printed on a printer in communication with the system, saved in a memory
device,
and/or transmitted over the network or can be provided in the form of the
computer
readable medium.
[00260] The system can be in communication with an input device for
providing data regarding data elements to the system (e.g., expression
values). In one
aspect, the input device can include a gene expression profiling system
including, e.g.,
a mass spectrometer, Ilene chip or array reader, and the like.
[00261] The methods and apparatus for analyzing lung cancer biomarkcr
information according to various embodiments may be implemented in any
suitable
manner, for example. using a computer program operating on a computer system.
A
conventional computer system comprising a processor and a random access
memory.
such as a remotely-accessible application server, network server, personal
computer
CA 3011730 2018-07-18
or workstation may he used. Additional computer system components may include
memory devices or information storage systems, such as a mass storage system
and a
user interface, for example a conventional monitor, keyboard and tracking
device.
The computer system may be a stand-alone system or part of a network of
computers
including a server and one or more databases.
[00262] The lung cancer biomarker analysis system can provide
functions and
operations to complete data analysis, such as data gathering, processing,
analysis,
reporting and/or diagnosis. For example, in one embodiment, the computer
system
can execute the computer program that may receive, store, search, analyze, and
report
information relating to the lung cancer biomarkers. The computer program may
comprise multiple modules performing various functions or operations, such as
a
processing module for processing raw data and generating supplemental data and
an
analysis module for analyzing raw data and supplemental data to generate a
lung
cancer status and/or diagnosis. Diagnosing lung cancer status may comprise
generating or collecting any other information, including additional
biomedical
information, regarding the condition of the individual relative to the
disease,
identifying whether further tests may be desirable, or otherwise evaluating
the health
status of the individual.
[00263] Referring now to Figure 7, an example of a method of utilizing
a
computer in accordance with principles of a disclosed embodiment can be seen.
In
Figure 7, a flowchart 3000 is shown. In block 3004, biomarker information can
be
retrieved for an individual. The biomarker information can be retrieved from a
computer database, for example, after testing of the individual's biological
sample is
performed. The biomarker information can comprise biomarker values that each
correspond to one of at least N biomarkers selected from a group consisting of
the
biomarkers provided in Table 1, Col. 2, wherein N = 2-61. In block 3008, a
computer
can be utilized to classify each of the biomarker values. And, in block 3012,
a
determination can bc made as to the likelihood that an individual has lung
cancer
based upon a plurality of classifications. The indication can be output to a
display or
other indicating device so that it is viewable by a person. Thus, for example,
it can be
displayed on a display screen of a computer or other output device.
[00264] Referring now to Figure 8, an alternative method of utilizing
a
computer in accordance with another embodiment can be illustrated via
flowchart
3200. In block 3204. a computer can be utilized to retrieve biomarker
information for
71
CA 3011730 2018-07-18
an individual. The biomarker information comprises a biomarker value
corresponding to a biomarker selected from the group of biomarkers provided in
Table 1, Col. 2. In block 3208, a classification of the biomarker value can be
performed with the computer. And, in block 3212, an indication can be made as
to
the likelihood that the individual has lung cancer based upon the
classification. The
indication can be output to a display or other indicating device so that it is
viewable
by a person. Thus, for example, it can be displayed on a display screen of a
computer
or other output device.
[00265] Some embodiments described herein can be implemented so as to
include a computer program product. A computer program product may include a
computer readable medium having computer readable program code embodied in the
medium for causing an application program to execute on a computer with a
database,
[00266] As used herein, a "computer program product" refers to an
organized
set of instructions in the form of natural or programming language statements
that are
contained on a physical media of any nature (e.g., written, electronic,
magnetic,
optical or otherwise) and that may he used with a computer or other automated
data
processing system. Such programming language statements, when executed by a
computer or data processing system, cause the computer or data processing
system to
act in accordance with the particular content of the statements. Computer
program
products include without limitation: programs in source and object code and/or
test or
data libraries embedded in a computer readable medium. Furthermore, the
computer
program product that enables a computer system or data processing equipment
device
to act in pre-selected ways may be provided in a number of forms, including,
but not
limited to, original source code, assembly code, object code, machine
language,
encrypted or compressed versions of the foregoing and any and all equivalents.
[00267] In one aspect, a computer program product is provided for
indicating a
likelihood of lung cancer. The computer program product includes a computer
readable medium embodying program code executable by a processor of a
computing
device or system, the program code comprising: code that retrieves data
attributed to
a biological sample from an individual, wherein the data comprises biomarker
values
that each correspond to one of at least N biomarkers in the biological sample
selected
from the group of biomarkers provided in Table 1, Col. 2; wherein N = 2-61 and
code
that executes a classification method that indicates a lung disease status of
the
individual as a function of the biomarker values.
72
CA 3011730 2018-07-18
[00268] In still another aspect, a computer program product is
provided for
indicating a likelihood of lung cancer. The computer program product includes
a
computer readable medium embodying program code executable by a processor of a
computing device or system, the program code comprising: code that retrieves
data
attributed to a biological sample from an individual, wherein the data
comprises a
biomarker value corresponding to a biomarker in the biological sample selected
from
the group of hiomarkers provided in Table I, Col. 2; and code that executes a
classification method that indicates a lung disease status of the individual
as a
function of the biomarker value.
[00269] While various embodiments have been described as methods or
apparatuses, it should be understood that embodiments can be implemented
through
code coupled with a computer, e.g., code resident on a computer Or accessible
by the
computer. For example, software and databases could be utilized to implement
many
of the methods discussed above. Thus, in addition to embodiments accomplished
by
hardware, it is also noted that these embodiments can be accomplished through
the
use of an article of manufacture comprised of a computer usable medium having
a
computer readable program code embodied therein, which causes the enablement
of
the functions disclosed in this description. Therefore, it is desired that
embodiments
also be considered protected by this patent in their program code means as
well.
Furthermore, the embodiments may be embodied as code stored in a computer-
readable memory of virtually any kind including, without limitation, RAM, ROM,
magnetic media, optical media, or magneto-optical media. Even more generally,
the
embodiments could be implemented in software, or in hardware, or any
combination
thereof including, but not limited to, software running on a general purpose
processor,
microcode. PLAs, or ASICs.
[00270] It is also envisioned that embodiments could be accomplished
as
computer signals embodied in a carrier wave, as well as signals (e.g.,
electrical and
optical) propagated through a transmission medium. Thus, the various types of
information discussed above could be formatted in a structure. such as a data
structure, and transmitted as an electrical signal through a transmission
medium or
stored on a computer readable medium.
[00271] It is also noted that many of the structures, materials, and
acts recited
herein can he recited as means for performing a function or step for
performing a
function. Therefore, it should be understood that such language is entitled to
cover all
73
CA 3011730 2018-07-18
such structures, materials, or acts disclosed within this specification and
their
equivalents.
EXAMPLES
[00272] The following examples are provided for illustrative
purposes only and
are not intended to limit the scope of the application as defined by the
appended
claims. All examples described herein were carried out using standard
techniques,
which are well known and routine to those of skill in the art. Routine
molecular
biology techniques described in the following examples can be carried out as
described in standard laboratory manuals, such as Sambrook at al., Molecular
Cloning: A Laboratory Manual, 3rd. ed., Cold Spring Harbor Laboratory Press,
Cold
Spring Harbor, N.Y., (2001).
Example L Multiplexell Aptamer A milysis of Samples For laingganeer
Iliornarker
Selection
[00273] This example describes the multiplex aptamer assay used to
analyze
the samples and controls for the identification of the biomarkers set forth in
Table 1,
Col. 2 (see Figure 9). In this case, the multiplexed analysis utilized 825
aptarners,
each unique to a specific target.
[00274] In this method, pipette tips were changed for each solution
addition.
[00278] Also, unless otherwise indicated, most solution transfers
and wash
additions used the 96-well head of a Beckman Biomek FxP. Method steps manually
pipetted used a twelve channel P200 Pipetteman (Rainin Instruments, LLC,
Oakland,
CA), unless otherwise indicated. A custom buffer referred to as SB17 was
prepared
in-house, comprising 40mM HEPES, 100mM NaCl, 5mM KC1, 5mM MgC12, 1mM
ED'I'A at pH7.5. All steps were performed at room temperature unless otherwise
indicated.
[00276] 1. Preparation of Aptamer Stock Solution
[00277] For aptamers without a photo-cleavable biotin linker,
custom stock
aptamer solutions for 10%, 1% and 0.03% scrum were prepared at 8x
concentration in
lx SB17, 0.05% Tween-20 with appropriate photo-cleavable, biotinylated
primers,
where the resultant primer concentration was 3 times the relevant aptamer
concentration. The primers hybridized to all or part of the corresponding
aptamer.
74
CA 3011730 2018-07-18
[00278] Each of the 3, 8x aptamer solutions were diluted separately
1:4 into
1xSB17, 0.05% Tween-20 (1500 pL of 8x stock into 4500 pL of 1xSB17, 0.05%
1'ween-20) to achieve a 2x concentration. Each diluted aptamer master mix was
then
split, 1500 pl., each, into 4, 2 mL screw cap tubes and brought to 95 C for 5
minutes,
followed by a 37 C incubation for 15 minutes. After incubation, the 4, 2 mL
tubes
corresponding to a particular aptamer master mix were combined into a reagent
trough, and 55 pL of a 2x aptamer mix (for all three mixes) was manually
pipetted
into a 96-well Hybaicl plate and the plate foil sealed. The final result was
3, 96-well,
foil-sealed Hybaid plates. The individual aptamer concentration ranged from
0.5-4
nM as indicated in Table 28.
[00279] 2. Assay Sample Preparation
[00280] Frozen aliquots of 100% serum, stored at -80 C, were placed
in 25 C.
water bath for 10 minutes. Thawed samples were placed on ice, gently vortexed
(set
on 4) for 8 seconds and then replaced on ice.
[00281] A 20% sample solution was prepared by transferring 16 p L of
sample
using a 50 p.L 8-channel spanning pipettor into 96-well llybaid plates, each
well
containing 64 pL of the appropriate sample diluent at 4 C (0.8x SB17, 0.05%
Tween-
20, 2 pM Z-block_2, 0.6 mM MgCl2 for serum). This plate was stored on ice
until the
next sample dilution steps were initiated.
[00282] To commence sample and aptamer equilibration, the 20% sample
plate
was briefly centrifuged and placed on the Beckman FX where it was mixed by
pipetting up and down with the 96-well pipettor. A 2% sample was then prepared
by
diluting 10 p.L of the 20% sample into 90 pL Of 1xS1317, 0.05% Tween-20. Next,
dilution of 6 pL of the resultant 2% sample into 194 pL of 1xSB17, 0.05% Tween-
20
made a 0.06% sample plate. Dilutions were done on the Beckman Biomek FxP.
After
each transfer, the solutions were mixed by pipetting up and down. The 3 sample
dilution plates were then transferred to their respective aptamer solutions by
adding
55 pL of the sample to 55 pL of the appropriate 2x aptamer mix. The sample and
aptamer solutions were mixed on the robot by pipetting up and down.
[00283] 3. Sample Equilibration binding
[00284] - The sample/aptamer plates were foil sealed and placed into a
37 C
incubator for 3.5 hours before proceeding to the Catch I step.
[00285] 4. Preparation of Catch 2 bead plate
CA 3011730 2018-07-18
[00286] An 11 mL aliquot of MyOne (Invitrog,,en Corp., Carlsbad, CA)
Streptavidin Cl beads was washed 2 times with equal volumes of 20 mM NaOH (5
minute incubation for each wash). 3 times with equal volumes of lx SB17, 0.05%
Twcen-20 and resuspended in 11 mL lx SB17, 0.05% Tween-20. Using a 12-span
multichannel pipettor, 501AL of this solution was manually pipetted into each
well of
a 96-well Hybaid plate. The plate was then covered with foil and stored at 4 C
for
use in the assay.
[00287] 5. Preparation of Catch 1 bead plates
[00288] Three 0.45 pm Millipore FIV plates (llurapore membrane, Cat#
MAHVN4550) were equilibrated with 100 1AL of lx SB17, 0.05% Tween-20 for at
least 10 minutes. The equilibration buffer was then filtered through the plate
and
133.3 !IL of a 7.5% Streptavidin-agarose bead slurry (in lx SB17, 0.05% Tween-
20)
was added into each well. To keep the streptavidin-agarose beads suspended
while
transferring them into the filter plate, the bead solution was manually mixed
with a
200 !IL, 12-channel pipettor, 15 times. After the beads were distributed
across the 3
filter plates, a vacuum was applied to remove the bead supernatant. Finally,
the heads
were washed in the filter plates with 200pL lx SB17, 0.05% Twecn-20 and then
resuspended in 200 iL lx SB17, 0.05% Tween-20. The bottoms of the filter
plates
were blotted and the plates stored for use in the assay.
[00289] 6. Loading the Cytomat
[00290] The cytomat was loaded with all tips, plates, all reagents in
troughs
(except NHS-biotin reagent which was prepared fresh right before addition to
the
plates), 3 prepared catch 1 filter plates and 1 prepared MyOne plate.
[00291] 7. Catch 1
[00292] After a 3.5 minute equilibration time, the sample/aptamer
plates were
removed from the incubator, centrifuged for about I minute, foil removed, and
placed
on the deck of the Beckman Biomek FxP. The Beckman Biomek FxP program was
initiated. All subsequent steps in Catch 1 were performed by the Beckman
Biomck
FxP robot unless otherwise noted. Within the program, the vacuum was applied
to the
Catch 1 filter plates to remove the bead supernatant. One hundred microlitrcs
of each
of the 10%, 1% and 0.03% equilibration binding reactions were added to their
respective Catch 1 filtration plates, and each plate was mixed using an on-
deck orbital
shaker at 800 rpm for 10 minutes.
76
CA 3011730 2018-07-18
[00293] Unbound solution was removed via vacuum filtration. The catch
1
beads were washed with 190 ML of 100 ?AM biotin in lx SB17, 0.05% Tween-20
followed by 190 1.t1_, of lx SB17, 0.05% Tween-20 by dispensing the solution
and
immediately drawing a vacuum to filter the solution through the plate.
[00294] Next, 190 !IL lx SB17, 0.05% Tween-20 was added to the Catch 1
plates. Plates were blotted to remove droplets using an on-deck blot station
and then
incubated with orbital shakers at 800 rpm for 10 minutes at 25 C.
[00295] The robot removed this wash via vacuum filtration and blotted
the
bottom of the filter plate to remove droplets using the on-deck blot station.
[00296] 8. Tagging
[00297] A NHS-PE04-biotin aliquot was thawed at 37 C for 6 minutes and
then diluted 1:100 with tagging buffer (S1317 at p1-1=-7.25 0.05% Tween-20).
The
NHS-PE04-biotin reagent was dissolved at 100 mM concentration in anhydrous
DMS0 and had been stored frozen at -20 C. Upon a robot prompt, the diluted NHS-
PE04-biotin reagent was manually added to an on-deck trough and the robot
program
was manually re-initiated to dispense 100 of the NHS-
PE04-biotin into each well
of each Catch 1 filter plate. This solution was allowed to incubate with Catch
1 beads
shaking at 800 rpm for 5 minutes on the obital shakers.
[00298] 9. Kinetic Challenge and Photo-cleavage
[00299] The tagging reaction was quenched by the addition of 150 p.L
of 20
mM glycinc in lx SB17, 0.05% Tween-20 to the Catch 1 plates while still
containing
the NHS tag. 'The plates were then incubated for 1 minute on orbital shakers
at 800
rpm. The NIS-tag/glycine solution was removed via vacuum filtration. Next, 190
RI, 20 mM glycine SB17, 0.05% Tween-20) was added to each plate and
incubated for 1 minute on orbital shakers at 800 rpm before removal by vacuum
filtration.
[00300] 190 L of lx SB17, 0.05% Tween-20 was added to each plate and
removed by vacuum filtration.
[00301] The wells of the Catch 1 plates were subsequently washed three
times
by adding 1904 lx SB17, 0.05% Tween-20, placing the plates on orbital shakers
for
1 minute at 800 rpm followed by vacuum filtration. After the last wash the
plates
were placed on top of a 1 mL deep-well plate and removed from the deck. The
Catch
1 plates were centrifuged at 1000 rpm for 1 minute to remove as much
extraneous
volume from the agarose beads before elution as possible.
77
CA 3011730 2018-07-18
[00302] The plates were placed back onto the Beckman Biomek FxP and 85
pi,
of 10 mM DxS0.4 in lx SB17, 0.05% Tween-20 was added to each well of the
filter
plates.
[00303] The filter plates were removed from the deck, placed onto a
Variomag
Thermoshaker (Thermo Fisher Scientific, Inc., Waltham, MA ) under the BlackRay
(Ted Pella, Inc., Redding, CA) light sources, and irradiated for 10 minutes
while
shaking at 800 rpm.
[00304] The photocleaved solutions were sequentially eluted from each
Catch 1
plate into a common deep well plate by first placing the 10% Catch 1 filter
plate on
top of a 1 mL deep-well plate and centrifuging at 1000 rpm for 1 minute. The
1% and
0.03% catch 1 plates were then sequentially centrifuged into the same deep
well plate.
[00305] 10. Catch 2 bead capture
[00306] The 1 mL deep well block containing the combined eluates of
catch 1
was placed on the deck of the Beckman Biomek FxP for catch 2.
[00307] The robot transferred all of the photo-cleaved eluate from the
1 mL
deep-well plate onto the Flybaid plate containing the previously prepared
catch 2
MyOne magnetic beads (after removal of the MyOne buffer via magnetic
separation).
[00308] The solution was incubated while shaking at 1350 rpm for 5
minutes at
25 C on a Variomag Thermoshaker (Thermo Fisher Scientific, Inc., Waltham, MA).
[00309] The robot transferred the plate to the on deck magnetic
separator
station. The plate was incubated on the magnet for 90 seconds before removal
and
discarding of the supernatant.
[00310] 11. 37 C 30% glycerol washes
[00311] The catch 2 plate was moved to the on-deck thermal shaker and
75 jut
of lx SB17, 0.05% Tween-20 was transferred to each well. The plate was mixed
for
1 minute at 1350 rpm and 37 C to resuspend and warm the heads. To each well of
the
catch 2 plate, 75 pL of 60% glycerol at 37 C was transferred and the plate
continued
to mix for another minute at 1350 rpm and 37 C. The robot transferred the
plate to
the 37 C magnetic separator where it was incubated on the magnet for 2 minutes
and
then the robot removed and discarded the supernatant. These washes were
repeated
two more times.
[00312] After removal of the third 30% glycerol wash from the catch 2
beads,
150 ML of lx SB17, 0.05% Tween-20 was added to each well and incubated at 37
C,
78
CA 3011730 2018-07-18
shaking at 1350 rpm for 1 minute, before removal by magnetic separation on the
37 C
magnet.
[00313] The catch 2 beads were washed a final time using 150 pl. lx
SI319,
0.05% Tween-20 with incubation for 1 minute while shaking at 1350 rpm, prior
to
magnetic separation.
[00314] 12. Catch 2 Bead Elution and Neutralization
[00315] The aptamers were eluted from catch 2 beads by adding 105 pL
of 100
mM CAPSO with 1 M NaC1, 0.05% Tween-20 to each well. The beads were
incubated with this solution with shaking at 1300 rpm for 5 minutes.
[00316] The catch 2 plate was then placed onto the magnetic separator
for 90
seconds prior to transferring 90 pL of the cluate to a new 96-well plate
containing 10
pL of 500 mM [-ICI, 500 mM HEMS, 0.05% Tween-20 in each well. After transfer,
the solution was mixed robotieally by pipetting 90 pl.. up and down five
times.
[00317] 13. Hybridization
[00318] The Beckman Biomek FxP transferred 20 pL of the neutralized
catch 2
eluate to a fresh Hybaid plate, and 5 I, of 10x Agilent Block, containing a
10x spike
of hybridization controls, was added to each well. Next, 25 pL of 2x Agilent
HYbridization buffer was manually pipetted to the each well of the plate
containing the
neutralized samples and blocking buffer and the solution was mixed by manually
pipctting 25 pi. up and down 15 times slowly to avoid extensive bubble
formation.
The plate was spun at 1000 rpm for I minute.
[00319] A gasket slide was placed into an Agilent hybridization
chamber and
40 HI, of each of the samples containing hybridization and blocking solution
was
manually pipetted into each gasket. An 8-channel variable spanning pipettor
was
used in a manner intended to minimize bubble formation. Custom Agilent
microarray
slides (Agilent Technologies, Inc., Santa Clara, CA), with their Number
Barcode
facing up, were then slowly lowered onto the gasket slides (see Agilent manual
for
detailed description).
[00320] The top of the hybridization chambers were placed onto the
slide/backing sandwich and clamping brackets slid over the whole assembly.
These
assemblies were tightly clamped by turning the screws securely.
[00321] Each slide/backing slide sandwich was visually inspected to
assure the
solution bubble could move freely within the sample. If the bubble did not
move
79
CA 3011730 2018-07-18
freely the hybridization chamber assembly was gently tapped to disengage
bubbles
lodged near the gasket.
[00322] The assembled hybridization chambers were incubated in an
Agilent
hybridization oven for 19 hours at 60 C rotating at 20 rpm.
[00323] 14. Post Hybridization Washing
[00324] Approximately 400 mL Agilent Wash Buffer 1 was placed into
each of
two separate glass staining dishes. One of the staining dishes was placed on a
magnetic stir plate and a slide rack and stir bar were placed into the buffer.
[00325] A staining dish for Agilent Wash 2 was prepared by placing a
stir bar
into an empty glass staining dish.
[00326] A fourth glass staining dish was set aside for the final
acctonitrile
wash.
[00327] Each of six hybridization chambers was disassembled. One-by-
one,
the slide/backing sandwich was removed from its hybridization chamber and
submerged into the staining dish containing Wash 1. The slide/backing sandwich
was
pried apart using a pair of tweezers, while still submerging the microarray
slide. The
slide was quickly transferred into the slide rack in the Wash 1 staining dish
on the
magnetic stir plate.
[00328] The slide rack was gently raised and lowered 5 times. The
magnetic
stirrer was turned on at a low setting and the slides incubated for 5 minutes.
[00329] When one minute was remaining for Wash 1, Wash Buffer 2 pre-
warmed to 37 C in an incubator was added to the second prepared staining dish.
The
slide rack was quickly transferred to Wash Buffer 2 and any excess buffer on
the
bottom of the rack was removed by scraping it on the top of the stain dish.
The slide
rack was gently raised and lowered 5 times. The magnetic stirrer was turned on
at a
low setting and the slides incubated for 5 minutes.
[00330] The slide rack was slowly pulled out of Wash 2, taking
approximately
15 seconds to remove the slides from the solution.
[00331] With one minute remaining in Wash 2 acctonitrilc (CAN) was
added to
the fourth staining dish. The slide rack was transferred to the acctonitrile
stain dish.
The slide rack was gently raised and lowered 5 times. The magnetic stirrer was
turned on at a low setting and the slides incubated for 5 minutes.
CA 3011730 2018-07-18
[00332] The slide rack was slowly pulled out of the ACN stain dish and
placed
on an absorbent towel. The bottom edges of the slides were quickly dried and
the
slide was placed into a clean slide box.
[00333] 15. Microarray imaging
[00334] The microarray slides were placed into Agilent scanner slide
holders
and loaded into the Agilent Microarray scanner according to the manufacturer's
instructions.
[00335] The slides were imaged in the Cy3-channcl at 5 pm resolution
at
the100% PMT setting and the XRD option enabled at 0.05. The resulting tiff
images
were processed using Agilent feature extraction software version 10.5.
Example 2. Biomarker Identification
[00336] The identification of potential lung cancer biomarkers was
performed
for three different diagnostic applications, diagnosis of suspicious nodules
from a CT
scan, screening of asymptomatic smokers for lung cancer, and diagnosing an
individual with lung cancer. Serum samples were collected from four different
sites
in support of these three applications and include 247 NSCLC cases, 420 benign
nodule controls and 352 asymptomatic smoker controls. Table 29 summarizes the
site
sample information. The multiplexed aptamer affinity assay as described in
Example
1 was used to measure and report the RFU value for 825 analytcs in each of
these
1019 samples. Since the serum samples were obtained from four independent
studies
and sites under similar but different protocols, an examination of site
differences prior
to the analysis for biomarkers discovery was performed. Each of the three
populations, benign nodule, asymptomatic smokers, and NSCLC, were separately
compared between sites by generating within-site, class-dependent cumulative
distribution functions (cdfs) for each of the 825 analytes. The KS-test was
then
applied to each analyte between all site pairs within a common class to
identify those
analytes that differed not by class but rather by site. In all site
comparisons among
the three classes, statistically significant site-dependent differences were
observed.
The KS-distance (Kolmogorov-Smimov statistic) between values from two sets of
samples is a non parametric measurement of the extent to which the empirical
distribution of the values from one set (Set A) differs from the distribution
of values
from the other set (Set B). For any value of a threshold T some proportion of
the
values from Set A will be less than T, and some proportion of the values from
Set B
81
CA 3011730 2018-07-18
will be less than T. The KS-distance measures the maximum (unsigned)
difference
between the proportion of the values from the two sets for any choice of T.
[00337] Such site-dependent effects tend to obscure the ability to
identify
specific control-disease differences. In order to minimize such effects and
identify
key disease dependent biomarkers, three distinct strategies were employed for
biomarker discovery, namely (1) aggregated class-dependent cdfs across sites,
(2)
comparison of within-site class-dependent cdfs, and (3) blending methods (1)
with
(2). Details of these three methodologies and their results follow.
[00338] These three sets of potential biomarkers can be used to build
classifiers
that assign samples to either a control or disease group. In fact, many such
classifiers
were produced from these sets of biomarkers and the frequency with which any
biomarker was used in good scoring classifiers determined. Those biomarkers
that
occurred most frequently among the top scoring classifiers were the most
useful for
creating a diagnostic test. In this example, Bayesian classifiers were used to
explore
the classification space but many other supervised learning techniques may be
employed for this purpose. The scoring fitness of any individual classifier
was
gauged by summing the sensitivity and specificity of the classifier at the
Bayesian
surface assuming a disease prevalence of 0.5. This scoring metric varies from
zero to
two, with two being an error-free classifier. The details of constructing a
Bayesian
classifier from biomarker population measurements are described in Example 3.
[00339] By aggregating the class-dependent samples across all sites
in method
(1), those analyte measurements that showed large site-to-site variation, on
average,
failed to exhibit class-dependent differences due to the large site-to-site
differences.
Such analytes were automatically removed from further analysis. However, those
analytes that did show class-dependent differences across the sites will be
fairly
robust biomarkers that were relatively insensitive to sample collection and
sample
handling variability. KS-distances were computed for all analytes using the
class-
dependent cdfs aggregated across all sites. Using a KS-distance threshold of
0.3 led
to the identification of sixty five potential biomarkers for the benign nodule-
NSCLC
comparison and eighty three for the smoker-NSCLC comparison.
[00340] Using the sixty-five analytes exceeding the KS-distance
threshold, a
total of 282 10-analyte classifiers were found with a score of 1.7 or better
(>85%
sensitivity and >85% specificity, on average) for diagnosing NSCLC from a
control
group with benign nodules. From this set of classifiers, a total of nineteen
biomarkers
82
CA 3011730 2018-07-18
were found to be present in 10.0% or more of the high scoring classifiers.
Tab1e30
provides a list of these potential biomarkers and Figure 10 is a frequency
plot for the
identified biomarkers.
[00341] For the diagnosis of NSCLC from a group of asymptomatic
smokers, a
total of 1249 classifiers, each comprised of ten analytes, were found with a
score of
1.7 or better using the eighty three potential biomarkers identified above. A
total of
twenty one analytes appear in this set of classifiers 10.0% or more. Table 31
provides
a list of these biomarkers and Figure 11 is a frequency plot for the
identified
biomarkers. This completed the biomarker identification using method (1).
[00342] Method (2) focused on consistency of potential biomarker
changes
between the control and case groups (nodules and smokers with lung cancer)
among
the individual sites. 'I'he class-dependent cdfs were constructed for all
analytes within
each site separately and from these cdfs the KS-distances were computed to
identify
potential biomarkers. Here, an analyte must have a KS-distance greater than
some
threshold in all the sites to be considered a potential biomarker. For the
benign
nodule versus NSCLC comparisons, a threshold of 0.3 yielded eleven analytes
with
consistent differences between case and control among the sites. Lowering the
threshold to 0.275 for the KS-distance yielded nineteen analytes. Using these
nineteen analytes to build potential 10-analyte Bayesian classifiers, there
were 2897
classifiers that had a score of 1.6 or better. All nineteen analytes occurred
with a
frequency greater than 10% and are presented in Table 32 and Figure 12.
[00343] For the asymptomatic smoker group versus the NSCLC group, a
similar analysis yielded thirty-three analytes with KS-distances greater than
0.3
among all the sites. Building ten-analyte classifiers from this set of
potential
biomarkers yielded nineteen biomarkers with frequencies > 10.0% in 1249
classifiers
scoring 1.7 or higher. These analytes are displayed in Table 33 and Figure 13.
[00344] Finally, by combining a core group of biomarkers identified by
method
(2) with those additional potential biomarkers identified in method (1) a set
of
classifiers was produced from this blended set of potential biomarkers. For
the benign
nodule diagnostic, the core group of biomarkers included those six analytes
with a
frequency > 0.5. These six analytes were used to seed a Bayesian classifier to
which
additional markers were added up to a total of fifteen proteins. For a
classification
score >1.65, a total of 1316 Bayesian classifiers were built from this core.
Twenty
five potential biomarkers were identified from this set of classifiers using a
frequency
83
CA 3011730 2018-07-18
cut-off of 10%. These analytes are displayed in Table 34 and Figure 14 is a
frequency
plot for the identified biomarkers. A similar analysis for the asymptomatic
smoker
and NSCLC groups identifies twenty six potential biomarkers from 1508 fifteen
protein classifiers with scores > 1.7 starting with a core from method (2) of
seven
proteins. Table 35 displays these results and Figure 15 is a frequency plot
for the
identified biornarkers.
[00345] Biomarkers from Figures 10-15 were combined to generate a
final list
of biomarkers for lung cancer in Table 36. Table 37 includes a dissociation
constant
for the aptarner used to identify the biomarker, the limit of quantification
for the
marker in the multiplex aptamer assay, and whether the marker was up-regulated
or
down-regulated in the diseased population relative to the control population.
Example 3. Naïve Ilayesian Classilication for Lung Cancer
[00346] From the list of biomarkers identified as useful for
discriminating
between NSCLC and benign nodules, a panel of ten biomarkers was selected and a
naïve Bayes classifier was constructed, see Table 41. The class-dependent
probability
density functions (pdfs), p(x, I c) and p(x, I d) , where x; is the log of the
measured
RFU value for biomarker i , and c and d refer to the control and disease
populations,
were modeled as normal distribution functions characterized by a mean and
variance cy2. The parameters for pdfs of the ten biomarkers are listed in
Table 41 and
an example of the raw data along with the model fit to a normal pdf is
displayed in
Figure 5. The underlying assumption appears to fit the data quite well as
evidenced
by Figure 5.
[00347] The naïve Bayes classification for such a model is given by
the
following equation, where P(d) is the prevalence of the disease in the
population
p(
\ 2 r 1.r) ,7 au 1 =v,-1-1,,, + In (1-- 1)(d))
In ______
pfd I õr) <Tr., 2 \ o",,. P(d)
appropriate to the test and n =10 here. Each of the terms in the summation is
a log-
likelihood ratio for an individual marker and the total log-likelihood ratio
of a sample
x being free from the disease of interest (i.e. in this case, NSCLC) versus
having the
disease is simply the sum of these individual terms plus a term that accounts
for the
84
CA 3011730 2018-07-18
prevalence of the disease. For simplicity, we assume P(d)= 0.5 so that
_____________ = 0 .
P(d)
[00348] Given an unknown sample measurement in log(RFU) for each of
the
ten biomarkers of x = (3.13, 4.13, 4.48, 4.58, 3.78, 2.55, 3.02, 3.49, 2.92,
4.44) . the
calculation of the classification is detailed in Table 42. The individual
components
comprising the log likelihood ratio for control versus disease class are
tabulated and
can be computed from thc parameters in Table 41 and the values of x. The sum
of the
individual log likelihood ratios is 5.77, or a likelihood of being free from
the disease
versus having the disease of 321:1, where likelihood = c5.77 = 321. The first
two
biornarker values have likelihoods more consistent with the disease group (log
likelihood < 0) but the remaining eight biomarkers are all consistently found
to favor
the control group, the largest by a factor of 3:1. Multiplying the likelihoods
together
gives the same results as that shown above; a likelihood of 321:1 that the
unknown
sample is free from the disease. In fact, this sample came from the control
population
in the training set.
Example 4. Greedy Algorithm for Selecting 13iomarker Panels for Classifiers.
Part 1
[00349] This example describes the selection of biomarkers from Table
1 to
form panels that can he used as classifiers in any of the methods described
herein.
Subsets of the biomarkers in Table 1 were selected to construct classifiers
with good
performance. This method was also used to determine which potential markers
were
included as biomarkers in Example 2.
[00350] The measure of classifier performance used here is the sum of
the
sensitivity and specificity; a performance of 1.0 is the baseline expectation
for a
random (coin toss) classifier, a classifier worse than random would score
between 0.0
and 1.0, a classifier with better than random performance would score between
1.0
and 2Ø A perfect classifier with no errors would have a sensitivity of 1.0
and a
specificity of 1.0, therefore a performance of 2.0 (1.0+1.0). One can apply
the
methods described in Example 4 to other common measures of performance such as
area under the ROC curve, the E-measure, or the product of sensitivity and
specificity.
CA 3011730 2018-07-18
Specifically one might want to treat specificity and specificity with
differing weight,
so as to select those classifiers which perform with higher specificity at the
expense of
some sensitivity, or to select those classifiers which perform with higher
sensitivity at
the expense of some specificity. Since the method described here only involves
a
measure of "performance", any weighting scheme which results in a single
performance measure can be used. Different applications will have different
benefits
for true positive and true negative findings, and also different costs
associated with =
false positive findings from false negative findings. For example, screening
asymptomatic smokers and the differential diagnosis of benign nodules found on
CT
will not in general have the same optimal trade-off between specificity and
sensitivity.
The different demands of the two tests will in general require setting
different
weighting to positive and negative misclassifications, reflected in the
performance
measure. Changing the performance measure will in general change the exact
subset
of markers selected from Table I, Col. 2 for a given set of data.
[00351] For the Bayesian approach to the discrimination of lung cancer
samples from control samples described in Example 3, the classifier was
completely
parameterized by the distributions of biomarkers in the disease and benign
training
samples, and the list of biomarkers was chosen from Table 1; that is to say,
the subset
of markers chosen for inclusion determined a classifier in a one-to-one manner
given
a set of training data.
[00352] The greedy method employed here was used to search for the
optimal
subset of markers from Table 1. For small numbers of markers or classifiers
with
relatively few markers, every possible subset of markers was enumerated and
evaluated in terms of the performance of the classifier constructed with that
particular
set of markers (see Example 4, Part 2). (This approach is well known in the
field of
statistics as ''best subset selection"; see, e.g., Hastie et al, supra).
However, for the
classifiers described herein, the number of combinations of multiple markers
can be
very large, and it was not feasible to evaluate every possible set of 10
markers, for
example, from the list of 40 markers (Table 39) (i.e., 847,660,528
combinations).
Because of the impracticality of searching through every subset of markers,
the single
optimal subset may not be found; however, by using this approach, many
excellent
subsets were found, and, in many cases, any of these subsets may represent an
optimal
one.
86
CA 3011730 2018-07-18
[00353] Instead of evaluating every possible set of markers, a
"greedy" forward
stepwise approach may be followed (see, e.g., Dabney AR, Storey JD (2007)
Optimality Driven Nearest Centroid Classification from Genomic Data. PLoS ONE
2(10): e1002. doi:10.1371/joumal.pone.0001002). Using this method, a
classifier is
started with the best single marker (based on KS-distance for the individual
markers)
and is grown at each step by trying, in turn, each member of a marker list
that is not
currently a member of the set of markers in the classifier. The one marker
which
scores best in combination with the existing classifier is added to the
classifier. This is
repeated until no further improvement in performance is achieved.
Unfortunately,
this approach may miss valuable combinations of markers for which some of the
individual markers are not all chosen before the process stops.
[00354] The greedy procedure used here was an elaboration of the
preceding
forward stepwise approach, in that, to broaden the search, rather than keeping
just a
single candidate classifier (marker subset) at each step, a list of candidate
classifiers
was kept. The list was seeded with every single marker subset (using every
marker in
the table on its own). The list was expanded in steps by deriving new
classifiers
(marker subsets) from the ones currently on the list and adding them to the
list. Each
marker subset currently on the list was extended by adding any marker from
Table I
not already part of that classifier, and which would not, on its addition to
the subset,
duplicate an existing subset (these are termed "permissible markers"). Every
existing
marker subset was extended by every permissible marker from the list. Clearly,
such
a process would eventually generate every possible subset, and the list would
run out
of space. Therefore, all the generated classifiers were kept only while the
list was less
than some predetermined size (often enough to hold all three marker subsets).
Once
the list reached the predetermined size limit, it became elitist; that is,
only those
classifiers which showed a certain level of performance were kept on the list,
and the
others fell off the end of the list and were lost. This was achieved by
keeping the list
sorted in order of classifier performance; new classifiers which were at least
as good
as the worst classifier currently on the list were inserted, forcing the
expulsion of the
current bottom underachiever. One further implementation detail is that the
list was
completely replaced on each generational step; therefore, every classifier on
the list
had the same number of markers, and at each step the number of markers per
classifier grew by one.
87
CA 3011730 2018-07-18
[00355] Since this method produced a list of candidate classifiers
using
different combinations of markers, one may ask if the classifiers can be
combined in
order to avoid errors which might be made by the best single classifier, or by
minority
groups of the best classifiers. Such "ensemble" and "committee of experts"
methods
are well known in the fields of statistical and machine learning and include,
for
example, "Averaging", "Voting", "Stacking", "Bagging" and "Boosting" (see,
e.g.,
Hastie et al., supra). These combinations of simple classifiers provide a
method for
reducing the variance in the classifications due to noise in any particular
set of
markers by including several different classifiers and therefore information
from a
larger set of the markers from the biomarker table, effectively averaging
between the
classifiers. An example of the usefulness of this approach is that it can
prevent
outliers in a single marker from adversely affecting the classification of a
single
sample. The requirement to measure a larger number of signals may be
impractical in
conventional "one marker at a time" antibody assays but has no downside for a
fully
multiplexed aptamer assay. Techniques such as these benefit from a more
extensive
table of biomarkers and use the multiple sources of information concerning the
disease processes to provide a more robust classification.
Part 2
[00356] The biomarkers selected in Table 1 gave rise to classifiers
which
perform better than classifiers built with "non-markers" (i.e., proteins
having signals
that did not meet the criteria for inclusion in Table 1 (as described in
Example 2)).
[00357] For classifiers containing only one, two, and three markers,
all possible
classifiers obtained using the biomarkers in Table 1 were enumerated and
examined
for the distribution of performance compared to classifiers built from a
similar table
of randomly selected non-markers signals.
[00358] In Figure 17 and Figure 18, the sum of the sensitivity and
specificity
was used as the measure of performance; a performance of 1,0 is the baseline
expectation for a random (coin toss) classifier. The histogram of classifier
performance was compared with the histogram of performance from a similar
exhaustive enumeration of classifiers built from a "non-marker" table of 40
non-
marker signals; the 40 signals were randomly chosen from 400 aptamers that did
not
demonstrate differential signaling between control and disease populations (KS-
distance < 1.4).
88
CA 3011730 2018-07-18
[00359] Figure 17 shows histograms of the performance of all possible
one,
two, and three-marker classifiers built from the biomarker parameters in Table
39 for
. biomarkers that can discriminate between benign nodules and NSCLC and
compares
these classifiers with all possible one, two, and three-marker classifiers
built using the
40 "non-marker" aptamer RFU signals. Figure I7A shows the histograms of single
marker classifier performance, Figure 17B shows the histogram of two marker
classifier performance, and Figure 17C shows the histogram of three marker
classifier
performance.
[00360] In Figure 17, the solid lines represent the histograms of the
classifier
performance of all one, two, and three-marker classifiers using the biomarker
data for
benign nodules and NSCLC in Table 39. The dotted lines are the histograms of
the
classifier performance of all one, two, and three-marker classifiers using the
data for
benign nodules and NSCLC but using the set of random non-marker signals.
[00361] Figure 18 shows histograms of the performance of all possible
one,
two, and three-marker classifiers built from the biomarker parameters in Table
38 for
biomarkers that can discriminate between asymptomatic smokers and NSCLC and
compares these with all possible one, two, and three-marker classifiers built
using 40
"non-marker" aptamer RFU signals. Figure 18A shows the histograms of single
marker classifier performance, Figure 18B shows the histogram of two marker
classifier performance, and Figure 18C shows the histogram of three marker
classifier
performance.
[00362] In Figure 18, the solid lines represent the histograms of the
classifier
performance of all one, two, and three-marker classifiers using the biomarker
parameters for asymptomatic smokers and NSCLC in Table 38. The dotted lines
are
the histograms of the classifier performance of all one, two, and three-marker
classifiers using the data for asymptomatic smokers and NSCLC hut using the
set of
random non-marker signals.
[00363] The classifiers built from the markers listed in Table 1 form
a distinct
histogram, well separated from the classifiers built with signals from the
"non-
markers" for all one-marker, two-marker, and three-marker comparisons. The
performance and AUC score of the classifiers built from the biomarkers in
Table 1
also increase faster with the number of markers than do the classifiers built
from the
non-markers, the separation increases between the marker and non-marker
classifiers
as the number of markers per classifier increases. All classifiers built using
the
89
CA 3011730 2018-07-18
biomarkers listed in Tables 38 and 39 perform distinctly better than
classifiers built
using the "non-markers''.
Part 3
[00364] To test whether a core subset of markers accounted for the
good
performance of the classifiers, half of the markers were randomly dropped from
the
lists of biomarkers in Tables 38 and 39. The performance, as measured by
sensitivity
plus specificity, of classifiers for distinguishing benign nodules from
malignant
nodules dropped slightly by 0.07 (from 1.74 to 1.67), and the performance of
classifiers for distinguishing smokers who had cancer from those who did not
also
dropped slightly by 0.06 (from 1.76 to 1.70). The implication of the
performance
characteristics of subsets of the biomarker table is that multiple subsets of
the listed
biomarkers are effective in building a diagnostic test, and no particular core
subset of
markers dictates classifier performance.
[00365] In the light of these results, classifiers that excluded the
best markers
from Tables 38 and 39 were tested. Figure 19 compares the performance of
classifiers built with the full list of biomarkers in Tables 38 and 39 with
the
performance of classifiers built with a set of biomarkers from Tables 38 and
39
excluding top ranked markers.
[00366] Figure 19 demonstrates that classifiers constructed without
the best
, markers perform well, implying that the performance of the classifiers
was not due to
some small core group of markers and that the changes in the underlying
processes
associated with disease are reflected in the activities of many proteins. Many
subsets
of the biomarkers in Table 1 performed close to optimally, even after removing
the
top 15 of the 40 markers from Table 1.
[00367] Figure 19A shows the effect on classifiers for discriminating
benign
nodules from NSCLC built with 2 to 10 markers. Even after dropping the 15 top-
ranked markers (ranked by KS-distance) from Table 39, the benign nodule vs.
NSCLC performance increased with the number of markers selected from the table
to
reach over 1.65 (Sensitivity + Specificity).
[00368] Figure 19B shows the effect on classifiers for discriminating
asymptomatic smokers from NSCLC built with 2 to 10 markers. Even after
dropping
the 15 top-ranked markers (ranked by KS-distance) from Table 38, the
asymptomatic
smokers vs. NSCLC performance increased with the number of markers selected
from
CA 3011730 2018-07-18
the table to reach over 1.7 (Sensitivity + Specificity), and closely
approached the
performance of the best classifier selected from the full list of biomarkers
in Table 38.
[00369] Finally, Figure 20 shows how the ROC performance of typical
classifiers constructed from the list of parameters in Tables 38 and 39
according to
Example 3. Figure 20A shows the model performance from assuming the
independence of markers as in Example 3, and Figure 20B shows the actual ROC
curves using the assay data set used to generate the parameters in Tables 38
and 39. It
can be seen that the performance for a given number of selected markers was
qualitatively in agreement, and that quantitative agreement degraded as the
number of
markers increases. (This is consistent with the notion that the information
contributed
by any particular biomarker concerning the disease processes is redundant with
the
information contributed by other biomarkers provided in Tables 38 and 39).
Figure
20 thus demonstrates that Tables 38 and 39 in combination with the methods
described in Example 3 enable the construction and evaluation of a great many
classifiers useful for the discrimination of NSCLC from benign nodules and the
discrimination of asymptomatic smokers who have NSCLC from those who do not
have NSCLC.
Exam*. 5. Aptamer Specificity IN.monstration in a Pull-down Assay
[00370] The final readout on the multiplex assay is based on the
amount of
aptamer recovered after the successive capture steps in the assay. The
multiplex assay
is based on the premise that the amount of aptamer recovered at the end of the
assay is
proportional to the amount of protein in the original complex mixture (e.g.,
plasma).
In order to demonstrate that this signal is indeed derived from the intended
analyte
rather than from non-specifically bound proteins in plasma, we developed a gel-
based
pull-down assay in plasma. This assay can be used to visually demonstrate that
a
desired protein is in fact pulled out from plasma after equilibration with an
aptamer as
well as to demonstrate that aptamers bound to their intended protein targets
can
survive as a complex through the kinetic challenge steps in the assay. In the
experiments described in this example, recovery of protein at the end of this
pull-
down assay requires that the protein remain non-covalently bound to the
aptamer for
nearly two hours after equilibration. Importantly, in this example we also
provide
evidence that non-specifically bound proteins dissociate during these steps
and do not
contribute significantly to the final signal. It should be noted that the pull-
down
91
CA 3011730 2018-07-18
procedure described in this example includes all of the key steps in the
multiplex
assay described above.
[00371] A. Plasma Pull-down Assay
[00372] Plasma samples were prepared by diluting 50 L EDTA-plasma to
100
L in SB18 with 0.05% Tween-20 (SB18T) and 2 M Z-Block. The plasma solution
was equilibrated with 10 pmoles of a PBDC-aptamer in a final volume of 150
l.LL for
2 hours at 37 C. After equilibration, complexes and unbound aptamer were
captured
with 133 I, of a 7.5% Streptavidin-agarose bead sluiTy by incubating with
shaking
for 5 minutes at RT in a Durapore filter plate. The samples bound to beads
were
washed with biotin and with buffer under vacuum as described in Example 1.
After
washing, bound proteins were labeled with 0.5 mM NHS-S-S-biotin, 0.25 mM NHS-
Alexa647 in the biotin diluent for 5 minutes with shaking at RT. This staining
step
allows biotinylation for capture of protein on streptavidin beads as well as
highly
sensitive staining for detection on a gel. The samples were washed with
glycine and
with buffer as described in Example 1. Aptamers were released from the beads
by
photocleavage using a Black Ray light source for 10 minutes with shaking at
RT. At
this point, the biotinylated proteins were captured on 0.5 mg MyOne
Streptavidin
beads by shaking for 5 minutes at RT. This step will capture proteins bound to
aptamers as well as proteins that may have dissociated from aptamers since the
initial
equilibration. The beads were washed as described in Example 1. Proteins were
eluted from the MyOne Streptavidin beads by incubating with 50 mM urr in SB17T
for 25 minutes at 37 C with shaking. The eluate was then transferred to MyOne
beads coated with a sequence complimentary to the 3' fixed region of the
aptamer and
incubated for 25 minutes at 37 'V with shaking. This step captures all of the
remaining aptamer. The beads were washed 2x with 100 L SB17T for 1 minute and
lx with 100 I, SB19T for 1 minute. Aptamer was eluted from these final beads
by
incubating with 45 L 20 mM Na011 for 2 minutes with shaking to disrupt the
hybridized strands. 40 p.1. of this eluate was neutralized with 101.11, 80 mM
FIC1
containing 0.05% Tween-20. Aliquots representing 5% of the eluate from the
first set
of beads (representing all plasma proteins bound to the aptamcr) and 20% of
the
eluate from the final set of beads (representing all plasma proteins remaining
bound at
the end of our clinical assay) were run on a NuPAGE 4-12% Bis-Tris gel
(Invitrogen)
92
CA 3011730 2018-07-18
under reducing and denaturing conditions. Gels were imaged on an Alpha
Innotech
FluorChem Q scanner in the Cy5 channel to image the proteins.
[00373] B. Pull-down gels for aptamers were selected against LBP (-
1x1(-
7 M in plasma, polypeptide MW ¨60 klla). C9 (-1x10-6M in plasma, polypeptide
MW ¨60 klla), and IgM (-9x1(16 M in plasma, MW ¨70 klla and 23 klla),
respectively. (See Figure 16).
[00374] For each gel. lane 1 is the elude from the Streptavidin-
agarose beads,
lane 2 is the final eluate, and lane 3 is a MW marker lane (major bands are at
110, 50,
30, 15, and 3.5 kDa from top to bottom). It is evident from these gels that
there is a
small amount non-specific binding of plasma proteins in the initial
equilibration, but
only thc target remains after performing the capture steps of the assay. It is
clear that
the single aptamer reagent is sufficient to capture its intended analyte with
no up-front
depletion or fractionation of the plasma. The amount of remaining aptamer
after these
steps is then proportional to the amount of the analyte in the initial sample.
[00375] The foregoing embodiments and examples are intended only as
examples. No particular embodiment, example, or element of a particular
embodiment or example is to be construed as a critical, required, or essential
element
or feature of any of the claims. Further, no element described herein is
required for
the practice of the appended claims unless expressly described as "essential"
or
"critical." Various alterations, modifications, substitutions, and other
variations can
be made to the disclosed embodiments without departing from the scope of the
present application, which is defined by the appended claims. The
specification,
including the figures and examples, is to be regarded in an illustrative
manner, rather
than a restrictive one, and all such modifications and substitutions are
intended to be
included within the scope of the application. Accordingly, the scope of the
application should be determined by the appended claims and their legal
equivalents,
rather than by the examples given above. For example, steps recited in any of
the
method or process claims may be executed in any feasible order and are not
limited to
an order presented in any of the embodiments, the examples, or the claims.
Further,
in any of the aforementioned mcthods, one or more biomarkers of Table 1 can be
specifically excluded either as an individual biomarker or as a biomarker from
any
panel.
93
CA 3011730 2018-07-18
0
0
0
CO
0 Table 1. Lung Cancer Biomarkers
CO
Column #1 Column #2 Column #3 Column
#4 Column #5 Column #6
Gene
Benign Smokers
Biomarker versus
Biomarker # Alternate Protein Names
Designation Nodule
Designation (Entrez versus NSCLC
Gene Link)
NSCLC !
Methionine aminopeptidase 2
4=, p67e1F2
p67
1 AMPM2 Initiation factor 2-associated 67
kDa METAP2 X
glycoprotein Peptidase M 2
MetAP 2
MAP 2
apolipoprotein A-I
2 Apo A-I AP0A1
X
Apolipoprotein A-1
FGF acidic
FGF1
3 b-ECGF FGF1
X
beta-ECGF
Beta-endothelial cell growth factor ;
C)
w
0
I-
I-.
=-.1
W
0 Table 1. (cont.)
n.)
0 .
,
1-. BLC B lymphocyte chemoattractant '
co Small inducible cytokine 813
, 4 BLC CXCL13
X X
0 CXCL13
=-.1
I BCA-1
,
co Bone morphogenetic protein 1
Procollagen C-proteinase
BMP-1 PCP BMP1 X X
Mammalian tolloid protein
mTld
Tyrosine-protein kinase BTK
Bruton tyrosine kinase
Agammaglobulinaemia tyrosine
6 BTK
BTK X
kinase
1/4.0 ATK
til
B-cell progenitor kinase
. ,
7 Cis
Complement Cis subcomponent
i
C1S X
à Cl s, Activated. Two-Chain Form
8 C9 Complement component C9 C9
X . X
Cadherin-1
1 Epithelial cadherin
i E-cadherin
9 Cadherin E
CDH1 X 1
Uvomorulin
i
CAM 120/80
. I CD_antigen=CD324
= ,
Kidney-cadherin
I
Cadherin-6 CDH6 X
K-cadherin
,
LA)
0
LA)
o Table 1. (cont.)
0
Calpain I (dimer of Calpain-1
co
catalytic subunit and Calpain small I
0 subunit 1)
synonyms of the catalytic subunit
co include Calpain-1 large subunit:
Calcium-activated neutral proteinase
1
Micromolar-calpain
CAPN1
11 Calpain I
X
Cell proliferation-inducing gene 30
CAPNS1
= =
protein
synonyms of the small subunit
include:
Calcium-dependent protease small
subunit 1
Calcium-activated neutral proteinase
small subunit CANP small subunit
12 Catalase Catalase I CAT
X
Dipeptidyl-peptidase 1 precursor
Dipeptidyl-peptidase I
DPP-I
13 CATC DPPI
CTSC X
Cathepsin C
Cathepsin J
Dipeptidyl transferase
14 I Cathepsin H , Cathepsin H
CTSH X
0
IA
0 Table 1. (cont.)
0
Tumor necrosis factor ligand
co superfamily member 8
15 CD30 Ligand TNFSF8
X X
0 CD3O-L
CD153 antigen
co CDK5/p35 is a dimer of Cell
division
protein kinase 5, and the p35 chain
of Cyclin-dependent kinase 5
activator 1
Cell division protein kinase 5 is also I
known as:
Cyclin-dependent kinase 5
Tau protein kinase ll catalytic
subunit
Serine/threonine-protein kinase
CDK5
16 CDK5-p35 PSSALRE
X
CDK5R1
p35 chain of Cyclin-dependent
kinase 5 activator 1 is also known
as:
Cyclin-dependent kinase 5
regulatory subunit 1
CDK5 activator 1
Cyclin-dependent kinase 5
regulatory subunit 1
Tau protein kinase II regulatory
, subunit.
0
W
0
I-.
I-.
--.1
W
0 Table 1. (cont.)
i..)
0
1-. Creatine Phosphokinase-MB i
1
co
1 Isoenzyme, which is a dimer of
l
0 17 CK-MB Creatine kinase M-type and B-type
CKB
--.1
X X
1-
l. Creatine kinase M and B chains
CKM
03 M-CK and B-CK
CKM and CKB ;
.
I Beta-Ala-His dipeptidase
Carnosine dipeptidase 1
i ,
,
CNDP .
18 CND P1 CNDP1
X X
Serum carnosinadipeptidase1 se
Glutamate carboxypeptidase-like
i
µ protein 2 ..
.
-
= =
Neural recognition molecule NB-2 I
=
19 Contactin-5
X
:.0 hNB-2 I CNTN5
..
00
' Tyrosine-protein kinase CSK
.
= ,
=
20 CSK C-SRC kinase
CSK X i X
protein-tyrosine kinase CYL i
I
Cyclophilin A
Peptidyl-prolyl cis-trans isomerase A i
PPlase i ,
21 Cyclophilin A ' Peptidylprolyl isomerase i
PPIA i X
Cyclosporin A-binding protein
,
Rotamase A
i
= =
PPlase A
Endostatin, which is cleaved from =
=
22 Endostatin COL18A1
.
i
= X
Collagen alpha-1(XVIII) chain
..
LA)
0
LA)
o Table 1. (cont.)
0 Epidermal growth factor receptor
I
Receptor tyrosine-protein kinase
0 23 ERBB1 ErbB-1 EGFR
X X
EGFR
co HER1
24 FGF-17 Fibroblast Growth Factor-17
FGF17 X X
Proto-oncogene tyrosine-protein
kinase Fyn
25 FYN FYN
X
Protooncogene Syn
=
p59-Fyn =
Glyceraldehyde 3-phosphate
26 GAPDH, liver GAPDH
X X
dehydrogenase
High mobility group protein B1
,c) 27 HMG-1 amphoterin HMGB1
X
Neurite growth-promoting protein ,
Heat shock protein HSP 90-alpha
28 HSP 90a HSP 86 HSP9OAA1
X X
Renal carcinoma antigen NY-REN-
38
Heat shock protein HSP 90-beta
29 HSP 90b HSP 90 HSP90AB1
X
HSP 84
Insulin-like growth factor-binding
30 IGFBP-2 protein 2 IGFBP2
X X
(IGF-binding protein 2; IGFBP-2;
IBP-2; BP2)
31 IL-15 Ra I Interleukin-15 receptor
subunit alpha IL15RA X
LA)
0
IA
IA
LA)
0 Table 1. (cont.)
0 Interleukin-17B
co Neuronal interleukin-17 related
0 32 IL-17B factor IL1713
X
Interleukin-20
co . Cytokine-like protein ZCYTO7
lmportin subunit beta-1
Karyopherin subunit beta-1
33 IMB1 KPNB1
X
Nuclear factor P97
Importin-90
Kallikrein-7
hK7
Stratum comeum chymotryptic
34 Kallikrein 7 KLK7
X
enzyme
hSCCE
0)
Serine protease 6
Protein kinase C iota type
nPKC-iota
Atypical protein kinase C-
35 KPCI PRKCI
X X
lambdanota
aPKC-lambda/iota
PRKC-lambda/iota
= =
L-lactate dehydrogenase B chain
LDH-B
LDH-H 1 LDH heart subunit
36 LDHB X
LDH-H
Renal carcinoma antigen NY-REN-
46
r)
W
0
I-.
I-.
,.1
W
0 Table 1. (cont.)
n.)
_ _______
0
1-. Legumain
03 37 LGMN Protease, cysteine 1
LGMN X
i
0 ______________________________________ Asparaginyl endopeptidase
,.1
.
1 Leucine-rich repeats and
1-.
03 38 LRIG3 immunoglobulin-like domains protein
LRIG3 X X
3
Macrophage
Macrophage mannose receptor 1
mmR
39 mannose
MRC1 X
C-type lectin domain family 13
receptor
member D CD_antigen=CD206 =
.
= =
Dual specificity mitogen-activated '
=
:
:
=
=
protein kinase kinase 1 X = =
40 MEK1 MAP2K1
X .
;
.
MAPK/ERK kinase 1
;
-5 ERK activator kinase 1 I
_
,
Methionine aminopeptidase 1
41 METAP1 MetAP 1 i METAP1
X
MAP 1
Peptidase M1
.
:
Neurite outgrowth-promoting protein
..
=
Neurite outgrowth-promoting factor 2
42 Midkine Midgestation and kidney protein
MDK X
Amphiregulin-associated protein
i
ARAP
i
C)
LA)
0
I-.
I-.
--.1
LA)
0 Table 1. (cont.)
iv
0 ..
_________________________
1-. C-C motif chemokine 15 ..==
1
,=
,
co ,
1 Small-inducible cytokine A15 i
0 Macrophage inflammatory protein 5 I
...1
I Chemokine CC-2
1-.
co HCC-2
43 MIP-5 ! MIP5
X
NCC-3
MIP-1 delta .==
=
Leukotactin-1
LKN-1
_________________________________________ Mrp-2b
,
¨Mitogen-activated protein kinase 13
,
,
MAP kinase p38 delta
44 MK13 Mitogen-activated protein kinase
p38 . MAPK13 X
_
delta 1
1.) i Stress-activated protein kinase 4
'
Matrilysin
: = =
I
Pump-1 protease
Uterine metal loproteinase
i
45 MMP-7 E MMP7
X 1
Matrix metalloproteinase-7
MMP-7
,
,
Matrin I
,
Nascent polypeptide-associated i
complex subunit alpha !
I
46 NAGA NAC-alpha NACA
X 1
Alpha-NAC
,
Allergen.Hom s 2 i
I
' = i
N-acetylglucosamine kinase I
,
'
47 NAGK ! NAGK
X 1
, GIcNAc kinase
0
IA
IA
0 Table 1. (cont.)
0
C-C motif chemokine 18
co
Small-inducible cytokine A18
0
Macrophage inflammatory protein 4 I
MIP-4
co I Pulmonary and activation-regulated
I
chemokine
48 PARC kine PARC CCL18
X
CC chemo
Alternative macrophage activation-
associated CC chemokine 1
AMAC-1
Dendritic cell chemokine 1
DC-CK1
Proteinase-3
PR-3
AGP7
P29
Myeloblastin
49 Proteinase-3 PRTN3
X
Leukocyte proteinase 3
Wegener's autoantigen
Neutrophil proteinase 4
I NP4
C-ANCA antigen
Prothrombin
50 Prothrombin factor II) F2
X X
- (Coagulation
0
IA
IA
0 Table 1. (cont)
n.)
0
Pleiotrophin
co
Heparin-binding growth-associated
0
molecule
HB-GAM
co 1 Heparin-binding growth factor 8
HBGF-8
51 PTN PTN
X
Osteoblast-specific factor 1
1
OSF-1
Heparin-binding neurite outgrowth-
promoting factor 1 HBNF-1
Heparin-binding brain mitogen
HBBM
Ras-related C3 botulinum toxin
substrate 1
p21-Rac1
52 RAC1 RAC1
X
Ras-like protein TC25
Cell migration-inducing gene 5
protein
Renin
53 Rerun REN
X
Angiotensinogenase
Hemojuvelin
54 RGM-C Hemochromatosis type 2 protein
HFE2 X
RGM domain family member C
Mast/stem cell growth factor
receptor
55 SCF SR 1 (SCFR; Proto-oncogene tyrosine-
KIT X X
protein kinase Kit; c-kit; 1
.=
CD_antigen=CD117)
C)
W
0
I-.
I-.
,.1
W
0 Table 1. (cont.)
I) _
0
...
sL-Selectin
co
1 Leukocyte adhesion molecule-1 I
0
1
Lymph node homing receptor I
.
1 LAM-1
: = 1-. ..
co L-Selectin
L-Selectin, soluble
i
56 I
sL-Selectin Leukocyte surface antigen Leu-8
SELL I X
TO1
I
gp9O-MEL
Leukocyte-endothelial cell adhesion
molecule 1
.
LECAM1
CD62 antigen-like family member L '
,
-5 Translationally-controlled tumor
.
t.r.
protein .
23 I
57 TCTP p ' TPT1
X
Histamine-releasing factor ,
HRF
Fortilin
1
.......
_...
Ubiquitin-conjugating enzyme E2 N
Ubiquitin-protein ligase N
Ubiquitin carrier protein N = 58 UBE2N
UBE2N = X
Ubc13
I
:
Bendless-like ubiquitin-conjugating
enzyme i
1
,
59 Ubiquitin+1 Ubiquitin 1 RPS27A
X
0
IA
(A)
0 Table 1. (cont.)
0
Vascular endothelial growth factor A
co
60 VEGF VEGF-A I VEGFA
X
0
Vascular permeability factor
Proto-oncogene tyrosine-protein
co kinase Yes
61 YES YES
X
c-Yes
________________________________________ ,p61-Yes
Table 2
100 Panels of3 Benign vs. Cancerous Nodule Biomarkers
Sens. +
Biomarkers Specificity
_Sensitivity Spec. AUC
1 ApoA -1 LR1G3 1-1SP90a 0.803 0.769 1.572 0.848
2 BLC CK-MB METAP1 0.779 0.795 1.575 0.839 .
...,
3 BMP-1 ERBB I METAP1 0.812 0.783 1.596 0.856
,
4 C9 ERBB I KPCI 0.789 0.802 1.591 . 0.853
CATC I-ISP90a F,RI3B1 0.779 0.776 1.556 0.832
,
6 CD30L iga nd SCFsR KPCI 0.784 0.793 .
1.577 0.839
7 CK-MB . CNDP I HSP90a 0.779 0.795 . 1.575
0.851
. 8 CSK CadherinE ERBB1 - 0.831 0.776 1.607 0.881
9 Calherin-6 CadherinE ERBB I ' 0.756
0.812 . 1.568 0.851
Calpainl ERBB1 CadherinE 0.808 0.805 1.612 0.88
11 Cal alase KPCI ERBB1 0.779 0.783 1.563
0.849
_
12 CathepsinH KPCI CadherinE 0.756 0.802 1.558
0.845 .
13 F6F-17 FISP9Ob -ERBB1 0.775 0.812 1.587 0.852
14 CadherinE GAPD1-1,1iver MMP-7 0.812 0.793 1.605 . 0.869
-
HMG-1 CK-MB ER BB I 0.775 0.81 1.584 0.849
16 IGEBP-2 ERBB1 GAPDILliver . 0.793 0.81 1.603
0.854
17 1L-17B CK-MB METAP1 0.798 0.776 1.574 0.839
18 CadherinE IMB1 ERBB1 0.808 ' 0.788 1.596
0.867
19 LGMN CadherinE ERBB I 0.775 0.8 1.575 0.856
MEK I CK-MB ERBB1 0.751 0,829 1.58 0.83 .
21 CK-MB MK13 IISP90a 0.779 0.81 4 1.589
0.854
22 MMR ..KPCI CadherinE 0.803 0.81 1.612 0.86
23 NAGA CadherinE C9 0.789 0.79 1.579 0.835
,
24 MMP-7 NAGK CadhcrinE 0.793 0.793 1.586 . 0.857
Proicinasc-3 CadherinE ER BB I 0.746 0.814 1.561 0.851
26 CK-MB Prothrombin IISP90a 0.803 0.762 1.565 0.857
27 . RGM-C IISP90b ERBB1 0.784 0.819 1.603 . 0.854
28 VEGF ERBB1 "CadherinE 0.77 0.817 1.587 0.848
29 YES HSP90a ERBB I 0.817 0.776 1.593 . 0.872
.. h-ECGF CK-MB HSP90a 0.793 0.795 1.589 0.857
31 ApoA-1 KPCI CadherinE 0.765 0.805 1.57 0.836
32 BLC CadherinE IMB1 0.803 0.769 1.572 . 0.847
33 CK-MB BMP-1 IETAP 1 0.789 0.793 . 1.582
0.852
34 CATC KPCI ERBB1 0.789 0.76 1.548 0.831
- -
CD3 OL i sand CadherinE ERBB1 0.77 0.8 1.57 0.846
,
36 CNDP1 ERBB I METAP1 0.808 0.767 1.574 0.854
_
37 CK-MB ERBB1 CSK . 0.793 0.807 1.601 0.874
_
, 38 Cadherin-6 CK-MB .ERBB1 0.732 0.826 1.559 0.827
39 MMP-7 _Cal ainI CadherinE 0.812 0.798 1.61
0.868
Catalase CadherinE ERBB1 0.775 0.779 1.553 0.854
41 CathepsinI-1 RGM-C .1-ISP90a 0.793 0.762 ,. 1.555
0.848
. 42 FGF-17 CIAPDH,liver ERBB1 0.779 0.798 1.577 0.858
43 HMG-1 .MMP-7 .-CadherinE 0.784 0.798 1.582 0.858
. 44 'ROM -C IGFBP-2 HSP90a . 0.803 0.774 1.577
.... 0.853
1L-17B CK-MB GAPDH.liver 0.784 0.786 1.57 0.842
107
CA 3011730 2018-07-18
=
Table 2 (cont.)
46 LGMN MMP-7 CadherinE 0.779 0.788 1.567 0.845
47 CK-MB LR1G3 IISP90a 0.817 0.795 1.612 0.866
48 YES MEKI ERBBI 0.732 0.838 1.57 0.839
49 'MK13 METAP I ERBBI 0.789 0.786 1.574 0.851
50 CadherinE CiAPDH,liver MMR 0.808 0.786 1.593 0.867
51 NACA METAP 1 _ ERBBI 0.798 0.781 1.579 0.837 ,
52 RGM-C NAGK ERBBI 0.779 0.8 1.579 0.856
53 ,Proleinase-3 , CiAPDH,liver ERBBI 0.761 0.79 1.551 ,
0.851
54 Prothrombin ,CSK ERBBI 0.812 0.752 1.565 0.847
55 CadherinE SCFsR KPCI 0.789 0.805 1.593 0.865
56 ,VEGF . Calpainl CadherinE 0.808 -
0.776 1.584 0.849
57 b-ECGF METAP I ERBBI 0.812 0 776 1.588 0.852
58 ApoA-I ERBBI METAP1 0.793 , 0.776 1.57 , 0.856
59 BLC CK-MB CSK 0.756 0.812 1.568 0.832
60 ,CNDP I MP-1B METAP I 0.779 0.793 1.572 0.838
61 CadherinE C9 KPCI 0.779 0.807 1.586
0.853
62 CATC Ca 1pai nl ERBBI 0.793 0.755 1.548
0.835
63 CD30Ligand IMB I ERBBI 0.789 0.779 1.567 0.848
64 Cadherin-6 I-ISP90a ERBBI 0.746 0.805 1.551 0.839
65 YES .Catalase ERBBI 0.784 0.769 1.553 0.848
66 Cathepsin1-1 ERBBI METAP I 0.765 0.788 1.553
0.849
, 67 FGF-17 Calpainl ERBBI 0.789 0.788 1.577 0.859
-1
68 HMG-1 CadherinE ERBBI 0.793 0.788 1.582 0.867
69 CadherinE , 1-ISP9Ob ERBBI 0.817 0.812 1.629
0.872
70 CadherinE , IGFBP-2 KPCI 0.775 0.8 1.575
0.863
71 IL-17B CK-MB HSP90a 0.789 0.779 1.567
0.839
72 LGMN , Calpainl ERBBI 0.761 ,
0.802 , 1.563 0.838
73 CK-MB LRIG3 HSP901, 0.779 0.814 1.594 0.836
74 MEK I CadherinE ERBBI 0.765 0.802 1.568
0.857
75 CadhcrinE MK I 3 ERBBI , 0.761 0.81 ,
1.57 0.853
76 MMR HSP90b ' CadherinE 0.793 0.786 1.579 0.852
77 NACA 'IISP90a ERBBI 0.789 0.788 1.577 0.846
78 CadherinE NAGK ERBBI 0.789 0.79 1.579 0.871
79 Proleinase-3 IMB1 ERBBI 0.77 0.776 1.546 0.838
,
80 Prothrombin . METAPI , ERBBI 0.793 0.767 1.56
0.842
_
81 SCFsR ERBBI KPCI 0.784 0.805 1.589 0.854
82 VEGF IISP9Ob CadherinE , 0.793 0.788
1.582 0.84
83 b-ECGF CadherinE Calpainl 0.779 0.793 1.572 0.848
84 ApoA -I CSK ERBBI 0.775 0.783 1.558 0.861
85 BLC CadherinE KPCI 0.779 0.783 1.563 0.852
86 BMP-1 , CadherinE KPCI 0.784 0.783 ,
1.567 0.849
87 C9 _ ERBBI CadherinE 0.756 0.829 , 1.584 0.845
88 CATC GAPD1-1,1iver ERBBI 0.779 0.767 1.546 0.843
89 CD30Ligand , METAP I ERBBI , 0.793 0.769 1.562
0.851
90 , CNDPI CadherinE KPCI 0.77 0.8 1.57 0.856
_ 91 Cadherin-6 HSP90b ERBBI 0.756 , 0.795 1.551
0.834
92 Catalase ' MK13 ERBBI ._. 0.77 0.774 1.544
0.838
-
93 CathepsinH METAP1 ,CadherinE 0.784 0.769 1.553 0.851
108
CA 3011730 2018-07-18
Table 2 (cont.)
94 , FGF-17 METAP I ERBB1 0.793 ' 0.783 1.577
0.855
95 IIMG-1 METAP I ERBB I 0.784 0.776 1.56 0.839
96 1G FBP-2 ERBB1 METAP1 0.789 , 0.786 1.574 ,
0.858
97 1L-17B CadherinE HSP9013 0.761 0.805 1.565 0.84
98 LCilVIN METAP1 ER BB I 0.779 0.779 .. 1.558
0.834
99 LR1G3 CadherinE HSP9Ob 0.798 0.788 1.586 0.852
100 MEK1 HSP9Ob ERBB I 0.761 0.795 1.556 0.841
Marker Count Marker Count
ERBB1 59 FOF-17 4 ,
CadherinE 39 CathepsinI I 4
METAP I , 18 Catalase 4
CK-MB 16 Cadherin-6 4
KPCI 14 CNDP I 4
FISP90a 13 , CD30Ligand 4
1-ISP9Oh 10 CATC 4 ..
GAPD11,1iver 7 C9 4
Calpain1 7 BMP-1 4
MMP-7 5 BLC 4
CSK 5 ApoA-I 4
RGM-C 4 b-ECGF 3
MK13 4 YES 3 ,
0
MEK1 4 VEGF 3 ,
LRIG3 4 SCFsR 3
LGMN 4 , Pro thrombin 3 ,
IMB1 4 Pro lei nase-3 3
IL-17B 4 NAGK 3
,
1GFBP-2 4 NACA 3
1-1MG-1 4 MMR 3
_
109
CA 3011730 2018-07-18
Table 3
100 Panels of 4 Benign vs. Cancerous Nodule Biomarkers
Sens. +
Biomarkers
Specificity Sensitivity Spec. AUC
1 ApoA-I KPCI CadherinE MMR 0.836 0.79 , 1.626 0.865
2 BLC ERBBI CSK CK-MB 0.808 0.821 1.629 0.859
3 CK-MB BMP-1 METAPI ERBBI 0.831 0.802 1.633 0.874
4 C9 ERBBI CadherinE KPCI 0.836 0.802 1.638 ,
0.873
CATC CadherinE HSP90b ERBBI 0.822 0.788 1.61 0.861,,
6 CD30Ligand KPCI CK-MB ERBB1 0.822 0.819 ,
1.641 0.86 '
7 CK-MB CNDP1 CSK ERBBI 0.817 0.817 1.634 0.869
8 Cadherin-6 KPCI ERBBI CadherinE 0.812 0.8 1.612 0.863
..
9 RGM-C CadherinE CalpainI ERBBI 0.845 0.8 1.645 0.892
Catalan METAPI ERBBI CK-MB 0.836 0.783 1.619 0.874,
11 CathepsinH SCFsR CadherinE KPCI 0.822 0.8 1.622 .
0.87 '
12 CK-MB FGF-I 7 ERBBI METAPI 0.85 0.793 1.643 0.874
13 CadherinE IGFBP-2 GAPDH,liver CK-MB 0.831 0.807 1.638
0.886
14 1-1MG-1 C9 ERBBI CadherinE 0.812 0.812 1.624
0.869:
YES CK-MB ERBBI TISP90a 0.831 0.821 _ 1.652 0.884õ,
16 IL-17B METAP1 ERBBI CK-MB 0.84 0.795 1.636 0.87
17 TGFBP-2 MMP-7 CadherinE IMB I 0.854 0.776
1.631 0.875
-
18 LG MN KPCI ERBBI CadherinE 0.822 0.798 1.619
0.865 .
19 CK-MB HSP90b CadherinE LRIG3 0.826 0.814 1.641
0.873
MEK1 METAPI ERBBI CK-MB 0.822 0.805 1.626 0.87
21 MK13 ITSP90b ERBBI CadherinE 0.822 0.814 1.636
0.875
22 NACA LRIG3 , HSP90a CK-MB 0.831 0.795 1.626
0.846
23 CK-MB ERBBI CadherinE NAGK 0.798 0.821 1.62
0.886
- .
24 Proteinase-3 KPCI ERBBI CadherinE 0.798 0.817 1.615
0.869
Prothrombin CadherinE MMP-7 Calpainl 0.85 0.776 1.626 0.868,
26 VEGF CSK ERBBI CadherinE 0.84 0.8 1.64 0.883-
27 CadherinE GAPDH,liver MMR b-ECGF 0.831 0.79 1.621
0.865
-
28 ApoA-I ERBBI METAPI CadherinE 0.845 0.779 1.624
0.882 .
29 BLC SCFsR KPCI CadherinE 0.831 0.79 1.621
0.867.
BMP-I CadherinE ERBBI METAPI 0.85 0.776 1.626 0.878
31 cATc CK-MB KPCI ERBBI 0.831 0.774 , 1.605 0.842
.
32 CD30Ligand METAPI CK-MB ERBBI 0.826 0.798 1.624
0.871_
33 CNDP1 SCFsR CadherinE KPCI 0.836 0.795 1.631
0.878
- _
34 Cadheri n-6 RGM-C ERBBI CadherinE 0.798 0.812
1.61 0.86
CK-MB Catalase KPCI ERBB1 0.812 0.805 1.617 0.863.
36 Cathepsinli ERBB1 CadherinE METAPI 0.84 0.781
1.621 0.876 .
37 CK-MB FGF-17 ERBB1 GAPDH,liver 0.808 0.826
1.634 0.868
38 HMG-I KPCI MMP-7 CadherinE 0.822 0.802 1.624
0.8654
39 IL-I 7B CadherinE ERBBI IISP90b 0.826 0.805
1.631 0.874 .
RGM-C CadherinE ERBBI IMB I 0.831 0.798 1.629 0.879.
41 YES CadherinE ERBBI LGMN 0.798 0.814 1.612
0.868.
42 MEK1 CadherinE HSP90b ERBB1 0.812 0.812 1.624
0.877
43 CadherinE MK13 MMR KPCI 0.826 0.8 1.626 _
0.871
110
CA 3011730 2018-07-18
Table 3 (cont.)
, 44 NACA CadherinE MMR ERBBI 0.84 0.781 1.621
0.87
45 RGM-C CadherinE ,MMR NAGK 0.812 0.807 1.619 0.867
-
46 Proteinase-3 KPCI CK-MB CadherinE 0.789 0.824 1.613 0.861
47 Prothrombin HSP90b ERBBI RGM-C 0.798 0.826 1.624 ,
0.856
48 VEGF ERBBI HSP90a CadherinE , 0.817 0.817
1.634 0.877
49 b-ECGE CadherinE, ER BB I FISP90b , 0.812 0.807
1.619 0.876
50 ApoA-I MMP-7 CadherinE KPCI 0.831 0.79 1.621 0.869
51 BLC ERBBI METAP I , CK-MB 0.826 0.793 1.619 0.864
52 CK-MB BMP-I KPCI CadherinE 0.808 0.814 1.622 0.869
53 C9 ERBBI ,METAP I CadhcrinE 0.845 0.781 ,
1.626 0.884
, 54 CD30Ligand KPCI CadherinE ERBBI 0.822 0.8 1.622 0.875
55 , CNDP1 ERBB1 CadherinE IMB I 0.831 0.795 1.626 0.878
56 Cadherin-6 CadherinE HSP90a ERBBI 0.803 0.807 1.61 0.864
, 57 RGM-C CK-MB ERBBI CalpainI 0.808 0.829 1.636 0.88
58 Catalase FISP9Ob ERBBI CadherinE 0.826 0.788 1.614 0.87
59 CathcpsinH CSK ERBBI CadhcrinE 0.822
0.795 1.617 ' 0.878
60 FGF-I 7 CadherinE ERBBI HSP90a 0.831 0.798
1.629 0.878
61 ,MMP-7 ERBBI 1-IMG-1 CadherinE 0.803 0.81 1.612 0.874
62 IGH3P-2 MMP-7 CadherinE KPCI 0.869 0.779 1.647 0.874
63 IL-17B SCFsR KPCI CadherinE , 0.826 0.802
1.629 0.868
64 LGMN METAP1 ERBBI -CadherinE 0.831 , 0.774
1.605 0.865
65 LRIG3 CadherinE ERBBI HSP90b 0.822 0.81 1.631 0.877
66 MEK I MMP-7 CadhcrinE GAPDH,liver 0.826
0.788 ' 1.614 0.874
67 MK13 KPCI ERBBI CadherinE 0.822 0.802 1.624 0.869
68 NACA CSK C9 CadherinE , 0.831 0.788
1.619 0.857
69 CK-MB MMP-7 CadherinE NAGK 0.798 0.819 õ.
1.617 0.873
70 Proteinase-3 CK-MB ERBBI 'GAPDII,liver 0.793 0.814
1.608 0.866
71 Prothrombin CadherinE ERBBI IMB I 0.831 0.786
1.617 0.866
72 VEGF , KPCI CadhcrinE SCFsR 0.826 0.8 1.626 0.868
73 YES RGM-C HSP90a ERBBI 0.836 0.807 1.643
0.887,
74 b-ECGF CK-MB ,METAP I ERBBI 0.822 0.798 1.619 0.875
75 ApoA-T RGM-C HSP90a IGFBP-2 0.84 0.776 1.617 0.862
- _
76 BLC ERBBI METAP I RGM-C 0.831 0.786 1.617 0.866
77 METAP1 FISP90b BMP-1 CadherinE 0.817 0.802 1.619
0.862
78 CD30Ligand METAPI ERBBI YES 0.836 0.786 '
1.621 0.857
79 CNDP1 IMBI Cadherin E IGH313-2 0.831 0.793 1.624
0.872
80 Cad herin-6 C9 CadherinE ERBBI 0.784 0.817
1.601 0.855
-
81 CK-MB ERBBI CadherinE Ca Ipa inI 0.817 0.817
1.634 0.894
82 Catalase CadherinE ERBBI IMB I 0.84 0.774
1.614 , 0.866
-
83 CathepsinH ERBBI HSP90b CadherinE 0.803 0.807 1.61 0.866
84 FGF-17 CadhcrinE ERBBI , CalpainI 0.817
0.807 1.624 0.881
85 1-1MG-1 MMR ERBBI ,CadherinE 0.808 0.805 1.612
0.878
86 , IL-17B , CK-M13 KPCI ERBBI 0.817 0.805 1.622 0.856
87 LGMN CadherinE ERBBI C9 0.789 0.814 1.603 0.857
88 . LRIG3 CadherinE HSP90a CK-MB 0.812 0.814 1.626 0.882
_
89 MEK I METAP I ERBBI CadherinE 0.822 0.788 1.61
0.875
III
CA 3011730 2018-07-18
Table 3 (cont.)
90 CadherinE MKI 3 KPCI CK-MB 0.798 0.824 1.622 0.862
91 NACA CadherinE IISP90a ERBB I 0.826 0.79
1.617 0.868
,..
92 MMP-7 NAGK CadherinE KPCI 0.817 0.8 1.617 0.862
, 93 Prolcinasc-3 KPCI , ERBB I CK-MB 0.798 0.807
1.605 0.855
94 RGM-C Prothrombin HSP90a CK-MB 0.836 0.781 1.617 0.875
95 VEGF METAP I CadherinE ERI3B1 0.845 0.779
1.624 0.88
96 b-ECGF - KPCI CadherinE C9 0.812 0.805 ,
1.617 0.851
97 ApoA-I BMP-I KPCI CadherinE 0.817 , 0.795 1.612 0.857
98 BLC IGFBP-2 KIT' CadherinE 0.817
0.795 1.612 0.865
99 CD30Ligand GAPDH,livcr ERBBI CadhcrinE 0.817 0.802 1.619 0.879
100 CNDP I ERBB1 CadherinE KPCI 0.817 0.8 1.617 0.875
Marker Count Marker Count
CadherinE 74 BLC , 5
ERBB1 68 A poA-I 5
CK-MB 30 b-ECGF 4
KPCI 29 YES 4
METAP1 18 VEGF 4
HSP9Ob 11 P roth rorn b in 4
RGM-C 10 Proteinase-3 4
1ISP90a 10 NAGK 4
MMP-7 9 NACA 4
C9 7 MK13 4
,
MMR 6 MEK I 4
-
IMB I 6 LRIG3 4
IGFBP-2 6 LGMN 4
GAPDH,liver , 6 IL-17B 4
SCFsR 5 11MG-1 4
Calpai n1 5 FGF-17 4
CSK 5 CathepsinH 4 .
CNDP I 5 Catalasc 4
CD30Ligand 5 Cadherin-6 4
BMP-1 _ 5 CATC 2
112
CA 3011730 2018-07-18
Table 4
100 Panels of 5 Benign vs. Cancerous Nodule Biomarkers _
Sens. +
Biomarkers
Specificity Sensitivity Spec. AUC
1 Apo,k-T F,RBBI METAP I RGTY1-C CadhcrinF. 0.873 0.79
1.664 0.89
2 BLC CadherinE HSP9Ou ERBB1 RGM-C 0.822 0.831
1.653 0.877
3 CK-MB IISP90b ERB131 'CSK BMP-1 0.84 0.814
1.655 0.873
4 CSK CadherinE (K-MB . C9 KPCI 085 0.805
1655 0.877
RGM-C CadhcrinE Calpainl ERBB1 CATC 0 854 0.786 1.64
0.877
,
6 CD30Ligund RGM-C ERBB 1 Culpainl CudherinE 0.859
0.807 1.666 0.891
7 CSK IMBI MMP-7 CadherinE CNDP I 0.878 0.793
1.671 0.879
8 Cadherin-6 KPCI ER13B1 CadherinE SCFsR 0.85 0.79
1.64 0.875
9 CadherinE IGF13P-2 GAPDH,liyer Catulase -CK-MB = 0.864
0.802 1.666 I 0.886
Catheps in1-1 ERBB1 CadherinE METAP I (K-MB 0.864 .. 0.795
.. 1.659 0.892
11 CK-MB FGF-17 ERBB I 14SP90a YES 0 822 0.831
. 1.653 . 0.884
12 IIMG-1 (K-MB CadherinE ERBB1 YES 0.836 0.829 1.664
0.893
. 13 CadherinE SCFsR GAPDH-liver (K-MB IL-17B 0.836 0.829
1.664 0.885
14 RGM-C CadherinE ERBB1 FISP90a LGMN 0.836 0.814
1.65 0.879
CSK 11S1'90b .CadherinE LIUG3 . (K-MB 0 859 0.817
1.676 0.88
16 MEK1 , RGM-C ERBB1 . CadherinE 1=ISP90b 0.84
0.829 1.669 0.887
17 YES CK-MB HSP90a MKI 3 ERBB I 0.831 0.829
1.66 0.878
18 MMR METAP I CadherinE RGM-C ERABI 0.873
0.795 . 1.668 0.901
19 NACA CadherinE CK-MB I ISP90a ERBB1 0.85
0.807 1.657 0.879
-
CK-MB ERBB1 CadherinE RGM-C ' NA GK 0.836 0.829 1.664
0.896
21 Proteinase-3 SCFsR KPCI CK-MB CadherinE 0.836
0.821 . 1.657 0.878
22 Prothrombin ,CadherinE CK-MB CalpainI EltBB1 0.854 0.812
1.666 0.895
23 VEGF FISP9Ob ERBB1 CadherinE RGM-C 0.854 0.817
1.671 0.886
24 b-ECGF CK-MB CadherinE GAPD14.1iver 1GFBP-2 0.836
0.819 1.655 0.887
lApoA-I KPCI ERBB I CadherinE MMP-7 0.845 0.812
1.657 0.881
,
26 RGM-C BLC 1-ISP90a .E1213B1 YES 0.822 0.831
1.653 0.871
27 BMP-1 CadherinE IMB1 RGM-C ERBB1 0.854 0.8
1.654 . 0.881
28 CSK SCFsR CadherinE C9 KPCI 0.854 . 0.8 1.654
0.879.
29 CATC METAP I ERBB I CK-MB YES 0.84 0.793
1.633 '. 0.858
CD30Ligaud 1-1SP9Ob CadherinE ER13131 RCM-C 0.84 ' 0.821
1.662 0.884
31 'CNDP1 LRIG3 KPCI SCFsR .CudherinE 0.85 0.812
1.662 0.879
32 Cadherin-6 CK-MB CadherinE ERBB I KPCI 0 822
0.817 1.638 0.878
33 Ca talasc METAP1 MMP-7 CadherinE CK-MB 0.878
0.776 . 1.654 0.886
34 Cathepsin I I ERBB1 Cadhcri n F. META P I RGM-C 0.873
0.781 1.654 0.89
CK-MB FGF-I 7 ERBB1 1-1SP9Ob Cu dherinE 0.826 0.824
1.65 0.886
36 MMR KPCI , CadherinE _ 1-IMG-1 SCFsR 0.845 0.805
1.65 0.876
37 IL-17B GA PDILliver ERBBI CK-MB CadherinE 0.84
0.824 1.664 . 0.889
38 (K-MB ERBB I CadherinE IISP90u LGMN 0817 0.829
1.645 0.887
-
39 ERBB1 14SP9Ou CaulherinE MEK1 RGM-C 0.845 0.814
1.659 0.885
CadherinE MK13 KPCI CK-MB ERBB1 0.826 0.831 1.657 0.883
-
41 NACA CadherinE EIU313 I CSK MMR 0.873 0.781
1.654 0.884
42 YES NA GK CadherinE ER13131 ,(K-MB 0.84 ,
0.821 1.662 : 0.895
43 Proteinase-3 KPCI ERBB1 CadherinE CNDP I 0.84
0.805 , 1.645 0.876
44 Prothrombin CalpainI ERB B I RGM-C CadherinE 0 859
0.8 1.659 0.889
VEGF Ca ipa MI ERBB I METAP I CadherinE 0.878 0.786
1.664 0.88
46 b-ECGF CK-MB CadhcrinE GAPDH.liver MMP-7 0.854
0.8 1.654 0.883
47 Calpain1 ERBB1 CadhcrinE ApoA-1 RGM-C 0.854 0.8
1.654 0.895
,
48 BLC ERBB1 METAP I . YES (K-MB 0.836 0.814
1.65 - 0.867
49 CNDP1 BMP-I IMB1 CadhcrinE ERBB I 0.845 0.807
1.652 0.879
-
113
CA 3011730 2018-07-18
Table 4 (cont.)
50 SCFsR C9 METAP I KPCI CadhcrinE 0.854 0.798
1.652 0.874-
_
51 CK-MB SCFsR KPCI CadhcrinE CATC 0.85 0.781 1.631
0.865
- _ -
52 ,CD30Ligand KPCI CK-MB CadhcrinE SCFsR 0 845 0.817
1.662 0.882
_ _
, 53 Cadhcrin-6 CadherinE -IISP90a F.RBB I RUM-C 0.826 0.807
1.633 0.874-
,
54 Ca ta lase HSP90b ERBB I Ca dherin E CK-MB 0.85
0.802 1.652 0,883
-
55 CathepsinH CSK ERBB I CadherinE CK-MB 0.836
0.817 1.652 0.894-
_
56 CK-MB CNDP I METAP I ERBB1 FGF-17 0,85 0.8 1.65
0.873
57 CK-MB MMP-7 CadherinE HMG- 1 . ERBB I õ
_
0.808 0.84 1.648 0.886
58 IGFBP-2 ERBB1 Calpa inI RUM-C CadherinE ' 0.845 -
0.826 - 1.671 0.901
_
59 IL-17B CadherinE ERBB I -Ill SP9Ob RUM-C 0.84
0.824 1.664 0.881
_ _
60 L GMN I ISP9Ob CadherinE ERBB I RGM-C 0.831
0.81 1.641 0.876-
61 LRIG3 CadherinE METAP1 1-ISP9Ob M MP-7 0.878
0.786 1.664 0.874-
62 MEK1 CalpainI ERBB I RGM-C CadherinE ' 0.831 -
0.821 -,_ 1.652 0.893
63 MK13 SCFsR KPCI CadherinE MMR 0.854 0.802 1.657
0.883
_
., 64 NACA CK-MB ERBB I CSK CadherinF, 0.85 0.8 1.65
0.885
_ -
65 Calpainl ERBB I Cad heri nE NAGK RGM-C 0.854
0.798 - 1.652 0.891
_
66 Proteinase-3 SCFsR CadherinE KPCI , CNDP I 0.836
0.807 1.643 0.877-
67 CK-MB MMP-7 Cadhcrin E Proilirombin METAP1 0.883 -
0.776 1.659 0.887-
, -
68 RUM-C CadherinE Calpainl VEGF ERBBI 0.869 0.793
1.661 0.897-
69 SCFsR MMP-7 METAP1 b-ECGF CadherinE 0.883 -
. 0.769 1.652 0.885-
_
70 - RUM-C CadherinE MMR CiAPDH.liver , ApoA -1
0.85 0.802 1.652 0.887
71 BLC SCFsR KPCI CadhcrinE MMP-7 085 0.798 1.647
0./175-
72 , BMP-1 ' CSK CadherinE 1-1SP9Ob , RGM-C 0.85
0.802 1.652 0.873-
73 BMP-1 CadherinE KPCI C9 M F.TAP 1 0.859
0.793 1.652 0.863-
74 CATC Cad herin E HSP90a ERBB I MT M-C ' 0.831
0.793 , 1.624 0.866
75 CD30Ligand KPCT CK-MB CadhcrinE ER BB I 0.84 0.817
1.657 0.887
76 Cadherin-6 RGM-C ERBB I CadherinE CalpainI 0.836
0.798 1.633 0.876
77 CK-MB Catalase KPCI CadherinE IGFBP-2 0.854 0.798
1.652 0.879-
-4
78 CathepsinI1 IMB I CadhcrinF, ERBB1 RUM-C 0.859
0.79 1.65 0.882-
79 CK-MB ERBB1 CadherinE NAGK FGF-17 0.826 0.821
1.648 0.888-
, - _
80 11MG-1 11SP90a ERBB I RUM-C CadherinE 0.836
0.812 1.648 0.886
81 YES CK-MB ERBB I META P1 IL-17B 0.845 0.814
1.659 0.871
_ _ _
82 LGMN CadherinE ERBB1 C9 CSK 0.84 0.8 1.64 0.875-
- , -
83 LRIG3 KPCI CadherinE SCFsR CK-MB 0.85 0.812 1.662
0.879-
84 YES CK-MB ERBB I METAP1 MEK1 0.831 0.817
1.648 0.873
-
85 MKI3 IISP9Ob MMP-7 CadherinE META PI 0 859 0.793
1.652 0.871
_ , - -
86 NACA CSK MMP-7 CadhcrinE ERBB I 0.873 0.776
1.649 0.883
87 Proteinase-3 , KPCI ERBB I CK-MB CadherinE 0.822
0.819 1.641 0.883
1
88 Prothrombin CadherinE ERBB I KPCI YES 0.845 0.807
1.651 0.872
_
89 VEGF CadhcrinF, HSP90a RUM-C ERBB1 0.84 0.817
1.657 0.89
90 b-ECGF Calpaird ERBB I CK-MB CadherinE 0.822
0.829 1.65 0.894
_
91 ApoA-I ERBB1 METAP1 RGM-C Cal pain1 0,85 0.8
1.65 0.865-
92 BLC CadhcrinE CalpainT ERBB I RUM-C 0.836
0.81 1.645 0.884
93 ,12GM-C CadherinE ERB131 11SP90a CATC 0.831 -4
0.793 1.624 0.866
_, 94 CD30Ligand ,CSK ERBB I CK-MB , YES 0.817 0.836
1.653 0.876
_
95 Cadherin-6 FISP90b CadhcrinE ERBB1 RUM-C 0.826 0.8 ,.
1.626 0.877
96 MMR KY CI CadherinE Cata lase SCFsR. 0.859
0.788 1.647 0.871
97 ' LRIC13 CadherinE METAP I 11 SP9Ob Ca thcpsi ril I
0.854 0.79 ..., 1.645 0.866
98 CK-MB ERBB1 CadherinE GAPDH.liver -FGF-17 - 0.826
0.821 ,,, 1.648 0.888-
99 HMG- I KPCI ERI313 I C ad herinE MMR 0.845
0.802 , 1.647 0.882
100 CK-MB ICIEB P-2 ,. CSK ERBB I CadherinE '
0.826 - 0 813 1.66 0.906
_ . _
-
114
CA 3011730 2018-07-18
Table 4 (cont.)
Marker Count Marker Count .
Cadherin E 89 C a theps hal 5
ERBB ] 71 Catalase 5
CK-MB 43 Cadhcrin-6 5
RGM-C 34 , CD3OLigand 5
KPCI 24 CATC 5
METAP I 19 C9 5
.,
SCFsR 15 BMP-1 5
HSP9Ob 14 BLC 5
Ca IpainI 14 ApoA-I 5
HSP90a 13 b-ECGF 4
CSK 13 VEGF 4
YES , 11 Pro throm bin 4 . MMP-7 Ii Pro
teina se-3 4
MMR 7 NACiK 4
GAPDH,liver 7 NACA 4
CNDP1 6 MK I 3 4
LRIG3 5 MEK I , 4
IGFBP-2 5 LGMN 4
._..,.
HMG-1 5 1MB 1 4
FGF-17 5 1L-17B 4
115
CA 3011730 2018-07-18
a
W
0
I-
I-
-.1
W
0 100 Panels of 6 Benign vs.
Cancerous Nodule Blom arkers
Sens. +
N
0 Biomarkers
Specificity Sensitivity Spec. AUC
I-'
CO 1 ApoA-I ERBB1 METAP I RGM-C Calpainl
CadherinE 0.873 0.802 1.676 0.888
O 2 B LC CadherinE METAP 1 ERBB1 CK-MB
YES 0.869 0.805 1.673 0.889
-4
I 3 RGM-C BMP-1 HSP906 CadherinE META P I
MIVIR 0.869 0.802 1.671 , 0.881
I-'
co 4 RGM-C C9 ERBB I , CadherinE METAP I
CK-MB 0.878 0.8 , 1.678 0.905
RGM-C . CadherinE Ca [pa inI ERBB1 ,CATC CK-MB ,
0.864 0.79 1.654 0.889
6 RGM-C CadberinE KPCI CK-MB SCFsR
CD30Ligand 0.859 , 0.819 1.678 0.888
7 RGM-C CK-MB ERBB1 CSK CadherinE CNDP1
0.864 0.819 1.683 0,904
8 Cadherin-6 RGM-C ERBB I CadherinE
Ca 1pa i nI VEGF 0.845 0.814 1.659 0.88
9 CK-M13 IGFI3P-2 KPC1 ERBB1 CadherinE
Cata lase 0.869 0.805 1.673 0.892
. 10 CathepsinH CadherinF, HSP90a ERBB1 RGM-C
IGFBP-2 0.836 0.836 , 1.671 0.889
11 RGM-C FGF-17 , ERBB1 Ca IpainI
CadherinE HSP90a 0.873 0.802 1.676 0.889
12 YES CadherinE ERBB I RGM-C
GAPDH.liver CK-MB 0.859 0.829 1.688 0.9
_
13 HMG-1 CK-MB CadherinE ,ERBB 1 HSP90a
YES 0.864 0.821 1.683 0.897 -I
_
14 METAN HSP9Ob CadherinE ERBB I RGM-C
IL-17B 0.878 0.81 1.687 0.882 cr
MMR , ERBB1 CadherinE liMB1 CalpainI RGM-C 0.873
0.805 1.678 0.894
a)
16 CK-MB ERBB1 CadherinF, HSP90a LGMN YES
0.859 0.821 1.681 0.891
CTI
17 CK-MB CNDP1 KPCI CadherinE SCFsR LIUG3
0.864 0.817 1.681 0.886
.,
18 MEK 1 Ca IpainI ERBB1 RGM-C
CadherinE CD30Ligand 0.869 0.807 1.676 0.889
19 ,MK13 MMP-7 KPCI CadherinE SCFsR ,CK-MB
0.869 0.812 1.68 0.889
,
NACA CadherinE ERBB1 IvIETAP1 CK-MB MMP-7
0.878 0.795 1.673 0.889
21 YES NAGK CadherinE ERBB1 CK-MB HSP90a
0.878 0.814 1.692 0.897
22 Proteinase-3 , KPCI ERBB1 CK-MB
CadherinE ,CNDP1 0.859 0.821 1.681 0.885
23 CK-MB CNDP1 KPC1 CadherinE SCFsR
Prothrombin 0.873 0.81 1.683 , 0.885
24 b-ECGF CadherinE ERBB1 HSP90b RGM-C CK-MB
0.845 0.829 1.674 0.895
ApoA-I CSK ERBB1 CK-MB
CadherinE .RGM-C - 0.85 0.824 1.674 0.907
26 ' RGM-C CadherinE ERBB1 ,CSK 'BLC
CK-MB 0.84 0.826 , 1.667 0.895
,.
27 B MP-1 CadherinF, IMB I CK-MB F,RBB I
LRIG3 0.859 0.81 1.669 0.883
28 , SCFsR C9 CadherinE
GAPDH,liver KPCI MMP-7 0.869 0.807 1.676 0.884
29 RGM-C CadherinE Calpainl CK-MB ERB131
cA-rc 0.864 0.79 1.654 0.889
a
(A)
0
1-,
I-'
--.1
w 30 RGM-C HSP9Ob ERBB I SCFsR
CadherinE ,Cadherin-6 0.859 0.8 1.659 0.885
o
, 31 RGM-C CadherinE ERBB I
GAPDH,liver CK-MB Cata lase 0.85 0.821 1.671 0.901
N
0 32 Cathepsinli RGM-C META P I CK-MB
CadherinE ERBB I 0.873 0.798 1.671 0.903
1-'
CO 33 RGM-C FGF-17 ERBB I CalpainI
CadherinE IGFBP-2 0.845 0.826 1.671 0.893
oi
34 HMG-1 RGM-C ERBB I CadberinE , MMP-7
CK-MB 0.85 0.833 1.683 0.896
--.1
1 35 IL- I 7B Ca Ipaini ERI3131 .RGM-C
CadherinF. CK-MB 0.864 0.817 1.681 0.898
1-'
co 36 LGMN 1-1SP9Ob CadherinE ERBB I 1RGM-C
SCFsR 0.869 0.81 1.678 0.886
-
,
37 MEK I GAPDH,liver ERBB1 CK-MB CadherinE
YES 0.845 0.829 1.674 0.902
38 MK13 FISP90b ERBB I RGM-C CadherinE
CK-MB 0.85 0.824 1.674 0.892
39 NACA CadherinE. ERB131 CSK RGM-C MMR
0.892 0.781 1.673 0.895
40 YES CadherinE ERBB I RGM-C NAGK
METAP I 0.897 0.788 1.685 0.885
41 Prot ein ase-3 KPCI CK-MB CadherinE
IGH3P-2 SCFsR 0.864 0.807 1.671 0.888
42 , Prot hrom bin Calpainl ERJ3B1 RGM-C
CadherinE CK-MB 0.864 0.812 1.676 0.904 H
CD
43 VEGF HSP90b ERB B I CadherinE RGM-C
YES 0.873 0.814 1.688 0.888 Cr
44 b-ECGF CadherinE ERBBI HSP90b RGM-C
METAP I 0.873 0.8 1.673 0.884- -
CD
_...
- 45 LR1G3 KPCI CadherinE SCFsR ApoA-
1 CNDP I , 0.869 0.805 1.673 0.88
46 CadherinE MK.13 KPCI CK-MB ERBB I
BLC 0.845 0.819 1.664 0.879
47 BMP- I CadherinE ERBB1 KPCI YES
SCFsR , 0.864 0.805 , 1.669 0.888 0
-
48 CSK CadherinE C9 ERBB I CD3OLigand YES
0.859 0.812 1.671 0.883 0
M
49 RGIVI-C CadherinE Calpainl ERBB I CATC
IGFI3P-2 0.85 0.802 1.652 0.881 ,--i-
50 LRIG3 KPCI CadherinE SCFsR CK-MB
Cadberin-6 0.85 0.807 1.657 0.874 '----
51 Cata lase , CadherinE ERBB1 KPCI RGM-C
CK-MB 0.85 0.819 1.669 0.89
,
52 CSK GAPDH,liver ERBB1 CadherinE YES
CathepsinH 0.873 0.798 1.671 0.89
53 RGM-C FGF-17 ERBB I CalpainI
CadherinE CD.10Li5and 0.859 0.812 1.671 0.884
54 HMG-1 RGM-C ERBB I , CadherinE MMR
CalpainI 0.859 0.819 1.678 0.901
55 IL-17B CadherinE ERBBI MF,TAP I RGM-C
VF,GF 0.883 0.795 1.678 0.884
56 CSK LMB I MMP-7 CadherinE , ERBB I
CK-MB 0.869 0.807 1 676 0.897,
57 MMP-7 ERBB I CadherinE LGIVIN CSK
YES 0.864 0.81 1.673 0.884
58 , CalpainI ERBB I CadherinE NAGK
RGM-C MF,K1 0.854 0.819 1.674 0.892
59 CK-MB IVIMP-7 CadherinE NACA METAP I
RGM-C 0.887 0.783 1.671 0.884
60 Proteina se-3 CadherinE ERBB1 RGM-C
CalpainI , MMP-7 0.859 0.81 1.669 0.893
61 Prothrombin CadherinE ERBB I HSP90b METAP
I YES 0.873 0.802 1.676 0.87
C)
w
0
I-
I-.
-.1
w
0 62 b-ECGF CadherinE ERBB I METAP1 RGM-C
VEGF 0.873 0.8 1.673 0.886
t..) 63 ApoA-1 ,HSP9Ob CadherinE ERBB1
RGM-C MEK 1 0.845 0.826 1.671 0.89
o 64 B LC ERBB1 METAP I RGM-C CK-MB YES
0.859 0.805 1.664 0.881
1-.
co 65 RGM-C BMP-I ERBB1 METAP1 CadherinE HSP90b
0.869 0.8 1.669 0.888
o1
66 CK-MB N1vIP-7 CadherinE HMG-1 KPCI C9
0.854 0.814 1.669 0.88
--.1
1 67 CK-MB ERBB1 CadherinE RGM-C HSP90a
I CATC 0.84 , 0.81 1.65 0.882
1-`
CO 68 Cadherin-6 RGM-C , ERBB I CadherinE
Ca IpainI MMR 0.836 0.814 1.65 0.885
69 C adherin E 1GFBP-2 METAP1 ERBB I
CK-MB Catalase 0.873 0.795 1.668 0.901
70 CathepsinH ERBB1 CadherinE META P I
RGM-C NAGK 0.869 0.798 1.666 0.889
71 FGF-17 CadherinE KPCI ERBB1 SCFsR
CK-MB 0.85 0.819 , 1.669 0.89
72 IL-17B CadherinE ERBB1 Calpai n1
VEGF METAP I 0.878 0.795 1.673 0.877
73 MMR ERBB1 CadherinE IMB1 RGM-C METAP1
0.883 0.793 1.675 0.894 ....1
74 RGM-C CadherinE ERBB1 HSP90a LGMN VEGF
0.85 0.814 1.664 0.881 0)
75 RGM-C ,IVIKI3 ERBB1 AETAP 1
CadherinE MMR 0.869 0.805 1.673 0.896 Cr
76 CNDP1 CadherinE CSK ERBB I VEGF
NACA 0.883 0.786 1.668 ' 0.884 a)
....
_
- 77 CadherinE HSP90b ERBB1
Proteinase-3 , RGM-C SCFsR 0.85 0.817 1.666 , 0.889 ()I
oo
78 Prothrombin CadherinE ERBB1 HSP90b RGM-C
VEGF 0.859 0.812 1.671 0.886 ==-===
0 79 b-ECGF CadherinE ERBB1 Calpaird
HSP 90b CK-MB 0.845 0.826 1.671 0.887 0
80 ApoA-1 MMP -7 CadherinE KPC1 SCFsR
LRIG3 0.869 0.802 1.671 0.885 n
1.--1-
81 RGM-C CadherinE ERBB1 , CSK BLC
MMP-7 0.836 0.824 1.659 0.883 =
.
- -.....=
82 BMP-1 ERBB1 HSP90a RGM-C CadherinE CK-MB
0.822 0.845 1.667 0.896
83 HMG-1 , KPCI ERBB I CadherinE MAR
C9 , 0.859 0.81 1.669 0.884
84 RGM-C HSP90b F,RBB1 SCFsR CadherinE
CATC 0.864 0.786 1.65 _ 0.879
85 RGM-C CadherinE ,CalpainI CK-MB
CD30LIgand ERBB1 .., 0.869 0.81 1.678 0.903
86 Cadherin-6 CK-MB CadherinE ERBB1
KPCI CNDP I 0.84 0.81 1.65 0.881
87 CadherinE IGFBP-2 GAPDH,liver CK-MB
MKI 3 Cata lase 0.859 0.807 1.666 , 0.885
88 CathepsinH RGM-C METAP I CK-MB
CadherinE MMP-7 0.878 0.788 1.666 0.901
89 SCFsR ,ERBB1 CalpainI FGF-17
CadherinE RGM-C 0.864 0.805 1.669 0.895
90 IL-178 CadherinE ERBB I NAGK , CK-MB
RGM-C 0.831 0.84 1.671 0.891
91 SCFsR ER13B1 CadherinE EMB I RGM-C
LRIG3 0.873 0.798 1.671 , 0.887
92 LGMN CadherinE ERBB1 C9 CSK 1GFBP-2
0.854 0.81 1.664 , 0.88
...
93 , MEK I RGIV1-C ERBB1 CadherinE
METAP I NAGK 0.878 0.795 1.673 0.885
0
t...)
o
1-.
1-=
-..1
co
o 94 NACA CadherinE ERBB I --
METAP1 MMR RGM-C 0.883 0.786 1.668 0.89
-
n.) 95 Proteinase-3 SCFsR CadherinE KPC1 ,
MMP-7 CK- MB 0.854 0.812 1.666 0.885
o .
1-= 96 CK-MB NLMP-7 CadherinE
Prothrotnbin GAPDH.liver ,SCFsR 0.869 0.802 1.671 0.897
co
1 97 b-ECGF C.a IpainI ERBB I , RGM-C
CadherinE HSP90b 0.854 0.817 1.671 0.885
o 98 ApoA -I ¨RGM-C -HSP90a
ERBB1 CadherinE CalpainI 0.869 0.802 1.671 0.897
-..1
-
1 99 BLC CadherinE MET AP I BABB] ,CK-
MB RGM-C 0.854 0.805 1.659 0.898
1-=
co 100 YES CK-MB ERBBI CadherinE
GAPDH,liver BMP-1 0.845 0.821 1.666 0.894
-
Marker Count . Marker Count
CadherinE 99 C9 6
ERBB I 84 B IVO -1 6
RGM-C 63 BLC 6
CK-MB 49 ApoA-I 6
¨I
METAP I 24 b-ECGF 5
2.) Calpa in' 22 Prothrombin 5 0-
_
¨ SCFsR 19 Proteinase-3 5
CD
:ID ,
KPCI 19 NACA 5
01
,
HSP90b 16 Iv1K13 5
YES 15 MEKI 5
0
0
MMP-7 14 LGMN 5
=
CSK 11 1MB I 5
.-4-
_
........,
MMR 9 1L-173 5
HSP90a 9 HMG-1 5
VEGF 8 FGF-17 5
,IGEBP-2 8 CathepsinH 5
GAPDH.liver 8 Ca tal ase 5
CNDP 1 7 Cadherin-6 5
NAGK 6 CD30Ligand 5
LRIG3 6 CATC 5
Table 6
100 Panels of 7 Benign vs. Cancerous Nodule Bionta rkers
Sens. +
Biotin arkers Specificity Sensitivity Spec. A
UC
1GF13P-2 ERBB I HSP90a RGM-C
1 0.859 0.833 1.692 0 903
CadhcrinE SCFsR ApoA-1
BLC Cad herin E META PI ER BB1
2 0.878 0.7911 1.676 0
901
CK-MB RGM-C MMP-7
1ISP9Ob GA PDH.liver ERBB 1 CadherinE
3 0.873 0.817 1.69
0,891
CI(-MB LRIG3 BMP-1
CK-MB CadherinE KPCI C9
4 0.892 0 807 I 699
0.891
SCFsR CSK LRIG3
SCFsR ERBEI1 CadherinE Cal pain]
0.869 0,802 1 671 0.88
HSP90b RUM-C CATC
CD30Ligand KPCI ERBB 1 SCFsR
6 0.878 0.814 1.692
089
CadherinE CK-MB Calpainl ,
YES CN DPI 11S P90a ER13B1
7 0.883 0.817 1 699 0
902
RUM-C CadherinE SCFsR
MMP-7 ERBB1 CadherinE Calpainl
8 0.85 0.831 1.681 0 895
CI(-M13 ROM -C Ca dherin-6
Catalase CalpainI CadherinE ERBB I
9 0.873 0.817 1.69 0
903
RUM-C CK-MB CNDP1
M M R SCFsR CadherinE GA P DH,liver
0.906 0.786 1.692 0.898
RUM-C Prothrombin Ca thepsinli
,
SCFsR ERBB1 RGM-C HSP90a
11 0 887 0.805 1 692
0.896
CadherinE FGF-17 Ca 1painl
,
HMG- 1 RUM-C ERBB I CadherinE
17 0.859 0.843 1 702 0
899
CK-MB YES SCFsR .
1L- 1 7B CadhcrinE ERBB I M ETAP1
13 0.883 0.81 1.692
0.894
CK-MB 11 S P9Ob SCFsR ,
SCFsR ERBB1 CadherinE IMB1
14 0.887 0.807 1 694
0.9
CSK CNDP I CK-MB
LGMN 11S P906 CadherinE ER13131
0.873 0.807 1.68 0 886
RUM-C SCFsR VEGF
MEK I RUM-C ERBB 1 CadherinE
16 0.883 0.814 1.697
0.9
CK-MB METAP1 NAGK ,
MMR ERBB I METAP1 CK-MB
17 0.887 0.802 169
0.909
CadherinE RGM-C MK13 ,.
RGM-C METAP1 SCFsR ERBB I
18 0.906 0 798 (704
0.886
HSP90a CadherinE NACA
C:K-MB CNDP I KPCI CadherinE
19 0.864 0.824 1 688 0
887
SCFsR Pro teinase-3 LRIG3
h-I(:(iF CadherinE ER13131 M ETA PI
0.883 0.817 1.699 090!
RGM-C CK-MB YES
YES CadherinE KPCI CK-MB
2 I 0.873 0.812 1.685
0.892
ER13131 I ISP90a ApoA-1
, .
RGM-C METAP1 SCFsR ERBB1
22 0.883 0 793 1 675 0.889
HSP90a CadherinE BLC
RUM-C KPCI SCFsR BMP-1
23 0.873 0.814 1.688
0.889
CadherinE CK-M B HSP90a
' RUM-C CadherinE KPCI CK-MB
24 0.878 0.817 1.695
089
HSP90a SCFsR C9
' M ETA PI HS P9Oh CadherinE F,RB Ill ,
0
887 0.774 1 661 0.884
RUM-C SCFsR CATC
120
CA 3011730 2018-07-18
Table 6 (cont.)
CD30Ligand GAPDH,liver ERBB I __ CK-MB
26 0 864 0.826 1.69 0.905
CadherinE RGM-C YES .
27 12.(-'iM-C HS P9Oh ER BB 1 SCFsR
0 869 0,805 1 673 0.886
CadherinE Cadherin-6 CNDP1 ,.
28 Catala se CalpainI CadherinE ERBB I
0.869 0.817 1.685 0 888
RGM-C CK-MB KPCI
CathcpsinH ERBB1 CodherinE METAP I
29 0.883 0.805 1 687 0 904
YES RGM-C CK-MB
CK-MB ERBB I CadherinE GAPDH,liver
30 0.873 0.817 1.69 0 902
FGF-17 MM P-7 METAP I
1-IMG-1 CK-MB CadherinE ERBB1
31 0.873 0.826 1.699 0 905
HSP90a RGM-C YES
IIMG-1 CK-MB CadherinE ER131.11
32 0.859 0 836 1.695 0.905
HSP9On RGM-C 1GFBP-2
METAP I 1-JSP90b CadherinE ERBB I
33 0.892 08 1.692 0.892
RGM-C SCFsR IL-17B
,
SCFsR ERBB1 CadherinE METAPI
34 0.901 0 793 1.694 0.9
IMB I RGM-C M MP-7
RGM-C FISP9Ob ERBB1 SCFsR
35 0.854 0.821 1.676 0.886
CadherinE MEK1 LGMN
CK-MB MMP-7 CadherinE KPC1
36 0,873 0.814 1 688 0,894
SCFsR CSK MK13
NACA CadherinE ER3131 M ETA P1
37 0 897 0.805 1.701 0 891
CK-MB MMR LRIG3
SCFsR ERBB I CadherinE Calpainl
38 0.892 081 1.702 0 902
I2GM -C NAG K C K -MI1
Proteinase-3 GAPDH.liver ERBB 1 CadherinE
39 0.854 0.829 I 683 0 901
CK-MB YES SCFsR
RGM-C CadherinE KPCI CK-M13
40 0.859 0.829 1.688 0.887
SCFsR CD30Ligand Prothrombin
VEGF RGM-C ERBB I METAP I
41 0.892 0.802 1.694 0.905
CK-MB CadherinE YES
b-ECGF Ca dherinE ERBB I IISP90b
42 0.892 0.8 1.692 0.895
RGM-C SCFsR METAP I ,
-
METAP1 GA PDH,livcr MMP-7 Ca c1herinE
43 0.892 0.793 1.685 0.894
ER13131 ApoA-I YES
-
CalpainI HSP90a CK-MB RGM-C
44 085 0.824 1.674 0 892
ERBBI CadherinE BLC ,
VEGF RGM-C ERBB 1 METAP I
45 0.887 0 798 1.685 0.895
CadherinE Calpaint B MP-1 =,
CK-MB CadlierinE KPCI C9
46 0.897 0.795 1 692 0.896
SCFsR CSK M MP-7
KPCI CalpainI CadherinE CK-MB
47 0 869 0,79 1 659 0.879
IGFBP-2 ERBB1 CATC
RGM-C CK-MB FRBF11 I M B I
48 0.873 0.8 1.673 0.888
CadherinE SCFsR Ca dherin-6 ,
SCFsR ERBB I CadherinE METAP I
49 0.897 0.788 1 685 0 903
RGM-C MMR Ca ta lase
-
i 21
CA 3011730 2018-07-18
Table 6 (cont.)
CathcpsinH ERBB1 CadherinE META P I
50 0 892 0.795 1 687 0 889
YES RGM-C GAPDH,liver
CK-M13 ER 3I31 CadherinE NAGK
51 0 854 0.833 1 688 0.896
FGF-17 RGM-C SCFsR
Ca Ipa inl ERBB1 CadherinE NAGK
52 0.869 0.819 1.688 0.898
CK-MB IL-17B RGM-C ...
VEGF Ca Ipainl CadherinE CK-MB
53 0.859 0.817 1.676 0 893
ERBB I RGM-C LGMN ,
MEK I RGM-C ERBB1 CadherinE
54 0.864 0.824 1.688 0.902
METAP1 YES CK-MB
SCFsR ERBB I CadherinE METAPI
55 0.887 0.8 1.687 0.901
RGM-C MMR MK13
CK-M13 MMP-7 CadherinE NACA
56 0.901 0.795 1.697 0.897
METAP1 RGM-C ERBBI
MM P-7 ERBB1 CadherinE Ca Ipainl
57 0.859 0.824 1.683 0.894
CK-MB Proteinase-3 YES
MMR ERBB1 METAP I CK-MB
58 0.901 0 786 1 687 0.9
CadherinE YES Prothrombin .
b-ECGF CK-M13 NAGK CadherinE
59 0.869 0.821 1.69 0 893
Calpainl ERBB 1 CD30Ligand .
CadherinE IGFI3P-2 HSP90a CK-MB
60 0.84 0.843 I 683 0.907
ERBB I RGM-C ApoA-1 -
SCFsR ER13131 CadherinE Calpain I
61 0.859 0,814 1 673 0.891
RGM-C CK-MB BLC
-
METAP I IMB I ERBB I CadhcrinE
6") 0.901 0.783 1.685 0.886
YES 13M P-1 RGM-C
CadherinE METAP1 CK-MB C9
63 0.883 0 807 1.69 0 907
ERBB1 IGFBP-2 SC FR .
YES CadherinE ERBB1 RGM-C
64 0.878 0.781 1 659 0.876
NAGK METAP1 CATC -
CadherinE IGFBP-2 HSP90a CK-MB
65 0.845 0.826 1.671 0.891
ERBB1 RGM-C Cadherin-6 ,
Cata1ase IISP90b ERBB1 CadherinE
0
66 ,878 0.802 1.68 0.893
CK-MB YES LRIG3
. .
CathepsinH CSK ERBB1 RGM-C
67 0.873 0.812 1.685 0.9
CadherinE SC l'sR 1G FBP-2
RGM-C CK-MB ERBB1 METAP I
68 0.878 081 1 687 0.893
FGF- I 7 CadherinE HSP90b
-
CadherinE HSP90b ERBB I HMG-1
69 0.878 0.821 1.699 0.897
RGM-C SCFsR CK-MB
1L-17B CK-MB KPC1 CadherinE
70 0 883 0.805 1.687 0.888
ERBB I SCRR NAGK
MMP-7 ERBB1 CadherinE LGMN
71 0 859 0.817 1 676 0.894
CSK YES CK-M13
-
MF.KI RGM-C ERI3131 CadherinE
77 ' 0.864 0.821 1 685 0.902
CK-MB Calpa i n1 CSK .
RGM-C CadherinE KPCI CK-MB
73 0.873 0 812 1 685 0 887
HSP90a IGEBP-2 MK13
. -
M M P-7 ER BB1 YES M ItTA PI
74 0 897 0.793 1 69 0.89
CadherinE NACA CK-MB
i 22
CA 3011730 2018-07-18
Table 6 (cont.)
'SCFsR _________ ERBB1 CadherinE Calpainl -
75 0.859 0.824 1 683 0 892
RGM-C MEKI Protein:kw-3
Prothrombin CadherinE ER B B I Ca Ipainl
76 0.854 0.831 1.685 0 883
YES CK-MB KPCI
b-ECGF CadherinE ERBB 1 FISP90a
77 0.873 0.817 1.69 0.901
CalpainI CK-MB RGM-C
METAPI HSP90b CadherinE ER BB 1
78 0.878 0 805 I 683 0.884
RGM-C AnoA-I YES
BLC CadherinE METAPI ERBB I
79 0.869 0.805 1.673 0.899
CK-MB RGM-C SCFsR .
RGM-C CadherinE ERBB I CSK
80 0.85 0.833 1.683 0.894
BMP-1 CK-MB LRIG3
CK-M13 161,13P-2 CSK CadherinE
81 0.887 08 1 687 0.896
KPCI SCFsR C9
82 GAPDH,liver Ca 'paint ERBB 1 CadherinE
0.859 0.795 1.654 0.89
CK-MB 101,111'-2 CATC
SCFsR ERBB1 CadherinE METAPI
83 0 883 0.807 1.69 0.894
CD30Ligand RGM-C I-I SP9Ob
b-ECGF CalpainI ERBB1 RGM-C
84 0.845 0.824 I 669 0.892
CadherinE CK-M B Ca dherin-6 .
Catalase CadherinE ERBB I KPCI
85 0.883 0.798 1.68 0.891
YES SCFsR CNDP1
RGM-C Cadherin I', KPCI C K -M11
86 0 883 0.802 1.685 0.887
HSP90a SCFsR CathcpsinH
-
RGM-C CK-MB ERBB I METAPI
87 0.883 0.805 1.687 0.898
FG1,-17 CadherinE NM:1K
RGM-C CadherinE KPCI CK-MB
88 0.869 0.819 1.688 0.893
SCFsR ERBB I HMG-1
IL-17B GAPDH.liver ERBB 1 CK -MB
0
89 .854 0.831 1.685 0 898
CadherinE RGM-C YES ,..
RGM-C CK-MB ERBB I IMB I
90 0.878 0.814 1.692 0.898
CadherinE SCFsR CNDP I
CNDP I ERBB1 CadherinE KPCI
91 0.873 0.802 1 676 0.885
SCFsR YES LG MN
92 CadherinE MK13 KPCI CK-MB
0.883 0.8 1.683 0.897
M MR ER13111 CSK
NACA CadherinE ERBB I METAPI
93 0.915 0.774 1.689 0.896
MMR RGM-C SCFsR
,
CD30Ligand KPCI ERBB 1 SCFsR
94 0.864 0.817 1.681 0.889
CadherinE CK-MB Proteinase-3 ,
-
CadherinE METAPI CK-MB HSP90b
95 0.869 0.817 1.685 0.884
ERBB 1 YES Prothrombin
'YES CadherinE ERBB I CSK
96 0.864 0.829 1.692 0.906
VEGF CK-MB RGM-C
METAPI HSP9Oh CadherinE ERBB1
97 0.878 0.805 1.683 0.895
RGM-C ApoA-1 1GF13P-2 ,
RGM-C METAPI SCFsR ERBB I
98 0.869 0.805 1.673 0 899
CK-MB CadherinE BLC . .
LR I G3 CadherinE META P I HS P901)
99 0.873 0.81 1 683 0.892
CK-MB BMP- 1 SCFsR
SCFsR M MP-7 METAPI b-ECG 17
100 0.892 0.795 1.687 0 901
CadherinE C9 CK-MB
-
123
CA 3011730 2018-07-18
Table 6 (cont.)
Marker Count -Marker Count
Cadherin E 100 CD3OLigand 6
ERBB I 87 C9 6
CK-MB 71 BM P- 1 6
RGM-C 68 BLC 6
SCFsR 50 ApoA-I 6
METAP I 38 VEGF 5
YES 26 Prothrorn bin 5
KPCI 11 Proteinase-3 5
CalpainI 21 NACA 5
HSP90b 17 MK13 5
FISP90a 16 MEK I 5 ,
MMP-7 12 LGMN 5
IGEBP-2 11 , 1MB I 5
CSK 11 1L-1715 5
GAPDH,liver 9 HMG-1 5
NAGK 8 FGF-17 5 ,
MMR 8 CatbcpsinH 5
CNDP1 8 Catala se 5
LRIG3 7 Cadherin-6 5
b-ECGF 6 CATC _ 5
124
CA 3011730 2018-07-18
Table 7
190 Panels of 8 Ben irni vs. Cancerous Nodule Biomarkers
Sens. +
Blomarkers Specificity
Sensitivity Spec. AUC
CadherinE IGFBP-2 IISP90a CK- MB
I 0.892 0 819 1.711
0.914
ERBBI RUM-C ApoA-1 CSK
RGM-C METAP1 SCFsR ERBBI
0 883 0 812 1 695 0.897
HSP90a Cad herin E I3LC CK-MB
RUM-C METAP I SCFsR ERBBI
3 0.892 0.81 1.702 0.909
YES CadherinE CK-MB BM P-I ,
SCFsR MMP-7 Ca dherinE KPCI
4 0.906 0 802 1.708 0.897
METAP I RGM-C CK-MB C9 .
CK-MB IGFBP-2 CSK CadherinE
0.869 0.812 1.68 0.892
RUM-C 11R13131 YES CAT(11
. -
RUM-C METAP1 SCFsR ERBBI
6 0.915 0.805 1.72
0.909
YES C ad herinE CD30Ligand CK-MB ,
SCEsR ERBBI HSP90a YES
7 1911. 0.798 1.708 0.899
CadherinE IMB1 RUM-C CNDP I
b-ECGF CadherinE ERBBI 1 ISP9Ob
8 0.878 0.802 1.68
0.885
RUM-C SCFsR HSP90a Cad herin-6
RUM-C CadherinE KPCI CK-M B '
9 0 901 0 812 1 713 0.893
HSP90a ERBBI Calpaial SCFsR
-
CK-MB IGFBP-2 KPCI Cadli erinE
0.897 0.8 1.697 0.891
META P1 SCI4s12 CNDP1 Ca la lase
Cathepsin H CSK ERBBI RGM-C
11 0.906 0.8 1.706 0.898
CadherinE SCFsR KPCI CK-MB
. .
CadherinE M ETA P1 CK-MI3 I IS190b =
12 0.892 0.817 1.709 0.889
ERBBI YES FGF-17 b-ECGF . .
CSK Cad herinE CK-MB GAP DI-Lli ver
13 0.901 0.821 1.723 0,916
ERBBI MMR YES RUM-C
14 CadherinE 1GEBP-2 11SP90a CK-M 3
0.873 0.831 1.704 0.907
ERBBI RUM-C ApoA-I 1-IMG-1
IL-17B CadhcrinE ERBBI METAP I
0.901 0.805 1.706 0.903
CK-M13 RUM-C YES SCFsR
RUM-C HSP90b ER13131 SCFsR
16 0.864 0.821 1.685 0.895
CadherinE CK-MB LRIG3 LGMN . ,
SCFsR ER13131 CadherinE Ca Ipainl
17 0.878 0.829 1.707 0.902
RGIvI-C NAGK CK-MB AIM 1 .
IGEBP-2 MMP-7 CadherinE METAP1
18 0.897 0.81 1.706 0.908
SCFsR RUM-C MK13 CK-MB
-
MMP-7 11R13131 YES CSK
19 0.93 0.779 1.708 0.899
CadherinE RUM-C NACA SCFsR
RUM-C CadherinE pETRBoteBinlase-3 ,(G,.TAisPDH,liver
0.873 0.829 1.702 0.906
SCFsR CK-MB
CadherinE SCFsR GAPDI-Lliver MEK1
2 1 0.901 0802 1.704 0.901
CK-MB RUM-C C a i hepsinH Prot hrombin .
RUM-C METAP1 SCEsit ERBB1
22 0.906 0.812 1.718 0.908
YES CadherinE CK-MB VEGF
RGIvI-C CK-M13 ERBBI METAPI
23 0.892 0.802 1.694 0.893
FGE-17 Cadherin E. NAGK BLC
RGM-C BMP-1 ERBB1 METAP I
24 0 883 0 817 1 699 0.888
CadherinE FISP9Ob SCFsR IMB 1
125
CA 3011730 2018-07-18
Table 7 (cont.)
CSK IG1713P-2 CadherinE ERBBI
C9 NAGK CK-M13 YES 0.878 0.829 1 707 0.903
CK-MB 1M MP-7 M ETAP I REM-C
26 . .
CadhermE M K13 ER13131 C:ATC 0.873 0.805 1
678 0.893
---=
CD30Ligancl RGM-C ERBBI KPCI
27 0.897 0.814 1.711
0.897
CadherinE CK-MB SCFsR Ca I pa inl
-
CD30Ligand REM-C ERBBI KPCI
28 0 869 081 1.678 0.89
CadherinE CK-MB SCFsR Cadherin-6
MEK I REM-C ERBBI CadherinE
29 0.883 0.81 1.692 0.899
METAL'! YES CK-MB Cilia lase .
b-ECGF Calpainl ERBB I RGM-C
0.883 0821 1.704 0.902
CadherinE HMG-1 CK-MB SCFsR
REM-C CK-MB ERBB I 1MB 1
31 0 887 0 817 1.704 0.898
CadherinE SCFsR CNDP I IL-1713
HSP90b KPCI ERBBI CadherinE
32 0.869 0.814 1.683
0.885
RGM-C SCFsR MMR LGMN
SCFsR ERB131 CadherinE, Ca 'pain I
33 0.892 0 814 1.706 0.905
REM -C I ISP90a CK-MB LRIG3 , ,
REM-C METAL'! SCFsR ERBBI
34 0.915 0.788 1.704 0.897
YES CadherinE MMP-7 NACA
,
CadherinE G A PDH,I i ver HSP90a SCFsR
0.878 0.819 1.697 0.901
ERBBI REM-C IGH3P-2 Proleinase-3
SCFsR MMP-7 CadherinE KPCI
36 0.906 0.798 1.704
0.894
Prothrombin REM-C CK-MB lISP90a
CK-MB ERBBI CadherinE NAGK
37 0.887 0.819 1.706
0.907
CSK YES REM-C VEGF .
,
MMR CSK CadherinE CK-MB
38 0.892 0.814 1.706 0.919
RGM-C ERBBI GAPDH,liver ApoA-I ,
BLC CadherinE METAP I ERBBI
0
39 0.897 .798 1.694 0.903
CK-M13 R GM-C MM P-7 GA P DH,liver
YES CadherinE MMP-7 1-IMG-1
0.873 0.824 1.697 0.893
ERBBI CK-MB KPCI BMP- 1
YES C9 ERBBI CSK
0
41 .873 0.831 1.704 0.901
CK-MB CadherinE NAGK FGF-17
REM-C CK-MB ERBBI METAP I
42 0.887 0.79 1.678 0.888 ,
FGF-17 CadherinE NAGK CATC
CN DP1 ERI3131 Cadherinli KPCI
43 0.869 0.81 1.678 0 891
SCFsR REM-C CK-MB Cadherin-6 , ,.
YES 1-ISP9Ob CadherinE ERBBI
44 0.887 0.805 1.692
0.897
CSK REM-C CK-MB Cata lase -
CatliepsinH R GM-C METAP I CK-MB
0.901 0.8 1.701 0.907
CadherinE ERBBI SCFsR YES
META P I 1-ISP9Oh CadherinE ERB B1
46 0.892 0.81 1.702 0.9
RG1vI-C 1L-17B CK-MB SCFsR
._
SCFsR ERBBI CadherinE METAP I
47 0.887 0.795 1.683
0.892
REM-c:MMRIISP9011 LGMN
YES CK-MB ERBBI CadherinE
48 0.883 0.814 1.697
0.907
GAPDH,liver LRIG3 MMR CSK
YES CK-MB ERBBI METAP1
0.897 0.807 1 704 0.907
49 REM-C Cadherin I I M K13 MM R
SCFsR ERBBI CadherinE Ca Ipa in I
0.901 0.8 1.701 0.885
REM-C HSP90a b-ECGE NACA -
126
CA 3011730 2018-07-18
Table 7 (cont.)
Cad herin E NI ETAP I CK-MB IISP9Ob
51 0.892 0 802 1.694 0.897
ERBBI RGM-C SCFsR Pro1einase-3 . _____________
YES NAGK CadherinE ERBBI
0.906 0.795 1.701
0.898
52 (K-MI] M M P-7 M I qA PI Prot hrornbin
-
VEGF METAP I ERBBI YES
53 0.906 0 798 1.704 0.902
CadherinE CK-MB NAGK RGM-C .
CadherinE 1G1113P-2 METAP I ERBBI
54 0.906 0 793 1.699 0.911
RGM-C I ISP90a CK-MB ApoA-I
RGIVI-C CadherinE ERBBI GAPDELliver
55 0.873 0.819 1.692
0.904
SCFsR CK-MB CSK BLC
CK-MB IGFBP-2 KPCI CadherinE
56 0.892 0.805 1.697
0.895
META P I SCFsR CNDP1 BMP- I
CSK SCFsR CadherinE C9
57 0.901 0.802 1.704 0.904
ERBBI IGTO3P-2 CK-MB 1M131
RGM-C METAP I SCFsR ERBBI
58 0.897 0.781 1.678 0.895
YES CadhcrinE CK-MB CATC .
CD3OLiganc1 RGM-C FIR13131 K PC1
59 0.887 0.819 1.706 0.899
CadherinE CK-MB SCFsR YES . ___________________________________
MMR ERBBI METAP I CK-M13
0.81 1.673 0.891
CadherinE RGIvI-C MK 1 3 Ca dherin-6 0.864
CadherinE 1GFBP-2 METAP I ERBB I
61 0.892 0.8 1.692 0.894
CK-MB Ca talasc RGM-C KPCI _________________ .
CSK KPC1 ERBBI CadherinE 0897 .
62 0.802 1.699 0.892
SC EsR YES CN DPI Ca thepsinl I
MMR SCFsR CadherinE Co Ipainl
63 0.878 0.821 1.699 0.908
ERBI31 RGM-C CK-MB HMG-1 ,
SCFsR ERBBI CadherinE METAP I '
64 0.906 0 795 1.701 0.897
IMB1 RUM-C M MP-7 11-1713 . YES CK-MB
ERBBI CadherinE
0
.85 0.831 1.681 0.893
GAPDH , liver V EG E 13MP-I LGM N .. -
CadherinE IGFE3P-2 KPC1 MMR
66 0.887 0.81 1.697 0.894
SCFsR GAPDH,liver CK-MB LRIG3
67 IVIETAP I GAPDH.liver M MP-7 Cad h crinE
0.892 0 812 1.704 0.908
ERBB1 CK-MB RGM-C MEK1 , NACA
CadherinE ERBBI CSK
68 0.92 0.781 1.701
0.899
RUM-C MMR YES SCFsR
-Proteinasc-3 SC Es R Cadhcrin E. K PC1
69 0.878 0.814 1.692 0.891
ERBBI RGM-C CK-M13 CathepsinH .
RUM-C CadlicrinE Calpa inI VEGF
0.883 0.817 1.699 0.903
ERF3131 CD:30Ligand CK-M13 Prot hrombin
IGFI3P-2 ERI3B1 IISP900 RUM-C
71 0.892 0.805 1.697 0.908
CadherinE SCFsR ApoA-I CSK .
CadherinE M ETA P I CK-M13 C9
72 0 878 0.814 1.692 0.896
ERBBI IGFI3P-2 SCFsR BLC
'MMR ERBBI GAPDH,liver CadherinE
73 0.901 0.776 1.678 0.895
RUM-C CSK SC NI CATC
RGIvI-C II S P9Ob ERBBI SCFsR
74 0.869 0,805 1.673
0.895
CadherinE CK-MB LRIG3 Cad heri n-6 -
CadhcrinE IG FBP-2 METAP I ERBBI
0.892 0.8 1.692 0.9
('K-MB Catalase RG M-C 1 ISP9Oh .
RUM-C FGF-I 7 ERBBI Calpainl
76 0 892 0.812 1 704 0.901
CadherinE CK-MB SCFsR NAGK ... __________
127
CA 3011730 2018-07-18
Table 7 (cont.)
_
IIMG-1 CaIpainl ER1313 I CadherinE
77 0.873 0.824 1.697
0.908
CK-MB RUM-C M MP-7 SCFsR . .
IL-17B GAPDFLIiver ERBB I CK-MB
780.883 0.817 1.699 0.901
CadherinE RGM-C Calpain I SCFsR
YES CadherinE ERBB I RGM-C
79 0.869 0.812 1.68
0.897
LGMN HSP90a ApoA-I CK-MB
MEK1 RUM-C ERBB I CadherinE
80 0.897 0.807 1.704 0.905
METAP I YES CK-MB SCFsR
' CK-MB M1vIP-7 METAP1 RUM-C
81 0.883 0.819 1.702 0.909
CadherinE M K13 ERBB I IGFBP-2
NACA CadherinE ERBB I METAP I
82 0.892 0.807 1.699
0.896
CK-MB MMR RUM-C Prothrombin
Proteinase-3 GA PDH,liver ERBB I CadherinE
83 0.845 0.845 1 69 0.896
CK-MB YES MEK1 C9
b-ECGF CadherinE ERBB I METAP1
84 0.906 0.807 1.713 0.902
RUM-C CK-MB HSP90b SCFsR .
CadherinE IGFI3P-2 1v1ETAP I ERBBI
85 0.892 0.798 1 69 0.9
CK-MB Catalase RGM-C BLC ,
-
RGM-C KPCI SCFsR BMP-1
86 0.878 0.817 1.695 0.888
CadherinE CK-MB GAPDH,liver 1-]SP90a .
M1v1P-7 ERBB1 YES METAP1
87 0.906 0.769 1.675
0.88
CadherinE NACA CK-MB CATC
CD30Ligand KPCI ERFiB1 SCFsR
0
88 901 0.805 1.706 0.897
CadherinE (K-MB CSK YES
RUM-C CadherinE KPCI CK-MB
89 0.869 0.8 1.669 0.881
FISP90a SCFsR C9 Cadherin-6
CK-MB CNDP1 KPCI CadherinE
90 0.897 0.8 1.697 0.891
SCFsR CSK CathepsinH LRIG3
RGM-C CK-M13 ERBB1 METAP1
0.906 0.798 1.704 0.904
91 H..iF-17 Cadherin Ft NAGK SCFsR
MK13 C a 1pa inl CadherinE ERBB1
92 0.873 0.824 1.697
0.904
MMR RGM-C HMG-1 CK-MB
(K-MB CNDP I KPCI CadherinE
0
93 .887 0.812 1.699 0 886
SCFsR Prothrornbin IL-17B YES ......
IMB I 1-ISP90a ERBB1 CadherinE
94 0.887 0.817 1.704 0.888
RUM-C SCFsR KPCI CK-MB
YES C9 ERBIll CSK
95 0.873 0.807 1 68 0.892
CK-MB CadherinE LGMN HSP90a
MMR SCFsR CadherinE CalpainI
96 0.869 0.821 1 69 0.902
ERBB I RUM-C (K-MB Proteinase-3 ,
RUM-C CadherinE ERBB1 GAPDH,liver
97 0.873 0.826 1.699 0.905
SCFsR CK-MB Calpainl VEGF
98 CK-MB SCFsRM ETA PI CadherinE
0.915 0.79 1.706 0.9
MMP-7 Fl SP9Ob b-ECGF RUM-C .
RGM-C METAP1 SCFsR ERBB1
99 0.901 0.795 1.697
0.909
YES CadherinE MM P-7 ApoA-I
CSK CadherinE CK-M13 GAPD}Lliver
100 0 873 0.812 1 685 0.901
ERBB1 YES RUM-C BLC
1 28
CA 3011730 2018-07-18
Table 7 (cont.)
Marker Count Marker , Count
CadherinE 100 ApoA-I 7 ,
ERBB I 88 b-ECGF 6
CK-M 13 85 Y EGP 6
RGM-C 81 Prothrombin 6 ,
SCFsR ' 64 Proleina se-3 6
M ETAP I 41 NACA 6
YES 36 4 MK13 6
,
i(PCI .)2 ' MEK I 6
CSK 21 LRIG3 6
IGFBP-2 17 LGMN 6
HSP90a 17 IMB1 6 ,
GA PDH,liver I 7 IL-17B 6
MMP-7 16 HMG-1 6
MMR 14 FGF-17 6
Calpainl 14 CathepsinH 6
HS P9Ob 13 Cata lase 6
NAGK 10 Cadherin-6 6
CNDP I 8 CD30Li gond 6
-
C9 8 CATC 6
BLC 7 BMP-1 6
129
CA 3011730 2018-07-18
=
Table 8
100 Panels of 9 Benign vs. Cancerous Nodule Blom arkers
Sens. +
Biomarkers
Specificity Sensitivity Spec. A I;C:
CSK IMB1 ERBBI CadhcrinE RGM-C
1 0 906 0 807 1
711 0.905
MMR YES CM-MB ApoA-I ,
META P I Calpain I ERBBI CadhcrinE MMP-7
2 0.906
0.802 1.708 0.901
RGM-C CK-MB SCFsR BLC .
CSK CaciberinE CK-MB GAPDH,livcr ERBBI
3 0.883
0.831 1.714 0.914
YES BMP-1 RGM-C MMR
RGM-C C9 ERBBI CadberinE METAPI
4 0,906 0 812 1
718 0.913
YES CM-MB MM P-7 SCFsR
.
Cathcpsinl 1 RGM-C M ETA P1 CM-MIS CadhcrinE
0.906 0.793 1.699 0 895
ERBB1 SCFsR YES CATC
YES CadherinE GAPDH,liver MMP-7 SCFsR
6 0.897
0.814 1711 0.906
CM-MB RGM-C CSK CD30Liga d
YES CadhcrinE ERBBI CSK VEGF
7 0.906 0 1307
1.713 0.901
RGM-C CalpainI CNDP1 MMP-7
CSK KPCI ERBB1 CadhcrinE CM-MB
80883 0.805 1.687 0.893
RGM-C SCFsR MMR Cadherin-6 -
RGM-C METAPI SCFsR ERBBI YES
9 0.911 0.798 1 708 0.912
CadhcrinE CK-MB Catalase MMP-7
SCFsR MMP-7 CadhcrinE KPCI METAPI
0.911 0.817 1 727 0.897
CM-MI) YES ERBBI FGF-17 .
CSK CadhcrinE CK-MB GAPDH,liver ERBBI
11 0.887
0.826 1.714 0.908
MMR YES RGM-C HMG-1
RGM-C M ETA PI SCFsR ERBBI HSP90a
12 0.915 0.814
1.73 0 898
CaclbcrinE IGFBP-2 KPCI CK-MB
CadlierinE METAPI CK-MB HSP906 ERBBI
13 0.906 0.8(2 1
718 0.897
YES SCFsR RGM-C HSP90a ,
11.-1713 CadherinE ERBBI METAPI CM-MI)
14 0.906 0.81 1
716 0.904
RGM-C GAPDH,livcr MMP-7 YES
YES CadherinE CalpainI ERBBI CK-M13
0 878 0.817 1 695 0.895
RGM-C SCFsR CD30Ligand LGMN
CK-MB SCFsR METAPI CadhcrinE MMP-7
16 0.915 08
1.715 0.901
11S P906 RGM-C LRTG3 b-ECGF
b-ECGF CK-M13 NAGK CadhcrinE Calpain I
17 0.883 0.831
1.714 0.901
ERBBI SCFsR RGM-C MEK1
CK-MB MMP-7 METAPI RGM-C CadhcrinE
18 0892
0.824 1.716 0.912
MKI3 ERBBI SCFsR IGFE3P-2
MMP-7 ERB B I YES META PI CadbcrinE
19 0.915 0.8
1.715 0.902
NACA CM-MB SCFsR RCIM-C .
SCFsR MM P-7 CadhcrinE KPCI METAPI
0.906 0.805 1.711 0.895
CK-M13 YES ERBBI Proteinasc-3
CSK Cad herinE CK-MB GAPDH,liver ERBB I
11 0.901 0.814
1.716 0.913
MMR YES RGM-C Pro thrombin
MMR ERBBI GAPDH,liver CadhcrinE RGM-C
21 0 906 0 807
1.713 0.913
CSK SCFsR YES ApoA-I ,
CM-MB SCFsR METAP1 CadhcrinE ER B131
, 23 0.892 0.81
1.702 0.901
IGEBP-2 RGM-C NAGK BLC
SCFsR MM P-7 METAPI b-ECGF 'CadhcrinE
24 0.915
0.798 1.71.3 0.895
HSP906 RGM-C GAPDH,liver 13MP-I
-
RGM-C C9 ERBBI Ca acrinE META PI
0.92 0 795 1 715 0.908
SCFsR CM-MIS NAGK YES
CM-M11 ER (III! CadlicrinE NAGK CSK
26 0.887 0.807
1.694 0.896
YES RCIM-C IGF13P-2 CATC
130
CA 3011730 2018-07-18
Table 8 (cont.)
SCFsR ER RI)] 11SP90a __ YES CatlherinE
27 0.91I 0.802 1.713 0.896
IMB1 RGM-C CNDP1 11MCI-1 ..
b-ECGF Cad herinE ERBB I METAP I RGM-C
28 0.897 079 1 687 0 892
CK-MB HSP90b SCFsR Cadhcrin-6
Ca thcpsi n1-1 CSK ERBB I RGM-C Cadhcrin E
79 0.92 0.788 I 708 0.893
SCFsR KPCI Cntalasc YES
METAP1 GAPDIL liver MMP-7 CndherinE CK-M13
30 0.915 0 812 1727 0.913
RGM-C EGE-17 ERI3131 SCFsR
1L-17B CK-N413 KPCI CadherinE ERBB1
31 0.892 0.819 1.711
0.896
CalpainI SCFsR CNDP1 RGM-C
YES CadherinE ERBB I CSK SCFsR
32 0.897 0.798 1.694
090!
RGM-C MMP-7 GA PDH,I ivcr LGMN
RGM-C HSP9Ob ERBB1 SCFsR CadherinE
33 0.911 0.8 17]! 0.906
YES CK-MB CSK ',RICO
RGM-C CadhcrinE ERBB I GAPDH,livcr SCFsR
34 0.887 0.826 1.714 0.909
CK-MB CSK MEK1 VEGF
SCFsR ERBB I CadherinE METAP1 RGM-C
35 0.892 0.817 1 709 091!
MMR MKI 3 1GFBP-2 CK-M13
RGM-C NACA ER13131 CadhcrinE HSP90a
36 0.915 0.8 1.715 0.895
META PI CK-M13 YES SCFsR .,
MM P-7 ERBB I YES META PI CadhcrinE
37 0.911 0.798 1.708 0.895
NACA CK-M13 SCFsR Proleinasc-3
Ca thcpsinH CSK ERBB I RGM-C CadherinE
38 0 901 0.812 1 713 0 898
SCFsR KPCI CK-MB Prothrornbin
MMR CSK CadherinE CK-MB RGM-C
39 0.897 0.812 I 709 0.901
ERBB1 KPCI ApoA-I YES ,
RUM-C CK-M13 ERBB1 METAPI FGF-I 7
40 0.897 0.805 1 701
0.897
CadherinE NAGK B LC SCFsR
RGM-C 13M1'-1 ER13131 METAP I CaclherinE
41 0.915 0.795 1 711
0.904
1-ISP9Ob SCFsR CK-MB YES
-
RGM-C C9 EFtBB1 CadherinE METAP1
42 0.906 0.807 1.713
0.912
SCFsR CK-MB NAGK IGFI3P-2
VEGF RGM-C ERBB1 METAP I CK-MB
43 0.911 0.781 1.692 0.895
CadherinE CalpainI SCFsR CATC
RGM-C METAP I SCFsR ERBB I YES
44 0 897 0.814 1 711 0.905
CadherinE CK-MB b-ECGF CD30Ligand
. '
IMB I HSP90a ERBB I CadherinE RGM-C
45 0.887 0.798 1 685 0 893
SCFsR I GED P-2 CK-MB Cadberin-6 .
CSK KPCI ER1.3111 CadherinE CK-M13
46 0.911 0.795 1.706 0.899
YES MMR RGM-C Catalase
RGM-C MMP-7 HSP90b METAP I CadhcrinE
47 0.897 0.814 I 711 0
903
SCFsR ERBB1 HMG-1 CK-MB
CNDP1 ER13131 CadherinE METAP I CK-Mil
48 0.911 0.8 1.711 0.893
YES NACA IL-1711 SCFsR
SCFsR ERRS! CadhcrinE Calpainl RGM-C
49 0.878 0.814 1.692 0.891
HSP9On b-ECGF IGFBP-2 LGMN
YES CadherinE ERBB I RGM-C CSK
50 0.892 0.817 1 709 0.912
CK-MB LRIG3 GAPDH,liver MMR
CK-MB SCFsR M ETAP I CarlherinE ERBB1
0
.51 0 .906 .807 1 713
0.907
IGEBP-2 RGM-C CalpainI MEK 1
RGM -C CK-M13 ERI3131 1M131 CadhcrinE
52 0.901 0.807 1.709 0.901
YES SCFsR MMR MK13
,
RGM-C FGF-17 ERBB I Calpain1 CadhcrinE
53 0 883 082] 1 704 0.898
CK-MB SCFsR NAGK Protein:Ise-3
NACA CadherinE ERBB I METAP1 CK-MB
54 0.906 0.805 1.711
0.9
MMR RGM-C Prothrombin IGFBP-2 ..
CK -MB MMP-7 METAPI RGM-C ERBB1
55 0.901 0.807 1.709 0.912
CadherinE HSP90a ApoA-I SCFsR
131
CA 3011730 2018-07-18
Table 8 (cont.)
RGM-C META PI SCFsR ERBBI I ISP90a
56 0.883 0 817 1,699 0.9
CadherinE I3LC CK-MB MMP-7
RGM-C BMP- I ERBBI METAP I CadhcrinE
57 0 911 0 798 1708 0 894
11 S P9Ob SCFsR GAPDH,liver YES ,
CSK CadherinE MMP-7 KPCI SCFsR
58 0.911 0.8 1 711
0.898
RGM-C CK-MB C9 GAPDH,liver .
b-ECGF CadhcrinE ERBB I META P I RGM-C
59 0.911 0 781 1 692 0.893
CK -MB I ISP90b SCFsR CATC
MMR ER13131 NI ETAP1 CK-MB CadhcrinE
60 0.901 0.81 1 711
0.907
YES RGM-C IGFI3P-2 CD30Ligand
RGM-C CadherinE KPCI CK-MB ERBBI
61 0.887 0 793 ... 1.68
089
METAP I MMR SCFsR Cadherin-6
62 CK-MB IG ?BP-2 KPCI CadherinE METAP I
0.915 0.79 1706 0.896
SCFsR MMR RGM-C Catalase
GithcpsinH CSK ERBBI RGM-C CadherinE
63 0.911 08 1.711 0.899 '
YES SCFsR KPCI CNDP1
MMR SCFsR CadherinE Calpainl ERBB I
64 0 892 0.817 I 709 0.906
RGM-C CK-MB I1MG-1 YES
SCFsR NAGK CaclhcrinE CK-MB RGM-C
65 0.901 0.807 I 309 0.89
ER13131 11,-1713 KPCI Calpainl
YES CadhcrinE ERBB1 CSK SCFsR
66 0.892 0.8 1.692 0.894
CK-MB MMP-7 KPCI LGMN
CNDP I ERBBI CadherinE KPCI SCFsR
67 090! 0 807 1 709 0.901
RGM-C CK-MB CSK LRIG3
YES CadherinE ER11131 CSK SCFsR
68 0.887 0.824 1.711 0.908
CK-MB MMP-7 GAPDH,livcr MEK1 .
RGM-C CadhcrinE KPCI CK-MB ERBBI
69 0.901 0.805 1 706 0.902
METAP I MMR SCFsR MK 13 _
YES CadhcrinE ERBBI CSK SCFsR
70 0.906 0.798 1 704 0.896
RGM-C MMP-7 KPCI Proteinasc-3
-
CK-MB MM P-7 METAP1 RGM-C SCFsR
71 0.92 0.79 1.711 0.903
CadherinE b-ECGF 11SP903 Prothrombin
SCFsR MMP-7 CadhcrinE KPCI METAP I
72 0.92 0 793 1.713 0.896
RGM-C ERBBI VEGF YES
RGM-C METAP I SCFsR ERBBI HSP90a
73 0.901 0.807 1.709 0 909
CadherinE VEGF CK-MB ApoA-I .
CK-MB MMP-7 METAP I RGM-C CarlherinE
74 0.873 0.824 1.697 0.898
MK13 ERBB I IGFBP-2 BI,C
YES CK-MB ERBB I CadherinE GAPD11,1iver
75 0.887 0.819 1706 0.900
VEGF CSK MMP-7 BMP-I ,
CK-M13 MMP-7 METAP I RGM-C CadherinE
76 0.892 0 817 1 709 0.913
NAGK SCFsR C9 ERBBI
CD301.igancl METAP1 CK-MB ER13131 CadherinE
77 0.892 0.798 1.69 0.887
YES NAGK RGM-C CATC
RGM-C KPCI SCFsR BMP-1 CadhcrinF,
78 0.873 0.805 1,678 0.889
CK-MB ERBBI CSK Cadhcrin-6
, ..
b-ECGF CadhcrinE ERBBI HSP906 RGM-C
79 0.897 0.807 1 704 0.894
YES M ETAP I CK-MB Catalase
CalhepsinH RGM-C METAPI CK-MB CadherinE
0 0
80 .887 .821 1.709 0.909
ERBBI SCFsR YES MMP-7 _
MMR ERBBI CiAPDH,liVCT CadherinE RGM-C
8 I 0.915 0.81 1.725
0.912
CK-MB METAP I SCFsR FGF-17 ,
HSP90b KPCI ERBB1 CadherinE RG M-C
82 0 892 0 817 1.709 0 888
SCFsR MMR CSK 11MG-1
SCFsR MMP-7 CadhcrinE KPCI META P I
83 0 906 0 802 1.708 0.89
R GM-C ERBBI IL-17B HS P90b ,
-
RGM-C CadhcrinE IISP90a CK-MB YES
84 09!! 0.8 1.711 0.896
ERBBI SCFsR IMBI META PI
õ
132
CA 3011730 2018-07-18
Table 8 (cont.)
RGM-C CK-MB ERTIB1 __ iMB I CadhcrinF.
85 01;83 0.805 1.687 0.895
SCFsR CNDP1 1.15090a LGMN
CK-MB IG FBP-2 KPCI CadhcrinE META P I
86 0.906 0.802 1 708 0.893
SCFsR M MR LRIG3 YES
NiETAP I GAPDILliver MMP-7 CadherinE ERB B I
87 0 897 082 1 709 0.912
CK-MB RGM-C MEK1 SCFsR
YES CadlierinE KPCI CK-MB ERB DI
0.8
88 87 0.814 1 702 0.897
CNDP1 Proteinase-3 SCFsR Catalase
Prothrom bin Cadlicrin E ERBB I METAP1 YES
89 0 906 0.802 1.708 0.896
MMP-7 CK-MB SCFsR KPCI -
REM-C METAP I SCFsR ERBB1 YES
90 092 0788 170$ 0.906
CadherinE MMP-7 ApoA-I HSP90a
YES CK-MB ERBB I CadllerinE, GAPDH,liver
0
91 0 .887 .81 I 697 0.904
MM P-7 RGM-C CSK I3LC
-
SCFsR ERBB I CadhcrinE IMB I CSK
92 0.901 0.807 1.709 0903
CNDP I CK-MB YES C9
CK-MB EBBS] CadherinE NAG K CSK
93 0 892 0 798 1.69
0.895
SCFsR REM-C YES CATC _________ .
CD30Ligand KPCI ER13131 SCFsR CadlierinF.
94 0.901 0.81 1 711
0.898
CK-MB CSK YES CNDP1
YES CadlicrinE KPCI CK-MB ERBB1
95 0.892 0.786 1.678 '
0.885
METAP I MMP-7 CNDP I Cadlierin-6 __ -
RGM-C METAP I SCFsR ERBB I YES
96 0 901 0 807 1.709 0 909
CadhcrinE MMR CathepsinH CK-MB . _______________
CK-MIS MM P-7 METAP1 RGM-C CadherinE
97 0.906 0.814 1.72
0.91
NAGK SCFsR FGF-17 ERBBI
RGM-C CadherinE KPCI MMP-7 ERBBI
98 0.892 0.812 1.704 0.895
CK-MB NAGK SCFsR I-IMG-1
1-ISP901.7 GAPDH,liver ERBB1 CacTherinE RGM-C .
99 C.892 0.814 1.706 0.898
IL-17B SCFsR CK-MB YES
Y F S CaillianIE. KPCI CK-MB SCFsR
100 0.883 0.805 1.687
0.892
ERBB1 I1SP90a. CNDP1 LGMN
Marker Count Marker , Count
CadlierinE 100 , VEGF , 6 ,
ERBB1 93 LGMN 6
RGM-C 86 . IL-17B 6
CK-MB 86 1TMG-1 6
SCFsR 82 FGF-17 6
YES , 56 CathepsinH 6
METAP I 55 Catalasc 6
MM P-7 36 Cadherin-6 6
CSK 30 CD30Ligand 6
KPCI , 29 CATC 6
!WM R 21 C9 6 µ
GAPDH Jiver 19 BMP-1 6
IGFBP-2 14 BLC 6
HSP90a 14 ApoA-I 6
,
NAG K 13 Prothrombin 5
,
IISP90b 13 ' Proteinase-3 . 5
CNDP I 12 NACA 5
Calpainl II MK13 5
6-ECG F 9 MEK1 5
IMB I 7 LRIG3 - 5
_
133
CA 3011730 2018-07-18
Table 9
100 Ponds or 10 Benign vs. Cancerous Nodule !Holum-kers
Bionsarkers
_Specilich,v_ Sensilivi1v Sens. + Spec. A1 IC
b-ECGF Cadinn inE ERBB1 METAP I fiai-c=
1 0.915 0.919 1.735
0.912
UK-MB Mtv11'-7 SCFsR ApoA-I YES
, UK-MB SCFsR M ETAP 1 CadhcrinE ER BB1
0 003 0.029 1 711 0 096
IGFBP-2 RUM-C CD301. igand MK13 B LC
b-ECGE CadlicrinE ERBB1 IISP90b RGN1-C
3 095 0 807 1 723 0
904
YES METAP I SCFsR CK-MB BMP-1
,
CD30Lignod METAP I CK-MR ERBB1 C*.lbet inE
4 11911 0 812 1 723
0.907
YES NAGK RUM-C SCFsR C9
YES CadherinE ERBB I CSK SCFsR
0 901 0.007 1.709 0.905
RGM-C MMP-7 GAPDH,liver CK-MB CATC
RUM-C CadherinE KPCI (2K-MB ERBB I
6 0911 0.819 1.73
0.904
METAP I MMR SCFsR MK 13 CN DP I
_
SCFsR ERBB I CadherinE Calpainl RGM-C
7 0 S73 0 819 1 692
0.894
ITSP90a h-ECGF CK-MB C9 Cadherin-6 .
CSK KPCI ERBB I CadhcrinE CK-MB
8 09!! 0.807 1 718
09
YES MMR RUM-C Calalasc ApoA-1
CK-MB MM P-7 METAP1 RCINI-C raft! inE
9 0.897 0.824 1.721
0.907
MK13 ERBB I SCFsR IGEBP-2 C.(06.1,41111 ,
METAP1 GAPDH,liver MMP-7 CadherinE ERBB I
0934 0.812 1746 0.912
YES CI(-MB SCFsR FGF-17 RGM-C
b-ECGF CadhcrinE ERE3B1 METAP1 RUM-C
II 0.911 0.81 1 72
0.903
UK-MB HSP90b SCFsR MMR KM G-I
-
CadherinE METAP I CK-MB IISP9Ob ERBB I
12 0.92 0 807 1 727
0.901
YES SCFsR RUM-C IGFBP-2 11:1711 ,
CK-1v113 CNDP I IMB1 CadherinE ER11131
13 092 0.805 1.725
0.9
YES METAP I SCFsR HSP90a RUM-C .
('N DPI ERBB I Cadheruth EEC) SCFsR
14 0892 0.912 1.704
0.892
RCM -C (2K-MB Calpain I 1.1t103 LGMN
CSK CadherinE CK-MB GAPDH.liver ERB131
0 906 0,821 1 728 0,912
MMR YES RUM-C MEK I SCFsR
RUM-C METAP I SCF512 ERBB1 I ISP90a
16 0.92 0.002 1.723 0
895
___________ CadherinE b-ECGF NACA CK-MB YES , 1 __
RGM-C CK-MB ERBB I CSK CadherinE
0
17 901 0.812 1.713
0.901
CN DP1 YES SCFsR KPC1 Proteirase-3
CK-MB hIMP-7 METAP I RUM-C SCFsR
IS 092 0.807 1.727
0.911
CadherinE b-ECGF YES Prothrombin ERBB I .
V EGF METAP I ERBB1 YES Cadhei in E
19 0 925 0.793 1.718
0.896
(2K-MB NACA HSP90a SCFsR RUM-C ,
RUM-C CadhcrinE ERBB I GAPDH.livcr SCFsR
0397 0.814 1.711 0.901
CK-MB CSK MEKI YES BLC
21 MMR ERBB I METAP1 CK-MB CadherinE
0 906 0912 1 718 0.912
YES RUM-C GAPDH,livcr BMP-1 IGFBP-2
i, CSK CadherinE CK-MB GAPDH.liver F.RBB 1
0.901 0.8 1.701 0.902
- YES F3MP I SersR RUM-C rATC .
.._
-kbm-c CadherinE KPCI CK-MB ERBI31
23 0897 0.793 1.69
0.851
___________ METAP I hEvIR SCFsR MK13 ________ Cadherin-6
-
RGM-C C9 BABB I CadherinE METAP I
24 awn 0.814 1 716
0.911
SCFsR UK-MB NAGK 1GEBP-2 Catala se
CadherinE METAP I CK-MB IISP906 ERBBI
0 915 0.9 1 715 0.898
YES SCFsR RUM-C HSP90a CalhepsinH
RUM-C CadherinE ERBB I GAPDH,liver SCFsR
26 0.906 0.824 1.73
0.914
CK -MB CSK MMR FGF-17 YES
,-=
RUM-C NIETAP1 SCF4R ERBB1 YES
27 0.901 0.814 1.716
0.9
CadherinE CK-MB BMP- I HMG- I HSP901) .
,
SCBR NACK CadhcrinE (2K-MB RUM-C
28 0.911 0.812 I 723
0.897
___________ ERBB1 1L-17B METAP I MMP-7 KPCI
CK-MB SCFsR METAP I CadherinE ER BB I
29 093 0.793 1.722 09
IGF BP-2 YES RUM-C IMB1 IL-17B
CSK Calpainl ERBB1 RUM-C CadherinE
0 987 0 812 1.699 0.9
MMP-7 CK-MB BMP-1 YES 1,6MN
134
=
CA 3011730 2018-07-18
Table 9 (cont.)
MMR ______________ ERBB 1 METAP I CK-MB Cadherin E
31 0 911 0.807 1 718
0.91
YES LRIG3 RGM-C IGFRP-2 GAPDILliver
SCFsR MMP-7 CadherinE KPCI IvIETAP I
32 0 911 08 1 711 0.9
RGM-C ERBI31 Prnteinase.3 CE-MB YES
RGM-C CadherinE KPCI CE-M13 I ISP90a
33 0 915 0.805 1.72 0
896
1(70 80-2 SCFsR FARB 1 Prnthrnmbin MF.TAP I
MMR ERBB1 GAPT/I-Llivel Carib m ME RGM-C
34 0301 0.8 I 4 1.716
0.906
CSK VEGF YES CNDP1 BMP-1
RGM-C METAPI SCFsR ER!)!)! 11S!'903
35 0.915 0 802 1 718
0.912
CadhcrinE CK-MB ApoA-.I YES MMP-7
YES CadhcrinE ERBB I CSK SCFsR
36 0 906 0.803 1 711
0.897
CK-MB MMP-7 KPCI RGM-C BLC
RGM-C CK-MB E813131 CSK Cadhel inE
37 0 901 0.8 1.701 0.903
CNDP1 YES SCFsR (1APD14,livei CATC
RGM-C CE-MB F,RRFI 1 CSK Cadhei inF,
38 0 92 0.805 1.725
0.902
CNDP I YES SCFsR KPC1 CD301.tv.nn1
CSK CadherinE CK-MB GAP DELli ver ER BB I
19 0878 0.81 1.687 0 898
YES 10MP-7 C9 RGM-C Cadherin-6
YES CadhcrinE ERR!)! CSK SCFsR
40 0.915 0.8 17(5 0.901
CK-MB NIMP-7 KPCI CNDP1 Catalasc
RGM-C KPCI SCFsR 11103131 Ca la lase
41 0 911 0.802 1 713
0.9
CK-MB Cadher inE METAP1 1GFBP-2 Ca th co sinll
. . .
MMR ERBB1 METAPI CE-MR CadherinE
42 0.923 0.805 1.73
0.91
YES RGM-C GAPDH,liver FGF-17 SCFsR .
.
. SCFsIt
43 MMP-7 CadhcrinE KPCI METAP I
0.906 0.81 1.716 0.899
CK-MB YES ORB!)! 11MG-1 RGM-C ,
SCFsR ERBB I CudherinE META P 1 I89I31
44 0.93 0.788 1.718
0.902
RUM-C 81140-7 CE-MB 1L-17B YES
YES CadherinE ERBB I CSK SCFsR
45 0 897 0.802 1,699
089!
RGM-C 1o1MP-7 CAPDILliver KPCI LGMN .
RGM-C METAP1 SCFsR 081181 YES
46 0.915 0.802 1.718 0.907
CadherinE MMP-7 CE-MB 1,121G3 1-19P901
RGM-C Cadhei inE ERB B I GAPD1-1.1ivei SCFsR
47 0 906 0.819 1.725
0.914
CE-MB CSK MEK I YES MMP-7 _______
-
RGM-C CK-MB ERBB 1 CSK CatiherinE-
48 0 915 0.802 1.718
0.902
CN DP I YES SCFsR H SP90a NACA .
RUM-C CadbcrinE ERB B1 GAPD1-1.1ivcr SCFsR
49 CND! I CK-MB Prothrombin YES Proteinase-3 0.887 0.821
1 709 0.908
VEGF RGM-C ERB131 METAP I CE-MR
50 0.92 0.795 1 715
0.915
CadhcrinE MMR GAPDH,livcr SCFsR C9
CE-MB M1s4P-7 METAP I ROM-C SCFsR
51 0923 0.793 1.718
0.906
Cull. inE h-ECCIF 149090a A n0A-1 PI nthrnmbin
RGIA-C METAP I SCFsR ERB B I HSP90a
52 0.915 0.795 1.711
0.892
__________ CadherinE IG000-2 KPCI CE-MB ____________ BLC __ .,......
.
METAP I GAPDH,liver MMP-7 CadherinE ERBB I
53 0.911 0.79 1.701
0.905
__________ YES CK-MB SCFsR RGM-C CATC
RUM-C METAPI SCFsR ERBB1 YES
54 0.925 0.795 1.72
0.901
CadhelinE CD3OLigand CK-MB MMR KPCI
. -
SCFsR ORB!)! CadherinE 11013 I CSK
55 0.883 0.805 1 687
0.395
CNTRI CE-MB h-ECCIF RGM-C Cadhel in-6
RGM-C META P 1 SCFsR 88 88! HS090a
56 0.913 0.805 1.72
0.896
CadherinE CalpainI CE-MB b-ECG F NAGK
METAP I HSP90a CadherinE ERR!)! CE-MB
57 0911 0.802 1713
0.902
, SCFsR YES NAGK RGM-C CathepsinH
FGF-17 CadherinE ERB B1 ITSP906 SCFsR
58 0 906 0 817 I 723 0
904
rtcm-c ME-MP I _____ CE-MB IGFBP-2 YES
_ ,
YES CadherinE MMP-7 IIMG-I ERBB I
59 0 892 0,821 1 713 0
907
CE -MB 8C1M-C SCFsR 1'7.011111)1111)41 HS P9011
CN DP1 ERBR1 CadlierinE KPC1 SCFsR
60 0 906 0.793 1.699
0.895
RGM-C CSK MMP-7 YES LGMN -
135
CA 3011730 2018-07-18
-
,
Table 9 (cont.)
YES ______________ ('K-MB E RBB I- CadherinE GAPD1-1,11cr
61 0 901 0.814 1 716 0.912
LRIG3 MMR CSK IGEBP-2 RGM-C ..
62 CadhcrinE MF.TAP I CK-MB I-I SP9Ob ERBB1
0 906 0,812 1 718 0.904
YES SCFsR REM-C IGFDP-2 MEK1 _
M/YIP-7 ERI3131 YES METAP I Cadh e rin E
63 095 0.802 I 718 0.9
NACA ('K-MB SCEs R CN DP I FGF-17
MMR ERBB1 GAPD1-1,1ircr Cadhct ME REM-C
&I 0 901 0.807 1.709 0 907
('K-MB METAP I SCFsR FGE-17 Iholein a se-3
METAP I HSP90a CadhcrinE. ERBB I CK-MB
65 0.92 0.795 1.715 0.903
SCFsR YES NAGE RC M-C N.IECIF . -
YES CK-MB ERBB1 CadherinE GAPDI Lli \ Tr
66 0 901 0 814 1.710 0.916
MMP-7 REM-C CSK ApoA-1 SCFsR
,
RGM-C CadherinE ERBB1 GAP DI-Llivcr SCFsR
67 0.878 0 831 1.709 0.906
CK-MB CSK MMR 1GFFIP -2 (SIC
'SCFsR MMP-7 CadhcrinF. KPCI METAP I
68 0906 0,79 1.697 0,894
CK-MB YES ERBB I RGM-C CATC .
,
REM-C METAP I SCFsR ERBB I YES
69 0925 0.795 1.72 0911
CadherinE CD30Ligand Di-MB MMR GAPD1-1,1iver
LRIG3 CadhcrinE ERBB I Caloa inl REM-C
70 0.878 0.307 I 685 0.893
('K-MB SCEsR. YES CD30 Lipand Cadhcrin-6 = , ,
REM-C KPCI SCFsR. ER13131 Catalase
0
71 0 906 .807 1.713 0.9111
CE-MB CadhcrinE METAP I IGFI3P-2 CNDP I
CSK CatlherinE CK-MB GAP DF1.1iver ER nR1
72 0 901 0.81 1 711 0.912
MMR YES REM-C Ca Ihcpsin Il SCFsR
=
SCFsR MMP-7 CadherinE KPCI METAP I
73 0 901 0.812 1.713 0.397
REM-C ERBB I IL-17B CE-MB 1 IMG- I ,
CadherinE MK13 WAR MIDI ERBB1
74 0.906 0.81 1.716 0.908
REM-C SCFsR METAP I CNDP1 CE-MB
YES CadherinE ERBB I CSK SCFsR
75 0 883 0.814 1.697 0.907
REM-C MMP-7 GAPD11,1 ivcr CK-MB LGMN
SCFsR ERFIF3 I CadherinF. MF.TAP I REMIT
76 0.911 0.305 1.716 OS
NAGK ('K-MB Calpa in1 M EK 1 b-E.C6F .
. _ - .
REM-C METAP1 SCFsR -ERB B1 HSP90a
77 0.92 0.798 1.718 0.899
___________ CadherinE b-ECGF NACA CE-MB IGFBP-2 .......õ-
REM-C METAP I SCFsR ERBB I YES
78 0.925 0.783 1.708 0.898
CadhcrinE CK-MB CNDP I NACA PI olcinase-3
RGM-C METAP1 SCFsR ERBB I I ISP90a
79 0925 0.79 1.715 0.894
CadherinE YES NACA BMP-1 VEGF
MMR CSK CadhcrinE CE-MB REM-C
SO 0 901 0.814 1 716 0.917
ERBB1 GAPDH.liver ApoA-I YES IGH3P-2
YE.S CK-MB EMI Cadhei in E. CIAPDH,Ii vet
81 0883 0.324 1.706 0.905
MMP-7 REM-C ('SE EEC SCFsIt
REM-C C9 ERBBI CadherinE METAPI
82 0 915 0.805 1.72 0.912
YES CE-MB Mh1P-7 NAGK SCFsR __ õ
YES METAP 1 WO -7 CadherinE REM-C
83 0.911 0.786 1.697 0.902
___________ ERBB I CK-MB Prothrom bin SCFsR CATC
MMR ERBB1 GAPDILIiver CadherinE REM-C
84 0 892 0.793 1.685 0.9
CE-MB METAPI C9 SCFsR Cadhcrin-6
_ CSK SCFsR CadherinE C9 ERBB I
8.? 0 906 0807 1.713 0.903
1GFBP-2 CE-MB KPC1 CNDP I Catalasc
SCFsR MMP-7 Cadhcz inF KPCI MF.TAP I
86 0.906 0.805 1.711 0.897
REM-C ERBB I IL-17B CE-MB CatherpsinH
CSK CadherinE CE-MB GAPDI-1.1iver ERBB I
87 0.392 0.819 1.711 0 911
MMR YES. REM-C 1-164C1-1 SCIFsR ,
SS METAP1 ESP90b CadherinE ERBB I REM-C
9911 0 805 1.716 0 896
___________ !L-17B CE-MB SCFsR IGEBP-2 IMB1
CNDP I ERBIll CadhcrinE KPCI SCFsR
89 0.892 0 005 1.697 0 895
REM-C YES HSP90a CE-MIS I.GMN
REM-C META P I SCFsR ERBB1 FISP90a
90 0.906 0.81 1.716 0.908
CadhetinE DC-MB ApoA-I YES LRIG3
METAP I GAPDH,livet Mh1P-7 CadherinE ERBB I
91 0 915 0.8 1.715 0.912
YES CK-MB SCEsR MFK1 REM-C
136
CA 3011730 2018-07-18
Table 9 (cont.)
ETAP I __ SCEsR ERBB1 IISP90a
92 143M-C NI 0.911 0.812 1.723
0.898
CadhcrinE IGEBP-2 KPCI CK-MB MK I3
YES CadhcrinE KPCI CK-MB ERBB I
= 93 0 397 0 81 1 706
0.394
CNDP I Pro lcinasc-3 SCEsR Catalasc b-ECGE
RGM-C CK-MB ERI3B1 CSK CadhcrinE
94 0 897 0.817 1.713
0.911
CD301,icand YES SCEsR GAPDH.livcr VET& .
CK-MB SCFsR METAP I CadhcrinE NAIP-7
95 0.906 0.8 1.706 0.904
GAP DH.livcr RUM-C ERBB I BLC EGE- I 7
CSK CadhcrinE CK-MB GAPD1-1.1iver ERBB I
96 0.901 0.793 1.694
0.9
YES NIMP-7 C9 RUM-C CATC
,
RUM-C CadherinE KPCI CK-MB IISP90a
97 0.983 0.8 1683 0.892
IGFI3P-2 SCFsR ERBB1 Prothrombin Cadherin-6
SCEsR ERBB I CadherinE Calpain1 RUM-C
98 0 911 0.807 1,718
0.895
HSP90a KPC1 Prothinnthin CK-MB MMR
RUM-C METAP I SCFsR ER r3s1 1-1SP90a
99 0.906 0.805 1.711
0.897
CadherinE IGEBP-2 KPCI CK-NIB Ca IhepsinH
.,
1MG-1 Calpainl EMI I CadlierinE CK-MB
100 0.901 0.81 1.711
0.906
RUM-C NP IM-7 SCEsR b-ECGE CSK
Marker Count Marker Count .
CadherinE 100 Calnainl a
ERBB I 99 NACA 7
RUM-C 96 IL-17R 7
CK-MB ' 96 HMG-1 7
,
SCFsR 91 FGF-17 7
YES 67 Ca thcpsin H 7
METAP I 60 Cala lose 7
MMP-7 34 'Lladh'crin-6 7
GAPDH,liver 32 CD30Ligan1 7
CSK 31 CATC 7
KPCI 28 IIMP-1 7
MMR 22 BLC 7
._.
IGFF1P-2 , 22 ApoAA 7
HSP90a 21 VEGE 6
CNDP1 19 Proleinase.-3 6
b-ECGF 13 MK13 6
HSP906 10 MEK I 6
C9 9 LRIG3 6
Prothrombin 1 8 LGMN 6
-NAGK 8 1MB I 6
I 37
CA 3011730 2018-07-18
,
0
t.,.)
o
F.
1-.
-..1
co
o 100 Panels of 11 Benign vs. Cancerous Nodule Biomarkers
I)
Sens. +
o
Biomarkers Specificity Sensitivity Spec. ,AUC
1-.
co RGM-C METAP I SCFsR ERBB1 YES CadherinE
oi 1
0.925 0.8 1.725 0.911
CK-MB Cata lase MMP-7 b-ECGF ApoA-I
....1
I -) CD30Ligand ME1'AP1 CK-MB ERBB I CadherinE
YES
0.901 0.812 1.713 0.896
1-.
03 RGM-C IGFBP-2 SCFsR b-ECGF BLC
RGM-C METAP1 SCFsR ERBB1 YES CadherinE
3
0.92 0.812 1.732 0.911
CK-MB CNDP1 GAPDH,liver b-F,CCiF BMP-1
CSK CadherinE CK-MB GAPDH,liver
ERBB I WAR
4
0.897 0.826 1.723 0.912
YES RGM-C C9 SCFsR MEK I
MMR CSK CadherinE CK-MB RGM-C ERBB1
0.92 0.802 1.723 0.904
GA PDH,I iver ApoA-I YES IGFBP-2 CATC
CK-MB GAPDH,liver ERBB1 HSP90a CadherinE
YES
6
0.878 0.817 1.695 0.902 _õI
_ SCFsR CNDP1 RGM-C IGFBP-2 Cad heri
n-6
t....)
CI)
oe b-ECGF CadherinE ERBB1 METAP1 RGM-C CK-MB
7
0.915 0.81 1.725 0.905 cr
MMP-7 SCFsR NAGK Calpainl EGF-17 CD RGM-C
METAP I SCFsR ERBB1 YES CadherinE
8
0.911 0.812 1.723 0.901 -=
CK-MB BMP-1 HMG-1 1-lSP9 Ob
CathepsinH CD
CNDP I ERBB1 CadherinE METAP I CK-MB YES
9
0.934 0.795 1.73 0.901
NACA IL-173 IGFBP-2 RGM-C SCFsR
.
SCFsR ERBB1 CadherinE METAP I IMB1
RGM-C
I 0
0.92 0.807 1.727 0.9
CNDP1 CK-MB HSP90a b-ECGF YES
RGM-C METAP I SCFsR ERBB1 YES CadherinE
11
0.93 0.805 1.734 0.903
CK-MB CNDP I KPCI IGFBP-2 CD30Ligand
YES CadherinE KPCI CK-MB SCFsR ERBB1
11
0.915 0.79 1.706 0.891
HSP90a CNDP1 METAP1 RGM-C LGMN
CadherinE METAP I CK-MB HSP90b ERBB1 YES
13
0.92 0.805 1.725 0.905
SCFsR RGM-C MMR LRIG3 IVIK13
YES CadherinE ERBB I CSK SCFsR RGM-
C
14
0.925 0.795 1.72 0.901
CK-MB NA CA CNDP I b-ECGF Pro tei
nase-3
_
C)
ta
o
1-.
1-.
-.1
w
o YES CK-MB ERBBI CadherinE
GAPDH,liver 1\34P-7
15
0.915 0.81 1.725 0.915
K.) RGM-C CSK MEK1 Prothrombin SCFsR
o ,
1-. YES CK-MB ERBB I CadherinE GAPDH,liver
VEGF
co 16
0.911 0.819 1.73 0.913
1 RGM-C CSK BMP-1 MMR. SCFsR
o 17 YES CadherinE ERBB I CSK
SCFsR RGM-C
---.1
0.892 0.819 1.711 0.9
1 CK-MB MMR GAPDH,liver BLC MEK I
1-.
co RGM-C CadherinE ERBB I GAPDH,liver
SCFsR CK-MB
18
0.901 0.821 1.723 0 913
CSK MMR FGF-17 C9 YES
MMR ERBB I METAP I CK-MB CadherinE YES
19
0.911 0.8 1.711 0.897
RCIM-C GAPDH.1 iver FGF- I 7 IGEBP-2
CATC
RGM-C CK-MB ERBBI CSK CadherinE CNDP1
20
0.887 0.807 1.694 0.896
YES SCFsR KPCI MMR Cadheri n-6
-I
RGM-C CadherinE KPCI CK-MB ERBB I
METAP1
21
0.915 0.81 1.725 0.897 CI)
IL-17B SCFsR IGFBP-2 CalpainI
CNDP1 CT
L a- RUM-C CadherinE. KPCI CK-MB ERF3B1 METAP1
CD
22
0.925 0.8 1.725 0.904
so MMR SCFsR YES Catalase IGH3P-2
CadherinE METAP I CK-MB HSP90b ERBB I YES
0
23
0.925 0.798 1.723 0.904
SCFsR RGM-C MMR LRIG3 CathepsinH
0
CD30Ligand METAP1 CK-MB ERBBI CadherinE YES
0
24
0.915 0.812 1.727 0.897 D
RGM-C IGFBP-2 SCFsR KPCI HMG-I
CK-MB CNDP1 IMB1 CadherinE ERBB I
YES .......
25
0.925 0.802 1.727 0.901
METAP1 SCFsR HSP90a VEGF RGM-C
CNDP1 ERBB I CadherinE KPCI SCFsR RGM-
C
26
0.892 0.812 1.704 0.89
CK-MB Calpainl CD30Ligand b-ECGF LGMN
RGM-C METAP1 SCFsR ERBB1 YES CadherinE
27
0.925 0.807 1.732 0.904
CK-MB CNDP1 KPCI MMR MK13
YES CadherinE ERBB I RUM-C NAGK
Calpaini
28
0.925 0.8 1.725 0.896
SCFsR CK-MB IL-17B METAP1 b-ECGF
.
YES CK-MB ER13B1 CadherinE GAPDH,liver
VEGF
29
0.897 0.819 1.716 0.908
RUM-C CSK CNDP1 SCFsR Proteina se-
3
0
(A)
o
1-.
1-.
---.1
co
o YES CadherinE ERBB I CSK SCFsR
CK-MB
30
0.901 0.821 1.723 0.914
Iv MMP-7 GAP DH, I iv er Prothrombin RUM-C
FGF-17
o
1-. YES CadherinE ERBB1 CSK SCFsR RGM-C
co
0.892 0.831 1.723 0.913 31
o1 MMP-7 GAPDH,liver MEKI ApoA-I CK-MB
=
=-.1 32 MMR ERBBI GAPDH,liver CadherinE
RGM-C CK-MB
0.901 0.81 1.711 0.907
1 META P I C9 SCFsR IGFI3P-2 BLC
1-.
co YES CadherinE ERBB1 CSK SCFsR RGM-C
33
0.906 0.802 1.708 0.906
IGFBP-2 CK-MB GAPDH,liver MMP-7 CATC
.
-
RUM-C C9 ERBB I CadherinE METAP I
SCFsR
34
0.892 0.8 1.692 0.895
CK -MB NAGK IGFB P-2 Cata lase
Cadherin-6
,
RGM-C CadherinE ERBB1 GAPDH,liver SCFsR CK-MB
35
0.901 0.819 1.72 0.908 -I
CSK MEKI YES BMP-1 Cathepsi nH
,
RUM-C BMP-1 ERBB1 METAP1 CadherinE HSP90b
36
0.906 0.814 I 72 0.902 -
SCFsR CK-MB YES VEGF HMG-1
CD
:r
- SCFsR ERBB I CadheriCadherinE'MB I CSK
CNDP I =', 37 0.925 0.802 1.727 0.905 co
CK-MB b-ECGF RUM-C YES VEGF
CK-MB GAPDH,liver ERBB1 HSP90a CadherinE
YES ' ..----.
38
0.878 0.824 1.702 0.905 0
SCFsR CNDP1 RUM-C IGFBP-2 LGMN
0
M
YES CK-MB ERBB1 CadherinE GAPDH,liver LRIG3
r'
39
0.901 0.821 1.723 0.914 =
MMR CSK IGFBP-2 RUM-C SCFsR
........
, ,
MMR F,RBB1 META P I CK-MB CadherinE YES
40
0.925 0.805 1.73 0.903
RGM-C IGFBP-2 MK13 SCFsR KPCI
YES CK-MB ERBB1 CadherinE METAP I TAMP-7
41
0.934 0.798 1.732 0.903
IGEBP-2 RUM-C SCFsR NACA HSP90a
.
,
METAP I GAPDH,liver MMP-7 CadherinE ERBB1 YES
4/
0.901 0.814 1.716 0.907
CK-MB SCFsR MEKI RUM-C Pro tei nase-
3
,
RUM-C CK-MB ERBB1 CSK CadherinE CNDP1
43
0.906 0.817 1.723 0.911
YES GAPDH,I iv er MMR VEGF
Prothrombin .
_
CK-MB 1GFBP-2 CSK CadherinE RUM-C ERBB1
44
0.901 0.821 1.723 0.914
YES FGF-17 GAPDH,liver MMR ApoA-I
=
0
ua
o
1-.
1-.
--.1
ua
0 RGM-C Cad heri nE ERBB1 GAPDH,liver
SCFsR CK-MB
45
0.883 0.826 1.709 0.908
I'.) CSK MMR 1GFB P-2 BLC ApoA-1
o
1-. YES CK-MB ERBB1 CadherinE METAP I
MIP-7
co 46
0.915 0.793 1.708 0.906
O IGFBP-2 RGM-C SCFsR GAPDH,liver CATC
CNDP1 ER13131 CadherinE KPCI SCFsR RGM-C
0.878 0.812 1.69 0.89
1 CK-MB Calpainl C D3 OLiga nd b-ECGF
Cadherin-6
1-.
,
co CNDP I ERBB1 CadherinE KPCI SCFsR RGM-
C
48
0.906 0.817 1.723 0.902
CK-MB C goal nI Cata lase IGF13P-2
CSK
MMR ERBB1 GAPDH,liver CadherinE RGM-C CK-
MB
49
0.911 0.81 1.72 0.902
HSP9Ob SCFsR YES LRIG3 Cat heps i
nH
,
CSK CadherinE CK-MB GAPDH,liver
ERBB1 MMR50 0.887 0.831 1.718 0.91
YES RGM-C HMG-1 SCFsR FGF-17
RGM-C METAP1 SCFsR ERBB1 YES CadherinE
-I
51
0.93 0.798 1.727 0.901 EI)
CK-MB CNDP1 KPCI 1GFBP-2 1L-17B
cr
SCFsR ERBB1 HSP90a YES CadherinE IMB1
_
51
0.915 0.81 1.725 0.9 CD
.--11-. CK-MB GAPDH,liver RGM-C CNDP1 b-ECGF _
. _%
,
METAP1 GAPDH,liver MMP-7 CadherinE ERBB1 YES
53
0.901 0.8 1.701 0.903 CI
CK-MB SCFsR MEK1 RGM-C LGMN
,
...
YES CadherinE ERBB1 RGM-C METAP1 NACA
0
54
0.93 0.793 1.722 0.903 0
MMR CK-MB SCFsR MK13 IGFBP-2
=
RGM-C METAP1 SCFsR F,RBB I YES CadherinE
55
0.911 0.81 1.72 0.91 -
NAGK MMP-7 CK-MB Catalase ApoA-I
CD30Ligand METAP1 CK-MB ERBB1 CadherinE YES
56
0.92 0.795 1.715 0.898
RGM-C IGF1313-2 SCFsR KPCI
Proteinase-3
-
,
CSK KPCI ERBB1 CadherinE RGM-C MMR
57
0.915 0.807 1.723 0.901
YES SCFsR ApoA-1 CNDP1 Prothrombin
CSK CadherinE CK-MB GAPDH,liver
ERBB1 YES
58
0.892 0.817 1.709 0.903
IGFBP-2 RGM-C CD3 OLiga nd SCFsR BLC
CSK CadherinE CK-MB GAPDH,liver
ERBB1 MMR39 0.906 0.817 1.723 0.913
YES RGM-C C9 SCFsR LRIG3
,
FGF-17 CadherinE ERBB1 HSP9Ob SCFsR RGM-C
60 0.915 0.79 1.706 0.894
METAP1 CK-MB IGEBP-2 YES CATC
C)
w
0
I-
I-.
-..1
w CNDP I Calpa inI ERBBI CadherinE RGM-C
OK-MB o 61 0.883 0.807 1.69 0.89
6.) SCFsR IMB I b-ECGF IL-17B Cadherin-6
.
õ
o 62 RGM-C METAP I SCFsR ERBB1 HSP90a
CadherinE
1-.
0.915 0.805 1.72 0.896
co CalpainI CK-MB b-ECGF NAGK
CathepsinH
o1
MMR CSK CadherinE CK-MB RGM-C ERBBI
--..1 63
0.897 0.821 1.718 0.912
1 GA PDH,I iver ApoA-1 YES TGEBP-2
HMG-1
1-,
co CK-MB SCFsR METAP I CadherinE MMP-7
GAPDH,liver
64
0.911 0.79 1.701 0.9
RGM-C ERBBI HSP90a YES LGMN
CNDP I ERBBI CadherinE KPCI SCFsR RGM-C
65
0.906 0.814 1.72 0.894
YES HSP90a CK-MB IMB I MK13
CK-MB SCFsR METAP1 CadherinE ERBB1 IGEBP-2
66
0.93 0.798 1.727 0.902
YES RGIVI-C HSP90a CNDP1 NACA
-I
YES CadherinE ERBB1 CSK SCFsR RGM-C
67
0.892 0.821 1.713 0.912
CK-MB MMR GAPDH,liver Proteinase-3 IGEBP-
2 cr
YES CadherinE ERBBI CSK SCFsR RGM-C
CD
68
0.92 0.802 1.723 0.914
õT. OK-MB VEGF GAPDH,liver Prothrombin MMR
._.%
CK-MB SCFsR METAP1 CadherinE MMP-7 GAPDH,liver
CI
69
0.897 0.812 1.709 0.902
RGM-C ERBB1 BLC FGF-17 NAGK
..
0
CSK CadherinE CK-MB GAPDH,liver ERBB1 YES
70
0.906 0.821 1.72.8 0.914 0
B1V1P-1 SCFsR RGM-C CNDP1 VEGF
=
õ ..
e=-l=
YES CadherinE GAPDH.liver MMP-7 SCFsR CK-
MB
71
0.911 0.812 1.723 0.91 '
RGM-C CSK LRIG3 CNDP1 C9
MMR ERBBI METAP1 CK-MB CadherinE YES
72
0.92 0.786 1.706 0.895
SCFsR KPCI IGFBP-2 RGM-C CATC
YES CadherinE ERBB1 CSK SCFsR RGM-C
73
0.883 0.805 1.687 0.904
IGFBP-2 OK-MB GAPDH,liver MMP-7 Cadherin-
6
RGM-C CadherinE KPCI CK-MB ERBBI METAP1
74
0.915 0.805 1.72 0.895
IL-173 SCFsR IGFBP-2 NAGK Catalase
RGM-C METAP1 SCFsR ERBBI YES CadherinE
75
0.92 0.8 1.72 0.903
CK-MB CNDP I IMB1 b-ECGF CathepsinH
SCFsR MMP-7 CadherinE KPCI METAP1 CK-MB
76
0.906 0.812 1.718 0.897
YES ERBBI IL-17B HMG-1 RGM-C
C)
w
o
1-.
1-.
....1
W RGM-C CadherinE HSP90a CK-MB YES ERBB
I
o
77 0.883 0.817 1.699 0.902
K.) ., SCFsR GAPDH.liver BMP-1 VEGF LGMN
...
o SCFsR ERBB I CadherinE METAP I
RGM-C MMR
1-. 78
0.906 0.814 1.72 0.909
co MK13 CK-MB HSP90b IGFBP-2 LRIG3
O RGM-C CadherinE KPCI CK-MB ERBB I METAP1
0.915 0.81 1.725 0.892
1 IL-17B SCFsR CNDP 1 NACA IGFBP-2
1-. YES CadherinE ERBB I CSK SCFsR CK-
MB
co 80
0.901 0.81 1.711 0.899
MMP-7 KPCI CNDP I Prothrombin
Proteinase-3 -
YES CadherinE ERBB I CSK SCFsR RGM-
C
81
0.901 0.807 1.709 0.902
CK-MB MMR GAPDH,liver BLC VEGF
CadherinE IGFBP-2 METAP1 ERBB I RGM-C
HSP90a
82
0.915 0.807 1.723 0.907 -1
CK-MB C9 SCFsR YES b-ECGF
CD
YES CadherinE E RBB 1 CSK SCFsR RGM-
C
83
0.897 0.807 1.704 0.905 -
MMP-7 GAPDH,liver CK-MB CATC ApoA-I
(1)
RGM-C METAP I SCFsR ERBB I HSP90a
CadherinE
84
0.911 0.776 1.687 0.889 -1
IGFBP-2 NACA VEGF CK-MB Cadherin-6
CI
Lo
MMP-7 ERB B I YES METAP1 CadherinE NACA
85
0.93 0.79 1.72 0.899
CK-MB SCFsR CNDE I b-ECGF Cata lase
0
CK-MB SCFsR METAP I CadherinE MMP-7
GAPDH,liver
860.925 0.795 1.72 0.91
RGM-C F.RF3B 1 C9 YES Ca t hepsi
nH
m .....-..=
RGM-C METAP I SCFsR ERBB I YES CadherinE
87
0.906 0.812 1.718 0.904
CK-MB B MP-1 HMG-1 HSP90b MMR .
MMR CSK CadherinE CK-MB RGM-C ER BB1
88
0.883 0.817 1.699 0.907
GAPDH,liver ApoA-I YES IGFBP-2 LGMN
RGM-C CadherinE KPCI CK-MB ERBB1 METAP1
89
0.911 0.81 1.72 0.905
MMR SCFsR MKI3 CNDP1 BMP-1
. ,
RGM-C METAP1 SCFsR ERB13 I YES CadherinE
90
0.915 0.795 1.711 0.901
CK-MB CNDPI. KPCI IGFBP-2 Proteinase-
3
RGM-C CadherinE KPCI CK-MB ERBB1 MET
AP 1
91
0.906 0.814 1.72 0.898
MMR SCFsR 'GI:BP-2 Prothromb in Ca
Ipa in I .
CD30Ligand METAP I CK-MB ERBB I CadherinE YES
92
0.915 0.793 1.708 0.894
RGM-C IGFBP-2 SCFsR KPCI BLC
0
t.,.)
o
1-.
i--,
-.1
t.,.) CK-MB IGFEP-2 CSK CadherinE RUM-
C ERBB I
o
93 0.897 0.807 1.704 0.898
I') YES FGF- 17 GAPDH,liver MMR cATc
_.
,
0 RGM-C CK-MB ERBB1 CSK CadherinE CNDP1
1-. 94
0.892 0.793 1.685 0.895
co YES SCFsR KPCI BMP-1 Cadherin-
6
O RGM-C C9 ERBB1 CadherinE METAP1 SCFsR
...1 95
0.901 0.817 1.718 0.909
I CK-MB NAGK IGFI3P-2 b-
ECGF Catalase
1-. YES CadherinE ERBB1 CSK SCFsR RUM-C
co
96
0.911 0.807 1.718 0.899
MMP-7 GAPDH,liver KPCI ApoA-I
CathepsinH
RUM-C METAP I SCFsR ERBBI YES
CadherinE
97
0.911 0.807 1.718 0.899
CK-MB B MP-1 HMG-1 KPCI IGFBP-2
CK-MB SCFsR METAP1 CadherinE ERBB1 IGEBP-2
98
0.925 0.8 1.725 0.904
YES RUM-C IMB I BMP-1 h-ECGF
CN DP I ERBI31 CadherinE KPCI SCFsR
RUM-C ¨I
99
0.887 0.812 1.699 0.893
CK-MB CalpainI Catalase b-ECGF LGMN
= a.)
cr
CSK CadherinE CK-MB GAPDH,liver ERBB1 MMR
100
0.906 0.814 1.72 0.907 (D
_
.41. YES RUM-C CD30Ligand LR1G3 CNDP1
.o.
¨.a
CD
1Marker Count Marker Count
Marker Count
CadherinE 100 b-ECGF 19
LGMN 8 '.(:)
0
ERBB I , 99 HSP90a 14
IMBI 8 D
RGM-C 98 BMP-1 12 IL-
17B 8 e-4-
,......,
CK-MB 98 VEGF 11
HSP90b 8
SCFsR 92 ApoA-I 11 HMG-
1 8
YES 81 Ca IpainI 10
CathepsinH 8
METAP I 53 FGF-17 9 Cad
heri n-6 8
GAPDH,liver 44 Catalase 9
CATC 8
IGFBP-2 43 CD30Ligand 9 BLC
8
CSK 37 C9 9
Prothrombin , .. 7
CNDP1 35 NAGK /3
Proteinase-3 7
MMR 34 NACA 8 MK
13 7
KPCI 28 LR1G3 8 MEK
I 7
MMP-7 21
0
(A)
0
I-.
I-.
--.1
LA)
0 100 Panels of 12 Benign vs.
Cancerous Nodule Biomarkcrs
n.)
o
Sens. +
i-.
co Biomarkers
Specificity Sensitivity Spec. AUC
O MMR ERBB I GAPDH,liver CadherinE RGM-C CK-
MB
I
0.92 0.81 1.73 0.914
--1 METAP1 SCFsR FGF-17 ApoA-I YES
IGF13P-2
,
i
i-. YES CadherinE ERBB1 CSK SCFsR RGM-C
co
0.892 0.821 1.713 0.903
2 CK-M13 MMR GAPDH,liver BLC VEGF IGH3P-2
RGM-C CK-MB ERBB I CSK CadherinE CNDP1
3
0.901 0.829 1.73 0.914
YES GAPDH,liver MMR SCFsR BMP- I HMG- I
_
RGM-C METAP1 SCFsR ERBB I YES CadhcrinE
4
0.925 0.807 1.732 0.906
CK-MB Catalase NAGK b-ECGF C9 IGFBP-
2
MMR ERBBI METAP1 CK-MB CadherinE YES
0.925 0.795 1.72 0.902
RUM-C GAPDH,liver FGF- 17 1GFBP-2 CATC
SCFsR ,
RGM-C METAP1 SCFsR ERBB I YES CadherinE
6
0.915 0.814 1_73 0911
CD30Ligand CK-MB FGF-17 GAPDH,Iiver MMR IGFBP-2
,
_
RGM-C CK-MB ERBB I CSK CadherinE
CNDP1 .. Cl.)
0.892 0.807 1.699 0.9 C
vi 7
r
YES SCFsR GAPDH,liver C9 LRIG3 Cadherin-
6 -
CD
CNDP I ERBB I CadherinE KPCI SCFsR
RGM-C
s
0.915 0.812 1.727 0.899
CK-MB CSK b-ECGF CalpainI IGFBP-2
CD30Ligand
RGM-C METAP1 SCFsR ERBB I YES CadherinE
9
0.915 0.81 1.725 0.899
CK-MB BMP-I HMG-1 KPCT IGFI3P-2
CathepsinH
RGM-C MF.TAP I SCFsR F.R BB I HSP90a
CadhcrinF.
0.925 0.805 1.73 0.9
1GFBP-2 KPCI CK-MB CN. DPI MKI3 YES
RGM-C CadherinE ERBB1 GAPDH,liver
SCFsR CNDP I
11
0.915 0.807 1.723 0.904
CSK CK-MB HSP9Ob YES b-ECGF Catalase
RGM-C CK-MB ERBB1 CSK CadherinE CNDP I
12
0.906 0.824 1.73 0.908
YES SCFsR GAPDH,liver FGF-17 IGH3P-2
IL-17B
SCFsR F.RBB I CadherinE METAP I IMB1
RGM-C
13
0.925 0.807 1.732 0.906
.MMR CK-MB ICIFBP-2 MK13 YES MF.K 1
RGM-C METAP1 SCFsR ERBB1 YES CadherinE
14
0,92 0.793 1.713 0.893
CK-MB CNDP1 NACA HSP90a b-ECGF LGIVLN
IL-17B CadherinE ERBB I METAP1 UK-MB
RGM-C
0.925 0.805 1.73 0.913
YES SCFsR GAPDH,liver MMP-7 ApoA-1
1GFBP-2
0
(A)
0
I-.
I-.
--.1
(A) RGM-C METAP1 SCFsR ERBB1 YES CadherinE
o 16 0.925 0.798 1.723 0.902
CK-MB CNDP1 NACA b-ECGF BMP-1
Proteinase-3
K.)
o RGM-C CK-MB ERBB1 CSK CadherinE CD30Ligand
i-. 17
0.92 0.81 1.73 0.903
co YES SCFsR IGFI3P-2 KPCI Prothrombin
CNDP1
O 18 MMR CSK CadherinE CK-MB RGM-C ERBB1
0.897 0.817 1.713 0.904
--.1 GAPDH,liver A poA-I YES SCFsR LRIG3
BLC
i
- -
i-. RGM-C METAP1 SCFsR ERBB I YES
CadherinE
co 19
0.92 0.79 1.711 0.897
CK-MB CNDP I NACA IGEBP-2 MKI3 CATC
SCFsR ERBB I HSP90a YES CadherinE IMB1
20
0.901 0.795 1.697 0.894
CK-MB GAPDH,liver RGM-C CNDP I b-ECGF
Cadherin-6
,
MMR SCFsR CadherinE Ca Ipain1 ERBB1
RGM-C
21
0.92 0.807 1.727 0.91
CK -MB CSK GAPDH,liver h-ECGF ApoA-I
LRIG3
22 CathcpsinH CSK ERBB I RGM-C CadhcrinE
SCFsR
0.92 0.802 1.723 0.90' -I
KPCI Catalasc YES CNDP I CK-MB
Prothrombin - Ci.)
b-ECGF CadherinE ERBB I HSF 90b RGM-C
YES CT
23
0.92 0.802 1.723 0.906 (IT
METAP1 SCFsR CK-MB Catalase CNDP1
IGFI3P-2
CK-MB SCFsR METAP I CadherinE ERBB1
IG17I3P-2
24
0.915 0.79 1.706 0.896 ._.%
YES RGM-C HSP90a CNDPI NACA LGMN
2s CadhcrinE IGFBP-2 METAP I E.RBF31
MK 13 CK -MB
0.93 0.81 1.739 0.904 0
SCFsR MEK1 RGM-C NACA YES CNDP I
0
RGM-C METAP I SCFsR ERBB1 YES CadherinE
Z
26
0.925 0.805 1.73 0.901
CK-MB CNDP I NACA MMP-7 GAPDH,liver IL-17B
......-
RCI M-C C9 ERBB1 CadherinE METAP1
SCFsR
27
0.911 0.814 1.725 0.907
CK-MB NAGK IGF13P-2 b-ECGF Catgase
VEGF
28 RGM-C METAP I SCFsR ERBB I YES
CadherinE
0.925 0.793 1.718 0.9
CK-MB CNDP1 NACA CathepsinH b-EC(iF Pro
teinase-3
MMR ERBBI GAPDH,liver CadherinE RGM-C CK-
MB
29
0.9(16 0.805 1.71 I 0.904
METAP1 C9 SCFsR IGFBP-2 BLC YES
YES CK-MB ERBB1 CadherinE METAP I MMP-7
30
0.911 0.798 1.708 0.904
1GFBP-2 RGM-C SCFsR GAPDH,liver ME-17 CATC
CSK CadherinE CK-MB GAPDH,liver
ERBB I MMR
31
0.887 0.807 1.694 0.901
YES RGM-C C9 SCFsR LRIG3 Cadhcrin-6
RGM-C METAP I SCFsR ERBB I YES
CadherinE
32
0.911 0.814 1.725 0.905
MMR CK-MB CalpainI MK13 CNDP1
GAPDH,liver
C)
ta
o
1-.
1-.
C..) RGM-C METAP I SCFsR ERBB I YES
CadhcrinE
o
33 0.925 0.805 1.73 0.896
CK-MB CNDP1 NACA HSP 90a HMG-1 b-ECGF
n.)
O RGM-C BMP-1 ERBB I METAPI CadherinE
HSP9Ob
!-= 34
0.906 0.814 1.72 0.896
co SCFsR CK-MB YES IMBI Catalase VEGF
0!
35 CSK CadherinE CK-M13 GAPDH,liver
ERBB I YES
0.887 0.817 1.704 0.902
--.1 BMP-I SCFsR RGM-C VEGF CD30Ligand LGMN
!
-
!-= RGM-C METAP1 SCFsR ERBB I YES
CadherinE
cc) 36
0.925 0.805 1.73 0.904
CK-MB CNDP 1 NACA IGFBP-2 MEKI Catalase
..
MMR CSK CadherinE CK-MB RGM-C ERBB I
37
0.92 0.805 1.725 0.899
KPCI NAGK SCFsR CalpainI LRIG3
IGF BP-2
RGM-C CadherinE KPCI CK-MB ERBB1 METAP I
38
0.906 0.81 1.716 0.89
TL-1 7B SCFsR CNDP1 NACA TGFBP-2
Protcinase-3
-I
MMP-7 ERBB I YES METAPL CadhcrinE NACA
39
0.934 0.795 1.73 0.904 ED
CK-MB SCFsR CNDP I b-ECGF Pro thrombin RGM-
C Cr
,
RGM-C METAP I SCFsR ERBBI YES Cadheri
nE
40
0.906 0.805 1.711 0.899
UK-MB Catalase NAG K b-ECGF IGF BP-2
B LC
--x
,
-7: METAP1 GAPDH.liver MMP-7 CadherinE ERBBI
YES -%
---.1 41
0.906 0.8 1.706 0.901
CK-MB SCFsR FGF-17 RGM-C Catalase CATC
SCFsR ERBB I CadhcrinE META P I IMB1
RGM-C 0
42
0.892 0.802 1.694 0.9 0
MMR CK-MB IGFI3P-2 MK 13 CNDPI
Cadhcrin-6
=
RGM-C METAP1 SCFsR ERBB I YES CadhcrinE
43
0.92 0.802 1.723 0.9 =
CK-MB CNDP I NACA CathepsinH b-ECGF
MEK1 -.........
CN DP I ERBB I CadherinE METAP1 UK-MB
YES
44
0.93 0.798 1.727 0.898
NACA IL-1713 IGEBP-2 RGM-C SCFsR
HMG-1
MMR ERBB I GAPDH,liver CadherinE RGM-C
CK-MB
45
0.906 0.814 1.72 0.905
HSP90b SCFsR YES LRIG3 FGF-17 ApoA-I
MMR CSK CadherinE CK-MB RGM-C ERBB I
46
0.887 0.814 1.702 0.904
GAPDH,liver ApoA-I YES b-ECGF IGFBP-2 LGI)./N
CK-MB MMR GAPDH,liver CadherinE RGM-C METAP
I
47
0.906 0.81 1.716 0.909
1GFBP-2 SCFsR FU-17 ERBB1 YES Proteinase-
3
UK-MB MMP-7 METAP1 RGM-C SCFsR
CadherinE
48
0.93 . 0.798 1.727 0.901
b-ECGF YES GAPDH,liver CNDP1 Prothrombin
HSP90a
RGM-C METAP1 SCFsR ERBB I YES CadherinE
49
0.92 0.79 1.711 0.897
CK-MB CNDP I NACA MMP-7 GAPDH,liver BLC
a
t.,.)
0
1-,
1-,
-.3
.
w RGM-C CK-MB ERBB I METAP I FGF-17
CadhcrinE
0 50
0.915 0.79 1.706 0.897
IGH3P-2 YES MMR SCFsR IMBI CATC
N
0 RGM-C METAP1 SCFsR ERBB I YES
CadherinE
i-t 51
0.92 0.807 1.727 0.903
co CK-MB CNDP 1 NACA IGEBP-2 MEK1 ..
CD30Ligand
o1 RUM-C CK-MB ERBB1 CSK CadherinE CNDP L
0.883 0.81 1.692 0.894
52
-.3 YES SCFsR KPCI MMR FGF-17 Cadherin-6
1
i-t CNDP1 ERBB1 CadherinE KPCI SCFsR RGM-C
co 53
0.915 0.81 1.725 0.897
CK-MB CSK b-ECGF CalpainI IL-17B
BMP-1 .. .
RGM-C METAP I SCFsR ERBB1 YES CadherinE
54
0.93 0.793 1.722 0.9
CK-MB CNDP I NACA Cathepsin H b-ECGF
Catalase
YES CadherinE ERBB I RUM-C METAP I NACA
55
0.92 0.802 1.723 0.902
MMR CK-MB SCFsR MK13 CNDP I HMG-1
--1
b-ECGF CadhcrinE ERBB1 HSP9Ob RUM-C YES
56
0.911 0.81 1.72 0.897 0.)
METAP1 SCFsR CK-MB HSP90a CNDP I HMG-1
0-
57 SCFsR ERBB I HSP90a YES CadherinE .. IMB1
0.892 0.81 1.702 0.896 a)
UK-MB GAPD1-1.1iver RUM-C CNDP1 b-ECGF
LGMN -N.
_
-4- RUM-C CK-MB ERBB1 METAP I FGF-17
CadherinE --a
oo 58
0.92 0.805 1.725 0.9
IGFBP-2 YES MMR NAGK KPCI SCFsR
UK-MB IGFEW-2 KPCI CadhcrinE METAP I
SCFsR 0
59
0.911 0.805 1.716 0.896 0
CNDP1 Catalasc YES ERBB I MK13 Pro
lcinasc-3 D
YES CK-MB ERBB I CadherinE METAP I MMP-7
60
0.92 0.805 1.725 0.913 '
IGFI3P-2 RUM-C SCFsR GAPDH,liver MEK I
Prothrornbin ......---
RUM-C METAP I SCFsR ERBB1 YES CadherinE
0.93 0.805 1.734 0.911
61 CK-MB CNDP I GAPDH,liver b-ECGF MMR
VEGF .. ,
RUM-C CadherinE ERBBL GAPDH,liver SCFsR CK-MB
62
0.873 0.836 1.709 0.906
CSK MMR IGFBP-2 BLC ApoA-I VEGF
63 MMR ERBB1 METAP I CK-MB CadherinE YES
0.915 0.81 1.725 0.913
RUM-C GAPDH,liver FGF-17 IGFBP-2 C9
SCFsR .
CK-MB IGFI3P-2 KPCI CadherinE METAP1 SCFsft.
64
0.915 0.79 1.706 0.891
CNDPI Catalase YES ERBB1 MKI3 CATC
.
CD30Ligand META P I CK-M13 ERBB1 CadherinE YES
65
0.93 0.798 1.727 0.903
RUM-C 1GFBP-2 SCFsR b-ECGF CNDP I
NACA
RUM-C CK-MB ERBB1 CSK CadherinE CNDP I
66
0.897 0.795 1.692 0.894
YES SCFsR KPCI BMP- 1 b-ECGF Cadherin-
6
0
W
0
I-.
I-.
-...1
W
0 RGM-C METAP I SCFsR ERBB I HSP90a
CadhcrinE
67
0.92 0.805 1.725 0.895
n.) IGH3P-2 KPCI CK-MB CNDP I Cal Niall
b-ECGF .
o MMR ERBB1 METAP 1 CK- MB CadherinE YES
1-` 68
0.906 0.814 1.72 0.908
co RGM-C GAPDH,liver BMP- I SCFsR CathepsinH
MEK1
b-ECG I' CadherinE ERBB I HSP9Ob RGM-C
YES . .
-...1 69
0.915 0.805 1.72 0.9
i META P I SCFsR CK-M13 Catalase CNDP
I 11MG-1 .
i-. CNDP I ERBB1 Cadhcrin E KPCI SCFsR RGM-
C
co 70
0.897 0.805 1.701 0.892
CK-MB CSK b-ECGF Cal pai nI Catalase
LGIvliN
RGM-C METAP1 SCFsR ERBBI YES CadherinE
71
0.92 0.805 1.725 0.902
CK-MB RIF-17 NACiK MMP-7 ICiEBP-2 KPCI
MMP-7 ERBB1 YES METAPI CadherinE NACA
72
0.925 0.79 1.715 0.904
CK-MB SCFsR RGM-C h-F.CGF CNDP I
Pro1cinasc-3 -I
,
RGM-C Cadhcrin E KPCI CK-MB ERBB1 METAP I
73
0.906 0.817 1.723 0.9 rr
MMR SCFsR IGF13P-2 Prothrombin
MKI3 GAP DH,liver . Z...-.-'
.
-
RGM-C Cadherin E. ERBB1 GAPDH,liver
SCFsR CK-MB CD
74
0.873 0.836 1.709 0.904
CSK MMR IGEBP-2 BLC ApoA-1 MEI( I
_%
RGM-C CK-MB ERBB I CSK CadherinE CNDP I
-s.r5 75
0.92 0.805 1.725 0.902
YES SCFsR GAPDH,liver C9 NACA CD3OLigand
.
. 0
RGM-C META P I SCFsR ERBB1 YES
CadhcrinF.
76
0.92 0.786 1.706 0.807 0
CK-MB CN1JP1 NACA MMP-7 GAPDH,livcr CATC
D
.
,
CK-MB IGF13P-2 KPCI CadherinE METAP I
SCFsR
77
0.897 0.795 1.692 0.889 -:.....-=
CNDPI Catalase YES ERBB1 FGF- 1 7
Cadherin-6
CK-M13 IGEBP-2 KPCI CadherinE METAP I
SCFsR
78
0.913 0.805 1.72 0.898
CNDP I Catalase YES ERBB I FGF-17
Cathepsinll .
b-ECGF CadherinE ERBB I HSP90b RGM-C
YES
79 0.925 0.795 1.72 0.906
METAP1 SCFsR CK-MB BMP-1 CSK MMP-7
SCFsR ERBB1 CadherinE METAP I IMB I
RGM-C
80
0.93 0.798 1.727 0.901
CNDP I CK-MB VEGF YES IL-17B Catalase
,
MMP-7 ERBB I YES METAP I CadherinE NACA
0.92
0.781 1.701 0.897
81 CK-M13 SCFsR HSP90a CNDP I RGM-C
LGMN ._ .
MMR CSK CadherinE CK-MB RGM-C ERBB I
82
0.901 0.824 1.725 0.917
GAPDH,livcr ApoA-I YES SCFsR LRIG3 IGFBP-2
-
SCFsR NAGK CadherinE CK-MB RGM-C ERBB I
83
0.93 0.795 1.725 0.899
IL-17B METAP 1 MMP-7 YES IMB1 b-ECGF
,
C)
(A)
0
1-.
I-.
--.1
(A) MMR ERBB I METAP I CK-MB CadhcrinE
YES
o
ft4 0.901 0.812 1.713 0.906
RGM-C GAPDH,liver FGF-17 IGFBP-2 ApoA-I
Proteinase-3
N
0 CSK CadherinE CK-MB GAPDH,liver
ERBB1 YES
85
0.906 0.817 1.723 0.916
co IGF BP-2 REM-C Prothrombin MMP-7 SCFsR
MEK1
i
o 86 CadherinE IGF13P-2 METAP1
ERBI31 REM-C HSP90a
0.897
0.812 1.709 0.901
--.1 C,K-M13 ApoA-T YES h-ECGF SCFsR
BLC
i
.
i-. RGM-C CK-MB ERBB I CSK CadherinE CNDP
I
co 87
0.92 0.805 1.725 0.903
YES SCFsR GAPDH,liver C9 NACA MEK I
88 RGM-C CK-M13 ERBB1 CSK CadherinE CNDP
I
0.892
0.812 1.704 0.903
YES SCFsR GAPDH,liver FGF-17 IGEBP-2
CATC
CSK CadherinE CK-MB GAPDH,liver
ERBB I YES
89
0.901 0.824 1.725 0.913 ,
IGFT3P-2 R GM-C CD30Ligand ApoA-I M EK 1
SCFsR -I
YES CadhcrinE ERBB I CSK SCFsR
RGM-C S:1)
90
0.906 0.786 1.692 0.894 cr
CK-MB NACA CNDP I b-ECGF Cathcps inH
Cadherin-6
CSK CadherinE CK-MB GAPDH,liver
ERBB1 YES CD
91
0.911 0.812 1.72.3 0.911
BMP-1 REM-C MMR CalpainI ApoA-1.
SCFsR --a
__a
t_n RGM-C METAP1 SCFsR ERBB I YES
CadherinE
92
0.934 0.788 1.722 0.9
MMP-7 NACA IL-17B CK-MB 11MG-1 IGFI3P-
2
0
CK-MB SCFsR META P I CadhcrinE MMP-7
ER11131
93
0.911 0.807 1.718 0.892
REM-C Prothrombin HSP9013 b-ECGF NACA
HSP90a D
"...P.
VEGF METAP I CadherinE ERBB I CK-MB
CalpainI
94
0.892 0.807 1.699 0.895 --:---,
CNDP I RGM-C SCFsR MEKI GAPDH,liver LGNEN
YES CadherinE GAPDH,liver MMP-7 SCFsR CK-
M13
95
0.906 0.817 1.723 0.912
REM-C CSK IGIT13P-2 MMR LRIG3
ApoA-I
SCFsR NAGK CadherinE CK-MB REM-C ERBBI
96
0.911 0.812 1.723 0.904
IL-17B METAPI MMP-7 Calpaira AppA-I b-
ECGF
97-YES CadherinE ERBB I CSK SCFsR REM-C
0.906
0.807 1.713 0.899
CK-MB NACA CNDP1 b-ECGF CD30Ligand
Proteinase-3
CD3 OLigand METAP I CK-MB ERBB1 CadherinE YES
98
0.901 0.807 1.709 0.9
RE M-C IGFBP-2 SCFsR b-ECGF BLC
GAPDH,liver
MMR ERBB I GAPDH,liver CadherinE RGM-C
CK-MB
99
0.92 0.805 1.725 0.913
METAPI C9 SCFsR IGFBP-2 Catalasc FGF-
17
-
MMR ERBB I METAP I CK-MB CadhcrinE YES
100
0.901 0.802 1.704 0.899
REM-C GAPDH,liver FGF-17 IGFBP-2 CATC
ApoA-I
0
W
0
I-.
I-.
-...1
W
0
Marker Count Marker Count
N)
o Cadherin E 100 HSP90a 12
1-`
co CK-MB 100 MK13 10
oi ERBBI 98 IL-1713 10
-...1 SCFsR 97 Calpainl 10
1 ,
i-. RGM-C 96 CD30Ligand 10
co
YES 84 BMP-1 10
METAP I 67 CATC 9
CNDP I 54 C9 9
IGFBP-2 53 BLC 9
G A PDH,liver 46 VEGF 8
¨I
b-ECGF 35 Prolhrornbin
8 CO
,
MMR 32 Proieinase-3
8 0-
CSK 31 NAGK 8
¨
CD
NACA 27 LRIG3 8
....µ
_...
LA MMP-7 19 LGMN 8
--a
,
_
KPCI 19 IMB1 8
FGF-17 19 HSP9Ob 8
0
Calalaso IS HMG-1 8 ..
0
=
ApoA-I 16 CathepsinH 8
.¨i-
MEK I 12 Cadherin-6 8
......
C)
(A)
0
1-.
I-.
--.1
W
0 100 Panels of 13 Benign vs.
Cancerous Nodule Bioniarkers
Sens. +
N
0 BionwrkerS
, Specificity, Sensitivity Spec. AUC
i-.
co I RGM-C METAP I SCFsR ERBB i YES
CadhcrinE CK-MB
0.92 0.812 1.732 0.908
O CNDP 1 GAPDH,liver b-ECGF BMP- I IL-
17B Apo:\ -1
--] -12GM-C METAP1 SCFsR ERBBI YES CadherinE CK-MB
i "1.
0.925 0.79 I 715 0.897
i-. CNDP I NACA b-ECGF IGFBP-2 Ca
talase BLC .
,
co
-
RUM-C METAP1 SCFsR ERBB I YES
CadherinE CK-MB
3
0.925 0.802 1.727 0.911
CNDP I GAPDH,liver b-ECGF IGFBP-2 C9
Ca ta lase
YES CadherinE ERB B1 CSK SCFsR RUM-C
CK-MB
4
0.92 0.798 1.718 0.898
MMR GAPDH,livcr NACA CNDP I MK I 3
CATC
RGM-C CadherinE ERB B1 GAPDH,liver
SCFsR CK-MB CSK
0.915 0.812 1.727 0.904
MEK1 YES NDPI IGFBP-2 NACA
CD30Ligand .
RUM-C METAP1 SCFsR ERBBI YES CadherinE CK-MB
6
0.911 0.795 1.706 0.894
Cata lase NAGK b-ECGF C9 IGEBP-2
Cadherin-6
7
MMR SCFsR CadherinE CalpainI ERBBI
RGM-C CK-MB ' -I
___
0.901 0.824 1.725 0.904 51)
CSK IGFBP-2 KPCI MK13 CNDP1
Prothrombin CT
N.)
RUM-C METAP1 SCFsR ERBBI YES CadherinE CK-MB
8
0.925 0.8 1.725 0.902 CD
CNDP1 NACA MMP-7 GAPDH,liver CathepsinH
b-ECGF _ .._.a
MMR ERBBI GAPDH,liver CadherinE RGM-C CK-MB
METAP I
9
0.92 0.81 1.73 0.911 r\-)
SCFsR EGF-17 ApoA-I YES b-ECGF
1GFBP-2 .
MMR ERBB I META PI UK-MB
CadherinE YES RGM-C
0.92 0.81 1.73 0.911
GAPDH,liver BMP- I SCFsR CNDP I VEGF HMG-
I
RGM-C CadherinE ERBBI GAPDH,liver
SCFsR CK-MB CSK
1 I
0.906 0.824 1.73 0.911
MMR IGFBP-2 CNDP1 YES HSP90a BMP-
1 .
CadherinE METAP I CK-MB HSP90b ERBB1 YES SCFsR
12
0.925 0.8 1.725 0.904
RUM-C IGFBP-2 BMP- I GAP DH,liver
Catalase b-ECGF
.
. . ,
SCFsR ERBBI. CadherinE METAP I IMB I RUM-
C CNDP I
13
0.93 0.8 1.73 0.902
CK-MB HSP90a h-ECGF YES ApoA-I VEGF
-
,
CSK Cadhcri n E CK-MB GAPDH,livcr
ERBBI YES BMP- I
14
0.897 0.812 1.709 0.902
SCFsR RUM-C VEGF CD30Ligand CNDP I
LGMN
YES CadherinE ERBB1 RUM-C CSK CK-MB LRIG3
0.897 0.826 1.723 0.912
CiAPDH,liver MMR BMP-1 SCFsR ApoA-1
VECiF
C)
(A)
0
1-.
I-.
--.1
W RGM-C METAP1 SCFsR ERBB I YES
CadhcrinE CK-MB
o
16 0.911 0.812 1.723 0.903
Ca talase NAGK b-ECGF C9 IGEBP-2
Proteinase-3
K.)
o M MP-7 ERBB I YES META P I
CadherinE NACA UK-MB
0.925
0.79 1.715 0.898
co SCFsR CNDP I b-ECGF
GAPDH,liver RGM-C BLC
i MMR CSK CadherinE CK-MB RGM-C ERBB I
GAPDH,liver
o
18 0.911 0.805 1.716 0.904
--.3 ApoA-I YES SCFsR LRIG3 IGHIP-2
CATC
i
i-. RGM-C CK-MB ERBB I CSK CadherinE CNDP I
YES
co 19
0.892 0.812 1.704 0.902
SCFsR GAPDH,liver Catalase IGH3P-2 BMP-
1 Cadherin-6
,
RGM-C CK-MB ERBB I CSK CadherinE CNDP I
YES
20
0.906 0.819 1.725 0.91
GAP DH,livcr MMR b-ECGF SCFsR BMP-1
Calpainl
CathepsinH CSK ERBB1 RGM-C CadherinE SCFsR KPCI
21
0.92 0.802 1.723 0.9
Catalasc YES CNDP I CK -MB Prothrombin
HMG- I
22 MMR ERBB I METAP I CK-MB
CadherinE YES RGM-C
0.92
0.81 1.73 0.912 -I
GAPDH,liver FGF- 17 IGFI3P-2 CNDP I SCFsR
MK13 a)
RGM-C CK-MB ERBB I CSK CadherinE
CD30Ligand YES CT
23
0.911 0.812 1.723 0.898 -
SCFsR IGH3P-2 KPCI Prothrombin CNDP I
HSP90b CD
_
LA RGM-C METAP I SCFsR ERBB1 YES
CadherinE CK-MB -=
t....) 24
0.92 0.805 1.725 0.899
CNDP I GAPDH,liver b-ECGF BMP-I IL-17B
NACA N.)
RGM-C CK-M13 ERBB I MF,TAP I FGF- I 7
CadhcrinE IGFBP-2
25
0.92 0.805 1.725 0.908 C)
YES MMR SCFsR IMB I CNDP I b-
ECGF 0
SCFsR ERBB I CadherinE METAPI IMB I RGM-C
CNDP I D
26
0.906 0.802 1.708 0.9
CK-MB VEGF YES BMP-1 MK13 LGMN
........-
RGM-C CadherinE ERBB I GAPDH,liver SCFsR CK-MB
CSK
27
0.92 0.812 1.732 0.914
MEK1 YES CNDP1 IGFBP-2 ApoA-I
Catalase
28 MMP-7 ERBB I YES METAP1 CadherinE NACA CK-
MB
0.925
0.795 1.72 0.9
SCFsR CNDP1 b-ECGF Prothrombin ApoA-I
Proteinase-3
YES CadherinE ERBB1 CSK SCFsR RGM-C CK-MB
29
0.892 0.821 1.713 0.904
MMR GAPDH,liver BLC VEGF IGFBP-2
ApoA-I
YES CadherinE ERBBI CSK SCFsR RGM-C IGFBP-2
30
0.901 0.812 1.713 0.906
CK-MB GAPDH,liver MMP-7 ApoA-1 LRIG3
CATC - -
CD30Ligand META P I CK -MB ERBB I CadherinE YES
RC1M-C
31
0.911 0.786 1.697 0.894
IGEBP-2 SCFsR b-ECGF CNDP I NACA
Cadhcrin-6
SCFsR ERBB I CadherinE METAP I RGM-C MMR
MK13
32
0.925 0.8 1.725 0.903
IGF13P-2 CK-MB NACA ApoA-I Calpain1
VEGF
a
W
0
I-
I-
-.1
W
- _______
RGM-C METAP1 SCFsR ERBB I YES
CadherinE CK-MB
o 33
0.925 0.798 1.723 0.903
CNDP I NACA 1GFBP-2 MEK L CathepsinH
Catalase
1µ)
-
0 CK-MB IGF BP-2 KPCI CadherinE METAP1
SCFsR CNDP I
1-' 34
0.911 0.814 1.725 0.9
co Catalase YES ERBB1 RGM-C MEK I HMG-1
-
O RGM-C CK-MB ERBBI CSK CadherinE CNDP I
YES
i
SCFsR GAPDH,liver EGF-17 RiFBP-2
HSP90a A poA-I 0.915 0.812 1.727 0.912 - ,
H MMR ERBB1 GAPDH,liver CadherinE RUM-C CK-MB
HSP90b
co 36
0.915 0.805 1.72 0.905
SCFsR YES LRIG3 BMP- I FGF-17
METAP I
RUM-C CadherinE KPCI CK-MB ERBB I
METAP1 IL-17B
37
0.906 0.817 1.723 0.897
SCFsR IGFBP-2 Calpain1 CNDP1
Prothrombin ApoA-1
CN DP I ERBB I CadherinE KPCI SCFsR RUM-C CK-
MB
38
0.897 0.81 1.706 0.897
CSK h-F.CGF CalpainI MMR BMP-1
LGMN
-
MMP-7 ERBB1 YES METAP1 CadherinE NACA CK-MB
-I
39
0.93 0.8 1.73 0.905 co
SCFsR RGM-C FGF-17 NAGK IGFBP-2
CNDP I , - CY
RUM-C METAP I SCFsR ERBB1 YES
CadherinE CK-MB
40
0.925 0.795 1.72 0.902 cco
CNDP I NACA b-ECGF IG1713P-2 Catalase
Proteinase-3
.
.
th RGM-C METAP1 SCFsR ERBBI. YES
CadherinE CK-M13 41 0.911 0.802 1.713 0.904 N.)
Catalase MMP-7 GAPDH,liver CNDP I b-ECGF
BLC
YES NAGK ERBB I HSP90a RUM-C CadherinE
METAP I ..----.
41
0.925 0.8 1.725 0.906
CK-MB b-ECGF SCFsR C9 IGFBP-2 ApoA-I
C..)
,
MMR ERBB I METAP1 CK-MB
CadherinE YES RGM-C =
43
0.915 0.798 1.713 0.9 .--i-
GAPDH,liver FGF-17 IGFBP-2 CATC SCFsR
Catalase
'
RUM-C METAP I SCFsR ERBB I YES
CadherinE CK-MB
44
0.915 0.781 1.696 0.895
CNDP I NACA b-ECGF IGEBP-2 Catalase
Cadherin-6 ... .
SCFsR ERBB I CadherinE METAP I IMB I RGM-
C CNDP I
45
0.925 0.798 1.723 0.901
CK-MB Catalase b-ECGF YES
CathepsinH MEK I
RGM-C CadherinE KPCI CK-MB ERBB1 METAPI MMR
46
0.911 0.814 1.725 0.903
SCFsR MKI 3 HMG-1 CNDP I BMP-1 YES
=
ROM-C CadherinE ERBB I GAPDH,liver
SCFsR CNDP1 CSK
47
0.906 0.812 1.718 0.902
CK-MB HSP90b YES HS P90a LRIG3 b-
ECG I' .
1L-17B CadherinE F.R BB I META PI CK -MB
RUM-C YES
48
0.915 0.807 1.723 0.901
SCFsR GAPDH,liver CNDPI b-ECGF NACA
MMP-7
=.
CD30Ligand KPCI ERBBI SCFsR CadherinE CK-MB CSK
49
0.906 0.8 1.706 0.895
YES CNDPI Prothrombin CathepsinH RUM-C
LG MN
C)
6.)
o
i-.
F.
-...1
1,3 MM P-7 ERBB1 YES METAPI CadherinE NACA
CK-MB
o
50 0.92 0.798 1.718 0.897
SCFsR CNDP I b-ECGF Prothrombin FGF -17
Proteinase-3
N.)
o b-ECGF CadherinE ERBB1 METAPI RGM-C CK-MB MMP-7
FA 51
0.911 0.802 1.713 0.907
co SCFsR ApoA-1 YES GAPDH,liver IGFBP -2
BLC
1
o YES CadherinE ERBB I CSK SCFsR RGM-C CK-M13
-
0.901
0.821 1.723 0.909
VEGF GAPDH,liver MMR ICIFI3P-2 HSP90a
C9
i
i-. MMR ERBB1 METAP1 CK-MB CadherinE YES RGM-C
co 53
0.915 0.795 1.711 0.904
GAPDH,liver FGF-17 IGEBP-2 CATC SCFsR ApoA-
I
.
.
RGM-C CK-MB ERBB1 CSK CadherinE CNDP1 YES
54
0.892 0.802 [.694 0.898
SCFsR GAPDH,liver b-ECGF Calpainl BMP
-1 Cadherin-6
RGM-C METAPI SCFsR ERBB I YES CadherinE CK-
MB
55
0.915 0.81 1.725 0.901
BMP-1 HMG- I KPCI IGFFIP-2 CNDP I
Prothromhin
RGM-C BMP-1 ERBB1 METAP1 CadherinE HSP 90b
SCFsR
56
0.906 0.812 1.718 0.895 -I
CK-MB YES IMB I Catalase VEGF Pro
thrombin Si)
IL-173 CadherinE ERBB1 METAPI CK-MB RGM-C YES
cr
57
0.92 0.802 1.723 0.903 -
SCFsR GAPDH,liver MMP-7 IGFBP-2 NACA
CNDP I CD
-
ul MMR CSK CadherinE CK-MB RGM-C ERBB1 GAPDH,liver
--a
58
0.892 0.812 1.704 0.904
LA
ApoA-1 BMP-1 YES IGFBP-2 b-ECGF LGMN
IV
RC.IM-C METAPI SCFsR ERBB1 YES CadherinE CK-MB
59
0.93 0.798 1.727 0.904 0
CNDP 1 NACA b-ECGF BMP-I NAGK MMP-7
.. 0
RGM-C METAPI SCFsR ERBB I YES CadherinE CK-
MB =
60
0.915 0.8 1.715 0.901 ,..t.
CNDP I NACA IGFBP-2 MEK1 b-ECGF
Proteinase-3 . .......
RGM-C C9 ERBB I CadherinE METAPI SCFsR
CK-MB
61
0.901 0.81 1.711 0.899
NAGK IGEBP-2 b-ECG F. Catalase
VEGF BLC ,
MMR ERBB I GAPDH,liver CadherinE RGM-C CK-
MB METAPI
62
0.915 0.795 1.711 0.904
SCFsR FGF -17 ApoA-I YES IGFBP-2
CATC
RGM-C CK-MB ERBB I CSK CadherinE CNDP1 YES
63
0.906 0.817 1.723 0.907
SCFsR GAPDH,liver b-ECGF CalpainI BMP-
I CD30Ligand
CD30Ligand KPCI ERBB1 SCFsR CadherinE CK-MB CSK
64
0.897 0.798 1.694 0.893
YES CNDP I Prothromb in Cathepsin H RGM-C
Cadheri n-6
RGM-C META P I SCFsR ERBBI YES
CadherinE CK-MB
65 .
0915 0.807 1.723 0.902
CNDP I KPCI IGFBP-2 FGE-17 BMP -1
HMG-1
RGM-C METAP1 SCFsR ERBB I YES CadherinE CK-
MB
66
0.911 0.807 1.718 0.908
CNDP I GAPDH,liver b-ECGF BMP-1 MMP-7
HSP90b
C)
ta
o
1-.
1-.
--.1
W CNDP I ERBBI CadherinE METAP1 CK-MB YES
NACA
o
67 0.92 0.802 1.723 0.898
IL-17B IGFI3P-2 RGM-C SCFsR HMG-1
MEK1 .
I')
0 MMR ERBBI CiAPDH,liver CadherinE RGM-C CSK
SCFsR
i-. 68
0.92 0.805 1.725 0.91
co YES BMP-1 CNDP I VEGF IMB I CK-
MB
'
O VEGF RGM-C ERBBI METAP L CK-MB CadherinE
MMR
69
0.901 0.802 1.704 0.905
--.1 GAPDH,liver SCFsR IGH3P-2 YES ApoA-
T LG MN
i
i-. MMR CSK CadherinE CK-MB ROM-C ERBBI GAPDH,liver
co 70
0.901 0.821 1.723 0.912
ApoA-I YES SCFsR LRIG3 IGEBP-2 MEK1 ..
RGM-C METAPI SCFsR ERBBI HSP90a CadherinE IGFBP-2
71
0.92 0.795 1.715 0.899
NACA CK-MB CNDP 1 b-ECGF YES
Proteinase-3
RGM-C META_Pl SCFsR ERBBI HSP90a CadherinE b-ECGF
77
0.92 0.79 1.711 0.891
NACA CK-M13 NAGK MMP-7 Prothromhin
BLC
RGM-C METAP I SCFsR ERBB1 YES CadhcrinE CK-
MB -I
73
0.906 0.817 1.723 0.91 a)
CNDP I GAPDH,liver b-ECGF IGFEIP-2
IvIEK1 C9
Cr
CK-MB IGFI3P-2 CSK CadherinE RGM-C ERBBI YES
74
0.897 0.812 1.709 0.903 FD-
FGF-17 GAPDH,liver MMR ApoA-I SCFsR
CATC
_
__.%
YES CadherinE ERBBI CSK SCFsR RGM-C MMP-7
aN 75
0.906 0.788 1.694 0.898 N.)
GAPDH,liver NACA CNDP I CK-MB b-ECGF Cad
herin-6
RCIM-C METAP1 SCFsR ERBBI YES CadhcrinE CK-MB
76
0.925 0.798 1.723 0.891 0
CNDP1 NACA Ca thcpsinH b-ECGF Catalasc
KPCI 0
CK-MB MMP-7 METAP I RGM-C SCFsR CadherinE
b-ECGF
77
0.911 O. 1.718 0.905 .-1-
YES GAPDH,liver CNDP 1 ERBBI HSP90b
Prothrornb in ...-...,
..
RE M-C METAP 1 SCFsR ERBBI YES CadherinE CK-
MB
78
0.93 0.793 1.722 0.902
CNDP I NACA MMP-7 GAPDH,liver ApoA-I
IL-17B ....
SCFsR ERBBI CadherinE METAP1 'MB' REM-C
CND PI
79
0.911 0.812 1.723 0.908
CK-MB VEGF YES BMP-1 MMR MK13
.
YES NAGK ERBBI HSP90a RGM-C CadherinE
METAP I
80
0.906 0.798 1.704 0.896
CK-MB b-ECGF SCFsR C9 ApoA-I LG MN
MMR ERBBI GAPDH,liver CadherinE RE M-C CK-
1..4.13 METAP I
81
0.92 0.802 1.723 0.914
C9 SCFsR YES LR1G3 ApoA-I
IGH3P-2
=
YES CadherinE ERBB I CSK SCFsR REM-C
KW F1P-2
82
0.901 0.812 1.713 0.91
CK-MB GAPDH,livcr MMR Catalasc ApoA-I
Protcinasc-3 . ,
CK-MB IGFBP-2 KPC I CadherinE METAP1 SCFsR
CNDP1
83
0.915 0.793 1.708 0.897
Catalase YES ERBBI MK13 REM-C BLC
0
(A)
0
I-.
I-.
--.1
LA) ,
______________________________________________________________________________
RGM-C METAP I SCFsR ERBB1 YES
CadherinE CK-MB
o 84
0.925 0.783 1.708 0.896
CNDP 1 NACA MMP-7 GAPDH,liver CathcpsinH
CATC
n.)
0 RCiM-C CadherinE ERB B I GAPDH,liver
SCFsR .. CK-MB .. CSK
i-. 85
0.911 0.812 1.723 0.906
co MMR IGFBP-2 CNDP1 YES KPC1
CD30Ligand
O MMR ERBB I GAPDH,liver CadherinE RGM-C CSK
SCFsR
86
0.878 0.814 1.692 0.902
--.1 YES BMP-1 CNDP I Catalase CK-MB
Cadherin-6
i
i-. RGM-C CadherinE ERBB I GAPDH,liver
SCFsR CK-MB CSK
co 87
0.897 0.824 1.721 0.907
MEKI YES BMP-1 CalpainI CNDP1 b-
ECGF
RGM-C METAP1 SCFsR ERBB1 YES CadherinE MMP-7
88
0.92 0.8 1.72 0.902
NACA 1L-17B CK-MB HMG-1 CNDPI
IGFBP-2 .
RGM-C METAP I SCFsR ERBB I YES
CadherinE CK-MB
89
0.915 0.802 1.718 0.901
CNDP I GAPDH,livcr b-F.CCiF BMP-1 IL-17B
HSP90h
RGM-C METAP1 SCFsR ERBBI YES CadherinE CK-MB
-I
90
0.911 0.812 1.723 0.895 a)
CNDP I NACA MMP-7 IMB I HSP90a ApoA-
I cr
MMR ERB B1 GAPDH,liver CadherinE RGM-C CK-
MB METAP1 91 0.892 0.81 1.702 0.905 CD
SCFsR EGF-17 ApoA-I YES IGFBP-2 LGMN
(A YES CadherinE ERBB I CSK SCFsR RGM-C
IGFBP-2
--a 97
0.892 0.829 1.721 0.915 N)
CK-MB GAPDH,liver MMP-7 ApoA4 LRIG3
BMP-1
RGM-C MF,TAP I SCFsR ERBB1 YES
CadhcrinF. CK -MB
93
0.901 0.812 1.713 0.904 ,
CNDP I CalpainI b-ECGF BMP-1 VEGF
Protcinasc-3 V
YES CK-MB ERBB I CadherinE METAP1 MMP-7
1GFBP-2 n
94
0.915 0.793 1.708 0.902
RGM-C SCFsR GAPDH,liver NAGK Prothrombin
BLC .........
MMP-7 ERBB1 YES METAP I CadherinE NACA
CK-MB
95
0.93 0.779 1.708 0.899
SCFsR REM-C b-ECGF CNDP1 IGFBP-2 CATC
METAP1 GAPDH,liver IMMP-7 CadherinE CK-MB
RGM-C ME-17
96
0.915 0.807 1.723 0.907
ERBB1 SCFsR b-ECGF YES Pro thrombin
CD30Ligand
RGM-C METAP1 SCFsR ERBB I YES
CadherinE CK-MB
97
0.901 0.79 I .692 0.895
CNDP I NACA b-ECGF MMR FGF-17
Cadherin-6 .
CSK Cad hcrin E CK-MB GAPDH,liver ERB
B1 YES BMP-1
98
0.93 0.793 1.722 0.903
SCFsR REM-C KPC1 CN DP1 Cathepsin H
Catalase
SCFsR FARB I CadherinE META P I IMB I RGM-
C CNDP I
99
0.92 0.8 1.72 0.906
CK-MB VEGF YES IGFBP-2 HMG-1 BMP-
1
RGM-C BMP-1 ERBB I METAP I CadherinE
HSP 90b SCFsR
100
0.915 0.802 1.718 0.898
CK-MB YES VEGF CSK Catalase
GAPDH,liver
0
(A)
0
I-.
I-.
--.1
(A)
0
Marker Count Marker Count
n.)
o ERBB1 100 FGF-17 , 15 ,
i-.
co Cadherin E 100 Prothrombin 14
oi CK-MB 100 MEK1 10
--.1 SCFsR 99 HSP90a 10
i
i-. RGM-C 98 NAGK 9
co
YES 94 IMB I 9
CNDP I 69 IL-17B 9
METAP1 67 HSP901) 9
GAPDH, liver 56 HMG-1 9
IGFBP-2 54 Cathepsin H 9
¨I
b-ECGF 45 Calpainl 9
SD
CT
CSK , 34 , Cadherin-6 9
¨
M MR 31 CD30Ligand 9
CD
BMP-1 31 CATC 9
-...a
.....
N)
LA NACA 29 C9 9
,
oo
ApoA- I 17 B LC 9
0
MMP-7 13 Protein asc-3
8 0
Catalaso 23 MK 13 8
=
VEGF 16 L RIG3 8
...-...
KPC1 15 LGMN 8
0
W
0
I-.
I-.
-.3
W
0 100 Panels of 14 Benign vs.
Cancerous Nodule Biomarkers
Sens. +
n.)
o Biomarkers Specificity Sensitivity Spec. AUC
-
i-. MMR ERBB I METAP1 CK-MB
CadhcrinE YES RGM-C
co I
0.93 0.802 1.732 0.915
i GAPDH,liver BMP- I SCFsR CNDP I VEGF
Catalase ApoA-I
0
-.3 MMR ERBB1 METAP1 CK-MB CadherinE YES LRIG3
I 2
0.911 0.805 1.716 0.904
i-. RGM-C IGFI3P-2 FGF-17 GAPDH,liver
SCFsR ApoA-I BLC
,
co YES (2K-MB ERBB1 CadherinE GAP
DH,liver VEGF RGM-C
3
0.906 0.819 1.725 0.91
CSK CNDP I MEK1 SCFsR C9 Catalase
IGF13P-2 ,
RGivi-C META P I SCFsR ERBBI YES
CadherinE CK-MB
4 -
0.93 0.79 1.72 0.896
CNDP I NACA MMP-7 GAPDH,livcr CathcpsinH b-ECGF
CATC -
RGM-C CadherinE ERBB1 GAP DH,liver
SCFsR CK-MB CSK
0.925 0.807 1.732 0.905
MMR 1GFBP-2 CNDP I YES KPCI MEK1
CD3 OLiga nd
CSK CadherinE (2K-MB CiAPDH,liver
ERBB I YES BMP-1
6
0.897 0.814 1.711 0.902
SCFsR RGM-C CNDP I VEGF Catalase IGFI3P-
2 Ca dherin-6
CSK CadhcrinE CK-MB GAP DH, Liver
ERBB1 YES BMP-1 -I
_ 7
0.925 0.81 1.734 0.909 (i)
c..n SCFsR RGM-C CND P1 VEGF Prothrombin Calpain I
h-ECGF CT ,
,c) CSK CadherinE CK-MB GAPDH,liver
ERBB I YES BMP-1 _
8
0.915 0.821 1.737 0.913 CD
SCFsR RGM-C CND PI VEGF Catalase 1GFBP-2
HMG-1
RGM-C METAP1 SCFsR ERBB I YES
CadherinE CK-MB
9
0.93 0.795 1.725 0.904 CO
CNDP1 NACA HSP90a ApoA-I MMP-7 Prothrorn
bin b-ECGF
RGM-C META P 1 SCFsR ERBB1 YES Ca
dherinC CK-MB
0.925 0.802 1.727 0.897
CND PI KPCI h-ECGF BMP-1 Prothrombin IGEBP-2
HSP9Ob
,
MMR SCFsR CadherinE CalpainI ERBB I
RGM-C CK-MB
11
0.92 0.805 1.725 0.9
CSK GAPDH,liver b-ECGF IGFBP-2 NACA IL- I
7B ApoA-I
-
RGM-C CK-MB ERBB I IMBI. CadherinE YES
SCFsR
12
0.911 0.819 173 0.902
MMR CSK CNDP I MK13 Prothrombin IGEBP-2
KPCI
SCFsR ERBB I CadherinE METAP1 IMB I RGM-C
CNDP I
13
0.915 0.795 1.711 0.901
(2K-MB Catalase b-ECGF VEGF YES BMP-1
LGMN
YES CadhcrinE ERBB I CSK SCFsR RGM-C
CK-MB
14
0.92 0.807 1.727 0.901
NACA CNDP 1 b-ECGF CD30Ligand MEK I IGFBP-2
NAGK
RGM-C METAP1 SCFsR ERBB I YES
CadherinE CK-MB
0.925 0.795 1.72 0.904
Catalase MMP-7 GAPDH,liver CNDP1 IGEBP-2 NACA
Proteinase-3
-
0
(A)
0
I-.
I-.
-4
W CSK CadhcrinE CK-MB GAPDH,liver
ERBB1 YES BMP-1
o
16 0.883 0.831 1.714 0.903
SCFsR RGM-C CNDP I VEGF Catalase IGFBP-2
BLC
ts.)
o CK-MB MMR GAPDH,liver CadherinE
RGM-C METAP1 IGFBP-2
F. 17
0.92 0.805 1.725 0.911
03 SCFsR YES ERBB I b-ECGF ApoA-I C9
EGF-17
O CK-MB MMR GAPDH,livcr CadherinE RUM-C METAP1
IGFBP-2
18
0.911 0.8 1.711 0.903
--.1 SCFsR YES ERBB I h-ECGF ApoA-I C9
CATC , ,
i
I-. RGM-C CK-MB ERBBI CSK CadherinE. CNDP1 YES
co 19
0.887 0.814 1.702 0.9
GAPDH.liver MMR b-ECGF SCFsR BMP-I CalpainI
Cadherin-6 .
CK-MB IGFBP-2 KPCI CadherinE METAP1 SCFsR
CNDP I
20
0.92 0.81 1.73 0.9
Catalase YES ERBB1 RUM-C BMP-1 Calpainl
CathepsinH
RUM-C METAP1 SCFsR ERBB1 YES CadherinE CK-MB
11
0.92 0.81 1.73 0.903
- B MP-1 HMG-1 KPC1 1GFBP-2 CNDP I GA
PDH ,1 i vcr MMR
22 0.92 METAP1
SCFsR ERBB1 YES CadhcrinE CK-MB
0.92 0.802 1.723 0.894 -I
CNDP I NACA VEGF IL-17B GAPDH,liver b-ECGF
HSP90a _ a)
RGM-C METAP I SCFsR ERBB I YES
CadherinE CK- MB CY
23
0.92 0.802 1.723 0.903 -
Catalase MM P-7 GAPDH,liver CNDP1 b-ECGF NAGK
HSP90b CD
-6; SCFsR ERBB1 CadherinE METAP 1 IMBI RUM-C
CNDP I _%
o
24 0.901 0.807 1.709 0.899
CK-MB VEGF YES BMP-1 MK13 LRIG3 LG1VIN
RUM-C METAP I SCFsR ERBB1 YES
CadhcrinE CK-MB
25
0.915 0.802 1.718 0.901 0
CNDP I NACA IGFBP-2 MEK I Catalase
Proteinasc-3 b-ECGF
0
CNDP1 ERBB I CadherinE KPCI SCFsR RUM-C
CK-MB
26
0.911 0.802 1.713 0,891
CSK b-ECGF Calpain I IGEBP.-2
CD30Ligand Prothrotnbin BLC r-I-
.
=-=' '........,
MMR ERBB I GAPDHJ iver CadherinE RUM-C CK-
MB METAPI
27
0.906 0.802 1.708 0.902
SCEsR FGF-17 ApoA-I YES IGFBP-2 CATC
LRIG3
YES CK-MB ERBB1 CadherinE
GAPDH,liver VEGF RGM-C
28
0.873 0.826 1.699 0.899
CSK CNDP1 MEKI SCFsR BMP- I IGEBP-2
Cadherin-6 . _
RGM-C METAPI SCFsR ERBB1 YES CadherinE CK-MB
29
0.93 0.795 1.725 0.899
CNDP I GAPDH,liver b-ECGF BMP-1 KPCI
CathepsinH Catalase
CSK CadherinE CK-MB GAPDH,liver
ERBB I YES BMP-1
30
0.897 0.831 1.728 0.91
SCFsR RUM-C CNDP I VEGF HMG-1 IGH3P-2 b-
ECGF
MMR ERBB I METAP1 CK-MB
CadherinE YES RUM-C
31
0.92 0.802 1.723 0.902
GAPDH,livcr BMP- I SCFsR KPCI IGFBP-2 CNDP I
HSP90a
RGM-C METAP I SCFsR ERBB I YES
CadherinE CK-MB
32
0.925 0.798 1.723 0.905
CNDP1 GAPDH,liver b-ECGF IGFBP-2 Catalase
HSP90b C9
0
W
0
I-.
I-.
--.1
w RGM-C METAPI SCFsR ERBB I YES
CadhcrinE CK-MB
o
33 0.925 0.8 1.725 0.903
CNDP1 NACA VEGF IL-17B GAPDH,liver MMP-7
ApoA-I
n.) ,
o CK-MB MMR GAPDH,liver
CadherinE RGM-C METAP1 IGF BP-2
0.911
0.798 1.708 0.905
co SCFsR YES ERBB1 b-ECGF ApoA-1 C9 LGMN
i YES CK-MB ERBB I CadherinE
GAPDH,liver VEGF RGM-C
o
35 0.887 0.843 1.73 0.908 .
--.1 CSK CNDP I MEK I SCFsR BMP-1 MK 13
IGFBP-2
i
1-. RGM-C METAP I SCFsR ERBB I YES
CadherinE CK-MB
co 36
0.925 0.802 1.727 0.909
Catalase MMP-7 GAPDH,liver CNDP1 b-ECGF NAGK
FGF-17 .
CSK CadherinE CK-MB GAPDH,liver ERBB
I YES BMP-1
37
0.883 0.833 1.716 0.907
SCFsR RGM-C CNDP I VEGF CathepsinH IGEBP-2
Protein ase-3
RGM-C METAP I SCFsR ERBB1 YES CadherinE
CK-MB
38
0.901 0.81 1.711 0.905
Catalase MMP-7 GAPDH,livcr CNDP1 h-F,CGF BLC
RIEBP-2
MMR ERBB I GAPDH,livcr CadherinE RGM-C CK-MB
METAP I H
39
0.915 0.793 1.708 0.904
C9 SCFsR YES LRIG3 ApoA-I IGFE3P-2
CATC CD
RGM-C METAP I SCFsR ERBB I YES
CadherinE CK-MB CT
40
0.923 0.305 1.73 0.911 aT)
Catalase MMP-7 GAPDH,liver CNDP1 h-ECGF ApoA-1
CD30Ligand
_
,-..1 RGM-C CK-MB ERBB1 CSK CadherinE CNDP I
YES _%
- 41
0.883 0.814 1.697 0.9 0,3
SCFsR GAPDH,liver Catalase IGFBP-2 BMP-1 FGF-
17 Ca d herin-6
CSK CadhcrinF, CK-MB GAP DH,livcr
ERBB I YES BMP-1
42
0.892 0 833 1.725 0.91 0
SCFsR RGM-C CNDPI VEGF 11MG-1 IGFI3P-2
MEK I 0
RGM-C METAP I SCFsR ERBBI YES CadherinE CK-
MB D
43 0.925 0.798 1.723 0.898 ,--rNDPI NACA
HSP90a ApoA-I .. VEGF .. b-ECGF .. GAPDH,liver
........,
,
b-ECGF CadherinE ERBB I HSP90b RGM-C YES
METAP I
44
0.925 0.798 1.723 0.905
SCFsR CK-MB BMP-1 CNDPI GAPDH,liver Catalase
VEGF
MMP-7 ERBB1 YES METAP1 CadherinE NACA CK-MB
45
0.93 0.795 1.725 0.902
SCFsR RGM-C FGF-17 NAGK IGFBP-2 IL-17B
CNDP1
RGM-C METAP I SCFsR ERBB I YES CadherinE
CK-MB
46
0.92 0.81 1.73 0.897
CNDP1 KPCI b-ECGF BMP-1 Prothrombin IGFBP-2
IMB 1
RGM-C CadherinE ERBB1 GAPDH,liver
SCFsR CNDP1 CK-MB
47
0.915 0.793 1.708 0.899
METAP I VEG I' YES HSP90a b-ECGF ApoA-1
LGMN .
RGM-C META P I SCFsR ERBB I YES
CadherinE, CK-MB
48
0.925 0.805 1.73 0.904
CNDP1 KPCI MMR MK 13 Prothrombin MEK1
IGFBP-2
YES CK-MB ERBB I CadherinE
GAPDH,liver VEGF RGM-C
49
0.883 0.833 1.716 0.907
CSK CNDP1 MEK1 SCFsR BMP-1 IGEBP-2
Proteinase-3
0
(A)
0
I-.
I-.
--.1
LA) RGM-C METAP I SCFsR ERBB I YES
CadhcrinE CK-MB
o
50 0.915 0.795 1.711 0.895
CNDP 1 NACA b-ECGF IGFBP-2 Catalase BLC
n.)
CD30Ligand
o MMR ERBB1 GAPDH,liver CadherinE
RUM-C CSK SCFsR
i-. 51
0.92 0.788 1.708 0.898
co YES BMP-1 CNDP I VEGF IMBI ApoA-1 CATC
O ,..) YES CadherinE ERBB I CSK SCFsR RUM-C
CK-MB
0.897
0.8 1.697 0.893
--.1 NA CA CNDP1 h-ECGF CD30Ligand MEK I IGEBP-2
Cadherin-6
i
i-. CK-MB IGFB P-2 KPCI CadherinE METAP I
SCFsR CNDP1
co 53
0.93 0.795 1.725 0.902
Catalase YES ERBB I RGM-C BMP-1 GAPDH,liver
Cathepsi n1-I ,
RUM-C CK-MB ERBB1 CSK CadherinE CNDP I
YES
54
0.915 0.807 1.723 0.906
CIAP DH,liver MMR SCFsR BMP- 1 HMCi- I KPC1
IGEBP-2
b-ECGF CadherinE ERB B I HSP9Ob RGM-C
YES METAP I
35
0.923 0.795 1.72 0.905
SCFsR CK-MB Ca tal asc CNDP I HMG-1
ICIFF3P-2 C9 ,
RUM-C METAPI SCFsR ERBBI YES CadhcrinE CK-MB
-I
56
0.925 0.798 1.723 0.899
CNDP 1 GAPDH,liver b-ECGF BMP- I IL-178 IMBI
CD30Ligand Ca
CSK CadherinE CK-MB GAPDH,liver
ERBB1 YES BMP-I Cr
57
0.892 0.814 1.706 0.907 c D-
S CFsR RUM-C CN DP I VEGF Catalase IGFBP-2
LGMN
_
a RUM-C CK-M13 ERBBI CSK CadherinE CNDP I
YES
NI 58
0.911 0.814 1.725 0.909 co
SCFsR GAPDH,liver b-ECGF CalpainI BMP-I
LRIG3 ApoA-1
CK-MB IGFBP-2 KPCI CadherinE METAP I
SCFsR CNDP I
59
0.92 0.807 1.727 0.9 0
Catalase YES ERBB I MK13 RUM-C MMR IMB1
. 0
,
RUM-C METAPI SCFsR ERBB I YES CadherinE CK-
MB
60
0.925 0.802 1.727 0.905 ,......
CNDP I NACA MMP-7 NAGK b-ECGF IGFBP-2 FGF-
17 -
........
RUM-C C9 ERBB I CadherinE METAP I SCFsR
CK-MB
61
0.901 0.814 1.716 0.905
NAGK IGEBP-2 b-ECGF Catalase VEGF
Proteinase-3 ApoA-I
CK-MB SCFsR METAP1 CadherinE ERBB I
IGFE1P-2 YES
62
0.915 0.795 1.711 0.901
RGM-C HSP90a CNDP1 ApoA-I GAPDH,liver FGF-17
BLC
RGM-C CK-MB ERBB I CSK CadherinE CNDP1 YES
63
0.911 0.795 1.706 0.901
GAPDH,liver MMR SCFsR BMP-1 MKI3 IMB1 CATC
..
CSK CadhcrinE CK-MB GAPDH,liver
ERBB1 YES BMP-1
64
0.883 0.812 1.695 0.901
RUM-C MMR Calpaint ApoA-1 SCFsR CNDP1
Cadherin-6
RGM-C META P I SCFsR ER BF3 I YES
CadherinE CK-MB
65
0.925 0.798 1.723 0.901
CNDP 1 NACA IGFBP-2 MEKI Catalasc HMG-1
Cathcpsi al
MMR ERBB I GAPDH,liver CadherinE RGM-C CK-MB
FISP9Ob
66
0.915 0.802 1.718 0.906
SCFsR YES LR1G3 BMP-1 FGF- 1 7 ApoA-1
METAP I
0
W
0
I-.
I-.
-...1
w RGM-C CK-MB ERBB I CSK CadhcrinE CNDP I
YES
o 67
0.911 0.81 1.72 0.909
SCFsR GAPDH,liver Catalase IGFBP-2 MMP-7
Prothrombin IL-17B L
IQ
CO YES CadherinE ERBB I CSK SCFsR RGM-C
CK-MB
1-` 68
0.897 0.81 1.706 0.9
co MMR KPCI MEK I GAPDH,liver CNDP1 BMP-1
LCiMN
O M MP-7 ERBB1 YES METAP1 CadherinE NACA CK-
MB
69
0.915 0.8 1.715 0.904
-...1 SCFsR R CI M-C b-ECGF CNDP I IGFBP-2
Prothrom hi n Proteinasc-3
1
i-. RGM-C CadherinE MMR GAPDH,liver
IGFBP-2 ER BB I METAP1
co
0.92 0.79 1.711 0.892
70
CK-MB SCFsR NACA HSP90a b-ECGF Prothrombin
BLC
RGM-C METAP I SCFsR ERBB I YES
CadherinE CK-MB
71
0.915 0.79 1306 0,905
Catalasc MMP-7 GAPDH,liver CNDP I 1CiFBP-2 FGF-
17 CATC
.,
.
YES CadhcrinE ERBB I CSK SCFsR RGM-C
CK-MB
72
0.883 0.812 1.695 0.897
MMR KPCI MEK 1 GAPDH,livcr CNDP1 BMP-I
Cadhcrin-6
CSK CadhcrinE CK-MB GAPDH,livcr ERBB
I YES BMP-I H
73
0.887 0.833 1.721 0.907 w
SCFsR RGM-C VEGF CD30Ligand CathepsinH IGFI3P-2
CNDP1
CT
RGM-C METAP I SCFsR ERBB1 YES CadherinE
CK-MB
74
0.92 0.798 1.718 0.906 cp
CNDP I GAPDH,liver b-ECGF IGEBP-2 Catalase
HSP90b BMP-1
-6. RGM-C CadherinE KPCI CK-MB ERBBI METAP
I IL-17B -..=
w 75
0.911 0.81 1.72 0.898 co
SCFsR IGFBP-2 CalpainI CNDP I
Prothrombin ApoA-I BMP-1
'RGM-C CK-MB ER R F3 I CSK CadhcrinE
CNDP I YES
76
0.906 0.8 1.706 0.901 0,õ,_
GAPDH.1 ism- MMR SCFsR FGF-17 KPCI BMP-1 LGMN
C...)
YES CadherinE ERBB I CSK SCFsR RGM-C CK-
MB D
77
0.915 0.81 1.725 0.905 .---r-
MMR GAPDH,liver NACA CNDP I. MK13 MEK I
LRIG3 ........-
YES CadherinE KPCI CK-MB ERBB I METAP
I MMP-7
78
0.925 0.802 1.727 0.902
CNDP I SCFsR MXI 3 RGM-C Prothrombin ICI:BP-2
NAGK
RGM-C METAP I SCFsR ERBB I YES CadherinE
CK-MB
79
0.915 0.8 1.715 0.904
I CNDP1 NACA MMP-7 MEK1 IGFBP-2 Pro thrombin
Proteinase-3
RGM-C METAP I SCFsR ERBB1 YES CadherinE CK-
MB
SO
0.92 0.79 1.711 0.896
CNDP I NACA b-ECGF IGFBP-2 Catalase BLC
HMG-1
MMR SCFsR CadherinE Calpainl ERBB I
ROM-C CK-MB
81
0.915 0.79 1.706 0.896
CSK GAPDH,liver b-ECGF ICI FI3P-2 NACA
CNDP I CATC
RGM-C CK-MB ERBF3 I CSK Cadherin E CNDP I
YES
82
0.901 0.793 1.694 0.9
GAPDH.livcr MMR b-ECGF SCFsR IMB1 BMP-1
Cadhcrin-6 .
RGM-C METAP I SCFsR ERBB1 YES CadherinE
CK-MB
0.915 0.805 1.72 0.901
83 CNDP I NACA MMP-7 GAPDH,liver C athe psi nH
Prothrombin b-ECGF
0
W
0
I-.
I-.
-...1
w RGM-C METAP I SCFsR ERBB 1 HS P90a
CadhcrinE IGEBP-2
o 84
0.925 0.798 I .723 0.901
NACA CK-MB ApoA-I MMR NAGK b-ECGF LRIG3
n.)
0 b-ECGF CadhcrinE ERBB I HS P 90b RGM-C
YES METAP1
0.92 0.798 1.718 0.901
co SCFsR CK -MB BMP-1 CN DP I
(.iAPDH,liver Catalase NACIK
,
O RGM-C METAP I SCFsR ERBB I YES
CadherinE CK -MB
86
0.92 0.8 1.72 0.9
-...1 CNDP I NACA VEGF IL-17B GAPDH,Ii ver h-ECCIF
BMP-1
1
i-. RUM-C METAP I SCFsR ERBB I YES
CadhcrinE CK-MB
co 87
0.911 0.795 1.706 0 896
CNDP I NACA HSP90a ApoA-I MMP-7 GAPDH,liver
LGIvfN
RUM-C METAP I SCFsR ERBB I YES
CadherinE CK-MB
88
0.925 0.79 1.715 0.904
CN DPI NACA b-ECGF 1GFBP-2 Catalase BMP-1
Proteinase-3
RUM-C METAP I SCFsR ERBB I YES
CadherinE CK-MB
89
0.93 0.781 1.711 0.895
CND P I NACA b-ECGF IG MP-2 Catalase BLC
CSK
,
RUM-C META P I SCFsR ERI3B1 YES Ca
dhcrinF, CK-MB -I
90
0.93 0.795 1.725 0.913 0)
CNDP I GAPDH,livcr b-ECGF IGH3P-2 C9 MiviP-7
Catalase , . Cr
MMP-7 ERBB I YES METAP1 CadherinE NACA CK-
MB _
91
0.92 0.786 1.706 0.894 CD
SCFsR CNDPI b-ECGF FGF- I 7 IGFBP-2
GAPDH,liver CATC _%
_
^.. RUM-C CadherinE ERBBI GAPDH,liver
SCFsR CK-M13 CSK
0.92 0.807 1.727 0.904 CO
MEK I YES CNDP I IGFEIP-2 NACA MMR
CD30Ligand ,
MMR ERBB I METAP I CK-MB
CadherinE YES RGM-C 0
93
0.901 0.793 1.694 0.895 0
IGFBP-2 MK13 SCFsR KPCI CIYDPI Prothrombin
Cadherin-6
=
RGM-C METAP1 SCFsR ERBB I HSP90a
CadherinE VEGF
94
0.92 0.8 1.72 0.901 -
CK-MB YES BMP-1 NACA ApoA-I Prothrombin
CathepsinH -.......-
RGM-C METAP1 SCFsR ERBB I YES CadherinE CK-
MB
95
0.915 0.807 1.723 0.899
CNDP1 KPCI 1G 113P-2 FGF-17 BMP- 1 HMG-
1 NAGK _
RUM-C META P I SCFsR ERBB I YES
CadherinE CK-M B
96
0.906 0.81 1.716 0.899
CND P I Cal pain! h-ECGF F3MP-I
GAPDH,livcr VEGF HS P9Oh
RUM-C CadherinE KPCI CK-MB ERBB1 METAP1 IL-17B
97
0.92 0.8 1.72 0.897
SCFsR CNDP I IGFBP-2 IMB I MMR YES
Catalase
,
RGM-C CK-MB ERBB I CSK CadherinE CNDP I
YES
98
0.887 0.817 1.704 0.905
SCFsR GAPDH,liver Catalase 1GFBP-2 BMP-1 b-
ECGF LGMN _
MMR ERBB I METAP1 CK-MB CadherinE YES
LRIG3
99
0.92 0.802 1.723 0.912
RUM-C ICIFBP-2 FGF-17 GAPDH,liver
SCFsR Apo A-1 C9 ,
RUM-C CK-MB ERBB I CSK CadherinE CNDP1
YES
100
0.897 0.817 1.713 0.907
SCFsR GAPDH,liver Catalase MEK I IGH3P-2 C9
Protein ase-3
C)
co
o
1-.
I-.
...1
co
o
Marker count Marker Count
Iv
o SCFsR 100 MEK1 17
i-.
co ERBB1 100 Prothrombin 16
o1 CadherinE 100 FG I:- 1 7 14
-.1 RGM-C 99 C9 11
i
i-. CK-MB 99 NAGK 10
co YES 93 IMB1 , 10 ,
CNDP I 87 I-ISP90a 10
GAPDH,liver 69 Calpainl 10
IGFBP-2 67 Proteinase-3 9
METAP1 64 MK13 9
¨I
b-ECGF 48 LRIG3 9
pa
-BMP-1 45 LGMN 9
CT
CSK 37 IL-17B 9
CD
,
_ Catalase 35 HSP9Ob 9
--1,
a MMR 32 HMG-1 9
CO
im
NACA 29 CathepsinH 9
VEC.iF 26 Cadherin-6 9
0
ApoA-I 24 CD3OLigand 9
0 D
KPCI , 21 CATC 9
MMP-7 19 BLC 9
.¨...=
C)
La
0
I-
I-.
--..1
W 100 Panels of 15 Benign vs.
Cancerous Nodule Biomarkers
0
Sens. +
N)
0 Bioma rkers
Specificity Sensitivity _ Spec. A UC
i-. h-ECGI: CaciherinE ER [3131 M FAA P I RGM-C
CK-M B M Iv1P-7 SCEsR.
CO 1
0.93 0.805 1 734 0.914
i .ApeA-1 YES GAPDH.liver 1GF BP-2 CNDP1
Prothromhin Catalase
0
CSK
/ CadherinE CK-M B GA PDH,liver ER B Bl
YES BM P- I SCFsR
0.883
0.829 1.711 0.9
I RGM-C CN DP I VEGF HMG-1 IGEBP-2 h-ECGE
B LC
I-,
co
3 RGM-C METAP I SCFsR ERBB I YES Cad
hcrinE CK-MB Catalase
0.93
0.798 1.727 0 912
MMP-7 GAPDH.liver CNDP1 b-ECGF ApeA-I
Prothrombin C9
b-ECGF CadherinE ERBB I HS P9Ob RGM-C YES
METAP I SCFsR
4
0.92 0.79 1.711 0.898
CK-MB BMP-1 CNDP I GAPDH,liver Catalase VEGF
CATC
RGM-C METAP1 SCFsR ERBB1 YES CadhcrinE MMP-7 NACA
0.92 0.805 1.725 0.9
CD30L igand CK-MB NAGK IGFBP-2 Pro thrombin CNDP1
GAPDH,liver
MN1P-7 ERBB1 YES METAP1 CadherinE NACA CK-MB SCFsR
6
0.911 0.795 I 706 0.899
RGM-C b-ECGF CNDP1 IMP-2 Pro thrombin
ApoA-I Cad herin-6
MMR SCFsR CadherinE CalpainI ERBB1 RGM-C CK-MB CSK
7
0.911 0.821 1.732 0.906
IGEBP-2 KPCI MK13 ApoA-I CNDP1 GAPDH.liver BMP-
I
-I
- RGM-C METAP1 SCFsR ERBB1 YES
CadherinE CK-MB CNDP I
a 8
0.93 0.802 1.732 0.901 Ci)
a NACA MMP-7 GAPDH.liver CathepsinH Catalase
b-ECGF Prothrombin cr
RGM-C CK-MB ERBB I CSK CadherinE CNDP1 YES
GAPDH,liver
9
093 0li . 1.73 0.907 a)
MMR b-ECGF SCFsR IMB1 BMP-I FGF-17
ApoA-1
RGM-C METAP1 SCFsR ERBB1 YES Cad hen
CK-MB CNDP I .-A.
0.934 0.798 1.732 0.9 .1,.
NACA HSP90a ApoA-I MMP-7 Prothrombin
b-ECGF NAGK .
MMR SCFsR CadherinE Calpainl ERBB I RGM-C
CK-MB CSK
11
0.925 0.805 1.73 0.899
GAPD11,1iver b-ECG I' IGF13P-2 NACA CNDP1 LRIG3
IL-17B
CSK CadherinE CK-MB G A PDH,1 iyer ERBB I YES
13MP-1 SCFsR
12
0.897 0.819 1 716 0.907
RGM-C CN DP1 V EG E Catalase ApoA-I C9
LGMN
RGM-C: (;K-MB ER BB I CSK CadherinE CN DP
I YES GA P DH, liver
13
0.915 0.814 1.73 0.904
MMR SC Fs R. 13MP-1 MK 13 KPCI Pro throm
hi n MEKI
RGM-C METAP I SCFsR ERBBI YES Cad
hcrinE CK-MB CNDP I
14
0.915 0.81 1.725 0.904
NACA b-ECGF MMR GAPDH,livcr IGFI3P-2 BMP-1
Proteinase-3
MMR ERBB I GAPDH,livcr CadhcrinE RGM-C CK-MB
METAP1 C9
0.906 0.805 1.711 0.899
SCFsR 1GFBP-2 Catalase FGF-17 b-ECGF YES
BLC
RGIvI-C METAP I SCFsR ERBB I YES
CadherinE CK-MB CNDP I
16
0.925 0 786 1.711 0.895
NACA CD30Li2and Prothrombin MMP-7 b-ECGF
GAPDH.li vcr CATC .
RGM-C METAP I SCFsR ERBB I YES Cad
hcrin E CK-MB CNDP1
17
0.911 0.795 1.706 0.899
NACA b-ECGF MMR GAPDH.liver IGFBP-2 BMP-1
Cad herin-6 -
a
W
0
I-.
I-.
--.1
W RGM-C METAP I SCFsR ERBB I YES
CadherinE CK-MB CND P 1
o
I S 0 93 0 795 1 725 0 902
NACA b-ECGF B MP-1 GAPDH,Iiver Catalase
CathepsinH ApuA -I ,
ts.) CSK CadherinE CK-MB GA PDII,liver ERB BI
YES BMP-1 SCFsR
0 19
0.906 0.819 1.725 0 91
i-. RGM-C CNDP I VEGF Catalase IGFBP-2 FGF-
17 I INIG-1
co MMP-7 EIBB1 YES METAP I CadherinE
NACA CK-MB SCFsR
i 70
0.92 0.802 1.723 0.905
o RGM-C b-ECGF CNDP I IGFBP-2
Prothrombin ApoA-I HSP90a
--.1
1
21 b-ECGF CadherinE ERB B 1 HSP90b RGM-C YES
METAP I SCFsR
0.92 0.802 1.723 0.908
i-. CK-MII BM P-1 CINDPI GA PD1-1,1iver
Catalase ApoA-I ICI FBP-2
co
IL-1713 CadherinE ER13131 METAP I CK-MB RGM-
C YES SCFsR
110.93 0.798 1.727 0.901
- GAPDI I, liver M M P-7 1G Fl3P-2 NACA Arx-A-1
MK13 MEKI
RGM-C METAP I. SCFsR ERBB I YES
CadherinE CK-MB .. CNDP I
'73
0.92 0.807 1.727 0.906
GAPDH.liver b-ECGF BMP- I MEKI MMR IGFBP-2 IMB I
CK-MB MMR GAPDH,liver CadherinE RGM-C METAP1
IGFBP-2 SCFsR
24
0.915 0.798 1.713 0 907
YES ERBB I b-ECGF Catalasc ApoA-I
BMP-I LGMN .
MMR SCFsR CadhcrinE CalpainI ERBB I RGM-C ..
CK-MB .. CSK
15
0.92 0.807 1.727 0.901 0-
GAPDH,liver b-ECGF IGEBP-2 NACA CNDP I LRIG3
ME K1 -
,
RGM-C METAP I SCFsR ERBB I YES
CadherinE CK-MB CNDP I CD
26
0.915 0.805 1.72 0.905
NACA b-ECGF MMR GAPDH,liver BMP-1 ApoA-I
Proteinase-3 --a.
_
a CSK CadherinE CK-MB GAPDH,liver ERBB1 YES BMP-
I SCFsR
--I 27
0.892 0.817 1 709 0.903
RGM-C CNDPI VEGF Catalase IGFBP-2 BLC HMG-I
RGM-C METAPI SCFsR ERBB I YES
CadherinE CK-MB Catalase 0
28
0.925 0.783 1.708 0 899 0.
MMP-7 GAPDH,liver CNDP1 b-ECGF NACA BMP-1
CATC
D
79 CSK KP CI ERBB I CadherinE RGM-C MMR CNDP1
SCFsR
0.92
0.805 I 725 0 897 7"
b-ECGF Calpa in 1 Ap0A-I BMP- I
YES GAPDIL liver CD30Li8and . N.-....-
RGM-C CK-MB ERBB I CSK CadherinE CNDP I YES
SCFsR
30
0.883 0.819 1 702 0.903
GAPD11,1iver Catalase IGEBP-2 BMP-1 ApoA-I VEGF
Cad herin-6
RGM-C METAP I SCFsR ERBB I YES
CadherinE CK-MB .. CNDP1
31
0.925 0.798 1.723 0 901
NACA Ca thepsinH b-ECGF IGFBP-2 Catalase
IVIEKI GAPDH,liver .
CadherinE IGFI3P-2 MF.TAP I ERBB I MK I 3 CK-MB
SCFsR MEK1
32
092 0.802 1.723 0 902
RC M-C NACA Y ES CNDP1 I IS P90a Apo A-I
Prot hrornhin .. '
h- I X;(11; CadherinE IA11131 I IS P9Oh RG M-C
YES ME:IAP I SCFsR
33
0.915 0.805 1.72 0.905
C K -MI3 II S P90a M MP-7 CAPIN ',liver CN DP1
ApoA-I LRIG3 .
RGM-C METAP I SCFsR ERBB1 YES
CadherinE CK-MB .. CNDP1
34
0.911 0.814 1.725 0.904
GAPDH.liver b-ECGF BMP- 1 IL-17B Cal pain! ApoA-I
VEGF
'RGM-C CK-MB ERBB I CSK CadherinE CNDP I YES
GAP DH, liver
35
0.915 0.81 1.725 0.907
MMR SCFsR BMP- I MK13 IME 1 FGF-17
Prothrornbin
YES CadherinE ERBB I CSK SCFsR RGM-C
IGEBP-2 .. CK-MB
36
0.897 0 814 1.711 0 903
GAPDH.liver MMR Catalase ApoA-I MEM C9 LGMN
,
-
o
w
0
I-
I-.
.....i
w _
RGM-C METAP I SCFsR ERBBI YES
CadherinE CK-MB CNDP I
o
37 092 0.81 173 0 901
KPCI MMR 1v1K13 Prothrombin NAGK MEK1
IGFBP-2
ts..)
o 38 YES CadherinE ERBBI CSK SCFsR
RGM-C CK-MB MMR
0.901
0817 1.718 0.902
i-. GAPDILliver NACA CNDP1 MICI3 MEKI LRIG3
Proteinase-3
co
1 CSK CadherinE CK-MB GAPDILliver ERB131 YES
BIs.IP-1 SCFsR
o
39 0.892 0.817 1.709 0.903
ROM-C CNDP1 VEGF Catalase IGFBP-2 HMG-1 BLC
-.1
I RGM-C METAPI SCFsR ERBBI YES CadherinE CK-MB
CNDPI
1-` 40
0.925 0.783 1.708 0.898
co NACA M M P-7 GAPDH,liver Cathepsinl I Prothromhin
C9 cATc =
MM}'-7 ER13131 YES m r:TA P 1 CadherinE
NACA CK-MB SCFsR
41
0.93 0.795 1.725 0.902
CNDP1 b-BCCi F Prothromhin ApoA-1 CD3OListand
NA GK RGM-C
RGM-C METAP I SCFsR ERBBI YES
CadherinE CK-MB CNDP I
42
0.911 0.79 1.701 0.896
NACA b-ECGF MMR GAPDH.liver BMP-1
Prothrornbin Cad herin-6 -
b-ECGF CadherinE ERBBI HSP90b RGM-C YES METAP1 SCFsR
43
0.915 0.805 1.72 0.9 _1
CK-MB HS P90a IvIMF'-7 GAPDH.liver CNDP1
ApoA-I CSK
RGM-C METAP1 SCFsR ERBBI YES
CadherinE CK-MB CND PI
44
0.92 0.805 1.725 0 902 cr
GAPDH.livcr b-ECGF BMP-1 1L-17B IMB1 ApoA-I
VEGF _ =
CNDP1 ERBBI CadherinE KPCI SCFsR RUM-C CK-MB CSK
45
0.906 0.805 1.711 0.898
b-ECGF CalpainI MMR BMP- I GAPDH,liver -
1.
- IGFBP2 LGMN
, -
a MMP-7 ERBBI YES METAP I CadherinE
NACA CK-MB SCFsR
00 46
0.915 0.802 1 718 0.906
CNDP I b-ECGF Catalase ApoA-I IGEBP-2
RGM-C Proteinase-3 ..-----.
MMR ERBBI METAP I CK-MB CadherinE YES
SCFsR KPCI C)
47
0.915 0 793 1.708 0.897 0
FGF-17 RUM-C CNDP1 IGFBP-2 Catalase
GAPDH.liver BLC - = =
RGM-C CK-MB ERBBI CSK CadherinE CNDP I YES
GAP DH,liver
48
0.911 0 795 1 706 0 896 r-i-
MMR b-ECGF SCFsR IMB1 BMP-1 Cal pain{
CATC .......
,
RGM-C CK-MB ERBBI CSK CadherinE CNDF'l YES
SCFsR
49
0.906 0 817 1 723 0 907
GAPDHliver b-ECGF CalnainI BMP-1 CD30Ligand
ApoA-I VEGF
RUM-C CK-MB ERBB I CSK CadherinE CNDP I YES
SCFsR
50
0.892 0 807 1.699 0.9
GAPDH.liver h-ECGF Ca1pain1 BMP- 1 C9 MMR Cad
herin-6
RGM-C METAP I SCFsR ERBBI YES
CadherinE CK-MB CND P I
51
0.925 0.798 1.723 0.903
NACA M M P-7 NAG K Catalase
Prothromhin Cat hepsin I I ApoA-I ,
RUM-C CK-M11 ERI1131 CSK CadherinE C N
DP1 YES SCEsIt
52
0.915 0.81 1 725 0.914
GA PD11.1iver Catalase 1G El3 P-2 13M P-1 AnoA-1 HMG-1
VEG I'
,
CK-MB IGFBP-2 KPCI CadherinE METAP 1 SCFsR
CNDP1 Catalase
53
0.906 0.812 1.718 0.895
YES ERBBI RGM-C BMP-1 Calpainl b-ECGF
HSP 90b
,
CNDP I ERBBI CadherinE KPCI SCFsR RGM-C CK-
MB CSK
54
0.911 0.812 1.723 0.9
b-ECGF CalpainI MMR BMP-1 GAPDH.liver
IL-17B 1GFBP-2
MMP-7 ERBBI YES METAP I CadhcrinE NACA CK-MB
SCFsR
55
0.92 0.79 1.711 0.903
CNDP1 b-ECGF Catalase ApoA-I IGF13P-2 RGM-C
LGMN
C)
ua
o
1-.
1-.
...1
ua
o 56 MMR ERBB I METAP I CK-MB
CadherinE YES RGM-C GAPDH,liver
0.911
0.812 I 723 0.908
BMP-I SCFsR CNDPI VEGF Calpainl IvIK13
LRIG3
Na
,
0 RGIvI-C METAP I SCFsR ERBB I YES
CadherinE CK-MD CNDPI
1-. 57
G APDII.11 ver b-ECGF IGFI3P-2 C9 Catalase
ApoA-I Proteinase-3 0.915 0.802 1.718 0.909
co
I MMP-7 ERBB I YES IvIETAP I CadherinE
NACA CK-MD SCFsR
o
58 0.92 0.788 1.708 0.9
--.1 CNDPI b-ECGF Catalase ApoA-I IGFBP-2
RGM-C BLC -
I MMR SCFsR CadherinE CalpainI ERBB I RGM-C
CK-MB CSK
0.915 0.79 1.706 0.897
co 0 APD11,1iver h-lICCIF IG1713P-2 NIACA CNDPI
ApoA-I CATC
RC1M-C C:adherinE ERI1131 GA PD11,1iver SCFslt
CK-MB CSK MEKI
60
0.911 0.812 1.723 0.905
YIS CNDPI IG FIIP-2 Prothrorn hin NACA
CD30Ligand MM P-7
,
RGM-C CK-MB ERBB I CSK CadherinE CNDPI YES
GAPDH,liver
61
0.897 0.802 .699 0.896
MMR b-ECGF SCFsR IMB I BMP-1 CalpainI
Cad herin-6
CK-MB IGFT3P-2 ICPCI CadherinE METAP 1
SCFsR CNDPI Catalase
62
0.925 0.798 1.723 0.902 _1
YES ERBB 1 RGM-C BMP-I GAPDH,livcr
FGF- 17 CathcpsinH
MMR ERBB1 METAP I CK-MB CadherinE YES
RGM-C GAP DH,liver Cl.)
63
0.92 0.805 725 0 901 r-r
BMP- I SCFsR KPC1 Catalasc b-ECGF CNDP I
HMG-1 ,t,-"_
'MMR ERBB1 METAP I CK-MB CadherinE YES
RGM-C GAPDH,liver
64
0.92 0.802 .723 0.896
_ BMP-I SCFsR ICPCI 1GFBP-2 CNDPI
HSP90a IMB I -1.
.", RGM-C METAP1 SCFsR ERBB I YES
CadherinE CK-MB CNDPI
,,o 65
0.911 0 807 718 0 901
GAPDH,Iiver b-ECGF IGFBP-2 Catalase HSP90b BMP-1
Calpaitil ------..
RGM-C METAP I SCFsR ERBB I YES
CadherinE CK-MB CNDPI 0
66
092 i 0.802 723 0 901 0
NACA VEGF IL-17B B MP-I GAPDH,liver
ApoA-I b-ECGF
,
à =
RGM-C CK-MB ERBB I CSK Ca dherin E CNDPI YES
SCFsR
67
0.892 0 817 I 709 0 905 rf-
GA PDH,liver FGF-17 IGEB P-2 HS P90a ApoA-I
C9 LGMN .
RGM-C CK-MB ERB B I CSK CadherinE
CNDPI YES GAPDH,liver
68
0.911 0 812 .723 0 903
MMR b-ECGF SCFsR IMB I BMP-1 Cal pa inI
LR1G3
RGM-C METAP1 SCFsR ERBB I YES
CadherinE CK-MB CNDPI
69
0.925 0 802 I 727 0 902
NACA MME-7 NAGK b-ECGF IGFEIP-2 MEK I
Prothrornbin E .
YES CK-MB ERBB I CadherinE G_APDH,liver VEGF
RGIvI-C CSK
70
0.883 0 833 1.716 0 904
C:N DP I MEKI SCI,s13 IIMP-1 IGN3P-2
Proteinase-3 MK 13
'
RGM-C Cadheri nE 13R13B1 GA PDI ',liver SCFsR
CK-MB CSK MMR
71
0.897 0.81 1.706 0.9
1(11,13P-2 CNDPI YES KPCI M K13 ApoA-1 I3LC
MMR SCFsR CadherinE Calpainl ERBBI RGM-C CK-MB CSK
72
0.915 0.79 1 706 0.895
GAPDH,liver b-ECGF IGEBP-2 NACA CNDPI FGF-17
CATC
RGM-C CK-MB ERBB I CSK CadherinE CNDPI YES
GAPDI ',liver
73
0.92 0.802 1.723 0,907
MMR b-ECGF SCFsR IMB I BMP-1
CD30Ligand AnoA4 ,
YES CadhcrinE ERBB1 CSK SCFsR RGM-C CK-MB MMR
74
0.883 0.814 1.697 0.896
GAPDH.11vcr NACA CNDPI MK 13 MEK I LRIG3
Cadhcrin-6
0
la
0
1-.
1-.
--.3
W RUM-C METAP1 SCFsR ERBBI YES
CadherinE CI(-MB CNDP I
o
75 0.925 0.798 1 723 0.903
NACA IG FBP-2 IvIEK1 Catalase ApoA-I
Prothrombin CathepsinH
K.) ,
o 76 YES CadherinE ERBBI CSK SCFsR
RGM-C CK-MB VEGF
0.897
0.826 1.723 0 914
1-. GAPDILliver MMR IG FBP-2 ApoA-I BMP-1 I1IvIG-
1 CNDPI
co
1
77 RGM-C METAP I SCFsR ERBB I YES
CadherinE CK-M13 CNDP I
0.911
0.807 1.718 0.905
o GAPDH,liver b-ECGF IGEBP-2 Catalase
HSP90b BMP-1 MEKI
-.3 .
i SCFsR ERBBI CadherinE METAP I IMB I RGM-C
CNDP1 CK-MB
H 78
0.915 0.805 1.72 0 905
V KW YIS IL-1713 IIM P-1 GAP DI
',liver ICiF13P-2 ApoA-1
CO
(:SK C:adherink CK-M 13 GA PDI ',liver ER 13
B I YES 1310 P-1 SC:FsR
79
0.892 0.817 1.709 0.904
RUM-C CN DP1 VEGF Catalase IGEBP-2 I IMG-1
LGMN
MMR SCFsR CadherinE Ca Ipain1 ERBBI RUM-C
CK-MB CSK
80
0.911 0.814 1.725 0 902
IGFB P-2 KPCI MK13 CNDP I Prothrombin NAGK ApoA-
I
RGM-C CK-MB ERBBI CSK CadherinE CNDP1 YES SCFsR
=
81
0.897 0.819 1.716 0.908
GAPDH,1 ivcr Ca talasc MEK I IGEBP-2 C9 Protcinasc-3
ApoA-I
MMR ERBBI GAPDH,liver CadherinE RUM-C CK-MB
METAP I SCFsR -1
82
0.901 0.805 I 706 0.901
FGF- I 7 ApoA-I YES b-ECGF IGFBP-2
Prothrombin BLC - 06.)
RGM-C METAP I SCFsR ERBBI YES
CadherinE CK-MB BMP-1 CT
83
0.915 079 1 706 0 896 -
I IMG-I KPCI 1GFBP-2 CNDP I GAPDH,liver
MMR CATC CD
_,
-..3 CSK CadherinE CK-MB GAPDH,liver ERBBI
YES BMP-1 SCFsR
84
092 0 802 1.723 0 905 -%
RGM-C CNDP I VEGF Cata1ase IGFBP-2 NACA CD30Lieand 4:1.
,
YES CadherinE ERBBI CSK SCFsR RGM-C CK-MB MMR
85
0.892 0.805 1 697 0.899 -^-",
GAPD1-1,1iver NACA CNDP1 MK13 BMP-1 ApoA-I
Cadherin-6 0
RGM-C METAP I SCFsR ERBBI YES
CadherinE CK-MB CNDP I
86
0.925 0 798 1 723 0 901
NACA b-ECGF BMP-1 GA PDH,liver Catalase
Cat hepsinH VEGF - p
r-t-
C K-MB SCFsR METAP I CadherinE ERBBI
IGEBP-2 YES RGM-C
87
0.93 0.793 1 722 0.911 s---,
liSP90a CNDP1 ApoA-I GAPDH,liver b-ECGF MMP-7
Prothrombin ,
b-ECGF CadherinE ERBBI HS P9Ob RUM-C YES
METAP I SCFsR
88
0.915 0802 1 718 0 902
CK-MB BMP- 1 CNDP I GAPDH,liver Catalase
NAGK VEGF .
RGIvI-C METAP I SCFsR ERBB1 YES
CadherinE CK-MB CNDPI
89
0.915 0.805 1.72 0.899
NACA VEGF 1L-1713 CiA PD11,1iver h-ECGF MM P-7
I IMG-1
-12GM-C CK-M13 ER13131 CSK CadherinE CN
DP1 YES SCFsR
90
0.897 0.812 1.709 0.904
GA P DI I, liver h-FC:C, V Ca Ipainl 13M P-1 C9 MMR
LC1MN
CNDP1 ERBBI CadherinE IC.P CI SCFsR RGM-C CK-
MB CSK
91
0.911 0.812 1 723 0 902
b-ECGF Calpain1 MMR BMP-1 GAPDH,liver
IGEBP-2 LRIG3
'
,
MMR SCFsR CadhennE CalpainI ERBBI RGM-C CK-MB CSK
92
0.901 0.814 1.716 0.9
GAPDEliver b-ECGF IGIBP-2 NACA CNDP1 FGF-17 Proteinase-
3 , RUM-C METAP1 SCFsR ERBBI YES CadhorinE
CK-MB Catalase
93
0.901 0.805 1.706 0.907
MMP-7 GAPDH.liver C1CDP I b-ECGF ApoA-I IGHIP-2
BLC
C)
u.)
0
I-
I-.
-..1
W MMR ERBB I IvIETAP I CK-MB CadberinE YES
RGM-C GAPDH, liver
0 94
0.911 0 793 1.704 0.898
FGF-17 IGEBP-2 CNDP1 SCFsR MK13 NACA CATC
ts..) YES CadherinE ERBB I CSK SCFsR RGM-C CK-
MB MMR
0 95
0.906 0.814 1.72 0.905
i-. GAPDII,liver NACA CNDP I 1v1K13 MEK1
CD30Ligand IGFBP-2
co
i 96 RGM-C CadherinE ERBB1 GAPDLI,liver SCFsR
CK-MB CSK MMR
0.897 0.8 1.697 0.898
0 IGFBP-2 CNDP1 YES KPCI Prothrombin
BMP-I Cad herin-6
--.1
1 CK-MB IG FBP-2 KPCI CadherinE METAP I
SCFsR CNDP1 Cata la se
0.911 0.81 1.72 0.902
YES ER11111 R(1 M-C [IMP-1 ApoA-I
Cathepsi n II Cal painl
co
RGM-C C:adherink ER11131 GA PDH, liver SCFsR
CK-M13 CSK MMR
98
0.897 0.824 1.721 0.911
1(11'11P-2 CN DP 1 YES HS P90a BM P- I VECi I'
ApoA-I
RGM-C METAP I SCFsR ERBB I YES
CadherinE CK-MB CNDP I
99
0.92 0.798 1.718 0.906
G A PDH.live r b-ECGF IGF13P-2 Catalase HSP90b MMP-
7 HIVIG-1
MMP-7 ER BB I YES METAP I CadherinE
NACA CK-MB SCFsR
100
0.92 0.8 1.72 0.902 ¨I
CNDP I b-ECGF Prothrombin ApoA-I RGM-C
GAPDH.li ver IL-17B
0.)
0-
Marker Count _ Marker Count
SCFsR 100 ,Calpathl 22
CD
¨ RGM-C 100 MEKI 17
¨=
---.1 ERB Bl 100 KPCI 17 ,
-I..
¨
CadherinE 100 MK13 13
,CK-MB , 99 -1-1MG-1 ,
II 0
0
CNDP1 95 FGF-17 11
=
YES _ 90 IMB1 , 10
r-t-
GAPDH.I iver 85 C9 10
........=
IGFBP-2 62 IL-17B 9
b-ECGF 60 HS P9Ob 9
METAP1 57 IISP90a 9
BMP-1 54 Ca thepsinH 9
ApoA-I 46 Cadherin-6 9
MMR 44 CD30Ligand , 9
CSK 44 CATC 9
NACA 39 13LC 9
Catala se 37 Proteinase-3 8
MivIP-7 25 , NAGK 8 ..,
Prothrombin 24 LRIG3 8
VEGF 22 LGMN 8
Table 15
100 Panels of' 3 Asy mptomatic Smokers vs. Cancer Biomarkers
Biomarkers
Specificity Sensitivity Sens. + Spec AUC
1 CK-MB , C9 AMPM2 0.789 0.812 1.601 0.852
2 BLC SCFsR Cyclophil MA 0.77 0.824 1.594 0.859
3 PTN BMP-1 HSP90a 0.784 0.821 1.605
0.875
4 BTK ' Kallikrein7 , E1U3B1 0.803 0.821 1.624
0.862
-
Cis CyclophilinA ERBBI 0.789 0.798 1.587 0.862
6 CD30Ligand GAPDH1iyer ERBBI 0.779 , 0.83 1.609
0.87
7 CDK5-p35 HSP90a ERBBI 0.793 0.804 1.597
0.876
8 PTN CNDP I 1-ISP90a 0.77 0.835 1.605 0.876
9 Kallikrein7 CSK E1213131 0.808 0.804 1.611 0.862,
Contact in-5 PTN HSP90a 0.789 0.801 1.59 0.869
11 sL-Selectin Endostatin HSP90a 0.798 0.81 1.608 0.851
12 FGF-17 IISP90a ERBBI 0.798 0.804 1.602 0.868
13 FYN PTN HSP90a 0.812 0.79 1.602 0.853
14 IGFBP-2 ERBBI RACI 0.779 0.841 1.62 0.875
, -
IL-15Ra PTN HSP90a , 0.793 0.812 1.606 0.866
16 , CK-MB ,ER13131 KPCI 0.803 0.81 1.612 0.853
17 LDH-H1 PTN HSP90a 0.793 , 0.807 1.6
0.853
18 PTN LR1G3 HSP90a 0.798 0,83 1.628 0.88
19 MEK1 PTN HSP90a 0.775 0.804 1.579 0.847
MIP-5 GAPDH.liver ERBBI 0.784 0.804 1.588 0.855
21 Midkine FIN HSP90a 0.793 0.793 1.586 0.858
22 CK-MB PARC HSP90a 0.812 0.815 1.628 0.864
23 Prothrombin PTN HSP90a 0.836 0.801 1.637 0.865
24 Renin PTN HSP90a 0.779 0.812 1.592 0.866 ,
CK-MB TCTP ERBBI 0.817 0.793 1.61 , 0.869
26 UBE2N PTN IGFBP-2 0.793 0.807 1.6 0.867
27 Ubiquitin1 PTN CD30Ligand 0.845 0.744 1.589 0.852
28 Kallikrein7 BM P-1 AMPM2 0.775 0.818 1.593
0.835
29 , BLC C9 AMPM2 0.756 0.818 1.574 0.849
BTK IGFBP-2 ERBBI 0.77 0.827 1.597 0.863
31 Cis UBE2N ,PTN 0.798 0.776 1.574 0.864
32 CDK5-p35 KPCI ERBBI 0.779 0.815 1.595 0.86
33 CNDP1 SCFs12 HSP90a 0.784 0.81 1.594 0.853
34 CK-MB ERBBI CSK , 0.808 0.795 1.603 0.87 ,
Contactin-5 CK-M13 AMPM2 0.746 0.83 1.576 0.84
36 Endostatin PTN HSP90a 0.779 , 0.821 1.6 ,
0.872
37 FGF-17 PTN - HSP90a 0.812 0.79 1.602 0.861
38 IL-1512a PTN RAC1 0.817 0.787 1.604 0.858
39 LDH-H1 B'I'K ERBBI 0.784 0.807 1.591 0.857
CK-MB -L121G3 HSP90a 0.817 0.81 1.627 0.865
41 MEK1 Kallikrein7 ERBB1 0.751 0.824 1.575 0.84
-
42 PTN GAPDELliver ,M1P-5 0.784 0.798 1.582 0.857
43 PARC RAC 1 ERBBI 0.793 0.827 1.62 0.867
...
.__ _
172
CA 3011730 2018-07-18
Table 15 (cont.)
44 Prothrom bin Endostatin I-I S P90a , 0.808
0.784 1.592 0.854
45 Ka11 ikrein7 TCTP ERBB I 0.822 0.787 1.609
0.862 ,
46 Ubiquiti II' I PTN 1GFBP-2 0.784 0.787 1.571
0.856
47 sL-Selectin PTN 1-1SP90a 0.798 , 0.801 1.599 0.87
48 TCTP BMP-1 ERBB I 0.803 0.795 1.598 0.862
-
49 C Is RAC I PIN 0.808 0.764 1.572 0.859
50 C9 ERBB1 Cyclophil inA , 0.798 0.818 1.616
0.872
51 PTN GAPD H Jiver CD30Li9and 0.803 0.801 1.604
, 0.861
52 CDK5-p35 PTN HSP90a 0.793 0.801 1.595 0.863 ,
_
53 CNDP I SCFsR KPCI 0.789 0.804 1.593 0.854
54 CSK IGH3P-2 PTN 0.784 0.812 1.597 0.856
55 ['GI:- I 7 GAPDH,liver ERBB1 0.775 0.815 1.59 ..
0.864 '
-
56 CK-MB IL-15Ra RAC I 0.793 0.798 1.592 0.85
57 LDH-H1 CSK ERBB I 0.789 0.793 1.581 0.856
,.
58 LR1G3 SCFsR HSP90a 0.808 0.787 1.594 0.863
59 MEK I RAC I ER.13131 0.77 0.804 1.574 0.86
60 , M1P-5 UBE2N PTN 0.793 0.784 1.578 0.855,
-
61 PARC Cyclophi linA ERBB I 0.775 0.821 1.596 0.869
62 Prothrornbin ERBB1 HSP90a 0.784 0.798 1.582 0.87
63 sL-Selectin CyclophilinA ERBB I 0.789 ..
0.798 .. 1,587 .. 0.865
_
64 SCFsR BMP-1 HSP90a 0.789 0.807 1.596 0.855
'
65 BTK CK-MB ERBB I 0.765 0.827 1.592 0.867
66 C9 ERBB I RAC1 0.779 0.821 1.6 0.869
67 CD30Ligand Cyclophil MA ERBB1 0.789 0.798 1.587 0.866
68 CDK5-p35 RAC I ERBB1 0.803 0.79 1.593 0.87
69 CNDP I ERBB I HSP90a 0.77 0.812 1.582 0.862
70 õ. CK-MB Endostatin HSP90a 0.789 0.807 1.596
0.856
71 FGF-17 RAC I ERBB I 0.789 0.798 1.587 0.868
72 I3TK IL-1512a PTN 0.793 0.795 1.589 0.858
73 SCFsR ERBB1 KPCI 0.789 0.815 1.604 0.862
74 LDH-H1 LR1G3 ERBB1 0.765 - 0.815 1.581 0.849
75 MIP-5 RAC I ERBBI 0.775 0.801 1.576 0.865
76 PARC RAC1 13MP-1 0.765 0.83 ' 1.595 0.867
77 Prothrornbin BMP- 1 HSP90a 0.789 0.793 1.581 0.85
-
78 PINT ERBB I Tcrp 0.798 0.793 1.591 0.871
.,
79 UBE2N 1GFBP-2 ERBB I 0.77 0.83 1.599 0.872 ,
-
80 sL-Selectin RAC I ERBB1 0.779 , 0.804 1.583
0.862
81 PTN IGFBP-2 AMPM2 0.775 0.818 , 1.593 0.856
82 SCFsR C9 KPCI 0.789 0.81 1.598 0.861
83 CD3 OLigand KPC1 ER13131 0.765 0.818 1.583 0.867
84 CDK5-p35 BTK E1213131 0.793 0.79 , 1.583 0.862
,
85 CK-MB 'CN DP I AMPM2 0.765 0.81 1.575 0.842
86 CK-MB C9 CSK 0.793 0.801 1.595 0.857
87 Endostatin LRIG3 HSP90a 0.798 0.793 1.591 0.859
88 FGF-17 Endostatin HSP90a 0.793 0.793 1.586 0.853
_
173
CA 3011730 2018-07-18
Table 15 (cont.)
89 PTN LR103 1L-1512a 0.775 0.81 1.584 0.848
90 LDH-H1 CyclophilinA ERBB1 0.775 0.804 1.579 0.858
91 MIP-5 RAC1 PTN 0.817 0.759 1.575 0.866
92 PARC CSK ERBB1 0.775 0.818 1.593 0.862
_
93 Prothrombin CyclophilinA ERBB1 0.817 0.764 1.581 0.851
94 1GFBP-2 TCTP PTN 0.803 0.787 1.59 0.858
95 UBE2N PTN ERBB1 0.765 0.824 1.589 0.87
96 sL-Selectin BMP-1 AMPM2 0.761 0.821 1.582 0.847
97 CD3OLigand PARC GAPDH,liver 0.742 0.841
1.583 0.846
98 CDK5-p35 AMPM2 ERBB1 0.756 0.824 1.58 0.864
99 CNDP I BMP-1 KPCI 0.77 0.804 1.574 0.848
100 PGP-17 UBE2N ERBB1 0.775 0.807 1.581
0.865
Marker Count , Marker Count
ERBB1 45 CD30Ligant 6
,
PTN 32 . C9 6
HSP90a 30 BTK 6
RAC1 13 sL-Selectin 5
CK-MB 12 Tc.rP 5
1GFBP-2 8 Prothrombin 5 .
CyclophilinA , 8 -mir-5 5
BMP-1 8 LDH-H1 5
AMPM2 8 Kallikrein7 5
SCFsR 7 1L-15Ra 5
KPCI 7 MEK1 3
UBE2N 6 Cis 3
PARC 6 Ubiquitin+1, 2
LRIG3 6 Contactin-5 2
GAPDH,liver 6 BLC 2
FG F-17 6 Renin 1 .
Endostatin 6 Midkine 1
CSK 6 FYN 1
CNDP I 6
CDK5-p35 6
174
CA 3011730 2018-07-18
Table 16
100 Panels of 4 Asymptomatic Smokers vs. Cancer Biomarkers
õ . ,
Sens. +
Biorna ricers Specificity Sensitivity
Spec. AUC
1 Kallikrein7 SCFsR AM PM2 C9 0.826 0.827
1.653 0.874
.. .
2 CK-M13 BLC CSK ERBBI 0.822 0.824
1.645 0.87
3 CNDP I BMP-I RACI PTN 0.822 0.835 1.657
0.886
4 BTK ,KPCI ERBBI CK-MB 0.822 0.827
1.648 0.872
IGFBP-2 SCFsR ' RACI (Is 0.812 0.844 1.656 0.886
,
6 CD30Ligand IGFBP-2 PTN GAPDH,liver 0.826 0.827 1.653
0.885
,
7 CDK5-p35 'SCFsR HSP90a ERBB1 0.817 0.844
1.661 0.889
8 Contactin-5 CSK CK-MB ERBBI 0.812 0.832
1.645 0.871
9 IGFBP-2 1Cyclophi1inA ERBBI Kallikrein7 0.826
0.832 1.659 0.8821
FGF-17 Kallikrein7 HSP90a ,Endostatin 0.822 0.824
1.645 0.871
11 CK-MB PARC HSP90a FYN 0.822 0.807 1.628
0.864
12 IL-15Ra CyclophilinA C9 SCFsR 0.812 0.835 1.647
0.881
. ________________________________________________________________________ .-
13 LDH -H1 PTN ERBBI HSP90a 0.793 0.852 1.646
0.882
14 LRIG3 SCFsR HSP90a PTN 0.84 0.835 1.676
0.896
LDH-HI Kallikrein7 ERBBI MEKI 0.817 0.815 ,
1.632 0.857
16 MIP-5 PTN ERBBI RACI 0.817 0.83 1.646
0.89
17 . Midkine PTN HSP90a jCiFBP-2 0.798 .. 0.838 1.636
0.877
18 PTN C'N DP1 I I SP90a Prothrombin 0.826 0.827
1.653 0.88
19 Ren in Kall1kre1n7 , I ISP90a LIUG3 0.84 0.81
1.65 0.866
CK-MB PARC TCTP -ER13B I 0.812 0.83 1.642 0.882
21 UBE2N , Kallikrein7 ERBBI , IGH3P-2 0.812 0.838
1.65 0.883
22 ybiquitin+1 BTK ERBBI PARC 0.803 0.818 1.621
0.874
23 sL-Seleetin CyclophilinA ERBBI PTN
0.817 0.835 1.652
' 0.879
24 LRIG3 IGFBP-2 AMPM2 SCFsR 0.831 0.821 1.652
0.873
BLC C9 CyclophilinA SCFsR 0.793 0.849 1.643 '
0.882
26 PARC BMP-I CSK Kallikrein7 0.808 0.841 1.648
0.866
27 Cls IGFBP-2 PTN RACI 0.822 0.818 1.64
0.894U
28 CD30Ligand SCFsR RACI C9 ' 0.822 ' 0.83
1.651 0.887
,
29 CDK5-p35 Kallikrein7 HSP90a ERBBI 0.831 0.818 1.649
0.885
Contacti n-5 CyclophilinA ERBB1 CK-MB 0.789 0.849
' 1.638 0.874
31 Endostatin GAPDH,liver HSP90a CK-MB 0.817 ' 0.824 1.641
0.866
32 FGF-17 SCFsR ERBB1 CyclophilinA 0.803 0.838 1.641
0.888
33 FYN GAPDH, liver ERBBI CD30Ligand 0.798 0.827
1 1.625 0.871
34 IL-15Ra sL-Selectin 1-1SP90a PTN 0.803 0.838
1.641 0.876
nis BTK KPCI SCFsR ERBBI , 0.826 , 0.821
1.647 0.877
36 MEK 1 HSP90a ERBBI PTN 0.77 0.855 1.625
0.875
37 MIP-5 KPCI PTN Kallikrein7 0.826 -,0.818 1.644
0.86
38 -Midkine CyclophilinA ERBBI Kallikrein7 0.817
0.807 , 1.624 0.869
39 Prothrombin 1C:1713P-2 I ISP90a PTN 0.822 0.821
1.643 0.887
PARC PTN II SP90a Rem', 0.817 0.821 1.638 0.879
-
41 BLC ERBB1 TCTP C:K-M B 0.822 0.818 1.64
0.87
42 PTN SCFsR UBE2N ' IGH3P-2 0.817 0.83 1.646
0.89
43 CDK5- 35 Ubi uitin+1 ERBBI IGFBP-2 0.793 0.827
1.62 0.879
I 75
Date Recue/Date Received 2021-06-09
Table 16 (cont.)
44 sL -Select In 1GFBP-2 AMPM2 , PTN 0.826 0.818
1.644 0.865
45 BMP-1 ERBB1 RAC1 Kallikrein7 0.812 0.832 1.645
0.878 ,
. 46 C I s C9 CyclophilinA SCFsR 0.822 ' 0.815 1.637
0.878
47 Kallikrein7 CNDP1 FISP90a ERBB1 0.812 0.841 1.653 0.872,
48 Coniacti n-5 CK-MB FISP90a GAPDH,liver 0.812 0.824
1.636 0.86
49 Endostatin Kallikrein7 I IS 1)90a CK-MB 0.822
0.815 1.637 0.874
50 FG12-17 Kallikrein7 EISP90a ERBB I 0.826 0.81
1.636 0.881
,
51 FYN ,CK-MB ERBB1 KPCI 0.808 0.815 1.623 , 0.857
52 IL-15Ra CyclophilinA PIN ERBB1 , 0.793 0.841 1.634 0.885
53 LD11-1-11 PTN ERBB1 BTK 0.808 0.835 1.643 0.878
54 MEK I 1-ISP90a ERBB1 Kallikrein7 , 0.803 0.818
1.621 0.864
55 PTN ,GAPDH,liver IGFBP-2 MIP-5 0.817 0.824
1.641 0.875
,
56 Midkine ERBB1 HSP90a PTN 0.77 0.852 1.622 0.886
57 Prothronnbin LR1G 3 IISP90a PIN 0.826 0.815 1.642
0.881
-
58 Rcnin Kallikrein7 FISP90a 'PTN 0.803 0.83 1.632
0.879
59 PTN ERBB I TCTP Kallikrein7 0.812 0.827 1.639
0.881 .
60 PTN ERBB I IGFBP-2 UBE2N 0.793 0.849 1.643 0.887
61 Ubiquitin+1 PTN IGFBP-2 sL-S electin 0.779 0.838
1.617 0.861,
_
62 CDK5-p35 SCFsR AMPM2 IGH3P-2 0.803 0.835 1.638 0.875
,
63 , BLC SCFsR KPCI IGF13P-2 0.812 0.815 1.628
0.871,
-
64 BMP-1 ERBB1 ' RACI CDK5-p35 0.812 0.832 1.645 0.884
, .
65 C 1 s PIN ERBB I HSP90a 0.784 0.852 1.636 0.887
,
66 CD30Ligand Kallikrein7 R AC1 -ERBBI 0.836 0.812
1.648 0.886
67 Kallikrein7 CNDPI II SP 90a PTN 0.798 0.852 1.65
0.885
68 CK-MB PARC CSK ERBB1 0.817 0.827 1.644 0.884
69 Contactin-5 BTK ERBB1 CK-MB 0.775 0.861 , 1.635 0.868
70 Endostatin , Kallikrein7 RAC I CD30Ligand 0.836
0.801 1.637 0.873
71 FGF- I 7 SCFsR ERBBI UBE2N 0.793 0.841 1.634 0.886
72 FYN KPCI ERBB1 C9 0.808 0.815 1.623 0.861
73 IL-15Ra CSK PIN IGFBP-2 0.808 0.827 , 1.634 0.87
74 LDH -II 1 PIN ERBB I CyclophilinA 0.812 0.827 1.639
0.876
75 PTN GAPDH,liver IGFBP-2 MEK1 0.793 0.824 1.617
0.861
76 MIP-5 , UBE2N ERBB I PIN 0.784 0.847 1.631 0.883
77 Midkine SCFsR FISP90a PTN , 0.798 0.824 1.622 0.877
_
78 Prothrombin CK-MB I-ISP90a PARC 0.831 , 0.81 1.641 0.881
79 Ren in PTH HSP90a GAPDFLIiver 0.826 0.804 1.63
0.869
80 GAPDH.liver , IIICTP ERBB1 IGEBP-2 , 0.817 0.818
1.635 0.872
81 Ubiquitin+1 BTK ERB B I IGFBP-2 0.812 0.804
1.616 0.875
_
82 PTN SCFsR AMPM2 1GFBP-2 0.803 0.832 1.635 0.879
-
83 BLC SCFsR TCTP ERBB1 0.817 0,81 1.627 0.873
84 . CDK5-p35 SCFsR HSP90a .BMP-1 0.817 0.824 1.641
0.872 ,
85 CI s Kallikrein7 ERBB I CyclophilinA 0.817 0.818
1.635 0.875
86 sL-Selectin CNDP I HSP90a PThl 0.798 0.844 1.642
0.881
87 IGFBP-2 ERBB1 RAC1 Contactin-5 0.779 0.852 1.632
0.879
88 Endostatin LRIG3 FISP90a PTN 0.798 0.838 1.636 0.892
89 FGF-17 Endostatin HSP90a Prothrombin 0.831 0.801 1.632
0.865
176
CA 3011730 2018-07-18
Table 16 (cont.)
90 , Kallikrein7 ERBB1 I-1SP 90a FYN 0.808 0.812 1.62
0.872
91 , IL-15Ra , LRIG3 IISP90a PTN , 0.798 0.835 ,
1.633 , 0.886
92 SCFsR ERBB1 LDH-141 HSP90a 0.789 0.847 1.635 0.869
93 MEK I CyclophilinA ERBB1 PTN 0.798 0.818 ..
1.616 0.866
94 BTK ERBB1 MIP-5 PTN 0.789 0.841 1.63 0.879
95 Midkine RACI ERBB1 PARC 0.798 0.821 , 1.619 ,
0.866
96 IGFBP-2 HSP90a , Renin PTN 0.793 - 0.835
1.629 0.885
97 PTN ERBB1 IGFBP-2 Ubiqui 611+1 0.765 0.849
1.615 0.876
98 PTN LR1G3 AMPM2 CD3 OLigand 0.798 0.835
1.633 0.868
99 BLC SCFsR TCTP C9 , 0.817 0.807 1.624 0.876
100 _UBE2N PARC SCFsR BMP-I 0.793 0.844 1.637 0.88
Marker Count Marker Count
ERBB1 51 BMP-1 6
PTN 42 BLC 6
HSP90a 35 AMPM2 6
IGFBP-2 24 sL-Selectin - 5
SCFsR 22 Ubiqu i t in+ I 5 _
Kallikrein7 22 , Renin 5
CK-MB 14 Prothrombin 5
CyclophilinA 12 Micikine 5
RAC1 11 MIP-5 5
PARC 9 MEK I 5
GAPDH.liver 8 LDH-H1 5
LRIG3 7 IL-15Ra 5
C9 7 FYN 5
BTK 7 FGF-17 5 ,
UBE2N 6 Contactin-5 5
TCTP 6 CSK 5
KPCI 6 , CNDP I 5
'
Endostatin 6 Cis 5
CDK5-p35 6
CD30Ligand 6
177
CA 3011730 2018-07-18
Table 17
100 Panels of 5 Asymptomatic Smokers vs. Cancer Biom a rkers
Sens. +
Biomarkers
Specificity Sensitivity Spec. AUC
1 CD3OLigand IGF BP-2 PTN sL. Se lec tin AMPM2 0.845
0.83 1 675 0.883
2 KPCI TCTP ERBB I CK-MB BLC 084 0.821 1.661
0.877
3 CNDP I BMP-1 RAC1 PTN LRIG3 , 0.826 0.855
1.681 0.891
4 IC.iFBP-2 SCFsR GAPDH,liver PTN BTK 0.854
0 838 1 693 0.899
. -
UBE2N 1GFBP-2 SCFsR C Is -PTN 0.822 0.861 1.682
0.906
6 Kallikrein7 ,CyclophilinA SCFsR 1GF BP-2 C9
0.845 0 838 1 683 0.889
7 CDK5-p35 KPCI ERBBI FISP90a SCFsR 0.84 0 841
1.681 0.886
8 PARC CSK ERBB1 Ka1likrein7 CK-MB 0.836 0 852
1 688 0.897
9 r. Coln:it:lin-5 _CSK ER13B I PARC CK-MB 0.812 0.861
1.673 0.882
Endos ta tin LRIG3 HSP9On CK-MB .PIN 0.812 0.872 1 684
0.903
11 ICiFBP-2 SCFsR RACI ERBB I FGF-17 0 812 ,
0.866 1.679 0.9
12 Kallikrein7 RACI IGFBP-2 ERBB1 FYN 0.84 0.83 1.67
0.886
,
13 Prot hrom bin PTN HSP90rt IL-15Ra s L-Selectin 0.85
0 827 1.676 0.887
14 LD11-1-11 CK-MB ERBB1 :CyclophilinA Kallikrein7 0.85 0.835
1.685 0.888
MEK I HSP90a ERBB I Kallikrcin7 PTN 0.817 0.849 I 666
0.887
,.
16 MIP-5 SCFsR RAC1 C9 PIN 0.826 0.847 1.673
0.898
..
17 Midkine ERBB1 HSP90a Kallikrein7 CK-MB 0.817 0.852
1.669 0.886
_
18 CK-MB Kallikrein7 HSP90a LR1(.33 Renin 0.84 0 827
1 667 0.885
19 CD30Ligand IGFBP-2 PTN sL-Selec tin Ubiquitin+1 0.84
0.849 1.69 , 0.889
CSK AMPM2 IGFBP-2 ERBB1 Kallikrcin7 , 0.84 0.832
1.673 0 876
21 BLC SCFsR CSK ERBB1 KPCI 0.84 0 818 1.659
0.883
22 KPCI HSP90a PTN Kallikrcin7 BMP-1 0.836 0.835
1.671 0.875 µ
23 BTK HSP90a ERBB1 PTN SCFsR 0.84 0.844 I 684
0.902
,
24 Cis PTN ERBB1 U13E2N LDI-1-H1 0.826 0.855
1.681 ' 0.891
CDK5-p35 CK-MB HSP90a ERBB1 Kallikrein7 0.831
0.849 , 1.68 0.898
26 Kallikrein7 LRIG3 IISP90a PTN CNDP I 0.826 0.852
1.679 0.893
27 Contact in-5 CK-MB HSP90a LRIG3 PTN . 0.808 ,
0.861 1.668 0.9
28 SCFsR C9 , CSK Kallikrein7 Endos ta tin 0.859
0.821 1.68 0.89
29 PTN ERBB I IGFBP-2 UBE2N -FGF- !7 , 0.822
r 0.852 1.674 0.892
Kali ikrcin7 ERBB1 HSP90a FYN CK-MB 0.831 0.835 1.666
' 0.889
31 IGFI3P-2 SCFsR GAPDT LI iver PIN CD30Li grind 0.836
0 852 1 688 0.906
32 IL-15Ra CyclophilinA ERBB I Ka10krein7 CK-MB 0.808
0.866 1 674 0.887
33 PARC GAPDI Liver SCFsR BMP- I MEK I 0.803 0.858
1.661 0 875
34 PTN RAC I IGFBP-2 PARC IVIIP-5 0.817 0 855
1 672 0.894
Midkine SCFsR HSP90a PIN LRIG3 0.831 0.838 I 669 0.893
36 P ro ['worn hi n CK-M13 I ISP90a LRIG3 PTN 0.845
0.844 1.689 0.9
37 Renin PIN HSP90a ERBB I BTK 0331 0.835 1.666
0.891
38 KIFBP-2 TCTP SCFsR ERBB I Kallikrein7 0.845
0 827 1.672 0.891
39 -LRIG3 SCFsR HSP90a PTN Uhicmitin+ I 0.854 0.81 -
1 664 0.894
, 40 CK-MB AMPM2 ERBB I BTK CDK5-p35 0,84 0.83 1.67
0.886
41 CDK5-p35 SCFsR AMPM2 KiFBP-2 BLC , 0.822 0.835 1.657
0.885
42 C I s HSP90a PTN Kallikrcin7 rERBB I 0.826
0.849 1.676 0.896
43 CNDP I ER13131 HSP90a PTN Kallikrein7 0.817 '
0 855 I 672 ' 0.897
44 IGFBP -2 CyclophilinA ERBB I Contact in-5 Kal1ikre1n7
0.808 0.858 1.665 0.882
Endos taint Kallikre1n7 Cyclophil MA ERBB1 IGF BP-2 0.822
0.852 1.674 0.88 \
46 SCFsR C9 CyclophilinA FGF-17 ERB131 0.817 0 855
1 672 0.897
47 .MIP-5 PIN ERBB I , RAC I FYN 0.836 0.83
. 1 665 0.889
48 sL-Sclectin LRIG3 HSP90a PTN IL-15Ra , 0.831 0.84) 1.672
0.894
õ
49 LDI1-111 Kallikrein7 ERBB1 HSP90a PTN 0.822 0.858
1.68 0.891
SO Kall ikrcin7 BMP- 1 Cyclophil MA ERBB I MEK I 0.808
0.844 1.651 0,872
i 78
CA 3011730 2018-07-18
Table 17 (cont.)
51 PARC LRIG3 HSP90a CK-MB Midkinc , 0.826 0.838 ,
1.664 0.881
52 Protbrombin 1GF13P-2 HSP90a ERBB I PTN 0.822 0.858
E68 0.898
53 1GFBP-2 HSP90a Renin PIN Kali ikrein7 0.822
0.844 1.665 0.896
54 CK-MB PARC TCTP ERBB1 GAPD11,1iver 0.831
0.838 1669 0.886
55 (K-MB CD30Ligand K P CI 'ER BB 1 Ubictuit in +1 0,831
083 1 661 0.875_
56 BLC SCFsR CSK ERBB I , PARC 0.822 0.832
1.654 0.879
57 PIN SCFsR RAC1 Cis C9 , 0.817 0 858
1.675 0.902
58 CNDP1 KPCI ERBB1 CK-MB HSP90a 0.845 0 827 I
672 0.878
59 Kallikrein7 PTN ' HSP90a C9 Contactin-5 0.812
08-19 1.662 0.884 ,
60 Endostatin ER [3B1 CSK Kallikrein7 SCFsR 0.85
0.824 1 674 0.887
61 FGF-17 SCFsR HSP90a , PTN ERBB1 0.817
0.855 1.672 0.903
62 FYN PIN HSP90a ERBB1 SCFsR 0.798 0.866
1.665 0,895
63 s L-Sclect in IGFBP-2 CyclophilinA PIN IL-15Ra 0.822
0.849 1.671 0.879,,
64 PTN ERBB1 IGFBP-2 UBE2N LD1-1-111 0.822
0.858 1.68 0.887
65 End osta tin Kallikrein7 Cyclopb il inA ER BB I MEK1
0.822 0.83 1.651 0.875
66 MIP-5 PTN ERBB I , RAC I , PARC s 0.817 0 855
, 1.672 0.892
57 CK-MB PTN HSP90a LRLG3 Midkine 0.808 0 855 1
663 0.895
. -
68 Pro thrombi n CK-MB HSP90a Kallikrcin7 ERBB1 0.826
0.847 1.673 0.897
69 CD30Ligand Kallikrein7 KPCI SCFsR Rcnin 0 845
0.818 1.663 0.875
70 Kallikrcin7 C9 BRBB1 TCTP LD11-111 0.845 0
824 1 669 0.881
71 Ubiquitin-1 BTK ERBB I ,IGF BP-2 Kallikrein7 0.845
0.815 1.66 0.888-
72 C9 ERBB1 AMPM2 , BTK ,Kallikrein7 0.822 0.847
1.668 088
73 CSK , KPCI ERBB1 CK-MB BLC 0.836 , 0.818
1.654 0.879,
74 PIN CNDP I CyclophilinA SCFsR BMP-1 0.812 0 858
1.67 0.9 ,,
75 CI s Kallikrcin7 ERBB1 GAPDH,liver BTK 0.85
0.824 1.674 0.881
76 IGFBP-2 SCFsR RAC I ERBB I CDK5-p35 0.826
0.849 1.676 0.902
77 IGFBP-2 KPCI CD30Ligan.d PIN Contact in-5 0.831
0.83 1.661 0.88
78 FGF-17 Ka11ikrein7 14SP90a PTN ERBB I 0.817 ,
0.852 , 1.669 0,901
79 Cis SCFsR GAPDH,liver C9 FYN 0.831 0.832 , 1.663
0.881
80 IL-15Ra PTN RAC I Kal11kre1n7 LRIG3 0.845 0
824 1,669 0.886
81 , MEK1 CyclopbilinA ERBB1 PIN Kallikrein7 0.812
0.838 1.65 0.88
82 M1P-5 CyclophilinA ERBB1 Kallikrein7 CK-MB -
0.822 0,849 1.671 0.884
83 BTK SCFsR C9 Kalli krei n7 Midkine 0.826
0.835 1.662 0.879
, 84 LRIG3 CNDPI 1-ISP90a ,PIN Protbrombin , 0.84
0.83 1.67 0.89
-
85 CSK C9 ERBB1 CK-M13 Renin 0.836 0.824
1.66 0.884
86 CD30Ligand PIN -ERBB I TCTP -Kallikrcin7 0.84
0.827 1.667 0.895
87 PIN SCFsR U13E2N 1GFBP-2 LRIG3 , 0.822 0
855 1.677 0.901
88 CD3 OLigand ,SCFsR ERBB I CyclopbilinA Ubiquitin+1
0.836 0.824 1.66 0.888
89 SCFsR ERBB I AMPM2 IGFBP-2 CDK5-p35 0.826
0.838 1.664 0.891
90 CDK5-p35 ..õ CK-MB ERBB I CSK BLC 0.822 , 0.83
1.651 0.88
-
91 SCFsR BMP-1 'HSP90a PTN CDK5-p35 0.826 0
844 1.67 0.896
92 CK-MB Kallikrein7 CSK ERBB1 Contact in-5 0.822 0
838 166 0.883
93 Endostatin Kallikrein7 KPCI CD30Ligand SCFsR
0.854 0 818 1.673 0.877
94 Ka1likrein7 IGFBP-2 . KPCI , SCFsR FGF-17
0.845 0 824 1.669 0.877,,
95 PTN LRIG3 HSP90a FYN SCFsR 0.822 , 0 841 I
663 0.893
96 KPCI TCTP ERBB I SCFsR IL-15Ra 0.845 0.821
1.666 0.876 ,
97 LDH-H 1 CK-MB ERBB1 CSK Kal11krein7 085 ,
0.827 1.676 0 887
98 MEK I 1-ISP90a FARB 1 Kallikrein7 C9 0.812 0 838
1.65 0.874
99 BTK MIP-5 PIN GAPD1-1,1ivcr ERBB1 0.826 0.841
1.667 0.894
100 sL-Sclectin PARC I ISP90a PIN Midkine 084
0.821 1.661 0.884
i 79
CA 3011730 2018-07-18
Table 17 (cont.)
Marker Count Marker Count
-
ERBB1 59 TCTP 6
PTN 48 Midkine 6
Kallikrein 7 42 MIP-5 6 .
HSP90a 35 MF,K I 6
SCFsR 34 LDH-H 1 6
10FBP-2 25 11-15Ra 6
CK-MB .75 FYN 6 ,
LRIG3 15 FGF- I 7 6 .
CyclophilinA 13 Endostatin 6
KPCI 12 Contaclin-5 6
CSK 12 CNDP I 6
C9 12 Cis 6
RAC1 10 BMP- I 6
PARC 9 BLC 6 .
CD30Ligzuld 9 AMPM2 6
BTK 9 Ubiquitin- I 5
CDK5-p35 8 UBE2N 5 ,
GAPDH,liver 7 Rcnin 5 ,
s L-Se lectin 6 Prothromhin _ 5
180
CA 3011730 2018-07-18
0
w
o
1-.
1-.
--.1
w
o
n.) 100 Panels of 6 Asymptomatic Smokers
vs. Cancer Biomarkers
o
1-.
Sens. +
co
O Biomarkers
Specificity, Sensitivity Spec. _AUC
....1 1 SCFsR ERBB I AMPM2 IGFBP-2 CDK5-p35
PARC 0.84 0.858 1.698 0.897
1 _
1-. 2 CSK KPCI ERBB I CK-MB BLC SCFsR
0.859 0.824 1.683 0.887
,
co 3 PARC BMP-1 CSK ERBB I CK-MB GAPDH.
liver 0,84 0.858 1.698 0.897
...
4 BTK HSP90a ERBB1 Kallikrein7 CK-MB
PTN 0.85 0.861 1.711 0.913
KPCI HSP90a PTN Kallikrein7 IGFBP-2 Cls
0.869 0.838 1.707 0.883
6 CD30Li gaud SCFsR KPCI C9 BTK PTN
0.869 0.835 1.704 0.898 ,
7 , LRIG3 CN DP I sHSP90a CK-MB PTN
Kallikrein7 0.84 0.878 1.718 0.903
8 Con tactin-5 BTK ERBB1 CK-MB
GAPDH,liver PARC 0.817 0.878 1.695 0.895
9 LDH-H1 PTN ERBB1 CyclophilinA CD30Ligand
Kallikrein7 0.854 0.855 , 1.71 0.901
CD30Ligand RAC1 PTN sL-Selectin ,Katlilcrein7
Endostatin 0.859 0.844 1.703 0.898
_ 11 ,LDH-H1 PTN ERBB I HSP90a FGF-17
. Kallikrein7 0.85 0.849 1.699 0.898_
oo 12 PTN SCFsR RAC1 IGFBP-2 FYN
CD30Ligand 0.873 0.835 1.708 0.908 C)
_
13 CD30Ligand KPCI PTN LIUG3 Kallikrein7 1L-
15Ra 0.85 , 0.844 1.694 0.879 Cr
14 CD30Ligand PTN ERI3131 RAC1 Kallikrein7
MEK I 0.836 0.855 1.691 0.893 CD
_ MIP-5 RAC1 PTN 1GFBP-2 ERBB I LDH-H1 0.826 0.866
1.693 0.892
16 Kallikrein7 SCFsR HSP90a ERBB1 CDK5-p35 Midkine
0.85 0.847 1.696 0.897 CO
, 17 LRIG3 ICiFBP-2 HSP90a PIN Prothrombin CK-
MB 0.85 0.861 1.711 0.91
18 CK-MB Kallikrein7 HSP90a LRIG3 Renin
Prothromb in 0.864 0.827 1.691 0.891
19 1C11-13 P-2 Tcrp SCFsR ERBB1
Kallikrein7 CDK5-p35 0.864 0841 1.705 0.896
,
PTN SCFsR UB E2N IGFBP-2 CD30Ligand LDH-H1 0.85
0.861 1.711 , 0.903
21 CD30Ligand SCFsR ERBB1 CyclophilinA Ubiquitin+1
FIN 0.85 , 0.852 1.702 0.91
22 CD30Ligand IGFBP-2 AMPM2 FM SCFsR CDK5-p35
0.845 0.849 1.695 0.898
23 CSK KPCI ERBB I CK-MB BLC Contactin-
5 0.854 0.824 1.678 0.879
24 IG FB P-2 BMP-1 RAC1 _ PTN SCFsR CDK5-
p35 0.831 . 0.864 1.695 0.906
C Is PTN ERBB1 ,UBE2N Kallikrein7 -LDH-H1 0.845 0.858
1.703 0.9
26 Kallikrein7 RACI SCFsR C9 IGFBP-2 PARC
0.831 0.872 1.703 0.904
27 FIN CNDP1 CyclophilinA Cis SCFsR
GAPDH.liver 0.864 0.838 1.702 0.906
28 Endostatin LRIG3 HSP90a CK-MB PARC
_Ka Ilikrein7 0.836 0.861 1.696 0.902
a
(A)
0
1-,
I-'
---.1
CO
0
N 29 BTK FGF-17 ERBB I GAPDHJiver SCFsR
PARC 0.826 , 0.872 1.698 0.906
0
1-' 30 CK-MB Kallikrein7 HSP90a PARC LRIG3
FIN 0.845 0.852 1.697 0.896
co
O 31 sL-Selectin LRIG3 HSP90a PTN Prothrombin IL-
15Ra 0.859 0.832 1.692 0.9
---.1 32 Kallikrein7 RAC1 SCFsR ERBB1 IGFBP-2 MEKI
0.845 0.841 1.686 0.896
I
1-' 33 Kallikrein7 IGFBP-2 -KPCI , SCFsR
M1P-5 CDK5-p35 0.878 0.81 1.688 0.884
co 34 ,Midkine CyclophilinA ERBB1 ,
Kallilcrein7 IGFBP-2 SCFsR 0.85 0.841 1.691 0.893
35 CD30Ligand RAC 1 PTN sL-Selectin
Kallikrein7 ,Renin 0.854 0.83 1.684 0.895
36 CD30Ligand PTN ERBB1 TCTP 1GFBP-2
Kallikrein7 0.845 0.847 1.692 0.9
37 Ubiquitin-1 BTK ERBB1 , IGFBP-2 Kal 1
ikrein7 PARC 0.85 0.849 1.699 0.901
38 BTK AMPM2 C9 SCFsR Kallikrein7 FGF-17
0.85 0.841 1.691 0.89
39 CDK5-p35 CSK ERBB1 PARC CK-MB BLC
, 0.817 0.861 1.678 0.89
40 LDH-H1 Kallikrein7 ERBB I FISP90a PTN
F3MP-1 0.831 0.861 1.692 0.895 -I
SD 41 CNDP I SCFsR 1-ISP90a PIN
ERBB I BTK 0.831 0.869 1.7 0.903 cy
_ 42 , CK-MB SCFsR CSK ERBB1 KP CI Contact
in-5 0.869 0.824 1.692 0.879 Fff
oo 43 Endostatin Kallikrein7 HSP90a PTN
CK-MB LRIG3 0 826 0.869 , 1.696 0.908
44 Ka1111crein7 CyclophilinA ERBB1 FIN IGFBP-2
SCFsR 0.854 0.835 1.69 0.892 CO
...
45 1GFBP-2 SCFsR RA Cl IL-15Ra PTN
HSP90a 0.831 0.858 1.689 0.898 .---..
46 CK-MB SCFsR CyclophilinA , ERBB1 KPCI
MEK1 0.85 0.832 1.682 0.874, 8
47 CD30Ligand KPC1 PTN LRIG3 Kallikrein7 MIP-5
0.854 0.832 1.687 0.88 D
,
,-1-
48 Midkine ERBBI , HSP90a Kallikrein7
CK-MB CDK5-p35 0.836 -.........
0.852
1.688 0.898 =
49 ,Renin LRIG3 HSP90a PTN Kallikrein7 IGFBP-
2 0.836 0.847 1.682 0.903
50 CK-MB Kallikrein7 HSP90a PTN ERBB1
TCTP 0.85 0.841 1.691 0.905
51 BTK IGFBP-2 ERBB I Kallikrein7 UBE2N
PARC 0.85 0.849 1.699 0.899
52 PTN C9 ,CSK CD30Ligand SCFsR
Ubiquitin+1 0.854 0.844 1.698 0.9
53 CK-MB ,IGFBP-2 AMPM2 LRIG3 PTN
CD30Ligand 0.845 0.844 1.689 0.898
54 CK-MB IGFBP-2 AMPM2 LRIG3 SCFsR BLC
0.84 0.835 1.676 0.89
55 Cis PTN ERBB I BTK Kallikrein7
BMP-1 0.812 , 0.878 1.69 0.892
56 LRIG3 CNDP1 HSP90a IGFBP-2 PTN SCFsR
0.826 0.872 1.698 0.904
57 Contactin-5 CK-MB RAC1 ERBB I
CD3 OLigand Kallikrein7 , 0.822 0.866 1.688 0.895
58 Endostatin , LRIG3 HSP90a CK-MB
Kallikrein7 CDK5-p35 0.843 0.849 1.695 0.898
59 CyclophilinA _GAPDH,liver ERBB1 PARC SCFsR
FGF-17 0.831 0.864 1.695 0.904
0
w
o
1-.
1-.
--.1
w
o
n.) 60 PTN SCFsR RAC1 Cis C9 FYN
0.831 0.858 1.689 0.901
o
1-. 61 IGFBP-2 SCFsR GAP DH,liv er PTN BTK
1L-15Ra 0.84 , 0.847 1.687 0.901
co
.
o1 62 C Is Kallikrein7 ERBB1 RAC I PTN
MEK1 0.826 0.855 1.681 0.893
-..1 63 MIP-5 SCFsR RAC I C9 PTN GAPDH,
liver 0.845 0.841 1.686 0.901
1
1-. 64 CD30Ligand 1GFBP-2 ,PTN RAC1 SCFsR Midkine
0.85 0.838 1.688 0.911
co 65 LRIG3 IGFBP-2 HSP90a PTN .
Prothrombin PARC
0.854 0.849 1.704 0.904
66 Cis KPCI ERBB1 CK-MB BTK Renin
0.864 0.818 1.682 0.882
67 CD30Ltgand KPCI PTN SCFsR C9 TCTP
0.864 0.827 1.691 0.891
68 PARC LRIG3 SCFsR F-ISP90a PTN UBE2N
0.854 0.844 1.698 0.906
69 IGFBP-2 CyclophilinA , ERBB1 Kallikrein7
Ubiquitin+1 SCFsR 0.864 0.83 1.693 0.899
70 PIN ,GAPDH,liver IGFBP-2 LRIG3 HSP90a
sL-Selectin 0.854 0.852 1.707 0.902 ,
-1
71 CDK5-p35 SCFsR A MPM 2 IGFBP-2 BLC
PARC 0.845 0.83 1.675 0.891
S1)
72 PTN RAC' ERBB1 BMP-1 Kallikrein7 Cls
0.826 0.864 1.69 0.901 cr
_ 73 CNDP1 ERBB I HSP90a CDK5-p35 PTN
Kallikrein7 0.84 _ 0.855 1.695 0.903 cp
co 74 C I s PTN ERBB1 IJBE2N LDH-H1
Contact in-5 0.836 0.852 , 1.688 0.891 __1
La
75 Endostatin Kallikrein7 HSP90a CK-MB
ERBB I BTK 0.859 0.832 1.692 0.898 CO
76 PARC LRIG3 HSP90a CK-MB FGF-17
,Kallikrein7 0.836 0.858 1.694 0.896 ----=-=
0
77 Kallikrein7 RAC 1 SCFsR ERBB1 IGFBP-2
FYN 0.85 0.838 1.688 0.898 0
,
78 1L-15Ra UBE2N PTN LRIG3 Kallikrein7 CK-MB
0.831 µ 0.855 1.686 0.898 =
79 Kallikrein7 GAPDH.liver ERBB I
CD30Ligand PTN MEK I 0.831 0.849 1.68 0.894 =
........
80 PTN GAPDH,liver IGFBP-2 Kallikrein7
MIP-5 UBE2N 0.845 0.838 1.683 0.891
81 BTK KPCI SCFsR ERBB I Midkine CDK5-
p35 0.859 ,. 0.827 1.686 0.888
82 IGFBP-2 SCFsR GAPDH,liver PTN CD3 OLi gand
Prothrombin 0.864 0.838 1.702 0.908
83 CD30Ligand Kallikrein7 KPCI SCFsR Renin HSP90a
0.854 0.827 1.681 0.881
84 CK-MB ERBB1 HSP90a SCFsR KPCI TCTP
0.869 0.821 1.69 0.88
85 Ubiquitin-1 BTK ERBB I IGFBP-2
Kallikrein7 SCFsR 0.859 0.832 1.692 0.899
86 CD30Ligand RAC I PTN sL-S electin
Kallikrein7 IGFBP-2 0.859 0.847 , 1.706 0.905
87 PARC A IVEP M2 ERBB1 CSK CK-MB
BLC 0.84 0.832 1.673 0.891
88 Cis PTN ERBB I CyclophilinA Kallikrein7
BMP-1 , 0.826 0.864 1.69 0.901
89 PTN SCFsR GAP DH,liver HSP90a LRIG3
CNDP I 0.84 0.855 1.695 0.905
90 Cis Kallikrein7 ERBB1 RAC I PTN
Contactin-5 0.831 0.855 1.686 0.896
-
0
w
o
1-.
1-.
--.1
w
o
n.) 91 SCFsR C9 CSK Kallikrein7 Endostatin
Prothrombin 0.859 0.832 1.692 0.896
o
1-. 92 Kallikrein7 SCFsR HSP90a C9
Prothrombin FG F-17 0.864 0.83 1.693 0.893
co ,
oI 93 IGFBP-2 SCFsR , RAC1 ERBB I CDK5-p35
FYN 0.84 0.847 1.687 0.9
, -
---.1 94 IL-15Ra PTN RAC1 sL-Selectin Cis LRIG3
0.859 0.827 1.686 0.902
1 _
1-. 95 SCFsR ERBB1 LDH-H1 CyclophilinA ,
Kallikrein7 MEK1 0.845 0.835 1.68 0.884
co 96 IGFBP-2 SCFsR GAPDH,liver PTN MIP-5
.RACI 0.845 0.838 1.683 0.904
97 Kallikrein7 CyclophilinA SCFsR IGFBP-2 C9
Midkine 0.836 0.849 1.685 0.888
98 PARC IGFBP-2 HSP90a PIN
Prothromb in Renin 0.831 0.849 1.68 0.896
99 TGFF313-2 TCTP SCFsR ERBB1 PARC CDK5-p35
0.822 0.866 , 1.688 0.898
100 PTN SCFsR BTK IGFBP-2 Cis
Ubiquitin+1 0.85 0.841 1.691 0.909
-
Marker Count Marker Count
--1
cl)
PTN 56 LDH-H1 8
0-
Kallikrein7 52 CSK 8
_
CD
oo
-P. SCFsR 49 CBE2N 7
_µ
ERBB I 49 , -AMPM2 7
00
IGFBP-2 39 sL-Selectin 6
HSP90a 30 Ubiquitin+1 6
0
0
CK-MB 26 TCTP 6
D
RAC I 21 Renin 6
r-t-
...--,
LR1G3 21 Midkine 6
CD30Ligand , 21 MIP-5 6
PARC 18 MEK1 6
BTK 15 IL-15Ra 6
KPCI 14 -FYN 6
CDK5-p35 , 14 FGF-17 6
GAPDH,liver 13 Endostatin 6
.
C Is 13 Contactin-5 6
CyclophilinA 11 CNDP1 6
C9 10 B MP-1 6 .
Prothrombin 8 B LC 6
Table 19
100 Panels of 7 Asymptomatic Smokers vs. Cancer Biomarkers
Sens. +
Biomarkers Specificity
Sensitivity , Spec. _AUC ,
LRIG3 IGFBP-2 A MPM2 SCFsR
1 0.878 0.844 1.722 0 897
Kallikrein7 PARC CD30Ligand ... .
, CSK K PC I ER BB I CK-MB
0.864 0.838 1 702 0 893
13LC SCFsR PARC
GAPDI-Lliver HSP90a BMP-I PTN
3 0.85 0.869 1.719
0.905
PARC LRIG3 Kal11krein7
BTK 1GFBP-2 PTN Kallikrein7
4 0,887 0.844 1 731 0.898
SCFsR KPCI CD30Ligand ......
Cls ?TN FRBB I 111-3F,2N
0.845 0.881 1.726 0.91
Kallikrein7 LDH-H 1 CK-MB
"CD30Ligand SCFsR RAC I C9
6 0.873 0.855 1.728
0.907
?TN LRIG3 HSP90at
CK-M 13 Kallikrein7 1 IS P90a PA RC
7 0.859 0.869 1 728 0.907
CDK5-p35 LR1G3 Endostatin .
PTN GAPDH,liver 1GFBP-2 LRIG3
8 0.854 0.866 1.721
0.911
SCFsR 11SP90a CNDP1 .
LDH-H1 Kallikrein7 ERBB1 HSP90a
9 0.836 0.881 1 716 0 904
PTN CK-MB Contactin-5
Kallikrein7 Cycloph ilinA SCFsR IGF BP-2
0.859 0.866 1.726 0.916
CD30Ligand PTN PARC .
Endostatin Kallikrein7 HSP90a CK-MB
11 0.85 0.872 1.722
0.902
FC.IF-17 LRIG3 PARC
'IGFBP-2 KPCI CD30Ligand SCFsR
12 0.883 0.832 1.715
0.894
PTN FYN Ka1likrein7 .
PTN GAPDH.livcr 1GFBP-2 LRIG3
13 0.85 0.858 1.708
0.905
SCFsR IL-1512a Kallikrein7 ,
, Kallikrein7 RAC1 SCFsR ERBB I
14 0 854 0 858 1.712 0.901
IGFBP-2 MEK1 CDK5-p35
'
Kallikrein7 SC14;12 11SP90a PIN
0.878 0.841 1.719 0.894
KPC1 IGFI3P-2 MIP-5 .
Ka II ikrein7 SCFsR 1-1SP90a PTN
16 0.873 0.844 1.717
0.892
KPCI IGFBP-2 Midkine
Prothrombin IGFBP-2 I ISP90a PIN
17 0.869 0.861 1.729 0.912
GAPDH.liver PARC SCFsR
-
LRIG3 ERBB I HSP90tt SCFsR
18 0.878 0.835 1.713
0.893
Kallikrein7 CSK Ren in
CD30Ligand s L-Selec tin GA PDH.liver PTN
19 0.869 0.847 1 715 0.894
IGH3P-2 Kallikrein7 TCTP
' PTN GA PD11,1iver IGN3P-2 LRIG3
0.864 0.852 1.716 0.913
SCFsR CD30Li gond Ubiquitin+1
SCFsR ERBB1 BTK IGFBP-2
21 0.878 0.844 1.722
0.899
CDK5-p35 Kallikrein7 AM PM2
CSK KPCI ERBB1 CK-MB
22 0.878 0 824 1.702 0.896
BLC SCBR C9
Prothrombin IGFBP-2 1-ISP90a ?TN
23 0.85 0.864 1.713
0.907
GAPDILliver SCFsR BMP-1 ,
CD30Ligand RAC I PTN sL-Selcctin
74 0.854 0.866 1.721 0 913
Kallikrein7 ERBB I CI s
LRIG3 KPCI IGHIP-2 SCFsR
0.864 0 855 1.719 0.9
CNDP I 1-1SP90a PTN
185
CA 3011730 2018-07-18
Table 19 (cont.)
IGFBP-2 KPCI CD30Lig3nd PTN
26 0 883 083 1 712 0 898
Coniactin-5 SCFsR BTK
CD3OLigand Cyclophil inA PTN sL-Selectin
27 0.873 0 852 1 726 0.898
IGFF3P-2 Kalliluein7 GAPDH.liver .
SCFsR ERBB I LDH-H1 CyclophilinA
28 0.873 0.847 1.72
0.904
Kallikt 6117 FOP-17 C9 ,
IGFBP-2 SCFsR RAC1 ERBB1
29 0.845 0.869 1.714 0 909
PTN FGF-17 FYN
...
IL-15Ra PTN RAC] sL-Selectin
30 0.854 0.852 1.707
0.905
Ka 11 i krein7 CD30Ligand LRIG3 ,
CD30Ligand Kalliktein7 KPCI PTN
31 0.873 0.838 1.711
0.889
IGFBP-2 SCFsR MEK I
CD30Ltgand Ka Ilikrein7 KPCI PIN
32 0.892 0.827 1.719 0.897
IGFBP-2 SCFsR MIP-5
4
CD30Ligand IGH3P-2 PIN sL-Selectin
33 0.864 0.852 1.716 0.906
RAC1 Midkine Ka II ikreirt7
CD30Ligand CyclophilinA PTN sL-Selectin
34 0.859 0.852 1.711
0.902
Ka Ilikrein7 Renin IGFBP-2 .
IGFBP-2 SCFsR KPCI PTN
35 0.873 0.841 1.714 0.893
TCTP CD30Ligand Kallikrein7
PTN SCFsR L:BE2N IGFBP-2
36 0.887 0.849 1.737
0.896
CD30Ligand Ka Ilikrein7 KPCI
LI hiquitin+1 BTK ER3111 IGNIP-2
37 0 864 0.852 1.716 0./199
Kallikrein7 SCFsR Midkine
PTN SCFsR AMPM2 IGH3P-2
38 0.873 0.847 1.72
0.889
Kallikrein7 CD30Ligand KPCI
-
CD30Ligancl SCFsR ERBB I CSK
39 0.869 0.83 1.698 0 898
KPC1 PTN BLC
'PTN RAC! 1GFBP-2 PARC
40 0 836 0.875 1 711 0.913
SCFsR 1!SP90a BMP-I
PTN KPCI IGFBP-2 Prot hrombin
41 0.859 0.858 1.717 0.894
HSP90a SCFsR Cis
CK-MB Kalliluein7 IISP90a LRIG3
42 0.854 0.861 1.715 0 902
PTN LDH-H1 CNDP I ,
CD30Ligand 1GFBP-2 PIN sL-Selectin
43 0.836 0.875 1.711 0.91
RAC I Contactin-5 PARC
CD30Ligand sL-Selectin GAPDH,liver PTN
44 0 873 0 844 1.717 0.9
BTK Kallikrein7 Endostatin
Kallikrein7 RAC1 SCFsR ERBB1
45 0.859 0.855 1.714 0.904
IGFBP-2 FYN CD30Ligand
,
CD30Ligand 1GFBP-2 PTN sL-Selectin
46 0.831 0.875 1.706 0.901
RAC I 1L-15Ra PARC
BTK KPCI ERBB I CD3 OLigand
47 0.859 0.847 1.706 0 891
PIN SCFsR MEK I
SCFsR C9 CSK Kallikrein7
48 0.878 0.827 1.705
0.896
Endosta tin Prothrombin MIP-5
Ka1likrein7 CyclophilinA SCFsR IGFBP-2
49 0.85 0 858 1.708 0.908
CD30Ligand PTN Renin
,
IGFI3P-2 TCTP SC SR ER13B I
50 0.873 0.838 1.711 It 894
Kallikrein7 CDES= 11;45 AMPM2
CBE2N HSP90a ERBB1 PIN
51 0.864 0.855 1.719 0.914
Kallikrein7 CK-MB CDK5-p35
-
186
CA 3011730 2018-07-18
Table 19 (cont.)
, _____________________________________________________________
CD30Ligand Ka1likrein7 KPCI PTN
(3887
52 0 827 1.714 0 897
IGF13P-2 SCFsR Ubiqui6n-1-1
CSK K PC I ER13131 CK-MB
53 . 0 873 0 821 1 694 II 893
BLC SCFsR LRIG3
-
Cls PIN ERBBI CyclophilinA
54 0.836 0.875 1.711
0.907
Kallikrein7 BMP-I sL-Selectin
CK-MB SCFsR CSK ERBBI
55 0.883 0.832 1.715 0
891
KPCI CNDP I FGF-17
CK-MB SCFsR CSK ERBBI
56 0.878 0.832 1.71 0.889
C9 KPCI Contactin-5
Protluornbin IGFBP-2 HSP903 PTN
57 0.864 0.849 1.713
0.901
GAPDH,liver SCFsR FYN
'
SCEsR ERB B I CSK PARC
58 0.822 0.884 1 705 09
CDK5-p35 IGFBP-2 1L-15Ra
Kallikrein7 SCFsR HSP90a PTN
59 0.836 0.869 1 705 0.897
UO63 IGFB1'-2 M FK I
LRIG3 KPCI CNDPI SCFsR
60 0.869 0.835 1 704 0 897
MIP-5 PIN IGFBP-2
CD30Ligand 1GFBP-2 PTN RAC I
61 0.859 0.852 1.711 0
905
SCFsR Midkine LDH-H I
-
PIN SCFsR AMPM2 IGFF3P-2
62 0.873 0.832 1.706 0.901
Kallikrcin7 CD3OLigand Renin
-
CD311Ligand PIN F12.13131 TCTP
0
63 0 .85 858 1 708 0.9
IGFI3P-2 Kallikrein7 Contactin-5
PIN GAPDH,liver IGFBP-2 LRIG3
64 0.859 0.858 1 717
0.915
SCFsR CD30Ligand LB E2N
-
Cls PIN ERBBI CyclophilinA
65 0.84 0.872 1 713 0 909
SCFsR PARC Dbiquilin-FI
CDK5-p35 CSK ERBB I PARC
0
66 .831 0.861 1.692 0.897
CK-MB SCFsR BLC
KPCI HSP90a PTN Kallikrein7
67 0.854 0.855 1.71 0.896
IGFBP-2 13MP-1 SCFsR
CD30Ligand SCFsR KPCI C9
68 0.859 0.855 I 714 0 901
BTK PTN Endostatin ,
PARC LRIG3 SCFsR FISP90a
69 0.845 0.872 1.717 0.905
Kallikrein7 CK-M13 FGF-17
' Prothrombin IGFI3P-2 HSP90a SCFsR
70 0.859 0 852 1.711
0.901
ERBBI Kal1ikrein7 FYN
sL-Selectin LRIG3 HSP90a PIN
71 0.85 0.855 I 705 0.908
Prothrombin 1L-15Ra PARC
Ka 11110.607 GAPDH.liver ERBB1 CD30Ligand
72 0.85 0.855 1.705 0 896
PTN MEK I BTK
. -
IGFBP-2 SCFsR GAPDH,liver PTN
73 0 845 0.858 1.703 0 912
MIP-5 RAC! PARC
Kallikrein7 SCFsR HSP90a ?TN
74 0.836 0.875 1.711
0.906
LRIG3 IGH3P-2 Midkine ,
Prothrombin CK-MB HSP90a LRIG3
75 0.859 0.844 1 703 0.899
Endosla tin Kallikrein7 Renin ..
CK-M13 FR1301 HSP90a SCFsR
76 0.869 D.838 17(17 0 887
KPCI TCTP ?ARC
PIN SCFsR liBE2N IGFBP-2
77 0.864 0.852 1.716 0 904
CD30Ligand LDH-H1 CDK5-p35
187
CA 3011730 2018-07-18
Table 19 (cont.)
.. ____________________________________________________________
LR1G3 SCFsR HSP90a PIN
78 0.854 0.858 1 712
0,905
Ubi quit in+I CD30Ligand IGF BP-2 ,
SC;F s IC ERBB I AM PM2 RiF BP-2
79 0 854 01(6 I 715
0.902
CDK5-p35 PARC BTK ,
CSK KPCI ERB B I CK-MB
80 0.859 0.832 I 692 0.89
BLC SCFsR FGF-17
CD30Ligand IGFBP-2 PIN CyclophilinA
81 0.869 0 841 I 709
01(98
SCFsR KPCI BM P-1 .
82 Kallikrein7 CyclophilinA SCFsR IGFBP-2
0.84 0.875 .715 0918
C Is PARC PIN
CNDP1 SCFsR HSP90a PIN
83 0.859 0.855 .714
0.906
ERB B I GAPDH,liver BTK
CK.-1v1B SCAR CSK ER13I31
84 0.864 0.844 I.708
0 886
KPCI PARC Contactin-5
1GF13P-2 SCFsR RAC1 ERBB I
85 0,859 0.852 1.711 0
905
CDK5-p35 FY NI Kallikrein7
BTK KPCI ERBB1 CD30Ligand
0.864
86 0 841 I 703 0 899
PIN SCFsR IL-15Ra .
IGF13P-2 SCFsR KPCI PIN
87 0.864 0.841 1.705
0.887
C 1 s Kallikrein7 MEK1
KPCI HSP90a IGFBP-2 SCFsR
88 0.859 0.844 1703
0.895
PIN LRIG3 MIP-5
LRIG3 C.N DPI I I SP90a CK-MB
89 0 831 0.878 I.709
0 903
PIN Ka llikrein7 Midkine
?TN KPCI 1GFBP-2 Prothrombin
90 0.878 0.824 1.702
0.891
11 SP90a SCFsR Benin
CK-MB SCFsR TCTP ERBB1
91 0.845 0 861 1.706
0 902
CD30Ligand PARC GAPDH,liver
92 PIN LRIG3 HSP90a UBE2N
0.854 0.861 1 715 0 906
SCFsR IGFBP-2 C1)101.i pad . Kallikrein7 C9
ERBB1 CyclophilinA
93 0.869 0.844 1.712
0.905
SCFsR Ubiquitin+1 IGFBP-2
,
PIN LRIG3 AM PM2 IGIB3P-2
0
94 0 .869 .847 1 715
0.888
Prothrombin sL-Selectin Kallikre1n7 .
CK-MB SCFsR CSK ERBB I
95 0.859 0.832 I 692 0.89
KPCI l'GF-17 13LC . -
CNDP1 SCFsR BTK PIN
96 085 0.858 1 708 0 908
GAPDH,liver BMP- I sL-Seledin
CD3 OLigand SCFsR ERBB I KPCI
97 0.864 0.841 1.705
089!
CK-MB BTK Contactin-5 .
..
Endosta i hi SCAR HSP90a LRIG3
98 0.864 0.849 1 713
0.911
PIN Prothrombin CDK5-p35
LRIG3 CNDP1 HSP90a CK-MB
99 0.836 0.875 1 711
0.902
PTN Kallikrein7 FYN
BTK GAPDH,liver ERBB I PARC
100 0.84 0.864 I 704 0.901
CI(-MB 1L-15Ra LRIG3
188
CA 3011730 2018-07-18
Table 19 (cont.)
Marker Count Marker Count ,
SCFsR 75 CNDP I 9 .
l'TN 69 IL-1512a 7
IGFBP-2 58 FYN 7 -
Ka Ilikrein7 53 PGF-17 7
CD3OLi paid 39 Endosla tin 7
ERBB1 38 Contactin-5 7
KPCI 33 C9 7
HSP90a 33 ¨ C Is 7
LRIG3 28 BMP-1 7
CK-MB 23 BLC 7
PARC 22 AMPM2 7
GAPDILliver 17 Ubiquitin+1 6
BTK 14 liBE2N 6
sL-Selectin 13 TCTP 6 .
R AC 1 13 Renin 6
CSK 13 Midkine 6
Prot hrombin 11 MIP-5 6
CDK5-p35 11 ¨ MEK1 6
CyclophilinA 10 LDH-H1 6
189
CA 3011730 2018-07-18
Table 20
Ion Nina, o18 A s, ntplomatir Smokers vs. Cancer 13iumarkers
Sens. +
Biomarkers Specificily Sensitivity
Spec. r AUC .
LRIG3 IGFBP-2 AMPM2 SCFsR
I 0.869 0 866 1.735
0.907
Kallikrein7 PARC CD30Li eand CK-MB -
.., CD30Ligand CyclophilinA PTN ERBB1
085 0 869 1.719 0.914
- GAPDH,liver SCFsR Kallikrein7 BLC _
PTN CyclophilinA BMP-1 ERBB I
3 0 854 0 875 1.729 0
917
Kallikrein7 GAPDH.liver SCFsR CD30Ligand
CD30Ligand Kallikrein7 KPCI PTN
4 0.897 0 855 1.752
0.904
IGFBP-2 SCFsR C9 BTK ,
1GFBP-2 SCFsR KPCI PTN
0.892 0.849 1,741 0,901
CI s CD3OLigand Ubiquitin+1 Kallikrein7
,
CDK5-p35 IGFBP-2 HSP90a PTN
6 0,873 0 861 1 734
0.902
SCFsR KPCI Kallikrein7 CD30Ligand
Eadostatin LRIG3 HSP90a PTN
7 0.869 0.872 1.741 0.912
CNDP I Kallikrcin7 CK-MB BTK . -
CK-MB SCFsR CSK ERBB1
8 0.887 0.847 1.734 0.893
KPCI CDK5-p35 HSP90a PARC ...
1GFBP-2 KPCI CD3OLigand PTN
0
9 .901 0.83 1 731
0,901
Contactin-5 SCFsR Kallikrein7 BTK
IGFBP-2 SCFsR GAPDH,livcr HSP90a
0.869 0.869 1.738 0.917
PTN FGF-17 PARC Pro thrombin
-
PTN RAC I 1GFBP-2 PARC
11 0.873 0.864 1.737 0.92
SCFsR Kallikrein7 CD3 OLigand FYN
BTK IGFBP-2 PTN Kal1ikrein7
17 0 897 0,835 1.732
0.898
SCFsR KPCI IL-15Ra CD30Ligand , ..
Ka1likrein7 CyelophilinA SCFsR 16F131,-2
13 0.883 0 858 1,741
0.91
CD30Liaand PTN Renin LDH-HI , ,
CD3OLigand CyclophilinA PTN ERBB I
14 11.864 0 861 1.725
0.907
GAPDH,liver SCFsR Kallikrein7 MEK I , . ,
,
IGFBP-2 SCFsR GAPDH,liver PTN
0.859 0 875 1.734 0.914
MIP-5 RAC I PARC Cis
CD30Ligand Kallikrein7 KPCI PTN
16 0.906 0.821 1.727
0.897
1GFBP-2 SCFsR MIP-5 Midkine
-
CD30Ligand KPCI PIN SCFsR
.
17 0 887 0 849 1.737
09
C9 TCTP Kallikrein7 1GF13P-2 .
SCFsR C9 UBE2N CD30Ligand
18 0.892 0 852 1.744 0
902
PTN KPCI Kallikrein7 IGFBP-2 ,
PARC GA PDH,li ver HSP90a PTN
19 0.869 0 866 1.735
0.912
1GFBP-2 LRIG3 sL-Selectin Prothrombin
'
-
Kallikre1n7 ERBB I A MPM2 IGFF3P-2
0 873 0 861 1.734 0.903
BTK SCFsR C9 CDK5-p35 ,
CSK KPCI ERBB I CK-MB
21 0 873 0 844 1.717
0.894
BLC SCFsR PARC Renin
12 CD30Ligand Kallikrein7 KPCI PTN
0.887 0 841 1.728 0.9
- 16FBP-2 SCFsR BM P-I 1113E2N
CNDP1 SCFsR HSP90a PTN
23 0.878 0 855 1 733
0.911
ER13131 GAPDH.liver BTK CDK5-p35
KPCI HSP90a IGFBP-2 SCFsR
24 0 878 0 852 1 73
0.899
FEN LRIG3 Kallikrein7 Conlactin-5 .
PARC LRIG3 SCFsR HSP90a
0.854 0.881 1.735 0.908
Ka1likrein7 CK-MB F,nclos ta On FG F-1 7
. .
190
CA 3011730 2018-07-18
Table 20 (cont.)
...
IGFBP-2 KPCI CD30Ligand SCFsR
26 0 883 0.849 1.732
0.903
Pm FYN Kallikrein7 ERBB1
PThl SCFsR BTK IGFBP-2
27 0.878 0.847 1.725
0.897
Cis Kallikrein7 KPCI 1L-15Ra .
CD30Li8and IGFBP-2 PThl RAC I
28 0 864 0 875 1 739
0 915
SCFsR C9 LRIG3 LDH-H I
. .
PTN SCFsR RAC1 CI s
29 0 845 0 875 1 72 0
902
IGFBP-2 LDH-H1 MEK1 PARC .
PIN SCFsR AMPM2 1GFBP-2
30 0 869 0.858 1.726
0.902
Kallikrein7 CD30Ligand LRIG3 Midkine ,
IGH3P-2 TCTP SCFsR FRI301
31 085 0.881 1 73 0.912
PARC CDK5-p35 Kallikrein7 CK-MB
32 CD30Ligand Kallikrein7 KPCI PTN
0.892 0 841 1 733 0.901
IGFBP-2 SCFsR Ubiquitin+ I LRIG3 .
CD30Ligand RAC I PTN sL-Sel cc tin
33 0.864 0 869 1.733
0.92
Ka11ikrcin7 1(11713P-2 Cls PARC
-
CSK KPCI ERBB I CK-MB
34 0.873 0 841 1 714
0.892
BLC SCFsR PARC AMPM2
CD30Ligand Kallikrein7 KPCI PTN
35 0 878 0 849 1.727
0.899
IGFBP-2 SCFsR BMP-I HSP90a
PTN KPCI 1GFBP-2 Prothrornbin
36 0.878 0.852
1.73 0.899
__________ HSP90a SCFsR CNDP I LRIG3
PARC LRIG3 SCIsR HSP90a
0
37 84 0.889 I 73 0.903
Kallikrein7 CK-MB Endostatin Contactin-5
- . .
CD30Ligand IGFBP-2 PTN RACI
38 0 859 0.878 1.737
0.915
SCFsR FGF-17 LDH-H1 PARC _
KPCI HSP90a PTN Kallikrein7
39 0.873 0.858 1.731
0.898
IGFBP-2 CD3OLigand ERBB I FYN
, .
CD30Ligand IGFBP-2 PIN RAC I
40 0 883 0 841 1.724
0 897
SCFsR Kallikrein7 KPCI IL-15Ra
IGFBP-2 CyclophilinA ERBB1 Kallikrein7
41 0 873 0.847 1.72
0.899
Dbiquitin+ I SCFsR MEK I C9
42 LRIG3 KPCI CNDP1 SCFsR
0.883 0.847 1.729 0.901
MW-5 PTN IGFBP-2 COK5-p35
SCFsR ERBB1 BTK IGFBP-2
43 0.883 0.844 1 726 0.907
CDK5-p35 Kallikrein7 Ubiquitin+I Midlcine
BTK IGFBP-2 PTN Kallikrein7
44 0 897 0,841 1.738
0.903
SCFsR KPCI CD30Ligand Renin .
LRIG3 ERBBI HSP90a SCBR
45 0 873 0.852 1.726
0.905
Kallikrein7 TCTP PTN LDH-H1 .
Cls IGFBP-2 PTN LIBE2N
46 0 887 0.849 1.737
0.9
Kallikrein7 SCFsR KPCI CD30Li gond
PTN RAC I IGH3P-2 PARC
47 0 854 0.878 1.732
0.913
sL-Selectin CD30Ligand Kallikrein7 FGF-17
..
CDK5-p35 CSK ERBB1 PARC
48 0 859 0 852 1.711 11
908
CK-MB SCFsR GAPDH,liver BLC .
SCFsR BMP-1 HSP90a PTN
49 0,864 0.861 1.725
0.899
PARC BTK KPCI ERBB I
50 IGFBP-2 KPCI CD30Ligand PTN
0.883 0.847 1.729 0.898
Contactin-5 SCFsR Kallikrein7 URF.2N
PTN SCFsR AMPM2 IGFBP-2
0 0
51 873 .858 1 731 0.903
Kallikrein7 CD30Ligand LRIG3 Endoslatin
'CD30Ligand Kallikrein7 KPCI PIN
52 0 887 0 844 1.731
0.901
IGFBP-2 SCFsR C9 FYN 1
191
CA 3011730 2018-07-18
Table 20 (cont.)
Kallikrein7 CyclophilinA SCFsR IGFBP-2
53 0 878 0 844 1.722 0,896
CD30Ligand PTN KPCI IL-15Ra . .
Kallikrein7 RAC I SCFsR ERBB1
54 0 859 0 858 1.717 0.902
IGFBP-2 CDK5-p35 Midkinc MEK 1 .
CD30Ligand Ka1likre1n7 KPCI PTN
0 0 55 897 832 1 .729 0.901
IGFBP-2 SCFsR MIP-5 RAC I
CD30Ligand SCFsR KPCI C9
56 0.887 0.855 1 742 0.899
ERBB I HSP90a Pro thrombin Kallikrcin7 ,
Kallikrcin7 SCFsR HSP90a PTN
57 0.892 0.841 .733 0.902
KPCI CD30Ligand 1(IFBP-2 Rcn in
PTN RAC1 1C1F3P-2 PA RC
58 () 887 0 838 1 725 0.912
SCFsR Kallikrein7 CD30Ligand TCTP
PTN RAC1 IGFBP-2 PARC
59 0 864 0.866 1.73 0.922
SCFsR Kallikrein7 sL-Seleelin CD3OLigand
, .
CSK KPCI ERBB I CK-MB
60 0.873 0.838 1.711 0.898
BLC SCFsR PARC LRRII
Kallikrein7 BM P-1 HSP90a PTN
61 0 878 0.847 1.725 091
LRIG3 PARC RAC! IGFBP-2
LRIG3 CNDP1 HSP90a CK-MB
6/ 0 859 0.869 1.728 0.913
PTN GAPDH,liver Ka11ikrcin7 PARC .
Prothrombin CK-MB HSP90a LR1G3
63 0 864 0.864 1.727 0.902
Endoslatin Kallikrein7 SCFsR Con (actin-5
.
C:D3OLigand ICIFI3P-2 PTN RAC1
64 0 864 0 872 1.736 0.921
SCFsR FGF-17 GAPDH,liver PARC
- -
PARC Kallikrein7 HSP90a ERBB1
65 0.864 0.866 1.73 0.911
IGFBP-2 FYN SCFsR CDK5-p35 .
Kallikrein7 SCFsR HSP90a PTN
66 0.869 0.852 1.721 0.896
KPCI CD30Ligand IGFHP-2 1L-15Ra
Kallikrein7 RAC I SCFsR ERBB1
67 0.859 0.858 1.717 0.901
C9 BTK IGFI3P-2 MEK1
CD30Ligand Kallikrein7 KPCI PTN
68 0.901 0.827 1.728 0.898
IGFBP-2 SCFsR M1P-5 1../BE2N
. -
KIFBP-2 KPCI CD30Ligand SCFsR
69 0.883 0.844 1.726 0.896
PTN GAPDH,liver Kallikrein7 Midkinc
IGFBP-2 SCFsR KPCI PTN
70 0 878 0 852 1.73 0.9
C1s Kallikrein7 HSP90a Renin . ..
...
FGF-17 Kallikrein7 ERBB I GAPDH,Iiver
71 0.878 0.847 1.725 0.912
C9 SCFsR TCTP PTN
. . ,
72 SCFsR ERBB1 BTK IGFBP-2
0.854 0.878 1.732 0.914
CDK5-n35 Kallikrein7 Ubiquitin+1 PA RC
. õ
CD30Ligand sL-Selectin GAPDH,livcr PTN
73 0.878 0,852 1.73 0.906
IGFBP-2 RAC1 Kallikrein7 LRIG3
PIN SCFsR AMPM2 IGFBP-2
74 0.887 0.847 1.734 0.892
Kallikrein7 CD30Ligand KPCI BTK
CSK KPCI ER3381 CK-MB
0 75 .873 0.838 1.711 0.894
BLC SCFsR PARC GAPDH,liver
CD30Ligand Kallikrein7 KPCI PTN
76 0.883 0.841 1.724 0.901
IGFBP-2 SCFsR BMP-1 CyclophilinA ,
Endosla tin LRIG3 FISP90a PTN
77 0.85 0,878 1.728 0.905
CNDP1 Kallikrein7 CK-MB LOH-HI . .-
IGFBP-2 SCFsR KPCI PTN
0
78 869 0 855 1 724 0.896
C I s Kallikrein7 HSP90a Contact in-5
Kal1ikrc1n7 CyclophilinA SCFsR 1GFBP-2
79 0.864 0.866 1.73 0.913
CD30Ligand PTN PARC FYN
192
CA 3011730 2018-07-18
Table 20 (cont.)
MN GAPDH.liver IGFBP-2 LRIG3
80 0.845 0 875 1 72 0.910
SCFsR IL-15Ra HSP90a PARC
CD30Li wind Kal10=1117 KPCI PIN
81 0.873 0.844 1.717 0.893
IGFBP-2 SCFsR MEK1 LRIG3
. ,
CD30Ligand Kallikrein7 KPCI PTN
FI2 0 897 083 1.726 0.9
IGFI3P-2 SCFsR MIP-5 GAPDH,liver
CD30Ligand Kallikrcin7 KPCI PTN
83 0.878 0.847 1 725 0.9
IGEBP-2 LRIG3 SCFsR Midkine
Prothrorabin IGFBP-2 HSP90a PTN
84 0.873 0.866 1.74 0.911
GAPDH,liver SCFsR CD30Ligand LR103
PTN SCFsR 131K 1G FBP-2
85 0 887 0 838 1 725 0.902
Cls Kallikrein7 KPCI Renin
CDK5-p35 KPCI ERBB1 HSP90a
86 0.883 0.841 1.724 0.892
CK-MB PARC SCFsR TCTP
PTN RAC I 1GFBP-2 PARC
87 0 887 0.849 1.737 0.92
SCFsR Kallikrein7 CD30Lieand 1.113E2N
. ,
PTN GAPDH,livcr IGFBP-2 LRIG3
88 0 864 0.861 1.725 0.921
SCFsR PARC CD30Ligand Ubiquitin+1
sL-Selectin CyclophilinA ERBB1 Kallikrcin7
89 0.859 0.869 1.728 0.914
CD30Ligand PTN Cls GAPDH,liver ..
PTN SCFsR AMPM2 IGFBP-2
90 0.878 0.852 1.73 0.894
Kallikrcin7 CD30Ligand LRIG3 KPCI
Kallikrein7 CyclophilinA SCFsR 161713P-2
91 085 0 861 1.711 0.905
CD3OLigand ERBB1 RAC1 BLC
92 Ka11i1crein7 BMP-1 HSP90a PTN
0.864 0.858 1.722 0.91
LRIG3 PARC UBE2N IGFBP-2 .
LRIG3 CNDP I HSP90a PTN
93 0.864 0.864 1.727 0.911
Prothrombin GAPDH,liver SCFsR IGFBP-2
CD30Ligand Kallikrein7 KPCI PTN
94 0.887 0.844 1.731 0.902
IGFBP-2 SCFsR C9 CSK
IGFBP-2 KPCI CD30Li wind PTN
95 0.887 0.835 1.723 0.9
Contactin-5 SCFsR Kallikrein7 LRIG3
CD30Ligand Kallikrein7 KPCI PTN
96 0.878 0.852 1.73 0.901
IGIBP-2 LRIG3 SCFsR F.ndostatin ,
Kallikrein7 SCFsR KPCI HSP90a
97 0 878 0 858 1.736 0.904
FGF-17 IGFBP-2 PIN PARC
CD3OLigand 1GFBP-2 PTN RAC1
98 0.869 0.861 1.729 0.91
SCFsR C9 LDH-H 1 FYN
BTK IGFBP-2 PTN Kallikrcin7
99 0.873 0.847 1.72 0.898
SCFsR KPCI IL-15Ra (79
CD30Ligand Kallikrein7 KPCI PTN
100 0.873 0.844 1 717 0.891
IGF13P-2 SCFsR MEK I BTK
,
193
CA 3011730 2018-07-18
Table 20 (cont.)
Marker 1 Count Marker Count
SCFsR 89 Protluonthin 7
PTN 79 MEK I 7
IGFBP-2 78 LDH-H I 7
Kall1kre1n7 77 , IL-15Ra , 7
CD30Ligand 58 FYN 7
KPC1 51 FGF-17 7
PARC 33 Endosia lin 7
'HSP90a 30 Contactin-5 7
LRIG3 29 CSK 7
ERT3131 27 , CNDP1 7
GAPDH,liver 20 BMP-1 7
RAC I 19 BLC 7
BTK 16 AMPM2 7
CK-MB 15 sL-Sclectin , 6
,
C9 13 Uhiquitin+I 6
C DK 5-p35 12 TCTP 6
,
Cyclophil inA 10 Renin 6
Cls 10 Midkine _ 6
UBE2N 7 MIP-5 6
_
194
CA 3011730 2018-07-18
Table 21
100 Panels of 9 A..:, mptomalic Smokers vs. Cancer Biomarkers
Sens. +
Biornarkers Specificity
Sensitivity Spec. ADC
Kalli krci n7 SCFsR IISP90a ER13131 CDK5-p35
1 0.887 0.858 1.745
0.905
IGH3P-2 AMPM2 PARC FYN ,
CSK KPCI ERBB1 CK-MB BLC
0.883 0.847 1.729 09
SCFsR PARC RC11111 CDK5-935 ,
K3l5krcin7 BMP- I I ISP90a PTN LRIG3
3 0 883 0.861 1.743
0.917
PARC RAC' IGFI3P-2 RCIlill
PTN RAC I IGFBP-2 PARC SCFsR
4 0.878 0.881 1.759
0.922
Kul likrein7 CD30LIgund 131K ReMn
Cis SCFsR GAPDILliver CO PTN
5. 0.897 0.855 1.752
0.914
Prothromb in CD3OLIgand Kallikrcin7 UBE2N
Kallikrein7 LRIG3 HSP903 PTN 1G FBP-2
6 0.873 0.872 1.745
0.912
CK-MB IDI I-111 CNDPI SCFsR ,
IGF BP-2 KPCI CD30Ligand PTN Contact in-5
7 0.906 0.344 1.75 0
902
SCFsR Kallikrcin7 RAC1 M W-.5
. .
Kallikrein7 SCFsR FISP9113 PTN FAR
s M 0.869 0.889 1.758
0.925
CyclophilinA IGFI3P72 CE-MB PARC .
CE-MB . LRIG3 11SP-911; SCFsR PARC
9 0.873 0.875 1.743
0.915
Pro thrombin F.ndostalin Kall ikrein 7 BTK
CDK5-p35 1GFBP-2 ILSP90a PTN SCFsR
0.878 0.872 1.75 0.906
KPCI Kallikrcin7 PARC FGF- 1 7
= ..
BTK IGIIIP-2 PTN Ka II ikrcin7 SCFsR
11 0 883 0.852 1.735
0.9
KPCI 11.-15Ra C9 I ISP90a
CD301igand Kallikrcin7 NPCI PTN ICIFF1P-2
12 0 883 0.852 1.735
0.893
SCFsR MEK1 LRI03 M kik i ne
CD3OLigand Kal lila cia7 KPCI PTN IGFBP-2
13 0883 0.864 1.746
0.903
SCFsR C9 LRIG3 TCTP
CD30Ligand KM likrein7' KPCI PTN 161713P-2 = =
14 0.901 0.849 1.751
0.904
SCFsR Ubiquitin+1 BTK C9
PTN RACI 1GFBP-2 PARC SCFsR
0.833 0.869 1.752 0.922
Kallikrcin7 sL-Sclectin FYN CD301 i..qtd
('TN SCFsR A01PM2 ICFBP-2 Kallikrcin7
16 0.873 0.858 1.736
0.898
CD301,igand I.RTG3 COK5-p35 KPCI
-
C10101,igand SCFsR FRBB1 CyclophilinA PTN
17 0.864 0.864 1.727
0.916
IGFBP-11 RAC! Kalliluein7 BLC
CyclophilinA FISP903 ERBB1 SCFsR PARC
18 0.873 0.869 1.743
0.913
1GFBP-2 Kai likrein7 BMP-1 CDK5-p35
CD30Ligand IGFBP-2 PTN RAC1 SCFsR
19 0.906 0.844
1.75 0.906
Ka Ililcrein7 KPCI Ream C 1 s
LRIG3 CNDP I I ISP90a CK-MB PTN
0.854 0.989 1.744 0.911
GAPDH, liver Kallikrcin7 Endosta tin Cls
----- ..,....... . .. , .
CD30Ligand Kal likicin 7 KPCI PTN IGFBP-2
21 0.887 0.858 1.745
0.903
SCFsR CO CSK
' PTN SCEsR 13TK IGM1P-2 CJs
22 0.897 0.849 1.746
0.902
Kallikre1n7 00 C9 Conlaclin-5
CK-MB LRIG3 I ISP90a SCFsR PARC
23 0.864 0.834 1.747
0.914
Pro thrombin Endo stalin Ka Ilikrein 7 FGF-17
BTK 1GF13P-2 PTN Kallikrcin7 SCFsft
24 0.883 0.852 1.735
0.898
KPCI 11SP90a BMP-1 IL-15Ra
Prothrombin 1GFBP-2 HSP903 PTN GAPDFILiver
0.378 0.866 1.744 0.907
SCFsR CD30Ligand LRIG3 LDH-H1
CD301.igand Cycl op hi lin A PTN ER13131 GAPDH.liver
26 0.864 0.369
1.733 0.91
1GFBP-2 Kallikrein7 SCFsR MEK I
CD30LiLiand 1::::;i 1 i k I 6.17 KPCI PTN 1GFBP-7
27 0.901 0.838 1.739
0.904
SCFsR C DK 5-p35 MW-5 RAC I
CD30Ligand Ka 1 likrein7 KPCI PTN IGIBP-2
28 0.897 0.849 1.746
0.905
SCFsR C9 BTK Midkinc
195
CA 3011730 2018-07-18
Table 21 (cont.)
LR1G3 ERBB1 HSP9aa SCFsR Ka110=617
29 0 883 0.861 1.743 0 903
TCTP PIN C9 . LDH-1-11
1111 PARC Kallikrcin7 1-ISP90a PTN IGFBP-2
0 378 0.872 Ill 0.92
LRIG3 SCFsR C9 116E2N
a CD30Licand Kallikrcin7 KPCI PTN IGFIIP-2
0 892 CM 1.739 0.905
SCFsR CDK5-p35 ('Is 1110quitin+ 1
IIII PTN RAC! IGIT3P-2 PARC SCFsR
0.883 =III 0.923
CD30Ligand GAPD11,1iver sL-Selcclin Kallikrein7
Kallikrcin7 SCFsR 11
CSK IISP90a ERBB1 CDK5-p35 0.878
1GFIIP-2 AMPM2 PARC BTK
ERBB1
SCFsR PARC CK-MB KPCI BLC
0.869 0.858 El 0 905
0.859
Rcnin ConIactin-.5 111:11:
11111 En dosiatin LRIG3 HSP90a PIN CNDP I
0.354 0 886 1 741 0.906
Kallikrcin7 ('K-MR [,DH-H1 Conlaclin-5
111 PI othrnmh in IGFT4P-2 FISP903 PIN GAPDH,livcr
0.878 11:12 1.744 MI
SCFsR FYN PARC FGF- 17
IIII CDK5-p35 I.RIG3 1-ISP90a PTN IGH3P-2
0.859 0.875 111:1
0.918
GAPDILlivcr SCFsR PARC 1L-15Ra
111 liTK RACI FRBBI Kallikrcin7 KiFBP-2
0.864 0 869 IOW
FIN SCFsR PARC MEK1
II lila
IGFBP-2 KPCI
FYN
TCTP CD3OLigand SCFsR PTN
Kali ikrcin7 M1P-5 Midkinc
CD301,igand KM PTN SCFsR C9 0.897 0.838 0 898
Kali iki cin PI7 IGFBP-2 ollyombin 0 91 0.1127
El
D BTK IGH3P-2 PTN Kal1iktcin7 SCFsR
0.901 0.844 0.902
KPCI CD30Li0and URE2N C9 El
1:111GFBP-2 SCFsR KPCI PTN Cm
0.901 0.835 EOM
CD30Licand Kallilacin7 Midkinc Ubiquilin+1
MI PIN LRIG3 CD30Ligand GAPDH,livcr PARC
0.878 0 866 11:1 0
918
IISP90a SCFsR Prothrornbin sL-Scicclin
1 PTN SCFsR AMPM2 1GFBP-2 Kai lilac in7
0.878 0.858 1.736
0903
C0301.igand 1.0163 Erkinstatin FYN _
CSK KPCI ERBB1 CK-MB BLC
0.369 0.852 1.721 0.9
SCFsR PARC RCI1111 PTN
BM IGFBP-2 PTN Ka Ilikrcin 7 SCFsR
0.378 0.864 1.742
0.904
KPCI HSP90a PARC BMP-1
11111 LRIG3 CNDP1 1-1SP903 ('K-MB PTN
lialla 1.741 1:11
Kallikrein7 CyclopliilinA Endoslalin Cls
CI FGF-17 SCFsR ER13131 BTK IGFDP-2
0.869 0.075 1.744
0923
Kallikrein7 PARC RACI PTN
ci PIN CAPD1-1,1ivcr IGFBP-2 ',RIM SCFsR
0.859 0.875 1.734 0 919
II.- 1 5 Rri HSPOCB PARC .c1.-Selcclin
III Kallikrein7 SCFsR 11SP90a PTN LRIG3
111:11 0.378 1.732 CO
IGF BP-2 Froth rombin PARC MEK1
CD3OLigand Kallikrcin7 KPC1 11 PTN
SCFsR
1GFBP-2 TCTP
CDK5-p35 841P-5 SCFsR ERBBI
CDK5- 335 Kallikrein7 CK-MB IGFBP-2
UBE2N
PARC
UBE2N 0 901 0.335 1.737 0 901
-
IIMICE 1 71 0.913
Ell IGEBP-2 Cyc1ophi linA ERBB I Kallikrcin7 Ubiquitin-11
0054 088! Ell 0.918
SCFsR PARC ('K-MR CD30Ligand
El PTN SCFsR AMPM2 1GFBP-2 Kalliknin7
0.373 Eli 1.734 0.911
CD30Ligan1 CDK5-055 ERI3131 BTK
1111PTN SCFsR AMPM2 IGH3P-2 Ka Ilikrcin7
0.864 0.355 0 907
CD3OLigand L113E2N LRIG3 BLC IIIII
El PTN CyclophilinA BMP-1 ERBB1 Ka Ililcrcin7 =MI 1.7 7 MI
GAPD11,1ircr SCFsR CD30 p:Ili 1 it FYN
1. Endostatin LRIG3 IISP90a CK-MB PARC
0 864 0.875 1 739 0.914
GA PDH ,livcr Kallikrcin7 CNDP1 PIN
RIGS FRI1111 HSP90a SCFsR Kallikrcin7
0.892 11:1 1.741 0.906
CSK TIN LD1-1-111 CDK5-p35
I 96
CA 3011730 2018-07-18
Table 21 (cont.)
_ ___________________________
CK-M13 LRIG3 FISP90a SCFsR PARC
39 0864 0.801 1.745 0.91
Prothromhin Endosialin Kallikrcin7 Contactin-5 ,
=
CD30Ligand ICE:BP-2 PTN RAC1 SCFsR
60 0864 0.373 1 742 0 922
FGF-17 GAPDILlivcr LR1G3 PARC
11=11;. 1G FIIP-2 PTN Ka II ikrein 7 SCFsft
61 0.887 0.847 1.734 0 896
K PC I I1.-15R a t '9 FYN .
"
62 CD30 Ligand CyclophilinA PIN ERBB1 GAPDH.livcr
0.873 0.853 1.731 0.908
SCFsR Kan krein7 11EK1 CDK5-035
'
IGH3P-2 SCFsR RACI Cls Kallikrcin7
61 0864 0.872 1.736 0.921
PARC GAPDH,livcr PTN M1P-5 ,
PTN GAPD11,1ivcr 10013P-2 LRIG3 SCFsR
64 0.373 0..866 1 74 0 911
IISP903 Midkinc Prothromb in CD301Jgand ,
'
1GFBP-2 SCFsR KPCI PTN CI s
65 0.878 0.852 1.73 0902
CD301,igand Kallikrcin7 TCTP C9
ICIFFIP-7 (yclophilinA F.RB B1 Kallikrein7 11Inquitin+1
66 0.864 0.869 1.733 0.92
SCFsR PARC CK-MB FGF-17
-
CD30 Ligand 1GFBP-2 PTN RAC) SCFsR
67 0.897 0.847 1.743 0.907
sL-Selcctin KPCI Kallikrcin7 Cls
CSK . KPCI ERBB1 CK-MB BLC
68 0.378 0.841 1 719 0.894
SCFsR PARC Ran ill M1(11(111
..
IGFI3P-2 SCFsR GAPDH,livcr HSP90a PTN
69 0..85 0.886 1.736 0.918
.
FGF-17 PARC Tholltrumbin BMP- I ...
, ....
PIN GAPDFLIivcr IGFBP-2 LRIG3 SCFsR
70 0.864 0.875 1.739 0.912
HSP90a Kalli1u'cin7 CP:DP1 Contactin-5 _
71 BTK 1GFBP-2 PTN Kallikrcin7 SCFsR
0881 0.849 1.732 0899
KPCI IL-15123 CD3OLigand Midkine . ,
= -
72 CD30Li2and IGFI3P-2 PIN RACI LRIG3
0.864 0.878 1.742 0.921
SCFsR 7.1313-H1 PARC Kallikrcin7
.. ,
C0301,igand Kallikrcin7 KPCI PTN 1GFRP-2
73 0.887 0,844 1.731 0.893
SCFsR MEK1 LRIG3 UBE2N .
CD3OLigand IGFBP-2 PIN RAC1 SCFsR
74 0.906 0.33 1.736 0.905
sL-Sclectin KPCI Kallikrcin7 M1P-5
_
CD30Ligand PTN ER13131 TCT? IGFDP-2
75 0.873 0.85.5 1.728 0.914
Kallikrcin7 SCFsR GAPD11,1ivcr sL-Sclectin . ,
CDK5-035 1330139-2 HSP90a PTN SCFsR
76 0.878 0.855 1.733 0.91
_________________ GAPDH,livcr CNDP I 1,12103 I Inplinn4 I ,
PIN SCFsR AMPM2 IGF3P-2 Kallikrcin7
77 0.864 0.869 1.733 0.91
C13101...i.oul LRIG3 C9 1
CD30Ligand CyclopinlinA PTN ERBB I GAPDH,liver
78 0.864 0.852 1.716 0.915
SCFsR Kallikrcin7 BLC 1.11302N
PTN RACI ICiFBP-2 PARC SCFsR
79 0.864 0.872 1.736 0.92
14SP90a Kallikrcin7 LRIG3 BMP-1 PTN C9 CSK CD30Ligand
SCFsR
80 0.887 0.852 1.74 0.909
KPCI 1009P-2 . ERBB1 Kallilcr0n7
PTN LRIG3 ERBB1 FISP90a Kallikrcin7
81 0.854 0.886 1.741 0.915
I. 13H-I4 I PARC CK-MB Contactin-5 .
82. CD30Ligancl CyclophilinA PTN ERBB I GAPDH,livci
0859 0.872 1.731 . 0.915
100130-2 Ka11acrcin7 IL-15Ra SCFsR
83- C I s CSK ERBB I Kallikrein7 PTN
0.887 0.844 1.731 0.9
SCFsR GAPDILliver LIM I-I It 811.',K 1 ,
,
CD30Ligand Kallikrcin7 KPCI PIN IG0BP-2
84 a 883 0 852 1 735 0.9
SCFsR CDK5-035 M1P-5 HSP90a
,
S.5 CD30Ligand KPC1 PTN SCFsR C9
0.837 0 841 1.723 0.893
TCTP K al 1 ikic1n7 R 010 = 2 131K
K allikicia7 FR 1391 AMPM2 1GFRP-2 RTK
86 0.878 0.855 1.733 0.904
SCFsR C9 CDK5-035 Ubiquil in+ I
_ ....-
CSK KPCI ER I3131 CK-MB BLC
87 0.878 0.838 1.716 0.899
SCFsR PARC Rollin FG0-17
-
LDII-1-11 Ka Ilikrcin7 ERBB I HSP90a SCFsR
88 0.873 0.861 1.734 0.908
LRIG3 131K PTN BMP-1 . , _
LRIG3 CNDPI I18P90a CK-M13 PTN
89 0.959 0,878 1.737 0909
GAPDH Jiver Kallikrcin7 Endoslatin CD30Ligand
-
197
CA 3011730 2018-07-18
Table 21 (cont.)
__________ IGFI3P-2 KPCI CD30Ligand PIN Contactin-5
90 0.892 0.847 1,739 0.903
SCTsR Kallikrcin7 RAC I a., Cis
IGI1RP-2 KPCI C11301.1gand MTs11t PIN
91 0.897 0.849 1.746 0 902
FYN Kull ikrein7 ___________ BTK C9
,
SCTsR ERI3B1 BTK IGFBP-2 CDK5-p35
92 0.859 0.872 1.731 0.906 .
Kallikre1n7 AM1PM2 IL-15Ra PARC
sL.Seleet in CyclephilinA ERBI31 Kallikrein7 CD30Lipan1
93 0.364 0.866 I 73 0.904
PIN GAPDH,liver MEK I Cis
CD3OLinnid Ka Ili krcin7 KPCI PIN IGFIIP-2
94 µ.., 0.887 0 847 1 734 0.907
SCFsR MIP-5 RAC1 CK-MB
,,.
PIN GAN-A-1,11,6r 1GFBP-2 LRIG1 SCFs12
95 0.864 0.872 1.736 0.913
I ISP90a M id inc CD301,i0and cr.A.;-pli
LR1G3 ERBB I 1-ISP90s SCFsR Kullikrcin7
96 0.878 0.849 1.727 0.906
TCTP PIN LDI-I-H I CNDP I __ ---.......---...
C'D30Littand Kul likre in7 KPCI sL-Selectin PIN
97 0.906 0.827 1.733 0.902
SCFsR BTK C9 Ubiquilin+ I .
,
CK-MB SCFsR CSK ERI3131 KPCI
98 0.878 0.838 1 716 0.897
PARC I ISP90a Pro thrombin BLC
,.
Kallikrein7 BMP- 1 I ISP90a PTN LRIG3
99 0.873 0.861 1 734 0.909
PARC RAC 1 IGFBP-2 FGF-17
1GP BP-2 KPCI CD30Lipand PIN Con tac lin-5
100 0 883 0.855 1.738 0.906
SCFsR Krill iktc in7 BTK C9 -
ManlaMMEMall Marker Counl
mn LEO-HI
CSK 10
sL-Scicclin 9
1GPBP-2 MEM FGF-17 9
C0301,icand 52 Endostatin 9
.,
KPCI 40 Coniaclin-5 9
PARC 39 CNDP1 9
I I SP90a 39 BMP-1 9
LR1G3 BLC 9 <
ERBB I AN4P1,42 ' 9
GAPDH.liver Ubisuitin+1 8
0011.111111111111=1.1 UBE2N 8
CK-MD Ma= TCTP 8
CDK5-635 20 Rcnin 8
C9 11.1Eall. Midkinc R
RAC 1 1111115111111111 MIP-5 8
Cis MU MEK1 8
WM= 12 IL-15Re , 8
Cr:61161111A 12 FYN 8
198
CA 3011730 2018-07-18
Table 22
100 Panels of 10 Avitiptontalic Smokers vs. Cancer Biornarkers
' Sens. +
Bin ma rkers Specificity Sensii ivitv
Spec. Al:C.
PIN SCFsR AMPM2 1GFBP-2 Kallikrein7
I 9 383 0,364 1 746 0 917
CD30Li nand LRIG3 CO BTK CK-MB .
CSK KPCI FARB I CK-MB FILC
0.892 0 844 1.736 090!
SCFsR PARC Resin CDK1-p35 HSP90a _
...,. . .
PARC SCFsR HSP90a PIN 1GFBP-2
3 0.887 0.866 1.754
0.92
Plothrumbin LRIG3 RAC! BMP-1 Kull ikrein7
- .
BTK RAC1 ERBB I Kallikrein7 IGFHP-2
4 0.873 0.336 1.76
0.925
PIN SCFsR sL-Scicclin CI s PARC
1.,R1G3 CNDP I IISP90a CK-MB PTN
0 878 0.875 1 753 0 914
GAPDH.livcr Kallikrein7 Endosialin CI s BTK
----4 =
BTK 1GFBP-2 PIN Kallilcrein 7 SCFsR
6 0.892 0.861 1.753 0.906
KPCI FISP90a rAgc. C9 Con tact in-5 . .
Kallikrcin7 CyclophilinA SCFsR IGFE3P-2 CD30Ligand
7 0.892 0.864 1.756 0,923
PIN PARC Midkine sL-Scleclin RAC) ,
PIN RAC:1 1GFBP-2 PARC SCFsR
8 0.883 0.881 I 763 0.925
Kallikrcin7 KW- I 7 BTK Rcnin CD3OLigand
PARC GAPDH,livcr SCBR HSP90a PIN
9 0.883 0.869 I 752 0.913
CN DPI LRIG3 Kallikrcin7 IL-15Ra FYN
'PTN RAC I 1GFBP-2 PARC SCFsR
0 887 0.869 1 757 0.92
Kalliktein7 CD3OLigaral BTK Rcn in LDH-H1
, ., .
IGFBP-2 SCFsR CiAPD1Lliver PTN CD30Ligand
I 1 0.854 0.892 1 747 0.914
BIN sL-Seleclin Ka II ikrein7 PARC MEN)
1GFBP-2 SCFsR RAC1 Cis Kallikrcin7
12 0.369 0.878 I 746 0.923
PARC GAPD1-1.1iver PIN M1P-5 LRIG3 ,
Cis SCFsR G AP DFLIivcr C9 PTN
13 0.392 0.852 1 744
0.91
Prothrombin CD30Li nand Ka Ililcrcin7 TCTP LRIG3
,,. ,
IGFI3P-2 SCFsR KPCI PIN C Is
14 0.906 0.847 1.753 0.905
Kallikrein7 Prodrombin CD30Licand !tenni UBE2N
CD30Ligand Kallikrein7 KPCI SCFsR LRIG3
13 0.901 0.849 1.751
0.906
(79 IGFBP-2 BIN PTN ilhiquitin1-1
BIN AMFM2 C9 SCFsR Kallikrein7
16 0.883 0.864 1.746 0.914
PTN )GFE3P-2 CD30Licand ERBB I CDK5-p35
--.
CyclophilinA IISP90a ERBB1 SCFsR PARC
17 0.84 0.892 1.732 0.917
ICIFI3P-2 Kallikrcin7 CDK5-p35 CK-MB BLC
PIN RAC I 11.3FBP-2 PARC SCFsR
Is 0 864 0.886 1.75
0.925
Kallikrcin7 CD30Ligand 131K Rcnin BMP-1
SCFsR ERBB I CSK PIN IGFBP-2
19 0 887 0.858 1 745 09)6
Kallikrcin7 CNDP1 C9 GAPDH,livcr Ubiquitin+ I
CD30Ligand IGFBP-2 PIN RAC1 SCFsR
0 859 0.836 1.746 0.923
BTK F.RBI31 K a II ilacin7 Cnntactin-5 PARC
.......-
Kallikrein7 SCFsR 1-1.3P90a PTN LRIG3
21 0.864 0.886 1.75
0.917
CNDP I 1GFBP-2 Endosla lin BTK CK-MB ,
PIN RAC1 IGFBP-2 PARC SCFsR
22 0.883 0.869 1 752 0.926
Kal1ikrcin7 FGF-17 CD30Li9and GAPDH,liver sL-Scicclin ..
PARC Kallikrcin7 HSP90a PTN 1GFBP-2
23 0.883 0.869 1 752 09)9
LRIG3 SCFsR C9 U13E2N FYN
CD30Ligand Kallikrcin7 KPCI PTN IGFDP-2
24 0.897 0.847 1 743
0.9
SCFsR C9 CSK Pro Ihronnb in 11.-15Ra
LD1-1-I-11 Ka0ikrein7 ERB 81 HSP90n SCFsR
0.897 0.855 1.752 0.91
LRIG3 BIN PIN GAPDFLIiver CNDP I
CD3OLigand CyclophilinA PIN ERBB I GAPDH,Iiver
26 0.883 0.864 1 746 0.912
SCFsR Kalli1u'cin7 MEKI CDK5-p35 IGFBP-2 _______________________ .
CD30Ligand Kallikrcin7 KPCI PIN I3FE1P-2
27 0.897 0.849 I 746 0.906
= SCFsR _ CDK5-p35 M IP-5 RAC1 LRIG3
IG013P-2 SCFsR GAPDILliver PIN CD30Ligand
28 0.373 0.878 1.751
0.924
RIK sl.-Selectin 'Kallilacin7 PARC Midk inc
CD301,igand Kallikrcin7 KPCI PTN ICFBP-2
29 0.892 0.852 1.744
11.906
SCFsR. C9 LRIG3 sL-SelecI in TCTP
199
CA 3011730 2018-07-18
Table 22 (cont.)
PIN SCFsR AMPM2 IGFBP-3 Kull ikrein7
30 0.873 0.872 1 745 0 919
C D3OLigand Renin BTK CK-MB PARC
PIN SCFsR FtAC I 1-ISP90a IGFBP-2
31 0.864 0,866 1.73 0 918
CI s CDK5-p35 E108131 Kallikrcin7 BLC ,
PARC Kallikrcin7 FISP90a PTN 1(31,13P-2
32 0 859 0989 I 749 092
LRIG3 sL-Scicctin Pratt' rombin SCFsR BMP-1
161,13P-2 KPCI CD30Ligand PTN Contaclin-5
33 0 887 0.858 1 745 0 905
SCFsR Kallikrcin7 FITK C9 Ulliquitin4 I .
CD301.1 gar d SCFsR KPCI C9 BTK
34 0.901 0.847 1 748 (1904
PIN Kallikrcin7 Prothrornbin Endosta tin 1GFBP-2
PARC GAPD1-1,1ivcr HSP90a PTN IGT8P-2
35 0.869 0.881 1.749 0 919
LR1613 sL-Selectin Prothromnin 111F-17 SCFsR
.-.--_
Kallikrcin7 SCFsR HSP90a PTN KPCI
0 0 16 897 0.855 1 752 .906
IGH3P-2 FYN CD30Ligand Rcnin PARC
CD30 Ligancl Kallikrcin7 KPCI PTN IGFBP-2
37 0 887 0.855 1 742 0 906
112103 SC:FsR II.-15R a BTK C9
PIN RAC I I0FF3P-2 PARC SCFsR
38 0 873 0.873 1 751 1392 1
CD30Ligand GAPDH.liver sL-Scicctin CI s LOU-HI
,
CD30Ligand 1GFI3P-2 PIN RAC I LRIG3
39 0.873 0.869 1.743 0 909 /
SCFsR LOU-HI Renin Kallikrein7 MEK I -
CD30Ligand KPCI PIN LRIG3 Kallikrcin7
40 0.901 0,844 1 745 0 903
NIP-5 SCFsR 161,13P-2 GAPDH,liver R.31,-17
PIN RAC I IGFBP-2 PARC SCFsR
41 0.878 0.872 1.75 0 922
Kallikrcin7 Midkinc CD30Linand I3TK Rcnin õ
CD30Ligand KaIlikrein7 KPCI PTN IGFBP-2
42 0.887 0 855 1742 0 908
SCFsR C9 LRIG3 TCTP Rcnin
Kallikrein7 1.10103 H9P900 PIN K3F8P-2
43 11.859 0.889 1.748 0,926
CK-MB SCFsR UBE2N PARC Renin
PIN SCFsR AMPM2 IGFBP-2 Kallikn6n7
44 0.883 0.861 1.743 0.915
C'D30Li nand Renin BTK Midkine CK-MB
CD30Ligand SCFsR ERBB1 CyclophilinA PTN
45 0.8(4 0,061 1 725 0 916
IGFE1P-2 RISC! Ka1likrein7 BLC sL-Scicctin
PTN RAC I IGFBP-2 PARC SCFsR
46 0.873 0.372 1 745 092
HSP90a Kallikrcin7 LRI03 FGF-17 BMP-1
C.I s SCFsR GAPDH,liver C9 PTN
47 0.901 0.844 1 745 0.909
Prothronth in CD30Ligand Uhiquitin 4- I Kallilo c in? CSK
- FOP- I 7 SCFsR ERBB I 81K IGF13P-2
48 0.864 0.881 1745 0.921
Kall1krc1n7 PARC RACI PIN Con tac lin-5
PTN RAC I 1013P-2 PARC SCFsR
49 0.869 0.878 1 746 0.923
Kallikrc in 7 CD30Ligand BTK Endostatin sL-Sclectin
PTN RAC I IGFBP-2 PARC sL-Sclectin
50 0.873 0.875 1 748 0.922
CD30Ligand Kallikrcin7 Midkine FYN SCFsR ..
CD30Ligand Kallikrcin7 KPCI PIN IGFBP-2
51 0.887 0.855 1.742 a9
1.10103 SCFsR FGF-17 Cyclophilin A IL-
15Ra .
LOU-HI Kan ikrcin7 ERBB I HSP90a SCFsR
52 0.892 0.849 1.741 0.901
LRIG3 BTK PIN GAPDH,livcr MEK1 ,
CD3OLigand Kallikrein7 KPCI PIN IGFBP-2
53 0.892 0.852 1.744 0.904
____________ SCI's R CO CSK M1P-5 CDK5-p35 ..
Kallikrcin7 BMP-I HSP90a PIN LRIC3
54 0.869 0.872 1.741 09(2
PARC ERBB I LDH-H1 SCFsR TCTP .
PIN SCFsR UBE2N IGHIP-2 LRIG3
35 0 873 0.875 1.748 0 912
I .DH-H1 CD30Ligand Kallikre1n7 GAPDFLIivcr FGF-17
SCFsR ERBRI CSK PTN IGFIIP-2
56 0,887 0.852 1.74 0.912
Kaltilcrcin7 CD30Ligand C9 AMPM2 CDK5-035
CD3OLigand IGFBP-2 PIN RAC1 SCFsR
57 0.864 0.861 1.725 0 918
Kallikrein7 GAPDH,liver ERBB I 131K BLC -
CD3OLigand Kallilcrcin7 KPCI PIN 16113P-2
58 0.892 0.852 1.744 0.906
SGI'sR CDK5-p35 CI s RISC! Contactin-5
IGFBP-2 KPCI CD30Ligand SCFsR LRIG3
59 0 883 0.864 1 746 0 909
PIN BTK Kallikrein7 Endoslalin C9
PIN SCFsR GAPDFLIiµcr HSP90a C9
60 0 878 0.369 1 747 (1921
II(103 IGFFIP-2 FYN Kallilocin7 PARC
,
-CD301,igand Kall ik rein? KPCI PTN 1(1143P-2
6: 0.887 0.855 1 742 0904
SCFsR C9 CSK LRIG3 IL-15Ra
200
CA 3011730 2018-07-18
Table 22 (cont.)
62 KPCI HSP90a PTN Kallikrcin7 IGFE1P-2
0.878 0.861 1 739 0.897
PruIhtombin Cis SCFsR Rcnin MEK1
CD3OLigand Kallikrein7 KPCI PTN IGH3P-2
63 0.901 0 841 I 742 0 906
SCFsR C9 RACI BTK M1P-5
CI s SCFsR GAPDFL liver C9 PTN
64 0.397 0.844 I 74 11 9
i I
PI oihrornbin CD30Ligand Kallikrcin7 TCTP Contactin-5
CI s SCFsR GAPDI LI ivcr C9 PTN
65 0 901 0 847 1 748 0 913
Prothmmhin C0301.19and Kallikrcin7 1113E2N FGF-I 7
IGFBP-2 SCFsR KPCI PTN Cm s
66 0.892 0.858 1 75
0.903
Kan' la cin7 LRIG3 Prothrombin CD30Ligand Ubiquitin+ 1
IGFHP-2. SCFsR KPCI PTN Cm
67 0.873 0 861 1 739 (I 896
Ka Ilikrein7 LRIG3 Pro thrombin CD30Ligand AMPM2
Kallikrcin7 GAP DH,livcr ER B B I CD30Ligand PTN
69 0.809 0.855 I 724 0 913
FGF-17 CyclophilinA SCFsR LDH-H1 BLC
Kallikrcin 7 BM-1 IISP90a PTN LRIG3
69 0 864 0.881 1 745 0 915
PARC ERBB I LDH-HI SCFsR UBE2N
CD301.igand 1GFRP-2 PTN RACI SCFsR
70 0 873 0.875 1 748 0.916
FGF-17 GAPDH,liver LRIG3 CNDP I Kalli1uein7
(K-MB ERBB1 HSP90a PARC BTK.
71 0.873 0.872 1.745 0.915
Kallikrein7 Endostat in Prothrornbin LRIG3 SCFsR
72 CD30Ligand CyclophilinA PTN ERBB I GAPDELlivcr
0.883 0.864 1.746 0 915
IUFBP-2 Kallikrcin7 SCFsR FYN sL-Sclectin
I CD3OLigand 1GFBP-2 PTN
Kallikrein7 GAPDILliver ERBB I
Kallikrcin7 SCFsR HSP90a
IGFBP-2 Prothrombin KPCI
Kal I ilcrcin7 SCFsR HSP90a
IGFBP-2 Prothrombin KPCI
PTN KPCI
SCFsR
LRIG3 ERBB1 HSP90a
TCTP RACI
BTK
PTN SCFsR
IL-I5Ra
LRIG3
CD3OLigand MEK1
?TN
MIP-5 LRIC,3
(K-MB
CD3OLigand 1LGRFBIGP3-2 MPRi'dilcihmnenbin PHASPR9CCa
PTN C9
CD30Ligand Kallikrein7 KPCI
SCFsR Ubiqui1in+1 BTK.
PCI SCFsR Kallikrcin7LDII-III CD3OLigand
PTN
C9 IGFBP-2
sL-Selectin PIN CD3OLigand Kallikrcin7 K 0.873
0.883
0.892
0.883
R873
0 901
0.892 0 866 1 74 0.918
0.855 I 738 0 894
0.349 1 741 0.908 I
_____i
0.866 1 749 0.9041
0.866 1 74 0.909
0.847 1 748 0 905
0.847 1 739 0.902
SCFsR BTK C9 IGFBP-2 AMPM2
11CD3OLigand SCFsR ERBB I CyclophilinA PTN
0.859 0.861 1.72 0.916
ICWBP-2 RACI Ka1likrein7 BLC Midlcine
CyclophilinA HSP90a ERBB1 SCFsR. PARC
81 0.854 RAM 1.744 0 918
IGFBP-2 Kallikrcin7 BMP-1 PTN CIs
CD30Ligand Kallikrcin7 ERBB1 BTK PTN
82 0.887 0.861 1.748 0 918
RACI SCFsR GAPDIL1 iver FGF-17 CNDPI
IGFBP-2 CyclophilinA ERBI31 Kallikrein7 Ubiquitin I 1
83 0.854 0.889 1 744 0.915
SCFsR PA RC CK-MB C1330Li9and Con tactin-5
T.
CK-MB Kallikrein7 HSP90a PARC CDK5-p35
84 0.873 0.872 1 745 0.918
ERBB I BTK Endosta tin SCFsR Prolltrombin
IGFBP-2 SCFsR KPCI PTN CI s
85 0.911 0.835 1.740 0 905
Kai li kr., in7 Prothrombin CD30Ligund Ren in FYN
PARC GAPDH,liver SCFsR HSP90a PTN
86 0.887 0.852 1 74 0
915
CNDP 1 LRIG3 Kollikrcin7 IL-15Ra C.;µ cloplubnA
CD30Ligand Kallikrcin7 KPCI PIN IGFBP-2
87 0 878 0.858 1 736 0.898
SCFsR MEK1 LR1Ci3 Midkinc C9
CD301.igand IGFRP-2 PTN RACI SCFsR
88 0 906 0.835 1 741
0.904
Kallikrein7 KPCI Renin MIP-5 Pi thrombin
201
CA 3011730 2018-07-18
Table 22 (cont.)
. _______________________________________________________________ _
'CD30Li0and KPCI PTN SCFsR C9
89 0.887 0.852 1.74 0.9
TCTP Kallikrein7 IGF BP-2 FGF-17 HSP90a
PTN SCFsR UDE2N IGFBP-2 LRIG3
90 0.892 0 .8.55 I 747
0.911
LDH-141 CD30Li Rand GAP DH,livcr Cis Prothrombin , .µ
PTN SCFsR AMPM2 IGF13P-2 Kallilarin7
91 0.873 0 864 1 737 0 913
CD30 Liaand LRIG3 CO BTK PARC
PTN RAC I IGFDP-2 PARC SCFsR
92 0.85 0 869 1 719 0 921
Ka 11 ilacin 7 CD3OLigand CyclophilinA Resin FILC
[RIGS CNDP I HSP90a CK-M F1 PTN
93 0.869 0 873 1 744 0.915
Kallikrcin7 ['AC) Endosta tin 131v1P- 1 Pl 0111/011111111
. ,
CD30Ligand KallOcrein7 KPC1 PTN 1CiFI3P-2
94 0.892 0.852 I 744 0.907
SCFsR C9 CSK sL-Sclectin LRIG3
PTN RAC! IGFBP-2 PARC SCFsR
95 0.869 0 875 1 744 (1922
Kallikrcin7 CD30Ligand BTK Rcnin Contaciin-5
IGFBP-2 CyclophilinA ERBB I Kallikrcin7 Ubiquinn 1 1
96 0 859 0 886 1 746 09)8
SCFsR PARC CK-MB FYN CD301,igand .
CD3013gand IGF0IP-2 PIN CyclophilinA SCFsR
97 0 887 0.852 1.74
0.905
KPCI LRIG3 Kallikrcin7 C9 IL-15Ra
98 CD3OLigand IGFBP-2 PTN CyclophilinA SCFsR
0 878 0.858 1 736 0.393
KPCI LRIG3 Kull i krein7 CO MEK I
BTK RAC I ERBB I Kallikrcin7 1013P-2
99 0.873 0.866 1.74 0.9231
PTN SCFsR PARC M1P-5 CDK5-p35 -. ,
LRIG3 ERI3131 IISP90a SCFsR Kallikrein7
100 0 897 0.852 1 74 0.91
TCTP PTN CO L.1)11-111 FGF- 1 7
Marker Count Marker _ Count
SCFsR 98 FGF-17 14
Kali ikrein7 95 CK-MB 14
['TN 94 LDH-I-11 12
IGFBP-2 81 CDK5-p35 12
CD30Li0and 69 CNDP I 9
LRIG3 45 Ubiouhin 1- I 8
PARC 41 TCTP 8
BTK 35 Midlcinc 8
KPCI 34 M1P-5 8
CO 32 M EK 1 fi
RAC I ' ' 31 IL-15Ra , 8
HSP90a 31 FYN ____ 8
_
BRBB 1 29 Endosta lin 8
GAPDH.liver , 27 Contaciin-5 3
Prothrombin 22 CSK 8 ,
Resin 17 BM1'-1 8
CI s 17 BLC s
st.-Scicctin 15 AMPM2 8
,
CyclophilinA 15 LJBE2N 7
202
CA 3011730 2018-07-18
0
CO
0
I-.
I-.
-4
l...3 100 Panels of 11 Asymptornat ic
Smokers vs. Cancer Biomarkers
o
Sens. +
n.)
o
Biomarkers Specificity Sensitivity Spec. AUC
i-. PTN SCFsR AMTM2 IGFBP-2 Kallikrein7 CD30Ligand
co I
0.892 0.858 1.75 0.912
oi LRIG3 C9 BTK sL-Selectin
GAP DH,liver .. ,
CSK KPCI ERBB I CK-MB BLC SCFsR
i
0.892 0.847 1.739 0.9
i-. PARC Rcnin CDK5-p35 HSP90a BTK
.
co PARC Kallikrein7 HSP90a PTN IGFBP-2 LRIG3
3
0.878 0.875 1.753 0.921
sL-Selectin Prothrombin SCFsR BMP-1 BTK
F
'LRIG3 NDPI HSP90a CK-MB PTN
GAPDH,liver
4
0.892 0.872 1.764 0.916
Ka I I ilcrein 7 Endostatin Cis sL-Selectin
13TK
1GFBP-2 SCFsR GAPDH,liver PTN C Is RAC I
0.892 0.861 1.753 0.918
PARC C9 Kal li krei n7 UFIE2N
Contactin-5
Kallikrcin7 CyclophilinA SCFsR IGFBP-2 CD30Ligand PTN
6
0.887 0.872 1.759 0.921 -I
Renin HSP90a PARC CK-MB LDH-H1
Ca
LRIG3 NDPI HSP90a CK-MB PTN
GAPDH,liver cr
0.892
0.869 1.761 0.912 -
c> Kallikrein7 Endostatin FGF-17 BTK sL-
Selectin CD
t.,..)
BTK RAC I ERBB1 Kallikrein7 IGFBP-2
PIN
8
0.878 0.886 1.764 0.922 I\.)
SCFsR sL-Selectin CD30Ligand PARC
FYN CO
CD30Ligand Kall ikrcin 7 KPCI PTN IGFBP-2 SCFsR
9
0.897 0.855 1.752 0.907
C9 CSK LRIG3 IL-15Ra sL-
Selectin
CD30Ligand IGFBP-2 PTN FtAC I LRIG3 SCFsR
0.887 0.869 1.757 0.909
LDH-H1 Renin Kallikrein7 BTK MEK I
_
CD30Ligand SCFsR RAC1 C9 PIN Cls
11
0.901 0.849 1.751 0.916
GAPDH,Liver Kallikrein7 Prothrombin MIP-5 CDK5-
p35 .,
BTK RAC I F.RBB I Kal 1 ikrcin7 ICiFFIP-
2 PTN
12
0.869 0.889 1.758 0.924
SCFsR PARC Midkine sL-Selectin
CD30Ligand
13 Kallikrein7 BMP-1 HSP90a PTN LRIG3 PARC
0.878
0.872 1.75 0.912
ERBB I WE-HI SCFsR TCTP Endostatin
14 BTK 1GFBP-2 PTN Kallikrein7 SCFsR KPCI
0.901
0.852 1.754 0.91
CD30Ligand Renin C9 CDK5-p35 Ubiquitin+1
C)
w
o
1-.
1-.
--.1
LA) LRIG3 IGFB P-2 HSP90a PARC PTN BTK
o
15 0.887 0.861 1.748 0.915
SCFsR Ka11 ilcrein 7 CNDP I AMPM2
Renin
I'.)
o CSK KPCI ERBB1 CK-MB B LC
SCFsR
1-` 16
0.897 0.841 1.738 0.896
co PARC Renin CDK5-p35 HSP90a TCTP
1 17 FGF-17 Ka Ililcrein7 ERBB IL RACI C9
LDH-H1
o
0.873 0.878 1.751 0.915
--.1 SCFsR BTK IGFBP-2 PARC Contactin-
5
i
RAC1 IGFBP-2 PARC SCFsR
Kallilcrein7
co 18
0.878 0.881 1.759 0.926
CD30Ligand CyclophilinA Renin Cis FGF-17
IGFBP-2 SCFsR KPCI PTN Cis Kallikrein7
19
0.887 0.872 1.759 0.907
Prothrombin CD30Ligand C9 PARC FYN
PTN RAC I IGFBP-2 PARC SCFsR
Ka1likrein7
20
0.873 0.875 1.748 0.925
CD3OLigancl CyclophilinA sL-Scl cctin TL-15Ra CK-M11
-I
21 CD30Ligand SCFsR RAC I C9 PTN Cls
0.897
a.)
0.852
1.749 0.907 cr
GAPDH,liver Kallila-ein7 Pro thrombin MIP-5 MEK1
PIN RAC1 IGFBP-2 PARC SCFsR
Kallikrein 7 a)
22
0.873 0.884 1.757 0.923
Midkine CD30 Ligand BTK sL-Selectin
Endostatin N.)
,
IQ
o IGFBP-2 SCFsR GAPDH,liver PTN
Cis RAC I CO
4=, 13
0.892 0.869 1.761 0.923
PARC C9 Ka1likrein7 1.113E2N
CD30Ligand
0
CD3OLigand Kali i krcin7 KPCI PTN IGFBP-2 SCFsR
24
0.906 0.847 1.753 0.908 0
C9 CDK5-p35 LRIG3
lib iquitin+ I BTK D
PIN SCFsR AMP M2 IGFBP -2
Kallilcrein7 CD30Ligand
25
0.869 0.878 1.746 0.918 =:.----
LRIG3 C9 BTK En dostatin CK-MB
CSK KPCI ERBB1 CK -MB B LC SCFsR
26
0.887 0.847 1.734 0.899
PARC Renin CDK5-p35 HSP90a Cyc loph
ilinA . PTN RAC1 IGFBP-2 PARC SCFsR Ka Ilikrein7
27
0.869 0.884 1.752 0.923
sL-S electin FYN Cis Prothrombin BMP-1
CD30Ligand IGFBP-2 PTN RAC I SCFsR BTK
28
0.864 0.886 1.75 0.921
ERBB1 Kallikrein7 Contactin-5 PARC Prothrombin
CD30Ligand 1GFBP-2 PIN CyclophilinA SCFsR
KPCI 29 0.901 0.847 1.748 0.906
LRIG3 Kallilcrein 7 C9 1L-15Ra
CDK5-p35
CD30Ligand Kali ikrein7 KPCI SCFsR LRIG3 C9
30
0.887 0.861 1.748 0.9
IGFB P-2 BTK PTN MEK1 Contactin-5
. ..
C)
ta
o
1-,
1-.
...1
W CD30Ligand Kallikrcin7 KPCI PTN IGFBP-2
SCFsR
o 3
I 0.897 0.852 1.749 0.909
CDK5-p35 MIP-5 RAC I LRIG3 C9
tv
o Kallikrein7 CyclophilinA SCFsR 1G FBP-
2 CD30Ligand PTN
i-. 32
0.901 0.855 1.757 0.912
co Renin Cis KPCI CK-MB Midlcine
O IGFBP-2 SCFsR KPCI PTN Cls Kallikrein7
33
0.892 0.858 1.75 0.906
...1 Prothrombin CD30Ligand C9 PARC TCTP
,
i
i-. CD30Ligand Kallikrein7 KPCI sL-Selec lin PTN
SCFsR
co 34
0.901 0.855 1.757 0.909
BTK C9 IGFBP-2 UBE2N C Is
.
BTK GAPDH,liver ERBB1 IGFBP-2 Ka1likrein7
PTN
35
0.897 0.855 1.752 0.918
Cis SCFsR CDK5-p35 Ubiquitin+1 LDH-HI
,
PTN SCFsR AMPM2 IGFBP-2 Kallikrein7 CD30Ligand
36
0.883 0.864 1.746 0.918
LRIG3 C9 BTK sL-Scl cctin PARC
-I
,
PARC SCFsR HSP90a PTN IGFBP-2 Pro
thrombin 11)
37
0.864 0.869 1.733 0.921 0-
LRIG3 RACI BMP-1 Kallikrein7 BLC
-
PTN RAC I IGFBP-2 PARC SCFsR
Kallikrein7 CD
38
0.883 0.875 1.758 0.918
CD3OLigand BTK CNDP1 Renin FYN
IV
..
N)
0)
CD BTK RAC I ERBB1 Kallikrein7 IGIMP-2 PIN
0.878
0.878 1.756 0.921
SCFsR PARC LDH-H1 FGF-17 Midkine
0
C.030Ligand ICiFBP-2 PIN CyclophilinA SCFsR KPCI
40
0.897 0.849 1.746 0.908
LRIG3 Kallikrcin7 C9 IL-15Ra sL-Sclectin
D
,
Kallikrein7 CyclophilinA SCFsR IGFI3P-2 CD30Ligand PTN
4'
0.878 0.869 1.747 0.906 `----'
Renin Cis LDH-H1 sL-S electin
MEK I
IGFBP -2 KPCI CD30Ligand PTN Contactin-5
SCFsR
42
0.901 0.847 1.748 0.904
Kallikrein7 RAC I MW-5 Cis Prothrombin
CD3 OLiga nd Kallikrein7 KPCI PTN IGFBP-2 SCFsR
43
0.887 0.861 1.748 0.906
C9 CDK5-p35 LRIG3 TCTP End
osta tin
Cis SCFsR GAPDH,liver C9 PTN Prothrombin
44
0.883 0.872 1.755 0.92
CD30Ligand Kallikrein7 UBE2N sL-Selectin
Endostatin
IGFBP-2 SCFsR KPCI PTN C Is Kallikrein7
45
0.897 0.852 1,749 0.91
LRIG3 Prothrombin CD30Ligand CK-MB
Ubiquitin+ I .
PTN SCFsR A MPM2 IGFBP-2 Kallikrein7
CD30Ligand
46
0.897 0.849 1.746 0.905
LRIG3 C9 BTK sL-Sclectin KPCI
C)
ta
o
1-.
I-.
-4
w LRIG3 IGFBP-2 HSP90a PARC PTN .. BTK
o 47
0.854 .. 0.878 1.732 0.916
SCFsR Kallikrein7 ERBB I LDH-H1
BLC
I\)
o PTN RAC I IGFBP-2 PARC SCFsR
HSP90a
i-. 48
0.869 0.884 1.752 0.921
co llil Kacrein 7 LRIG3 BMP- I Renin
FYN
,
.
oi CD3 OLigand SCFsR RAC I C9 PTN Cis
49
0.901 0.852 1.754 0.919
-.1 GAPDH,liver Kallikrein7 cNnp 1 BTK
sL-Selectin
i
i-. IGF BP-2 SCFsR KPCI PTN C I s
Kallikrein7
co 50
0.897 0.864 1.76 0.907
Prothrombin CD30Ligand C9 CSK PARC
=
PIN RAC 1 IGFBP-2 PARC SCFsR
Kallikrein7
I
0.869 0.886 1.755 0.924
FGF-17 CD30Ligand GAPDH,liver sL-Selectin
.. Endostatin
PTN SCFsR RAC I HSP90a IGFBP-2 C Is
52
0.864 0.881 1.745 0.923 --I
CDK5-p35 ERBB I Kallikrein7 PARC IL-
15Ra
LI)
CD30Ligand Ka 1 likrein7 KPCI SCFsR LRIG3 C9
53
0.887 0.855 1.742 0.898 Cr
TGFBP-2 BTK PTN MEK1 LIBE2N
a)
,
CD3 OL iga nd SCFsR EtAC I C9 PTN Cls
54
0.901 0.847 1.748 0.914 N.)
GAP DH,liver Ka1likrein7 Prothrombin M IP-5 .. FGF-17
0..)
rs.) PTN. RAC I IGFBP-2 PARC sL-Selectin
CD3OLigand
55
0.873 0.881 1.754 0.919 ...----..
o, Kallikrein7 Prothrombin SCFsR Midlcine
Endostatin 0
CD30Liga nd Ka 1 111u-ein7 KPCI PIN IGFBP -2 SCFsR
0
56
0.883 0.861 1.743 0.91 D
CO CDK5-p35 LRIG3 TCTP
Rcn in , ,-1-
CD3OLigand Kallikrein7 KPCI SCFsR LRIG3 CO
........-
57
0.897 0.852 1.749 0.909
IGFBP-2 BTK PTN Ubiquitin+ I CNDPI
BTK AMPM2 C9 SCFsR Kallikrein7 PTN
51i
0.873 0.872 1.745 0.918
IGFBP-2 CD30Ligand ERBB I CDK5-p35
PARC
PTN SCFsR AMPM2 IGF13P-2 Kallikrein7 CD30Ligand
59
0.883 0.849 1.732 0.912
LRIG3 C9 BTK sL-Selectin BLC .
PTN RAC! IGFF3P-2 PARC SCFsR HSP90a
60
0.883 0.869 1.752 0.919
Proihrombin FGF-17 Kallikrein7 LRIG3
BMP-I .. ,
CD30Ligand Kallikrein7 KPCI PTN IGFBP-2 SCFsR
61
0.915 0.841 1.756 0.906
C9 CDK5-p35 CSK Prothrombin Renin
,
CD30Ligand SCFsR ERBB1 CyclophilinA PTN 1GFBP-2
6.7
0.883 0.866 1.749 0.92
RAC1 Kallila-ein7 Contactin-5 PARC ..
Prothrombin
a
)"
W
0
I-.
I-.
--.1
W PT1µ.1 GAPDH,livcr IGFBP-2 LRIG3 SCFsR
HSP90a
o 63
0.878 0.881 1.759 0.922
Kallikrein7 CD30Ligand PARC FYN C9
tv
o CyclophilinA HSP90a ERBB I
SCFsR PARC 1GFBP-2
i-. 64
0.864 0.881 1.745 0.917
co Kallikrein7 CDK5-p35 sL-Selectin CK-M13 IL-
15Ra ,
O CD30Ligand Kallikrein7 KPCI SCFsR LRIG3 C9
65
0.887 0.855 1.742 0.9
--.1 IGFBP-2 BTK PTN MF,K 1
Uhiquitin+1
1
i-. IGFBP-2 SCFsR RAC1 Cis Kallikrein7 PARC
co 66
0.878 0.869 1.747 0.923
GAPDH,Liver PIN MIP-5 LRIG3
Prothrombin ..
FGF-17 SCFsR ERBB I BTK IGFBP-2
K311ilcrein7
67
0.873 0.878 1.751 0.922
PARC RAC I sL-Selectin Midlcine
PTN
LRIG3 ERBB1 HSP90a SCFsR Kallikrein7 TCTP
68
0.883 0.861 1.743 0.911
PTN CO LDH -HI CD30Ligand
Prothromhin
--1
õ.
CD30Ligand sL-Sclectin GAPDH,livcr PTN IGFBP-2
Kallikrein7 Ct)
69
0.883 0.872 1.755 0.929
PARC SCFsR UBE2N Cls CDK5-p35
Cr
CSK KPCI ERBB I CK-MB BLC SCFsR
70
0.883 0.849 1.732 0.903
PARC Renin CDK.5-p35 HSP90a Prothrombin
N.)
n.)
Kallikrein7 BMP- 1 HSP90a PTN LRIG3 PARC
0.)
----1 71
0.859 0.892 1.751 0.914
ERBB I LDH-H1 SCFsR FYN C9
CD30Ligand SCFsR RAC1 C9 PTN C 1 s
CI
72
0.892 0.861 1.753 0.919 0
GAPDH,livcr ICallilacin7 CNDP1 MX. IGFBP-2
D
BTK IGFBP-2 PTN Kallikrein7 SCFsR KPCI
73
0.883 0.866 1.749 0.911 ..:,
CD30Ligand Renin CK-MB HSP90a Contactin-
5 ,
CD30Ligand Kallikrein7 KPCI PTN IGF13P-2 SCFsR
74
0.892 0.852 1.744 0.905
C9 RAC1 BTK CDK5-p35 IL-I5Ra
CD30Ligand IGFBP-2 PTN RAC I LRIG3 SCFsR
75
0.887 0.855 1.742 0.906
LDH-H1 Renin Kallikrein7 HSP90a MEK1
,.. .. -
EG113P-2 SCFsR GAPDH,liver PTN Cis RAC I
76
0.892 0.855 1.747 0.913
CD30Ligand Kallikrein7 LDH-H I Prothromb in MIP-
5
1GF BP-2 SCFsR GAPDH,liver PIN CD30Ligand BTK
77
0.873 0.878 1.751 0.921
PARC Kallikrein7 FYN sL-Selectin
Midlcine
CD3 OLigand Kallikrein7 KPCT PTN IGFBP-2 SCFsR
78
0.892 0.849 1.741 0.907
C9 DK5-p35 LRIG3 TCTP sL-Sclectin
PTN SCFsR UBE2N IGFBP-2 LRIG3 LDH-H1
79
0.878 0.875 1.753 0.919
CD30Ligand Kallikrein7 C9 Prothrombin PARC
C)
LA)
0
I-.
I-.
...1
Lo IGFBP-2 KPCI CD30Ligand SCFsR PTN BTK
o 80
0.901 0.847 1.748 0.902
Prothrombin C9 Kallikrein7 Ubiquitin+1
LRIG3
N.)
,
o BTK AMPM2 C9 SCFsR
Kallikrein7 PIN
1-. 81
0.887 0.858 1.745 0.912
co 1G FBP-2 CD30Ligand ERBB1 CDK5-p35
CyclophilinA
oi LRIG3 ERBB1 HSP90a SCFsR Kallikrein7 CyclophilinA
82
0.859 0.872 1.731 0.923
---.1 PARC PTN CK-MB GA PDH,liver BLC
.
1
-
1-. Kallikrein7 BMP-1 HSP90a PTN LRIG3 PARC
co 83
0.873 0.878 1.751 0.917
ERBB1 LDH-111 SCFsR UBE2N CDK5-
p35
CD30Ligand SCFsR ERBBI CyclophilinA Kallikrein7
GAPDH,liver
84
0.883 0.869 1.752 0.918
CDK5-p35 PTN C1s UBE2N CN DP I
LRIG3 ERBBI HSP90a SCFsR Kallikrein7 CSK
85
0.873 0.875 1.748 0.916 co
C9 PARC sL-Sclectin PIN CNDP
I
0"
IGFBP-2 SCFsR GAPDH,liver PTN Cis UBE2N
-
86
0.887 0.861 1.748 0.914 CD
CD30Ligand Kallikrein7 LDH -HI Prothrombin Con
tactin-5 .
CD30Ligand IGFBP-2 PIN RAC1 SCFsR sL-Setectin
87
0.892 0.852 1.744 0.91 CO
KPCI Kallikrein7 LRIG3 1L-15Ra C9
NJ
(=> BTK GAPDH,liver ERBB1 CD30Ligand PTN
SCFsR 0
oo 88
0.878 0.864 1.742 0.913
IGFBP-2 Kallikrein7 UBE2N CDK5-p35 MEKI
0
CD30Ligand SCFsR RAC 1 C9 PIN Ch
D
89
0.883 0.864 1.746 0.919 r+
GAPDH,liver Kallikrcin7 Prothrombin MIP-5
sL-Selectin ....-.,
LRIG3 IGFBP-2 HSP90a PTN Prothrombin SCFsR
90
0.873 0.878 1.751 0.919
CK-MB LDH-H1 PARC Renin Midlcine
ICIFBP-2 SCFsR KPCI PTN Cis CD3OLigand
91
0.883 0.858 1.741 0.91
Kallikrein7 TCTP C9 sL-Selectin PARC
92 CD30Ligand Kallikrein7 KPCI PTN IGFBP-2 SCFsR
0.892
0.855 1.747 0.907
Ubiquitin+1 BTK C9 FGF-17 LRIG3
PTN SCFsR AMPM2 IGEBP-2 Kallikrein7 CD30Ligand
93
0.883 0.861 1.743 0.911
LRIG3 C9 BTK sL-Selectin CNDP I
CSK KPCI ERBB I CK-MB BLC SCFsR
94
0.887 0.844 1.731 0.908
PARC Renin CDK5-p35 HSP90a PTN
C)
LA)
0
I-.
I-.
...1
Lo PTN RACI IGFBP-2 PARC SCFsR
Kalldcrein7
o 95
0.864 0.886 1.75 0.923
CD3 OLigand BTK CNDP1 BMP-1 Ren in
N)
o BTK IGFBP-2 PTN Kallikrein7
SCFsR KPCI 1-. 96 0.887 0.861 1.748 0.908
co HSP90a PARC CDK5-p35 C9 Contactin-5
i PTN RAC1 IGFI3P-2 PARC SCFsR
Kallikrein7
o 97
0.883 0.875 1.758 0.919
...1 CD3 OLi gan d HSP90a LRIG3 C9 FYN
1
. ,
1-.
98 CD30Ligand Kallikrein7 KPCI PTN IGFBP-2
LRIG3
co
0.892 0,852 1.744 0.905
SCFsR IL-15Ra BTK C9 RAC1
LDH-H I Kallikrein7 ERBB1 HSP90a SCFsR
LRIG3
99
0.892 0.849 1.741 0.904
BTK PTN CiAPDH,1 Ivor MEK1 CDK5-
p35
.. -.
¨
CD30Ligand Kallikrein7 KPCI PTN IGFE3P-2
SCFsR
100
0.897 0.849 1.746 0.908 ¨I
MIP-5 GA PDH,liver C9 FYN sL-
Seleetin
CI)
Cr
_
Marker Count Marker Count
CD
SCFsR 98 LDH-1-11 17 ,
PTN 94 CK-MB 16
Kallikrein7 94 CyclophilinA 13
so
IGFBP-2 79 UBE2N 11
0
CD30Ligand 70 CNDP I 11
0
=
PARC 50 FYN 10 ,
C9 50 MIP-5 9
.......-
LRIG3 45 MEK1 9
BTK 43 1L-15Ra 9
RAC1 37 FGF-17 9
KPCI 36 Endostatin 9
sL-S electin 31 Contactin-5 9
HSP90a 29 CSK 9
C Is 78 , BMP-1 9
ERBB1 27 BLC 9
Prothrombin 26 AMP M2 9
COK5-p35 26 Ubiquitin+1 R
GAPDH,livcr 25 , TCTP 8
4.
Renin 20 Midkine 8
C)
1...)
o
i-.
F.
-...1
W 00 1 Panels of 12 Asyut ptotna tic
Smokers vs. Cancer Biomarkers
o .
Sens. +
N.)
o
Biomarkers , Specificity Sensitivity Spec. AUC
1--` PTN SCFsR AMPM2 IGFBP-2 Kallikrcin7 CD30Ligand
co '
0.883 0.878 176 0.922
I ' LRIG3 CO BTK PARC CK-MB C I s
0
-...1 KaElikrei n7 BMP- I HSP90a PTN LRIG3
PARC
i 2
0.859 0.884 1.743 0.916
ERBB I LDH-H1 SCFsR UBE2N CDK5-p35 BLC
i-.
co CD30Ligand IGFBP-2 PTN RAC I LRIG3
SCFsR
3
0.897 0.866 1.763 0.915
LDH-Hl Renin Kallikrein7 BTK CNDP I
Prothrombin
-
CD30Ligand IGFHP-2 PTN RAC1 SCFsR Kallikrein7
4
0.887 0.869 1.757 0.925
LDH-H1 LRIG3 CK-MB PARC Rcn in CSK ,
IGFBP-2 SCFsR GAPDH,liver PTN Cis RAC1
50.906
0.855 1.761 0.913
CD30Ligand Kallikrein7 LDH-H I Prothrombin MIP-5
Contactin-5
Kallikrein7 SCFsR HSP90a PTN ERBB I
CyclophilinA
6
0.873 0.889 1.762 0.924
IGFBP-2 CK-MB PARC LDH-H1 LRIG3 C Is
H
Cis SCFsR GAPDH,liver C9 PTN Prothrombin
S1)
0.897 0.869 1.766 0.919 0-
_ CD30Ligand Kallikrein7 UBE2N sL-S clectin
Endostatin FYN
c:5 PTN RAC I IGFBP-2 PARC SCFsR
Kallilcrein7 CD
8
0.897 0.864 1.76 0.922
FGF-17 CD3 OLigand LDH-H1 Renin BTK
GAPDFLIiver i\.)
CD30Ligand Kallikrein7 KPCI sL-S electin PTN
SCFsR
9
0.897 0.858 1.755 0.908
BTK C9 IGF13P-2 UBE2N LRIG3 1L-
15Ra
BTK IGFBP-2 PTN Kallikrein7 SCFsR KPCI
0.911 0.847 1.757 0.901
CD3 OLi gand HSP90a C9 Prothrombin Rcnin MF.K 1
PARC Kallikrein7 HSP90a PTN IGFBP-2 LRIG3
11
0.883 0.881 1.763 0_92
sL-Selectin Prothrombin SCFsR BMP-1 BTK Midicine
11 CD30Ligand Kallikrein7 KPCI FEN IGFBP-2 SCFsR
0.897 0.855 1.752 0.91
C9 CDK5-p35 LRIG3 TCTP Renin Ubiquitin+1
PTN SCFsR AMPM2 IGFBP-2 Ka Ililcrein7
CD3OLigand
13
0.883 0.872 1.755 0.921
LRIG3 C9 BTK PARC CK-MB N4idkine
SCFsR C9 UBE2N CD3OLigand PTN KPCT
14
0.901 0.841 1.742 0.905
Kallikrein7 IGFB P-2 Pro thrombin BTK LRIG3
BLC
IGFBP-2 SCFsR KPCI PTN Cis CD30Ligand
0.897 0.864 1.76 0.909
Kallikrein7 RAC1 CNUP I LR1G3 Endostatin
Prothrombin
a
(A)
0
1-,
1-,
-..,
w PTN C9 CSK CD30Ligand SCFsR
GAPDH,liver
o
16 0.8R7 O.R69 1.757 0.916
Kallilcrei n7 LRIG3 IGFBP-2 Renin FGF-17
Prothrombin .
N
0 CD30Ligand SCFsR KPCI C9 BTK PTN
i-, 17
0.906 0.855 1.761 0.91
co Kallikrcin7 Cis IGFBP-2 sL-Selectin RAC1
Contactin-5
I BTK IG113P-2 PTN Kali ikrein7 SCFsR
KPCI
o
18 0.901 0.861 1.762 0.909
--.1 CD30Ligand Renin C9 CDK5-p35 Cycl ophi 1 inA
LR1C;3
I
i-, CD30Ligand IGFBP-2 PTN RACI LRIG3
SCFsR
co 19
0.883 0.878 1.76 0.916
LDH-H t Renin Kali ilacin7 Cis FYN
Prothrombin
CD30Ligand Kallikrein7 KPCI PTN IGFI3P-2 SCFsR
20
0.897 0.858 1.755 0.91
CO CDK5-p35 LRIG3 BTK 1L-15Ra sL-S
el eetin
CD30Ligand IGFBP-2 PTN RAC1 LRIG3 SCFsR
21
0.873 0.881 1.754 0.91
LDH-141 Rcnin Kallikrein7 Cls Prothrombin
MEK 1
CD3OLigand SCFsR RAC I C9 PTN C is
22
0.897 0.858 1.755 0.917 H
GAPDH,liver Kallikrein7 Pro thrombin MIP-5 sL-Selectin
FYN ea
CD30Ligand Kallikrein7 KPCI PIN IGFBP-2 SCFsR
cr
23
0.892 0.858 1.75 0.907 -
C9 CDK5-p35 LRIG3 TCTP Renin BTK
CD
ts.)
- IGFBP-2 SCFsR GAPDH,liver PTN
Cis RAC1
-
24 0.897 0.869 1.766 0.927 1'..)
PARC C9 Kallikrein7 LRIG3 sL-Selectin
Ubiquitin+1
,
PTN SCFsR AMPM2 IGFBP-2 Kalii krcin 7
CD3OLigand
?5
0.883 0.872 1.755 0.918 "."6'
LRIG3 C9 BTK sL-Sclectin PARC C 1 s
0
IGFBP-2 KPCI CD30Ligand SCFsR PTN BTK
26
0.897 0.841 1.73R 0.907 D
Prothrombin C9 Kallikrein7 Ubiquitin+1 LRIG3 BLC
KPCI HSP90a PTN Kallikrein7 IGFI3P-2
Prothrombin .._...--
27
0.915 0.858 1.773 0.908
Cis SCFsR BMP-1 Renin RAC1
CD30Ligand
PTN RACE IGFBP-2 PARC SCFsR HSP90a
28
0.901 0.858 1.759 0.919
Prothrombin FGF-17 Cis GAPDH,liver Kallikrein7
CNDP1 f
PTN C9 CSK CD30Ligand SCFsR
GAPDH,liver 1
29
0.901 0.855 1.757 0.917
Kallikrein7 LRIG3 1GFBP-2 Renin sL-Selectin
Prothrombin .
PARC Kallikrein7 HSP90a PTN 1GFBP-2 LRIG3
30
0.887 0.869 1.757 0.918
SCFsR CO UBE2N R_AC I CD30Li8and
Contactin-5
Kallikrein7 Cyclophi lin A SCFsR IGFBP-2 Cis
C9 1
31 :
0.883 0.878 1.76 0.922
GAPDH,livcr PARC PTN LDH-HI LRIG3 sL-
Sclectin
, .
BTK RAC1 ER BB I Kallikrein7 IGFBP-2
PTN
32
0.869 0.889 1.758 0.926
SCFsR PARC Cis CD30Ligand sL-Selectin
Prothro mbi n
C)
w
0
I-.
1-`
-4
W Prothrombin IGFB P-2 1-ISP90a PTN
GAPDH,livcr SCFsR
o B
0.887 0.872 1 759 0.92
Kallikrein7 FGF- 1 7 PARC FYN Endostatin sL-
Selectin
t\.)
o 34 CD30Liga nd Kallikrein7
KPCI PTN IGF BP-2 SCFsR
0.901
0.852 1.754 0.908
i-. C9 CDK5-p35 CSI( LRIG3 1L-15Ra sL-Selectin
co,
I KPCI HSP90a PTN Kallikrein7 IGFI3P-2
Prothrombin
0 35
0.906 0.847 1.753 0.9
-4 Cis SCFsR Renin BTK C9 M EK 1
i
CD30Ligand Kallikrein7 KPCI PTN IGFBP-2 SCFsR
1-` 36
0.901 0.852 1.754 0.908
co C9 RAC1 BTK MIP-5 LRIG3 CDK5-p35
PTN RACE IGFBP-2 PARC sL-Selectin
CD30Ligand
37
0.878 0.881 1.759 0.919
Kallikrein7 Prothrombin S CFsR FYN Midkine
Endostatin
IGFBP-2 SCFsR KPCI PTN Cl s Kallikrein7
38
0.887 0.861 1.748 0.907
Prothromhin CD30Ligand C9 PARC TCTP LRIG3
PTN SCFsR AMPM2 IGFBP-2 Kallilercin7 CD30Ligand
-1
39
0.901 0.852 1.754 0.915
LRIG3 C9 BTK LDH-H1 Prothrombin CK-MB
CI)
PTN RAC I IGFBP-2 PARC SCFsR
Kallikrein7
40
0.869 0.866 1.735 0.924 (D
PG17-17 CD30Ligand GAPDH,liver Renin
CyclophilinA BLC .
I.)
- KPCI HSP90a PTN Kallikrein7 IGFBP-2
Prothrombin N)
NJ 41
0.901 0.858 1.759 0.909 .p..
Cis SCFsR BMP-1 Renin BTK CDK5-p35
PTN RAC I TGFRP-2 PARC SCFsR
Kallikrcin7
42
0.873 0.884 1.757 0.921 0
CD30Ligand FYN Rcnin BTK BMP- I CNDP1
0 Kallikrein7 SCFsR HSP90a PTN KPCI CD30Ligand
=
43
0.897 0.858 1.755 0.91 ,-o-
IGFBP-2 Renin CDK5-p35 BTK BMP-1 Contactin-5
........-
BTK RACE ERBB I Kallikrein7 1GFBP-2 PIN
44
0.873 0.884 1.757 0.926
SCFsR PARC Midkine sL-Selectin Cis
CDK5 -p35
CD3OLigand IGFBP-2 PTN CyclophilinA SCFsR KPCI
45
0.901 0.852 1.754 0.907
LRIG3 Kallikrein7 C9 IL-15Ra sL-Selectin BTK
.
CD30Ligand SCFsR RACE C9 PTN C Is
46
0.897 0.855 1.752 0.91
GAPDH,livcr Kallikrein7 Pro thro mbin LRIG3 sL-Selectin
MEK I
IGFBP-2 KPCI C D30 Ligand SCFsR LRIG3
PTN
47
0.901 0.852 1.754 0.911
UBE2N Kallikrein7 C9 CDK5-p35 sL-Selectin MIP-5
LRIG3 ER BB I 1-ISP90a SCFsR Kallikrein7
TCTP
48
0.883 0.864 [ .746 0.91
PIN C9 LDH-H1 CD30Ligand Prothrombin
Contactin-5 ,
BTK GAPD1-1,1iver C9 SCFsR Kallikrein7
PARC
49
0.887 0.869 1.757 0.923
IGFB P-2 PT.N CD3OLigand LRIG3 Ubiquitin+ I LDH-
H I
0
W
0
I-.
I-.
-...1
w PTN SCFsR AMPM2 IGFBP-2 Kallikrein7 CD3OLigand
0 50
0.869 0.884 1.752 0.922
LRIG3 C9 BTK PARC CK-MB F.nd
ostatin
ts.) ..
o 51 Kallikrein7 BMP-I HSP90a PTN LRIG3
PARC
0.869
0.866 1.735 0.912
1-` ERBB I LDH-H1 CSK Endostatin ' SCFsR BLC
co
o1 52 CD30Ligand SCFsR RAC I C9 PTN LRIG3
0.887
0.869 1.757 0.914
-.3 Kallikrein7 IGFRP-2 LDH-H1 BTK Endostatin CNDP1
, ,
1
CD30Ligand IGFBP-2 PTN CyclophilinA SCFsR KPCI
i-. 53
0.901 0.852 1.754 0.909
co LRIG3 Kallikrein7 C9 IL-15Ra sL-S
electin CDK5-p35 ,
C Is SCFsR GAPDH,liver C9 PTN
Prothrombin
54
0.887 0.864 1.751 0.916
CD30Ligand Kallikrein7 UHE2N 1GFBP-2 PARC MEKI
.
CD30Ligand Kallikrein7 KPCI PTN IGFBP-2 SCFsR
55
0.906 0.847 1.753 0.906
CDK5-035 C I s RAC I MIP-5 C9 FYN .
CD30Ligand IGFBP-2 PTN RAC I SCFsR CDK5-p35
0.897 -I
56
0.861 1.758 0.921
Kallikrein7 PARC FYN Renin HSP90a Mid kine
iD
LRIG3 ERBB I HSP90a SCFsR
Kallilcrein 7 TCTP 0-
57 I
0.897 0.849 1.746 0.904 cc,
PTN C9 LDH-HI CD30Ligand Prothrombin
KPCI ,
iv
- IGFBP-2 KPCI CD30Ligand SCFsR
Kallikrein7 CSK 1=)
U.) 58
0.901 0.855 1.757 0.911
PTN Cis C9 CDK5-p35 Ubiquitin+1 Renin
PIN SCFsR A MPM2 IGFBP-2 Kallikroin
7 CD3OLigand
59
0.883 0.869 1.752 0.92 0
LRIG3 C9 BTK sL-Scicclin Rcnin
PARC 0
PIN RAC1 IGFBP-2 PARC SCFsR
Kallikrein7
60
0.859 0.875 1.734 0.921 ,-1-
CD30Ligand CyclophilinA Renin Cis Midkine BLC
-----
PTN RAC I IGIFHP-2 PARC SCFsR Ka
II iicrein 7
61
0.892 0.864 1.756 0.924
FGF- 17 13Th Renin CD30Ligand Ubiquitin+1 CNDP
I
-
PTN RAC I IGFBP-2 PARC SCFsR
Kallikrein7
62
0.878 0.875 1.753 0.924
CD3 OLigand Cyclophi linA sL-Selectin ERBBI CDK5-p35 Con
Lactin-5
CD30Ligand IGFBP-2 PTN RACI SCFsR sL-
Selectin
63
0.897 0.855 1.752 0.908
KPCI Kallikrein7 LRIG3 IL-15Ra C9 BTK .
,
PTN RACI 1CiFBP-2 PARC SCFsR
Kallikrein7
64
0.878 0.872 1.75 0.912
CD30Ligand Cis LDH-H1 C9 Prothromb in MEK I
-
CD30Ligand Kallikrein7 KPCT PTN IGFF3P-2 SCFsR
65
0.906 0.847 1.753 0.909
C9 RAC I BTK MIP-5 sL-Sclectin CI
s
CD30Ligand Kallikrein7 KPCI PTN IGFBP-2 SCFsR
66
0.887 0.858 1.745 0.904
C9 CDK5-p35 LRIG3 TCTP Endostatin F'YN
C)
(A)
0
1-.
1-.
...,
LA) PIN SCFsR AMPM2 IGFBP-2 Kallikrcin 7
CD3OLigand
o 67
0.883 0.869 1.752 0.917
LRIG3 C9 BTK sL-Selcctin CNDP1 PARC
.
K.)
0 BTK GAP DH, liver C9 SCFsR Ka1likrein7
PARC
0.836
0.898 1.733 0.924
co IGFBP-2 PIN CD30Ligand LRIG3 CK-M13 BLC
O IGFBP-2 KPCI CD30Ligand SCFsR Kallikrein7
CSK
69
0.901 0.855 1.757 0.915
-1 mr Renin CK-MB Cis Prothrombin PARC
i
i-. PIN RACE IGFBP-2 PARC SCFsR HSP90a
co 70
0.878 0.875 1.753 0.922
Kallikrein7 LRIG3 BMP- 1 Renin Prothrombin
Contactin-5
PIN RACI IGFBP-2 PARC SCFsR HSP90a
71
0.901 0.855 1.757 0.92
Prothrombin FGF- 17 C Is GAPDH,liver Kallikrein7
C9
1GFBP-2 SCFsR KPCI FIN Cis Kallikrein7
72
0.892 0.858 1.75 0.906
Prothrombin CD30Ligand C9 CSK PARC IL-15Ra
CD30Ligand Kallilcrcin 7 KPCI PIN IGFBP-2 SCFsR
-1
73
0.897 0.852 1.749 0.904 Q)
Ubiquitin-1-1 sL-Selectin C9 BTK LRIG3 MEK I
0-
PIN RAC1 IGFBP-2 PARC SCFsR
Kallikrein7 _
74
0.883 0.869 1.752 0.923 CD
FG F-17 CD30Ligand GAPDH,liver Renin MIP-5
FYN
t....
1\..)
- PIN RAC1 EGFE3P-2 PARC SCFsR HSP90a
0.873
0.884 1.757 0.919 -i.,
Kallikrcin7 LRIG3 BMP-1 Renin Midkine CD30Ligand
.0-,
CD30Ligand K allikrcin 7 KPCI PIN IGFBP-2 SCFsR
0
76
0.883 0.861 1.743 0.909
C9 CDK5-p35 LRIG3 TCTP sL-Scicctin Cis
0
IGFBP-2 SCFsR KPCI PTN Cis CD3OLigand
D
77
0.897 0.855 1.752 0.908 r-1-
Kallikrcin7 AMPM2 BTK Prothrombin Renin
CK-MB ....-.0
LDH-1-11 Kallikrein7 ERBB1 HSP90a SCFsR LRIG3
78
0.864 0.869 1.733 I 0.915
BTK PIN GAPDH,liver CNDP1 PARC BLC
.
I
IGFBP-2 SCFsR KPCI PIN C I s CD3OLigand
79
0.906 0.847 1.753 0.906
Kallikrein7 RAC1 CNDP1 LRIG3 Prothrombin Con
tacti n-5
CD30Ligand Kallikrein7 KPCI PIN IGFBP-2 SCFsR
80
0.883 0.866 1.749 0.908
C9 CDK5-p35 LRIG3 BTK IL-15Ra Contactin-5
PIN RAC1 IGFBP-2 PARC SCFsR
Kallikrein7
81
0.873 0.875 1.748 0.915
CD30Ligand BTK Renin C9 LDH-H1 MEK1
.
CD.10Ligand SCFsR RAC I C9 PIN Cls
82
0.897 0.855 1.752 0.918
GAPDH,livcr Kallikrc in 7 Prothrombin MIP-5 ERBBI
CyclophilinA
,
PIN RAC I IGFBP-2 PARC SCFsR
Kallikrein7
83
0.878 0.878 1.756 0.926
CD30Ligand CyclophitinA sL-Selectin C9 Cis Midkine
0
(A)
0
I-.
I-.
....1 Ã
W LRIG3 ERBB I HSP90a SCFsR Kallikrcin7
TCTP
o
84 0.883 0.861 1.743 0.91
PTN C9 LDH-H1 CD30Ligand Prothrombin
Endostatin
n.)
o CD30Ligand sL-Selectin GAPDH,
liver PTN IGFBP-2 Kallikrein7
i-. 85
0.892 0.872 1.764 0.924
co PARC SCFsR UBE2N LRIG3 C9 HSP90a ,
'
O Kallikrein7 SCFsR HSP90a PTN LRIG3 IGFBP-2
86
0.892 0.864 1.756 0.92
...1 Prothrombin PARC GAPDH,liver Cis CDK5-p35
Ubiquitin+1 .
iõ
i-. PTN SCFsR AMPM2 IGFBP-2 Kallikrein7 CD30Ligand
co 87
0.873 0.878 1.751 0.916
LRIG3 C9 BTK PARC FGF-17
Endostatin
IGFBP-2 SCFsR GAPDH,liver PTN Cis RAC1
88
0.883 0.847 1.729 0.917
CD30Ligand Kallikrein7 LDH-H1 sL-Selectin Prothrombin BLC
KPCI HSP90a PTN Kallikrein7 IGFBP-2
Prothrornbin
89
0.911 0.844 1.755 0.907
Cis SCFsR BMP-1 Rcnin CDK5-p35 CSK
H
PIN C9 CSK CD30Ligand SCFsR
GAPDH,livcr CD
90
0.881 0.866 1.749 0.916 D-
Kallikrein7 LRIG3 IGFBP-2 Renin Prothrombin IL-
I 5Ra
,
CD30Ligand Kallikrein7 KPCI SCFsR LRIG3 C9
91
0.901 0.847 1.74g 0.902
1G [BP-2 BTK PTN MEK I Ubiquitin+1 CDK5-
p35 NJ
- CD30Ligand SCFsR RAC I C9 FIN Ch
92
0.911 0.841 1.752 0.915
GAPDH,liver Kallikrein7 Prothrombin MIP-5 CDK5-p35
Midkine
0
LRIG3 ERBB1 HSP90a SCFsR Kallikrein7 TCTP
93
0.897 0.847 1.743 0.91
PTN C9 LDH-H1 CD30Ligand Prothrombin
GAPDH,1 iver D
SCFsR,-I-
C9 UBE2N Cis PIN RAC I
94
0.901 0.861 1.762 0.927 ------
CD30Ligand IGFBP-2 Kallikrein7 GAPDH,liver
sL-Selectin PARC .
FIN SCFsR AMPM2 IGFBP-2 Kallikrein7
CD30 Ligan d
95
0.901 0.849 1.751 0.91
LRIG3 C9 BTK LDH-H I Prothrombin sL-
Selectin
LDH-H I SCFsR 1-TSP90a PTN ERBB I PARC
96
0.845 0.884 1.729 I 0.923
LRIG3 K all ikrcin7 CK-M13 UBE2N TGFIIP-2
BLC I
CD30Ligand SCFsR RAC1 C9 PTN C I s
97
0.892 0.864 1.756 0.919
GAPDH,liver Kallikre in7 CNDP I BTK sL-Selectin FGF-
17
'
PTN RAC1 IGFB P-2 PARC SCFsR
Kallikrein7
98
0.883 0.869 1.752 0.922
CD30Ligand CyclophilinA sL-Selectin ER13131 Prothrombin Con
tact i n-5 ... ,
1GFBP-2 KPCI CD30Ligand SCFsR LRIG3 PTN
99
0.897 0.852 1.749 0.91
1.111F.2N Kallikrein7 C9 CDK5-p35 sL-Selectin IL-
15Ra
pi-N SCFsR AMPM2 IGFBP-2 Kallikrein7 CD30Ligand
100
0.878 0.869 1.747 0.911
LRIG3 C9 BTK sL-Selectin PARC MEK I
a
(A)
0
1-,
1-,
...,
co
0
Marker Count Marker Count
N
0 SCFsR 100 ERBB1 14
i-,
co PTN 100 UBE2N 11
o1 Kallikrein7 100 CyclophilinA 11
--.1 IGFBP-2 87 AMPM2 II
1
I-' CD30Ligand 83 MEK I 10
co
C9 63 IL-15Ra , 10
LRIG3 60 FYN 10
PARC 47 FGF-17 10
Prothrombin 43 Endostatin 10
RACI 42 Contact1n-5 10
H
BTK 42 CSK 10
Si)
Cls 40 CNDP I 10 ,
cr
KPCI 36 CK-MB 10
a)
sL-Selectin 35 BMP-I 10
N.)
¨ Rollin 30 BLC 10
,
as
GAPDH, liver 27 Ubiquitin+ I 9
0
HSP90a 25 , TCTP 9
0
CDK5-p35 24 Midkinc 9
D
LDH-H I 23 MIP -5 9
....-.-=
0
w
o
i-.
i-.
-.1
w 100 Panels of 13 Asymptomatic
Smokers vs. Cancer Biomarkers
o
Sens. +
ts.)
o
Biomarkers Specificity Sensitivity Spec. AUC
1-.
co 1 PTN SCFsR AMPM2 IGFBP-2 Kallikrein7
CD30Ligand LRIG3
0.887 0.875 1.762 0.919
i C9 BM sL-Selectin PARC CDK5-p35 Cis
o
--.3 PTN RAC I IGFBP-2 PARC SCFsR CD30Ligand
GAPDH,liver
i 2
0.883 0.869 1.752 0.923
1-. sL-Selectin C Is LDH-H1
Prothrombin Kallikrein7 BLC
co
KPCI HSP90a PTN Kallikrein7 IGFBP-2
Prothrombin C I s
3
0.915 0.849 1.765 0.907
SCFsR BMP-1 Renin RAC I CD30Ligand
FYN ,
PTN RAC I TGFFIP-2 PARC SCFsR
Kallikrein7 CD30Ligand
4
0.887 0.881 1.768 0.926
CyclophilinA Renin Cts CK-MB Midkinc LDH-
HI ........... -
CD30Ligand SCFsR RAC I C9 PTN Cis G APDH.I
i ver
0.906 0.861 1.767 0.917
Kallikrein7 CNDP I BTK sL-Selectin Prothrombin
LRIG3 .
RIFBP-2 KPCI CD3OLigand SCFsR Kallikrein7 CSK
PTN
6
0.901 0.858 1.759 0.915
Renin CK-M13 Cis Prothrombin PARC
Midkine .
CD30Ligand C9 GAPDH,liver SCFsR PTN
CyclophilinA C I s H
7
0.901 0.861 1.762 0.916 a)
1,..) sL-Selectin Kallikrein7 UBE2N Endos
Latin Prothrombin Contac tin-5
_
CT
---1 BTK RAC I ERBB I Kallikrein7 IGFBP-2 PTN
SCFsR -
8
0.897 0.875 1.772 0.925 a)
sL-Selectin C Is PARC C9 HSP90a LRIG3
PIN LRIG3 CD30Ligand GAPDH,liver PARC HSP90a
SCFsR r\.)
9
0.901 0.866 1.768 0.92 cyi
Prothrombin IGFBP-2 RAC1 C9 Kallikrein7 ['GP-
17
PTN R AC1 1GFBP-2 PARC SCFsR
Kallikrein7 FGF-17
0.887 0.869 1.757 0.921
CD30Ligand GAPDH,liver Rcnin 131-K Prothrombin 1L-
15Ra
KPCI HSP90a PIN Kallikrein7 IGFB P-2
Prolhrombin C I s
1 1
0.901 0.858 1.759 0.902
SCFsR BMP-1 Renin RAC1 MEK I
CD3OLi.and
,,,,
,
CD30Ligand SCFsR RAC1 C9 PIN Cis
GAPDH,liver
12
0.911 0.849 1.76 0.916
Kallikrein7 Prothrombin MIP-5 ERBB1 FYN
CyclophilinA
LRIG3 ERBB I HSP90a SCFsR
Kallikrein7 TCTP PTN
13
0.897 0.852 1.749 0.906
C9 LDH-HI CD30Ligand Prothrombin KPCI
TGFBP-2 ,
IC.IFBP-2 SCFsR GA PDH,liver PIN
CD30Ligand BTK sL-Scl cctin
14
0.901 0.861 1.762 0.924
Kallikrein7 PARC Cis C9 Ubiqui tin+ I
LDH-H I
PIN SCFsR AMPM2 IGFBP-2 Kallikrein7
CD30Ligand Renin
0.883 0.878 1.76 0.92
BTK Midlcine CK-MB PARC C Is
LRIG3
a
W
0
I-
I-
-.1
W PTN RAC1 IGFBP-2 PARC SCFsR Kallilcrein7 FGF-
17
o
I 6 0.873 0.872 1.745 0.927
CD30Ligand GAPDH,liver Renin CyclophilinA Cl s BLC
I')
o PARC Kallikrein7 HSP90a PTN
ICIFBP-2 LRIG3 sL-Selectin
H 17
0.897 0.875 1.772 0.922
co Prothrombin C Is SCFsR
CyclophilinA C9 CDK5-p35
oi CD30Ligand SCFsR RAC I C9 PTN Cis GAPDH, I
iver
18
0.915 0.849 1.765 0.92
--I Kallikrein7 CNDP I 131K sL-Sclectin
Prothrombin Renin
i
H CD30Ligand Kallikrein7 KPCI PTN IGFBP-2 SCFsR
C9
co 19
0.906 0.852 1.758 0.916
CDK5-p35 CSK Prothrombin Renin Cis
CK-MB
LRIG3 CND P I HSP90a CK-MB PTN
GAPDH,liver Kallikrein7
20
0.883 0.878 1.76 0.918
End ostatin FGF-17 BTK sL-Selectin PARC
Contactin-5
1
.
CD3OLigand IGFBP-2 PTN RAC I SCFsR sL-Selectin
KPCI
21
0.906 0.849 1.756 0.909
Ka Ilikmin 7 LRIG3 TL- 1 5Ra C9 CDK5-p35
FYN
CD30L igand IGFBP-2 PTN GAPDH,livcr FYN SCFsR RAC
I
22
0.901 0.858 1.759 0.915 -I
C9 Cis Ka1likrein7 Prothrombin PARC
MEK1 CD
CD30Ligand SCFsR RACI C9 PTN Cis GAPDH, I
iver ' 0-
23
0.901 0.855 1.757 0.922 -
Kal likrei n7 Prothrombin MIP-5 ERBB I
CyclophilinA PARC CD
- LRIG3 ERBB I HSP90a SCFsR
Kallikrein7 TCTP PTN
oo 24
0.906 0.841 1.747 0.902 1\)
C9 LDH-H1 CD30Ligand Prothrombin KPCI
Ubiquitin+1 01
CD30Ligand sL-Sclectin GAPDH,livcr PTN ICiFBP-2 K all
ikrcin7 PARC
25
0.901 0.875 1.776 0.928 C)
SCFsR UBE2N LEUG3 C9 RAC I CI s
0
PTN SCFsR AMP M2 IGFBP-2
Kallikrein7 CD30Ligand LRIG3 =
26
0.887 0.872 1.759 0.921
C9 BTK PARC CK-MB FGF-17
Midkine
.......,
PTN RAC1 IGFBP-2 PARC SCFsR HSP90a Ka
I likrein7
27
0.864 0.881 1.745 0.921
LRIG3 Cis BMP-1 CDK5-p35 Prothrombin
BLC
- ,
PTN C9 CSK CD30Ligand SCFsR GAPDH,liver
Kallikrein7
28
0.883 0.875 1.758 0.918
LRIG3 IGFBP-2 Renin CDK5-p35 Cis
Prothrombin
BTK IGFBP-2 PIN Ka1likrein7 SCFsR KPCI HSP90a
29
0.892 0.866 I .758 0.911
PARC Renin CD30Ligand BMP-I
Prothrombin Contactin-5 .
CD30Ligand Kallikrein7 KPCI sL-Selectin PTN SCFsR BTK
30
0.906 0.855 1.761 0.911
C9 IGFBP-2 U13E2N LRIG3 Endostatin CDK5-p35
31 PTN RAC I IGFBP-2 PARC SCFsR HSP90a
Kallikrein7
0.878
0.875 1.753 0.923
LRIG3 BMP-1 Ronin Prothrombin IL-15Ra
CDK5-p35
SCFsR C9 UBE2N Cis FIN RAC I
CD30Ligand
. 32
0.906 0.849 1.756 0.912
IGFBP-2 Kallikrein7 PARC Prothrombin
Ubiquitin+1 MEKI 3
C)
t.....)
o
i-.
F.
....1
t.,... CD30Ligand Ka11ikrein7 KPCI PTN IGFBP-2
SCFsR C9
o
33 0.901 0.855 1.757 0.91
RAC I MK MIP-5 LRIG3 CDK5-p35 CNDP1
.
N.) LRIG3 ERBB t HSP90a SCFsR Kallikrein7 TCTP
PTN
o
34 0.897 0.849 1.746 0.905
1--` C9 LDH-H 1 CD30Ligand Prothrombin KPCI
BMP- 1
co
1 PTN SCFsR AMPM2 ICiFB P-2 Kallikrein7
CD30Ligand LRIG3
o
35 0.887 0.872 1.759 0.92
....1 C9 BTK PARC CK-MB Midkine FYN
i 1GFBP-2 SCFsR GAPDH,liver PTN
CD30Ligand BTK Renin
i-. 36
0.869 0.875 1.744 0.927
co PARC Kallikrcin7 CK-MB Cis Ubiquitin+1 BLC
SCFsR ERBB1 CSK PTN IGFB P-2 Kallikrein7
CNDP I
37
0.897 0.861 1.758 0.916
C9 GAPDH,liver Ubiquitin+1 FGF- 1 7 LDH-H I
Contactin-5 . PTN RAC I 1GFBP-2 PARC
SCFsR Kal I ilcrei n7 CD30Ligand
38
0.887 0.872 1.759 0.92
BTK Endostatin C9
Prothrombin sL-Selectin LDH -H1
-I
PTN C9 CSK CD30Ligand SCFsR GAPDH,liver
Kallikrein7
39
0.878 0.875 1.753 0.917 11)
LRTG3 IGFI3P-2 Renin Prothromhin TL- I
5Ra CDK5-p35 CT
_...
?TN RAC1 IGFBP-2 PARC SCFsR H S P 9 0 a
Kallikrein7 0
40
0.883 0.872 1.755 0.915
LRIG3 Cis Prothrombin sL-Selectin C9
MEK1
NJ CD30Ligand Kallikrein7 KPCI PTN IGFBP-2
SCFsR C9 01
_
41
0.911 0.844 1.755 0.909
sr) RAC I BTK MIP-5 sL-Selectin Prothrombin
LRIG3
KPCI HSP90a PTN Kallikrein7 IGFBP-2
Prothrombin CI s 0
42
0.911 0.835 1.746 0.904 0
SCFsR BMP-1 Rcnin RA CI CD30Ligand
TCTP D .
PTN SCFsR AMPM2 IGFBP-2 Kallikrein7
CD30Ligand LRIG3 e-1-
43
0.887 0.872 1.759 0.924
C9 BTK sL-Seleclin PARC C Is CK-
MB
CD3OLigand SCFsR ERBB I CyclophilinA PTN IGFBP-2
RAC1
44
0.859 0.884 1.743 0.925
Kallikrein7 PARC LDH-H1 Prothrombin CK-MB
BLC .
KPCI HSP90a PIN Kallikrein7 IGFBP-2 Prothrombin
Cls
45
0.892 0.866 1.758 0.912
SCFsR CD30Ligand CK-MB Renin BTK
Contacti n-5 .
LRIG3 CNDP I HSP90a CK-MB PIN Kal I
ikrein7 RAC 1
46
0.878 0.881 1.759 0.923
Endos Latin Cis sL-Selectin FGF-1. 7
IGFBP-2 SCFsR . .
CD30Ligand Kallikrein7 KPCI PTN IGFBP-2 SCFsR
CDK5-p3 5
47
0.892 0.861 1.753 0.912
Cis RAC1 C9 LRIG3 IL-15Ra sL-
Selectin .
CD30Ligand Kallikrein7 KPCI PTN IGFBP-2 SCFsR C9
48
0.901 0.852 1.754 0.901
LRIG3 sL-Selectin BTK HSP90a Prothrombin
MEKI . .
PTN RAC I IGFBP-2 PARC SCFsR CD30Ligand
Prothrombin
49
0.892 0.861 1.753 0.918
GAPDH,livcr Cis LRIG3 LDH-H I Kallikrein7
MIP-5
=
0
CO
0
I-.
I-.
===.1
LA.) CD3OLigand IGFBP-2 PIN RAC1 SCFsR
Kallikrcin7 LDH-H1
o
50 0.873 0.872 1.745 0.925
LRIG3 CK-MB PARC Renin Cis TCTP
K.)
o PARC Kallikrein7 HSP90a PTN
ICiFEIP-2 LRIG3 SCFsR
i-. 51
0.901 0.866 1.768 0.923
co C9 UBE2N RAC1 Cis sL-Selectin
Prothrombin .
oi PTN SCFsR AMPM2 IGFBP-2 Kallikrein7
CD30Ligand LRIG3
52
0.901 0.858 1.759 0.92
===-.1 C9 BTK sL-Selectin Resin
Prothrombin CK -MB
i
I-. CD3OLigand IGFBP-2 PTN RAC I SCFsR
Kallikrein7 LDH-H1
co 53
0.878 0.864 õ 1.742 0.924
LRIG3 CK-MB PARC Resin CSK BLC
PTN RAC I IGFB P-2 PARC SCFsR
Kallikrein7 CD30Ligand
54
0.897 0.861 ' 1.758 0.916
HSP90a LRIG3 C9 FYN Contactin-5
UBE2N
CD30Ligand SCFsR RAC1 C9 PTN Cis
GAPDH,liver -I
55
0.892 0.866 1.758 0.922
Kallikrcin7 CNDP1 BTK sL-S stet:tin
Endostatin LRIG3 Ca
CD30Ligand Kallikrcin7 KPCI PTN IGFBP-2 SCFsR
Ubiquitin+1
56
0.906 0.847 1.753 0.91 FIT
sL-Sc Ecctin C9 BTK LRIG3 CDK5-p35 IL-
I 5Ra
PTN SCFsR AMPM2 IGFBP-2 Kallikrein 7
CD30Ligand LRIG3 N..,)
57
0.878 0.875 1.753 0.912 cri
C9 BTK sL-Selectin PARC CDK5-p35
MEK I
Ka
6..) PTN C9 CSK CD30Ligand SCFsR GAPDH,liver
Kallikrein7
c:o 58
0.892 0.861 1.753 0.918 0
LRIG3 IGFBP-2 Renin Prothrombin MIP-5
sL-Selectin 0
CD30Ligand IGFBP-2 PIN RAC! LRIG3 SCFsR LDH-
H1
59
0.892 0.872 1.764 0.92.3 g--i-
Rcnin Kallikrcin7 HSP90a Midkinc CK-MB PARC
........
LRIG3 ERBB1 HSP90a SCFsR Kallikrein7 TCTP
PTN
60
0.887 0.858 1.745 0.908
C9 LDH-HI CD30Ligand Prothrombin KPCI
PARC ,
1GFBP-2 SCFsR GAPDH,liver PTN CD30Ligand BTK sL-
Selectin
61
0.845 0.895 1.74 0.92
Kal1ikrein7 PARC Cis C9 FYN BLC
,
-
IGFBP-2 SCFsR KPCI PTN Cis Kallikrein7
Prothrombin
62
0.897 0.861 1.758 0.908
CD30Ligand Resin RAC1 HSP90a ConIactin-5
BMP-1
SCFsR C9 UBE2N CD30Ligand PTN KPCI
Ka1likrein7
63
0.906 0.852 1.758 0.909
IGFBP-2 Prothrombin BTK Cis sL-Selectin
Endostatin
CD30Ligand Kallikrein7 KPCI PTN IGFB P-2 SCFsR C9
64
0.897 0.855 1.752 0.91
CDK5-p35 CyclophilinA LRIG3 Cis IL-15Ra
sL-Selectin
TGFBP-2 SCFsR G A PDH,liver PTN
CD30Ligand BTK Renin
65
0.873 0.878 1.751 0.922
PARC Kallikrcin7 CK-MB Cis Ubiquitin+1
MEK I
IGFBP-2 SCFsR GAPDH,liver PTN C Is RAC I
CD30Ligand
66
0.897 0.855 1.752 0.915
Kallikrein7 LDH-H1 CDK5-p35 Prothrombin MIP-5
LRIG3
0
CO
0
I-.
I-.
-4
W PTN RAC1 IGFBP-2 PARC SCFsR Ka11ikrcin7
CD30Ligand
o
67 0.869 0.895 1.763 0.931
CyclophilinA sL-Selectin C9 Cis Midkine CK-
MB
I'.)
o LR1Ci3 ERB B 1 HSP90a SCFsR
Kallikrein7 TCTP PTN
i-. 68
0.901 0.844 1.745 0.905
co C9 LDH-H1 CD3 OLigand Prothrombin KPCI
M1P-5
oi PIN SCFsR AMPM2 IGIBP-2 Ka Ililcrein7
CD30Ligand LRIG3
69
0.883 0.875 1.758 0.92
--.1 C9 BTK PARC FGF-17 sL-Selectin
Renin
i
i-. Kallikrein7 CyclophitinA SCFsR IGFBP-2
CD30Ligand PTN Renin
co 70
0.859 0.881 1.74 0.922
LDH-H1 LRIG3 CK-MB PARC HSP90a BLC
,
71 PARC Kallikrein7 HSP90a PTN IGFBP-2
LRIG3 SCFsR
0.878
0.886 1.764 0.923
C9 BTK sL-Selectin CND PI Cis
GAPDH,liver
IGFBP-2 KPCI CD30Ligand SCFsR Kallikrein7 CSK
PTN
72
0.901 0.855 1.757 0.913 H
Renin CK-MB Cls Prothrombin PARC
Uhiquitin+1
co
BTK GAPDH,livcr C9 SCFsR Kallikrcin 7 PARC
IGFBP-2
73
0.911 0.847 1.757 0.924 Cr
PTN CD30Ligand RAC I Con Lactin-5 sL-
Selectin Ubiqui tin+ I
CD
PIN RACI IGFBP-2 PARC SCFsR HSP90a
Kallikrein7
74
0.883 0.875 1.758 0.922 Na
LRIG3 C9 Cis Prothrombin Endostatin
FYN
NJ
CJ1
NI BTK IGFBP-2 PIN Kallikrein7 SCFsR KPCI HSP90a
- 75
0.887 0.864 1.751 0.91 ------..
PARC Renin CD30Ligand LRIG3 BMP- I
IL-15Ra 0
IGFBP-2 SCFsR GAPDH,livcr PTN Cls RAC1 CD3
OLi gaud 0
76
0.887 0.864 1.751 0.912 D
Kallikrcin7 LDH-H L Prothrombin Rcnin LRIG3 ME
K1
Kallikrein7 LRIG3 HSP90a PTN IGFBP-2 CK-MB SCFsR
77
0.883 0.881 1.763 0.921
UBE2N PARC Renin CD30Ligand Midkine
LDH-H1
CD30Ligand Kallikrein7 KPCI PIN IGFI3P-2 SCFsR C9
78
0.892 0.852 1.744 0.908
CDK5-p35 LRIG3 TCTP Renin Ubiquitin+1
IL15Ra ,
PTN SCFsR AMPM2 IGFBP-2 Kallikrein7
CD30Ligand LRIG3
79
0.897 0.861 1.758 0.919
C9 MK sL-Selectin Renin Prothrombin
PARC
BTK GAPDH,liver ERBB I IGFBP-2
Kallikrein7 PTN Cis
80
0.873 0.866 1.74 0.928
SCFsR CDK3-p35 PARC RAC1 sL-Selectin BLC
.
CD30Ligand IGFBP-2 PTN RAC I LRIG3 SCFsR LDH-
H1
81
0.906 0.858 1.764 0.92
Renin Kallikrein7 131K CNDP I
Prothrombin CK-MB
Kallikrein7 BMP-1 HSP90a PTN LRICi3 PARC ERBB1
82
0.878 0.878 1.756 0.914
LDH-131 CSK Endostatin SCFsR Cis
Prothrombin
,
PTN RACI IGFBP-2 PARC SCFsR HSP90a
Kallikrein7
83
0.873 0.884 1.757 0.92
LRIG3 BMP-1 Renin Midkine CDK5-p35
Contacti n-5
-
a
(A)
0
1-,
I-'
---.1
CO PTN RAC I IGFBP-2 PARC SCFsR HSP90a
Prothrotnb in -
o 84
0.887 0.875 1.762 0.925
FGF-17 Kallikrein7 LRIG3 C9 CK-MB FYN
I'.)
0 Cls SCFsR GAPDH,liver C9 PTN Prothrombin
CD3OLigand
0.901 0.849 1.731 0.914
co Kallikrein7 UBE2N IGIF BP-2 PARC
MEK1 RAC1
O CD30Ligand Kallikrein7 KPCI PTN IGFI3P-2
SCFsR C9
86
0.911 0.841 1.752 0.906
---.1 RAC1 BTK MIP-5 sL-Selectin Prothrombin
FC;F-17 .
1
i-, PTN/ RAC I IGFBP-2 PARC SCFsR HSP90a
Kallikrein7
co 87
0.883 0.861 1.743 0.915
LRIG3 BMP-1 Renin Midkine CD30Lig.and
TCTP
PARC Kallikrein7 HSP90a Priv IGFBP-2 LRIG3
SCFsR
88
0.892 0.864 1.756 0.916
C9 BTK sL-Selectin CNDP1 Cis AMPM2
,
IGFBP-2 SCFsR KPCI PTN C Is Ka I likrein7
Prothrombin
89
0.887 0.852 1.74 0.908
CD30Ligand C9 Cyclophi I in A sL-Scl ccti n
HSP90a BLC
Ca
LDH-HI SCFsR HSP90a PTN ERBBI PARC LRIG3
90
0.883 0.872 1.755 0.922 0".
Kallikrein7 CK-MB CSK C Ls IGFBP-2
Ubiquitin+1 . __________ CD
IGFBP-2 SCFsR GAPDH,liver PTN Cis RACI PARC
91
0.887 0.869 1.757 0.925 N.)
C9 Kallikrein7 LRIG3 sL-Selectin
Contactin-5 Ubiquitin+1
t..) IGFBP-2 SCFsR GAPDH,liver PTN Cis RAC1
CD30Ligand
ts..) 92
0.883 0.875 1.758 0.916 ..--...
LRIG3 LDH-H1 Prothrombin Kallikrein7 CNDPI
Endostatin 0
K all i krcin7 SCFsR HSP90a PIN LRIG3 TGFBP-2
Prothrombin 0
93
0.892 0.878 1.77 0.924 D
PARC FYN Cis RAC I C9 sL-
Sclectin .
IGFBP-2 KPCI CD30Ligand SCFsR LRIG3 PTN
UBE2N ..-.., ,
94
0.901 0.849 1.751 0.909
Kallikrein7 C9 CDK5-p35 sL-Selectin IL-15Ra
BTK
PTN KPCI IGFBP-2 Prothrombin HSP90a SCFsR
Renin
95
0.901 0.849 1.751 0.9
Kallikrein7 CD30Ligand FYN C9 BTK MEK1
PIN GAPDH,liver IGFBP-2 LRIG3 SCFsR
CD3OLigand Kallikrein7
96
0.887 0.864 1.751 0.923
RAC1 PARC sL-Seleclin C9 1vflP-5
HSP90a
CD3OLigand KPCI PTN SCFsR HSP90a LRIG3 PARC
97
0.887 0.835 1.742 0.912
IGFBP-2 CK-MB Renin Kallikrein7 Cls TCTP
. _________________
PTN SCFsR AMPM2 IGFBP-2
Kallikrein7 CD30Ligand LRIG3 98 0.892 0.864 1.756 0.919
C9 I31K sL-Selectin Renin PARC FYN
.
LDH-H I SCFsR HSP90a PTN ERBB I PARC
LRIG3
99
0.85 0.889 1.739 0.923
Kallikrein7 CK-MB UBE2N IGFBP-2 FYN BLC
,
LRIG3 IGFBP-2 HSP90a FIN
Prothrombin SCFsR CK-MB
100
0.883 0.872 1.733 0.923
LDH-H1 PARC Renin C Is CSK
Kallikrein7
-
_______________________________________________________________________________
____________________ -
C)
w
0
I-
I-.
-4
W
0
Marker Count , Marker Count
N)
o PTN 100 CDK5-p35 19
i-.
co Kallikrein 7 100 ERBB I 14
oi SCFsR 99 FYN , 13 ,
-4 ICIFBP-2 /TR Ubiquitin+1 12
i
1-` CD30LIgand 79 BMP- I 12
co
LRIG3 66 . UBE2N 11
PARC , 61 CyclophilinA 11
C9 61 CSK 11
Cls 55 CNDP I 11
Prothrombin 53 BLC I 1
¨1
RAC 1 50 AMPM2 11
ea
0-
sL-Selectin _ 42 ., TCTP _ 10
CD
HSP90a 41 Midkine 10
Renin 38 M1P -5 10
IV
NJ BTK 38 MEK I 10
w
GAPDH, liver 31 IL-15Ra 10
0
KP CT 30 FGF-17 10
0
CK-MB 27 ,Endostatin 10
=
r-1-
LDH-H1 25 Contactin-5 10
...-..
a
W
0
I-.
I-.
--.1
W 0 100 Panels of 14 A s.!. mptomatic
Smokers vs. Cancer BM markers
'
Sens. +
ts.)
0 Biomarkers
Specificity , Sensitivity I Spec. AUC
t
i-. PIN SCFsR AM PM2 101,13P-2 Kallikrcin7
C D3OLigand Renin
co 1
0.887 0.875 1.762 0.921
1 BTK Ivridkine CK-MB PARC Cis sL-Selectin FYN
0
PIN RAC1 IGFBP-2 PARC SCFsR
Kallilcrein7 CD30Ltgand 0 878
--.1 2
0.872 1.75 0.927
I C yclophil inA Renin Cis Prothrombin LDH-
H1 CK-MB BLC
i-.
co 3 C D30 Ligand Kallikrein7 KPCI PTN IGFBP-2
SCFsR CDK5-p35
0.915
0.849 1.765 0.909
Cis RAC1 Renin IISP90a BM P-1 FYN
Prothromhin
PIN RAC1 IGFT3P-2 PARC SCFsR HSP90a
Kallikrein7
4
0.897 0.881 1.777 0.923
LRIG3 C9 C I s FYN sL-Selectin CDK5-p35
Prothrombin
-
C D30 Liaand SCFsR RAC1 C9 PTN Cis
GAPDH,liver
0.901
3 ._0.866
1.768 0.921
Kallikrein7 CNDP I BTK sL-Selectin Endostatin
Prothrombin LRIG3
PIN C9 CSK CD3OLigand SCFsR GAPD
11,1iver Kallikrein7
6
0.897 0.866 1.763 0.919
LRIG3 IGFBP-2 Renin CDK5-p35 C Is
Prothrombin RAC I
1GFBP-2 SCFsR GAPDILliver PTN Cis RAC1
PARC
7
0.901 0.864 1.765 0.924
C9 Kallikrein7 LRIG3 sL-
Selectin Ubiguitin+1 FYN Contactin-5
--I
PARC Kallikrein7 11S P90a PIN IGFBP-2
LRIG3 SCFsR
t..) 8
0.887 0.886 1.774 0.925 0.)
C9 BTK sL-Selectin ERBBE FYN
GAPDH,liver Cls cr
4=.
PIN RAC1 IGFBP-2 PARC SCFsR HSP90a Prothrombin
-
9
0.897 0.869 1.766 0.919 a)
FGF- I 7 Kallikrein7 LRIG3 C9 Cis CDK5-p35
FYN
Cis SCFsR GAPDH,liver C9 PIN Prothrombin
CD30Ligand
0.906
N.)
0.858 1.764 0.918 (3)
Kallikrein7 L113F.2N LRIG3 sL-Selectin CN
DPI RAC I IL-15Ra
-
CD3OLio N and SCFsR RAC1 C9 PIN
Cis GAN-1,111,er
11 '
0.892 0.866 1.758 0.908
Kallikrein7 Prothrombin LRIG3 PARC FGF-17 BTK MEKI
IGFBP-2 SCFsR GAPDHliver PIN Cis RAC1
CD30Ligand 0.001
11
0.861 1.762 0.921
Kallikrein7 LDH-H1 CDK5-p35 Prothrombin M0P-5 LRIG3
CK-MB
-
,
KPC1 11S P90a PIN Kallikrein7 IGFBP-2
Prothrombin Cis
13
0.906 0.847 1.753 0.905
SCFsR BMP- l Renin RAC1 CD301-ieand TCTP
FGF-17
PIN SCFsR AMPM2 IGFBP-2 Kallikrein7
CD30Liond LRIG3
14
0.892 0.869 1 761 0.919
C9 BTK sL-Selectin Renin PARC
CyclonhilinA BIVIP-1 .
PIN RAC1 1GFBP-2 PARC SCFsR CD30Li.and
GAPDH,liver
r
13
0.887 0.861 1.748 0.922
sL-Selectin C I s LDH-1-11 Prothrombin
Kallikrein7 BLC FYN
IGFBP-2 KPCI CD30Ligand SCFsR
Kallikrcin7 CSK WI N
16
0 906 0 855 1.761 0.915
Rclin CK-MB Cis Prothrombin PARC LDH-I-11
Midkine
CD30Ligand IGFBP-2 PTN R.AC1 SCFsR BTK ERB B1
17 -
0 897 0.866 1.763 0.922
PARC CDK5-p35 Kallikrein7 sL-Selectin LD11-
111 CAPIN Over Contactin-5
C)
:,.
w
0
1-.
I-.
-4
W PIN RAC1 IGFB P-2 PARC SCFsR 1-ISP90a
Kai] ikrein7
o
18 0.897 0.872 1.769 0.922
LRIG3 C9 CI s Prothmm hin Endostatin CD K5-
p35 FYN ,
N IGFTIP-2 SCFsR GAPDH,livcr PTN
CD30Ligand BTK sL-Sclectin
o
19 0.887 0.875 1.762 0.924
i-. Kallikrein7 PARC Cis C9 Ubiquiti n+ I
Prothrombin IL-15Ra
co CD30Ligand IGFBP-2 PTN RAC1 SCFsR
Kallikrein7 LDH-111
1 20
0.873 0.884 1.757 0.92
o LRIG3 CK-MB PARC Renin Cis
UBE2N IvIEKI
NJ PARC SCFsR HSP90a PTN 1GFBP-2
Prothrombin LRIG3 ,
i 21
0.897 0.864 1.76 0.923
i-. RAC1 CD30Ligand Kallikrein7 CK-MB C9
CyclophilinA MIP-5
co
LRIG3 ERBB I HSP90a SCFsR
Kallikrein7 TCTP FIN
22
0.897 0.855 1.752 0.908
C9 LDH-Hl CD30Lieand Prothrombin KPCI IGFBP-
2 CDK5-p35 -
PIN SCFsR AMPM2 IGF13P-2 Kallikrein7
CD30Ligand Itenin
23
0.892 0.869 1.761 0.922
BTK Midkinc CK-MB PARC Cis LRIG3
Prothrombin . .
PTN RAC1 1GFBP-2 PARC SCFsR
CD30Ligand GAPDH,liver
24
0.864 0.884 1.747 0.928 _1
sL-Selectin C I s Kallikrein7 Prothrombin C9 CDK5-p35
BLC
,
PIN RAC1 1GFBP-2 PARC SCFsR IISP90a
Kallikrein7 su
25
0.887 0.878 1.765 0.918 cr
LRIG3 C9 Cis FGF-17 B'rK CNDP1
Prothrombin -
.,
2 and Kallilaci n7 KPCI PTN IGFBP-2 SCFsR
C9 (D
6 CD3OLi" . 0.892 0.866 1.758
0.914
CDK5-p35 CSK LRIG3 Renin Ubinuitin+1 PARC
Cis Ni
t...) BTK RAC1 RABBI Kallikrein7 IGFBP-2 PIN
SCFsR
1,..) 27
0.869 0.892 1.761 0.928 Cr)
f..., PARC CI s CK-M13 LIDII-II1 FGF-17 C9
Contactin-5 ...---..
C D30 L i eand Cyc lophi lin A C9 SCFsR PIN Kallikrein7
CI s
78 -
0.906 0.858 1.764 0.919 0
Prothrombin GAPDH,liver LRIG3 sL-Selectin CNDP1 RAC I
Endosiatin
1GFBP-2 SCFsR GAPDH,liver PTN C 1 s RAC I
PARC ' D
29
0,906 0.855 1.761 0.919 0-1-
C9 Kallikrein7 LRIG3 Prothrombin
HSP90a IL-15Ra FYN . ..,_..,
C'D30 Li c,and 1GF Br-2 i,TN RAC I SCFsR Kallikrein7
L DH-H1
30 .. . _
LRIG3 CK-MB PARC 'tenni C Is
CyclophilinA ME K I 0.869 0.886 1.755 0.92
CD30Ligand CyclophilinA C9 SCFsR PTN Kallikrein7 C
I s
31
0 901 0.858 I 759 0.918
Prothrombin GA PDH.liver LRIG3 sL-Selectin CNDP I RAC I
IvIIP-5 ,
CD110Lic,and SCFsR RAC1 C9 PTN Cls
GAPDII,liver
31 - '
0.897 0.852 1.749 0.915
- Kallikrein7 CN DP I LRIG3 sL-Selectin I GF
BP-2 Prothromh in TC:r1'
Kali ikrcin7 SCFsR HSP90a PTN ERBB1 CyclophilinA
IGFB P-2
33
0.883 0.886 1.769 0.925
CK-MB PARC LDH-H1 LRIG3 Cis UBE2N
C9 .
PTN SCFsR AMPM2 EGFBP-2 Kallikrein7 CD30L
igand LRIG3
34
.
C9 BTK sL-Selectin KPCI
Prothrombin CDK5-035 Midkine 09_ 0,841 1.761 0 905
Cis SCFslt CiAPD1-1,1 iver C9 'TN
Prothromhin C D30 Ligand 35 0 864 0.884 1.747 0.924
Ka1likrein7 UBE2N 1GFBP-2 PARC FYN sL-Selectin BLC
36
PTN RAC I 1GFBP-2 PARC SCFsR
Kallikrein7 CD30Ligand 0 878 0 886 1.764 093
CvclophilinA sL-Selectin BMP-1 Cis Mi dlcine Renin
CK-MB
a
W
0
I-.
I-.
--.1
W PIN C9 CSK CD30Ligand SCFsR GAPDII,liver
Kallikrein7
o
37 0.892 0.866 1.758 0.913
LRIG3 IGEBP-2 Renin Prothrnmhin CI s
EGF-17 WM .
ts.) PARC Kallikrein7 HSP90a FIN IGFBP-2 LRIG3
SCFsR
0 38
0.883 0.878 1.76 0.923
i-. C9 BTK sL-Selectin ERBB I FYN
GAPDH,liver Contactin-5
co CD3OLi.and SCFsR
., KPCI C9 BTK PIN
Ka1li1rein7
1 39
0.897 0.866 1.763 0.914
o C Is IGFBP-2 sL-Selectin RAC I
CDK5-p35 Endostatin LRIG3
--.1 PTN SCFsR RAC I HSP90a LRIG3 PARC
C9 -
1 40
0.887 0.872 1.759 0.922
i-. IGFB P-2 Prothrombin Kallikrein7 Renin BTK
FGF-17 IL-15Ra
co CD3OLigand SCFsR RAC I CO PIN LRIG3
Kallikrein7
41
0.897 0.858 1.755 0.911
IGFBP-2 LDH-HI BTK Renin Prothrombin sL-
Selectin MEKI -
PIN GAPDH,liver 1 CiF13 P-2 LRIG3
SCFsRCD3OLigand Kallikrein7
42
0.892 0.866 1.758 0.923
RAC1 PARC sL-Selectin CO IvIIP-5 HSP90a
Pmthrombin
KPCI HSP90a PIN Kallikrein7 IGFBP-2
Prothrombin Cm s
43
0.901 0.847 1.748 0.907
SCFsR BMP-1 Renin RACI CD30Li2and TCTP
PARC -I
-
CD30Ligand SCFsR RAC] C9 PIN LRIG3
Kallikrein7 CD
44 -
0.906 ' 0.864 1.77 0.922
IGH3P-2 LDH-H I BTK Renin Prothrombin PARC
Ubiquitin+ I CY
PIN SCFsR AMPM2 IGFBP-2
Kallikrcin7 CD30Ligand LR1G3 -
45
0.887 0.872 1.759 0.923 (D
C9 BTK sL-Selectin PARC Cis FYN CK-
MB
N.) PIN SCFsR AMPM2 IGFBP-2
Kallikrein7 CD30Ligand LRIG3 N)
I,...) 46
0.869 0.875 1.744 0.917 0)
C9 BTK sL-Selectin PARC Cis Endostatin
I3LC
,
LRIG3 1GF BP-2 HSP90a PIN Pmthrom
bin SCFsR CK-MB - .---..
47
0.892 0.866 1.758 0.922 0
LDH-H I PARC Renin CI s CSK Kallilcrein7
Midkine 0
Kallikrein7 SCFsR HSP90a PIN KPCI CD30Ligand
IGFBP-2
48
0 897 0 864 1.76 0 913
Renin CDK5-p35 BTK BMP-1
Prothrombin Con tactin-5 PARC r-4-
IGH-11)-2 SC:ERR GA PD H,liver PIN CI s RAC1
PARC =-......,
49
0.901 0.858 1.759 I 0.924
CO Kallikrcin7 LRIG3 sL-Sclectin
HSP90a CDK5-p35 IL-15Ra
IGFBP-2 SCFsR 50 GAPDH.li vet PIN Cis RAC I
CD30Ligand
0887 .
0 866 1.754 0.912
Kalli krei n7 LDH-H I Prothrombin Renin LRIG3 MEK I
CNDPI
IGFBP-2 SCFsR GAPDILliver PIN Cis R_AC1
CD3OLigand
0.897
51
0.866 1.758 0 918
, Kallikrein7 LDH-H 1 Prothrom hi n Renin LRIG3 CDK5-
p35 M113-5
LRIG3 ERBB1 HSP90a SCFsR Kallikrcin7 TCTP PIN
52
0 901 0.847 1.748 0.904
C9 LDH-H1 CD30Li nand Prothrombin KPCI IGFBP-
2 FYN
PIN RAC I IGFBP-2 PARC SCFsR HSP90a
Kallikrein7
53
0.892 0.872 1 764 0.918
LR1G3 C9 C Is Prothrombin CD30Ligand UBE2N
FGT.-17
1GEH P-2 SCEsIt GA I'D H , I iver PIN CI s
RAC I PARC
54
0.901 0.864 1.765 0.928
C9 Kallikrein7 LRIG3 sL-Selec
lin Ubinuitin+1 FYN CD30Ligand
PIN RAC I IGFBP-2 PARC SCFsR
Kallikrein7 sL-Selectin
55 FYN CD30Ligand GAPDHliver CI s
Prothrombin C9 BLC 0.869 0 875 1.744 0 926. -
0
W
0
I-.
1-.
--.1
cd IGFBP-2 KPCI CD30Ligand SCFsR
Kallilcrein7 CSK PIN'
o
56 0.906 0.852 1.758 0.911
Renin CK-MB C Is Prothromhin 'ARC AMPM2
Midkine
6.) PARC Kallikrein7 HSP90a PTN IGEBP-2 LRIG3
SCFsR
o
57 0.873 0.886 1.76 0.928
I-. C9 UBE2N RAC1 CD30Ligand sL-Selectin
Contactin-5 CK-MB
co CD30Ligand SCFS, , RAC] C9 PTN Cis
GAPDH,liver 0.887
I 58
0.875 1.762 0.922
o Kallikrein7 CNDP I LRIG3 sL-
Selectin IGFBP-2 BTK Endostatin
--.1 CD30Ligand C9 GAPDH.liver SCFsR PIN
CyclophilinA C Is
1 59
0.892 0.866 1.758 0.926
i-. sL-SelecLin Kallikrein7 IGFBP-2 PARC LRIG3
RAC I IL-I 5Ra
co
PIN RAC I 1GFBP-2 PARC SCFsR HSP90a
Kallikrein7
60
0.873 0.878 1.751 0.92
LRIG3 Cis Prothrombin sL-Selectin C9 CK-MB
MEK I
CD30Ligand SCFs12 RAC I C9 PTN Cis
GAPDH,liver
61
0.892 0.864 1.756 0.919
Kallikrcin7 Prothrombin MIP-5 CNDP I LTBE2N
Endostatin sL-Scleetin
62 CD30Lieand KPCI PTN SCFsR HSP90a LRIG3 PARC
0.887
0.858 1.745 0.913
1GFB P-2 CK-MB Renin Kallilcrein7 Cis
Prothrombin TCTP -I
PTN RAC1 IGFBP-2 PARC SCFsR Kallikrein7 FGF-17
Ci)
63
CD3OLigand GA PDH,liver Renin " BTK C9 LRIG3 LI bi
quitin+1 0.901 0.861 1.762 0.926 CD-
-
PIN RAC I IGFBP-2 PARC SCFsR
Kallikrcin7 CD30Ligand
0.869
64
0.875 1.744 0.925 (D
.CyclophilinA Renin Cis CK-MB MidkMe LDH-H1 BLC
NJ PTN RAC1 IGFI3P-2 PARC SCFsR HSP90a
Kallikrein7 NJ
6..) 65
0.892 0.872 1.764 0.921 0)
---.1 LRIG3 BMP- I Renin
CD3OLigand CyclophilinA CDK5-p35 Midkine
.
..-----.
PIN C9 CSK C1/30Ligand SCFsR GA PIKI
iver Kallikrein7
66
0 883 0.875 1.758 0.921 0
LRIG3 IGFBP-2 Renin
CDK5-935 Prothrombin Ubiquitin 1 C Is 0
BTK IGFBP-2 PIN Kallikrein7 SCFsR KPCI
HSP90a =
67
PARC Renin CD30Ligand BMP-1
Prothrombin Contactin-5 Endostatin 0.887 0.872 1 759 0 912 .-
-p-
('IN RAC:1 IGFI3P-2 PARC SCFsR
CD30Ligand CiA PDH, 0.89, liver ...ft..'
68
0 866 1.758 0.926
sL-Selectin Cis Kallikmin7 Prothrombin C9 BTK IL-
15Ra
....
PTN RAC I IGFBP-2 PARC sL-Selectin
CD30Ligand Ka1likrein7
69
0 873 0.878 1 751 0.92
Prothrombin SCFsR Cis LRIG3 GA PDI-Lliver C9 MEK
I
PTN RAC I IGFBP-2 PARC SCFsR
Kallikrein7 FGF-17
70
0.892 0.864 1.756 0.919
CD30Ligand GA PDH, liver Renin HT K Prothrombin LDH-H 1
M1P-5
LRIG3 ERBB I HSP90a SCFsR
Kallikrein7 TCTP PTN
71
0.892 0.852 1.744 0.907
C9 LDH-H1 CD3OLigand Prothrornbin KPCI IGF8P-
2 Contactin-5
PTN SCFsR AlvfPlvI2 IGFBP-2 Kallikrein7
CD30L igand LRIG3
72
0.892 0.866 1.758 0.919
C9 BTK sL-Selectin CNDP1 Cis CK-MB
IvIicikine
BTK 1GF BP-2 PIN Ka 11i krei n7 SC Fs P.
KPCI C D30 Ligand
73
0.883
0.861 1.743 0.918
Renin CK-MB Cis Ubiquilin 1 PARC Prothrombin
BLC
IGFB P-2 SCFsR KPCI PIN Cis Kallikrein7
Prothrombin
74
0 897 0.861 1758 0 913
CD30Lieand C9 CSK PARC LRIG3 sL-Selectin
GAPDH,liver
C)
w
0
1-.
I-.
....1
W CD30 Liaand Kallikrein7 KPCI PTN IGFB P-2
SCFsR CDK5-p35
o
75 0.906 .. 0.852 1.758 0.907
Cls RAC1 Renin HSP90a BM P-1 BTK 1L-
15Ra
n) CD30 Ligand IGFBP-2 PTN RAC1 LRIG3 SCFsR
.. LDH-111.
o
76 0.901 0.849 1.751 0.913
i-. Renin Kallikrein7 BTK CNDP I
Ubiquitin+ I C9 MEKI ,
co CD3OLigand SCFsR RAC I C9 PTN Cis
GAPDH,liver
1 77
..Ø911 0.844 1.755 0.916
o Kallikrein7 Prothrombin MIP-5
CNDP1 UBE2N Endostatin BTK
--.1 PTN RAC I IGFBP-2 PARC SCFsR HSP90a
Kallikrein7
1 78
0.892 0.852 1.744 0.91
i-. LRIG3 BMP-1 Renin CD3OLigand KPCI
CDK5-p35 TCTP
PIN SCFsR AMPM2 IGFBP-2 Kallikrein7
CD30Ligand LRIG3
79
0.892 0 866 1.758 0.924
C9 BTK sL-Selectin PARC C 1 s CK-MB
Prothrombin ,
PIN RAC1 1GF B P-2 PARC SCFsR
CD30Ligand SO GAP DH, liver 0.873 0.869 1.743 0.923
sL-Selectin C Is LDH-H1 Prothrombin Ka11ikrein7
BLC Midkine
CD30Ligand Kallikrein7 KPCI PTN 1GFBP-2 SCFsR C9
81
0.911 0.847 1.757 0.908 _,.1
CDK5-o35 CSK Prothrombin Renin C I s RAC I
LRIG3
,
CD30Ligand C9 GAPDILliver SCFsR PTN
CyclophilinA Cis CI .)
82
0.901 .. 0858 1.759 0.923 cy
sL-Selectin Kallikrein7 1GFBP-2 RAC1 ('ARC Prothromhin
Contactin-5 _
Kallikrcin7 SCFsR HSP90a PIN LRIG3 IGFBP-2
Prothrombin CD
83 PARC FYN Cis RAC I C9 ERBB I sL-
Selectin 0.878 0.889 1.767 0.926INO
IJ
84 Kallikrein7 SCFsR HSP90a PTN LRIG3 IGFBP-2
Protluombin
t,..)CY)
00 PARC BTK CDK5-p35 CI s C9 RAC1
IL-15Ra 0.897 0.861 1 759 0.919
85 1G141 P-2 SCFsR GA I'D H Jiver PTN
C:D30Ligand BTK Renin
0.878 0.872 1.75 097 0C)
PARC Ka 1 likrein7 CK-MB Cis Ubioui
611+1 MEK I Midkine
CD3OLigand SCFsR RAC I C9 PTN Cis GAPDH,
liver
86
0.911 p
..Ø844
1 755 0.919 I-I-
1Callikreir:7 Prothrombin MIP-5 ERBB 1 Cycloai
linA PARC BTK
..-..
1 GRIP-2 SChsR KPCI PIN C 1 s Kallikrein7
Prothmmhin
87
0.897 0.847 1.743 0.906
CD1OLivand Rcnin Ubionitin 1 LRIG3 HSP90a PARC
TCTP
- ,
SCFsR C9 UBE2N Cis PTN RAC I
CD30Ligand
88
0.897 0 866 1.763 0.924
1GFBP-2 Kallikrein7 PARC Pro thrombin CDK5-
p35 HSP90a sL-Selectin
PIN SCFsR AMPM2 IGFBP-2 Kallila-ein7
CD30Ligand LRIG3
89
0.883 0.875 1.758 0.92
C9 131K sL-Selectin PA RC CDK5-p35 Renin
FYN ,
CD30 Ligancl C9 GAPDH, liver SCFsR PTN
CyclophilinA Cls
90 _
0.873 0.869 1.743 0.92
,sL-Selectin Kallikrein7 UBE2N Endostatin CNDP I
LRIG3 BLC
.
CD30 Ligand Kallikrein7 KPCI PTN IGFI3P-2 SCFsR
C9
91
0.901 0.855 1.757 0.908
CDK5-035 CSK Prothrombin Renin Cis UBE2N
LRIG3 . .
PA RC Kallikrein7 HSP90a PTN IGFBP-2
LRIG3 SCFsR
92
0.864 0.895 1.759 0.924
C9 BTK sL-Selectin ERBB I
GAPDH,liver Cis Contactin-5
= 93 PTN RAC I IGFBP-2 PARC SCFsR
HSP90a Kallikrein7
0.887 0.869 1.757 0.921
LRIG3 BMP-1 Renin Prothrombin IL-15Ra CDK5-
p35 BTK
a
W
0
1-
I-
-.1
W' PIN RAC1 IGFBP-2 PARC SCFsR HSP90a
Kan ikrein7
o 94
0.878 0.872 1.75 0.913
LRIG3 Cls Prothrombin s L-Selectin C9 MEKI
FYN
1µ) LRIG3 IGFBP-2 HSP90a PTN
Prothrombin SCFsR CK-1v13
0 95
0.878 0.875 1.753 0.92
H LDH-H1 PARC Renin FYN BMP-1 RAC'
M1P-5
co KPCI HS P90a PTN Kallikrein7 IGFBP-
2 Prothrombin Cis .....
i 96
0.911 0.832 1.743 0.906
0 SCFsR BMP-I Renin RAC1
CD30Lip.,and TCTP CDK5-p35
-.3
PTN SCFsR AMPM2 IGFBP-2 Ka1likrein7
CD30Ligand LRIG3
i 97
0.897 0.861 1.758 0.914
H C9 BTK LDII-II I Pro thrombin CK-
M13 CND P 1 RACI
co
98 I BTK RAC1 ERBB1 Kallikrein7 IGFBP-2 PTN
SCFsR
0.864 0.878 1.742 0.923
PARC Cis BMP-1 sL-Selectin CD30Ligand UBE2N
BLC
C D30 L igand Kallikrein7 KPCI FIN IGFEIP-2 SCFsR
C9
99
0.901 0.855 1.757 0.917
CDK5-p35 CS K Prothrombin Renin dc CK-MB
Midkine
PTN GAPDH,liver 1GFBP-2 LRIG3 SCFsR
CD30Ligand Kallikrein7
100
0.878 0.881 1.759 0.927
RAC1 PARC sL-Selectin C9 BTK Cis Con
tactin-5
¨I
Marker Count Marker Count ,
CO
SCFsR 100 KPCI 23
CT
PTN , 100 u FYN 19
¨
a)
r....) ,Kallikrein7 , 99 ,CvelophilinA 14
N..)
..c) ICF13P-2 91 CNDP1 14
CD30Licand 80 BM P-1 14
0)
'C 1 s 76 Midkine 13
0
PARC 69 UBE2N 12
0
LRIG3 68 ERBB I 12
D
Prothrornhin 67 Uhiquitin+1 11
r.4.
C9 67 Contaetin-5 11
--........-
RAC I 66 . CSK 11
sL-Selectin 46 BLC 11
Renin 4/ AMPM2 . 11 u
GA I'D H,liver 41 TCTP 10
BTK 40 MIP-5 10
IISP90a 37 MEKI 10
CDK5-p35 27 1L-15R a 10 ,
CK-MB 25 FGF- I 7 10
LDH-Hl 23 F,ndostatin 10
0
W
0
1-=
1-=
--.I
W 100 Panels of 15 Asymptomatic
Smokers vs. Cancer Biomarkers
0
Sens. +
ts.) Biomarkers
Specificity Sensitivity Spec. AUC
0
1-, PTN SCFsR AM PM2 IGF13P-2 Kati
ilercin7 CD30Ligand LRIG3 C9
03 1
0.906 0.858 1.764 0.916
BTK LDH-H I Prothrombin CK-MB CNDPI RACI
Cis
O ' PIN RACI IGFBP-2 PARC SCFsR Kal I
ikrei n7 sL-Selectin FYN
1
0.883 0.878 1 76 0.927
--.I _
CD30Ligand GAPDH.liver Cis Prothrombin C9 CDK...5-p35 B
LC
1
1-. CD30Ligand CyclophilinA C9 SCFsR PTN
Ka11ikrein7 Cis Prothrombin
CO 3
0.911 0.861 1.772 0.919
GAPDILliver 1.RIG3 sL-Selectin CNDP I RACI
Endostatin OM PI
t
CD3OLioand IGFBP-2 PIN
.:-. RACI LRIG3 SCFsR LDH-H1
Renin
4
0 887 0.884 I 771 0 925
Ka11ilaein7 Cis CSK PARC CK-MB BMP- 1
Proatromb in
'
PARC Kali ikrcin7 HS P90a PIN IGH3P-2 LRIG3
SCFsR C9
0 878 0.895 1 773 0.924
BTK sL-Selectin ERBB I GAPDH.liver Cis
Contactin-5 FYN
PI N RACI IGH3P-2 PARC SCFsR Kali
ikrein7 CD30Ligand 81K
6
0.878 0.892 1 77 0.927
Renin C Is CK-MB LDH-H1 BMP- I LRIG3
FGF-17
PIN GAPD H, liver IGFBP-2 LRIG3 SCFsR
CD30Lieand Ka 1 likrein7 RACI
7
0.897 0 869 1.766 0 925
PARC sL-Sclectin C9 BTK IL-15Ra Rcnin
Pro thrornb in
-
KPCI HSP90a PTN Kallikrein7 IGEBP-2
Prothrombin Cls SCFsR
8
0 906 0 864 1.77 0.913 ..1
IV 13MP-1 Resin RACI CD30Ligand En
dostatin CDK5-p35 PARC . Q). ,
,.,
9 CD30Lieand IGFBP-2 PTN RACI SCFsR
Kallikrein7 LDH-H I LRIG3
0.883
0.884 I 766 0.92 Cr
CK-MB PARC Ren in Cis UBE2N MEKI BTK
a)
c 1 s SCFsR GAPDILliver C9 PIN Prothrombin
CD30Ligand Kallikrein7
0.901 0.861 1.762 0.921
UBE2N LRIG3 sL-Selectin CNDP I RACI M IP-
5 Endostatin
PARC Kallikrein7 HS P90a PIN IGFBP-2
LRIG3 sL-Selectin Prothrornbin
II
0.892 0.881 1 773 0.925
Cis SCFsR CycluphilinA ERBB I C9 GAP
DH.liver Midkinc
LRIG3 ERBB I HSP90a SCFsR Ka1Ii1crein7
TCTP PTN C9
12
0.901 0.855 1 757 0.906
LDI I-III CD30Lieand Prothrnmbin KPCI IGFBP-2
CDK5-n35 FYN .
CD3OLigand SCFsR RAC1 C9 PTN Cis GAPDH,liver
Kallikrein7
13
0.915 0.858 1 773 0.921
CNDP I BTK sL-Selectin Endostatin LRIG3
LIbiquitin+ I Prothromb in
PIN SCFsR AMPM2 IGH3P-2
Ka11i1rein7 CD30Ligand LRIG3 C9
14
0.897 0.866 1.763 0.915
BTK LDH-HI Pro thrombin CK-MB CNDP I UBE2N
Cis
PTN RACI IGFBP-2 PARC SCFsR
Kallilcrein7 CD30Ligand BTK
0.873 0.886 1.76 0.931
Renin CK-MB Midkine Cis sL-Selectin
GAPDH.liver BLC
CD30Ligand IGFBP-2 PTN RACI LRIG3 SCFsR LDH-HI
Renin
16
0.878 0.892 1.77 0925
Kallikrein7 C 1 s CSK PARC CK-MB B MP- I FGF-I
7
LRIG3 IGFBP-2 HSP90a PARC PTN BTK
SCFsR K.allikrein7
17
0.887 0.878 1.765 0.923
F.RB B1 LDH-HI CK-MB GAPDH.liver Cis
Contactin-5 IIRE2N
Cis SCFsR GAPDH,liver C9 PIN Prothrombin
CD30Lieand Kallikrein7
18
0.901 0.864 1.765 0923
UBE2N LRIG3 sL-Selectin CNDPI RACI IL-15Ra PARC
a
LA)
o
1-.
1-.
--,1
W PTN SCFsR AMPM2 IGFBP-2
Kallikrein7 CD30Ligand LRIG3 C9
0 19
0.887 0.875 1.762 0.912
BTK sL-Selectin PARC CDK5-1)35 Cis
Prothrombin MEK1
N.7 PTN LRIG3 CD3OLigand GAPDH, liver PARC
HSP90a SCFsR Pro thrombin
0 20
0.906 0.855 1.761 0,918
1-. IGFRP-2 RAC] C9 Kallikrein7 FGF-17 M TP-5
UbiquitinF I
co KPC1 HSP90a PIN Kalliksein7 IGFB P-2
Prothrombin C 1 s SCFsR
0.906
0 849 1 756 0.909
O 21
BMP-1 Renin RAC1 PARC CD3OLigand CDK_5-p35
TCTP
,..1 PI N RAC I IGH3P-2 PARC SCFsR Kal I
ikscin7 CD30Ligand CyclophilinA
0.878
1 22
0 875 1.753 0 927
i-. Renin C i s CK-MB Midkine LDH-H1
Prothrombin BLC
CO
73 LRIG3 IGFFIP-2 HSP90a
PTNProthmmbin SCFsR CK-MR LDI-1-H1
0 892
0,869 1.761 0.922
PARC Renin Cis CS K Ka llikrein7
CD30Ligand GAPDH,1 i tier
1GFBP -2 SCFsR KP CI PIN CI s Kallikrein7
Proihromb in CD3OLigand
24
0.901 0.864 1 765 0.908
Rcnin RAC1 I IS P90a Contactin-5 B.MP-1
Endostatin BTK
PIN LRIG3 CD3OLigand GAPDH,liver PARC HSP90a
SCFsR Pro thrombin
25
0.897 0.866 1 763 0.917
IG FRP -2 R AC1 CO Kallikrein7 FGF-17 TL-15Ra
FYN .
26 CD30Ligand IGFBP-2 PIN RAC1 SCFsR
Kallikrein7 LDH-H1 LRIG3 -I
0.878
0.884 1.761 0.921 ci)
CK-MB PARC Renin Cm s U13E2N h4EK1
Prothrombin
IGFFIP-2 SCFsR CiAPIN ',I iver PTN Cis RAC1
CD30Ligand Kallikrein7 cr
27
0.892 0.866 1 758 0.918 -
LDH-H1 Prothrombin Renin LRIG3 CDK5-p35
M IP-5 Midkine a)
6.) 28 PTN RAC I IGFBP-2 PARC SCFsR HSP90a
Kallikrein7 LRIG3
0.892
0.861 1.733 0 921 N.)
(......) BMP-1 Rcnin CD3OLigand LD11-1-11
CK-MB Prothrom bin ICIP --...4 _
CD30Ligand CyclophilinA C9 SCFsR PTN Kallikrein7 C I
s Prothromb in
29
0,915 0.852 176% 0.919
GAP DILI iver LRIG3 sL-Selectin CNDP I libiquitin I
1 BTK Endostatin 0 -
PIN SCFsR AMPM2 IGFBP-2
Kallikrein7 CD30Ligand LRIG3 CO
30
0.887 0.875 1 762 0.924
STK sL-Selectin PARC CDK5-p35 CI s
Midkine CK-MB D
CD301-igand IGFFIP-2 PIN RAC1 SCFsR Kallikrein7 1,DII-
111 LRIG3
31
0.869 0.884 1.752 0.925 .....
CK-MB PARC Renin CI s CyclophilinA Midkine
BLC
PIN C9 CSK CD30Littand SCFsR GAPDH,liver
Kallikrein7 LRIG3
32
0.892 0.869 1.761 0.922
IGFBP-2 Rcnin CD1(5-D35 Prothro mb
in Ubiquitin+1 CI s sL-Scicctin
-
PARC Kallikrein7 HSP90a PTN IGFBP-2 LRIG3 SCFsR C9
33
0.878 0.886 1 764 0.925
BTK sL-Selectin ERBB1 GAPDH,liver CI s
Contactin-5 Pro thrombin
PIN LRIG3 CD3OLigand GAP DH,liver PARC
HSP90a SCFsR Prothrombin
34
0.897 0.866 1.763 0 921
IGFBP-2 RAC I C9 Kallikrein7 Cis 1L-15Ra
CDK5-p35
IGFBP-2 KPC1 CD3OLigand SCFsR LRIG3 PTN
Prothrombin Kallikrein7
35
0.906 0.855 1.761 0.905
C9 BTK Renal CDK5-p35 RAC 1 Cls MEKI
,
PTN GA PDH,liver 1GFBP-2 LRIG3 SCFsR CD301-
igand Kallikrein7 RAC1
36
0.883 0.873 1.758 0.926
PARC sL-ScIectin CO BTK Rcnin Prothrombin
MIP-5
CD30Ligand 1GFBP -2 PIN RAC' LRIG3 SCFsR LDH-H I
Renal
37
0.906 0.847 1.753 0.914
Kal 1 ilcrein7 BTK CNDP1 Ubiquitin II C9 sL-Selectin
Tcrp
PTN SCFsR AMPM2 1GFBP-2
Kallikrein7 CD3OLigand LRIG3 CO
38
0.892 0.869 1.761 0.922
BTK sL-Selectin PARC Cis CK-MB Midkine FYN
ra
ua
o
1-.
1-.
-.3
ua PTN RAC I IGFBP-2 PARC SCFsR
Kallikrein7 CD30Ligand CyclophilinA
0883 . o
39 0.869 1.752 0.927
Renin LDH-H1 Cis Midkine CDK5-535 CK-MB BI,C
na LRIG3 IGFBP-2 HSP90a PIN Prothrombin
SCFsR CK-MB LDH-H1
0 40
0 901 0.858 1 759 0.916
1-. PARC Renin Cis CSK Kallikrein7 CD301,ipand
AMPM2 ,
co PIN RAC! IGFBP-2 PARC SCFsR Ka1likrein7 sL-
Selectin FYN
I 41
0.892 0 872 1 764 0 926
o CD30Ligand GAPDH.liver CI s
Prothrombin C9 Con1actin-5 Midkine
-.3 PARC SCFsR HSP90a PIN IGFHP-2
Prothrombin LR1G3 RA C I
I 42
0 892 0.875 1.767 0 922
1-. CD3OL inand Ka 11110 ein7 sL-Selectin C9 Cis
UBE2N FGF-17
CO Kan ilcrein7 SCFsR HSP90a PIN LRIG3 IGFHP-2
RAC:1 C9
43
0.901 0.861 1.762 0.921
CDK5-p35 PARC Prothrombin Renin
Cyc1ophilinA IL-15Ra FGF- I 7 ,
CD30Ligand IGFBP-2 PTN RAC I LRIG3 SCFsR LDH-
H1 Renin
44
0.897 0 864 1.76 0.912
Kallikrein7 BTK CNDP I LIMP-! Prothrombin
GAPDH,liver MEKI
CD30Ligand CyclophilinA C9 SCFsR PIN Kallikrein7
Cls Pro thromb in
45
0911 0,847 1 757 0.918
CIAP DH.liver 1,121C.13 sL-Selectin CNDP I RAC1 M IP-5
COK5-p35 -I
KPC I HSP90a PIN Kallikrein7 IGFBP-2
Prothrombin C 1 s SCFsR
46 0.911 0.841 1.752 0 LIMP-1 Resin
RAC I CD30Ligand Midkine CDK3-p35 TCTP 906CT
PTN SCFsR AM PM2 IGFB P-2 Kallikrein7
CD301.,igand I,RTG3 C9
47
0.873 0.878 1.751 0.923 CD
BTK sL-Selectin PARC CI s CK-MB
Prothrombin B LC ,
N.) 48 PTN C9 CSK CD30Ligand SCFsR
GAPDH,liver Kallikrein7 LRIG3 0881 I .759 0925 0.878 1\..)
..
-.4
t...) 1GFB1'-2 Ream CDK5-o35
Prothrombin Ubiquitin11 Cis PARC
I'.)
LRIG3 IGFBP-2 HSP90a PIN Prothrombin
SCFsR CK-MB LDH-H1
49
0.892 0.872 1.764 0.926 C)
PARC Resin Cis GAPDILliver Kali ilcrein 7
BTK Con lacti n-5
' 0
PARC Kallikrein7 HSP90a PIN IGFBP-2 LRIG3 SCFsR C9
50
0.897 0.872 1.769 0.925 D
BTK sL-Selectin ERBB I GAPDILliver Cis
CNDP I RAC1 .-4-
51 KiFBP-2 SCFsR GAPDILI iver PIN Cis
RAC! PARC C9 ........."
0.906
0.855 1.761 0924
Kallikrein7 LRIG3 Prothrombin HSP90a IL-15Ra sL-
Selectin CDIC5-035
BTK IGFBP-2 PTN Kallikrein7 SCFsR KPCI HSP90a
PARC
5/
0.901 0.858 1.759 0.905
Rcnin CD30Ligand BMP-1 Prothrombin
Contactin-5 RACI MEKI
PARC SCFsR HSP90a PIN IGFBP-2
Prothrombin LRIG3 RAC1
53
0.887 0.869 1.757 0.923
CD3OLigancl Ka1l1kre1n7 CK-MB C9 CyclophilinA FGF-17 MIP-
5
,
CD30Ligand SCFsR RAC1 C9 PIN C Is GAPDH,liver
Ka11ikrein7
54
0.906 0.844 1.75 0 914
CNDPI LRIG3 sL-Selectin IGFFIP-2 Prothrombin
Ubiquitin+1 TCTP
1GFEIP-2 SCFsR GAPDILliver PIN CD30Ligand
BM Renin PARC
53
0.854 0.895 1 749 0_929
Kallikrein7 CK-MB C Ls LIbiqui t in+1 FGF-17
Prothrombin B LC
CD301,igancl IGFBP-2 PIN RACI LRIG3 SCFsR I,DH-H1
Renin
56
0.883 0.875 1.758 0.928
Kallikrcin7 C Is CSK PARC CK-MB C9 CDK5-o35
^
CvclophilinA HSP90a ERBB I SCFsR PARC IGFBP-2
Kallikrein7 PTN
57 .e
0.897 0.872 1.769 0.923
C9 LRIG3 sL-Selectin FYN C I s
GAPDII. liver CNDP I .
CD30Lbtand SCFsR
.. RAC I C9 PIN C I s
GAPDH,1iver Kall1krein7
58
0.92 0.858 1 778 0 919
CNDP1 BTK sL-Selectin Pro thro mb in
LRIG3 UBE2N Endostatin
C)
La
0
I-
I-.
-.3
.
t
W PIN SCFsR AMPM2 IG PEI P-2 Ka11
ikrein 7 CD30Ligand LRIG3 C9
0 59
BTK sL-Selectin PARC Cis CK-MB
Prothrombin IL-15Ra 0.883 0.878 I .76 0 922
..
n.) CD30Li8and IGFBP -2 PTN RAC I LRIG3 SCFsR
LDH-H I Renin
0 60
0 883 0.875 I 75% 0.921
Kal1ikrein7 Cis GA PDI [Jiver PA RC CK-MB BTK
MEKI
1-.
CO PTN RAC I IGFBP-2 PARC SCFsR K
all ilucin7 FGF-17 CD30Ligand 0.887
0 869
I 757 0 919
1 61
GAP DELI ivcr Ren in BTK Pro thro rnbin LDH-Hl MIP-5
LRIG3
0
,
-.3 LRIG3 ERB B I HSP90a SCFsR Kallikrein7
Tcrp PIN C9
1 62
LDH-H1 CD30Li aand Prothromb in KM. IG FB P-2
CDIC3- p.35 PARC 0.883 0 864 1 746 0.911
i--,
CO Kalil krei n7 Cycl phi linA SCFsR IGFBP-2
CD3OLigancl PIN Renin LTN-1-111
63
0.873 0.875 1.748 0.922
LRIG3 CK-MB PARC HSP90a C9 FYN B LC
CD30L in-aid Kallikrein7 ICPCI
..".- PTN IGFBP-2 SCFsR C9
CDIC3-p35
64
0.897 0.861 1 758 0.912
CSK Prothrombin Rcnin Cis RAC I LRIG3
PARC
C I s SCFsR GAPDH,liver C9 PTN
Prothrurnbin CD3OLigand Kallikrein7
65
0.887 0 875 1 762 0.919 -I
1113F.2N LRIG3 sL-Selectin CNDP I RAC'
E.ndostatin Cnn lacti n-5
CO
PTN LRIG3 CD30Ligand GAPDH,liver PARC HSP90a
SCFsR Prothrornbin
66
0.897 0.864 1.76 0.917 Cr
IGFBP-2 RAC I C9 Kallikrein7 FGF-17 IL-15Ra
BTK
CD301 i.and IGFBP-2 P
.. ' IN RAC1 LIUG3 SCFsR LDH-T-
11 Renin i CD
67
0.892 0.864 1.756 0.914 . ..
Kallikrein7 BTK ex-DP 1 C9 GAPDH.liver C15
MEK1 IV
N.) IGFBP-2 ICPCI CD30 Li Rand SCFsR
LRIG3 FIN Prothrombin Kallilcrein7 -.4
t.,..) 68
0.915 0.841 1.756 0.908
t.....) C9 BTK Renin CDK5-n35 RAC I M1P-5
FYN
CD30Ligand KPCI FIN SCFsR HSP90a LRIG3 PARC
IGEBP-2 0
69
0.897 0.849 1.746 0.911 0
CK-MB Renin Kallikrein7 CI s Pmthrombin
RAC I TCTP
- - =
PTN SCFsR AMPM2 IGFB P-2
Kallikrein7 CD3OLigand LRIG3 C9
70
0.883 0.878 1.76 0.925 ri-
BTK sL-Selectin CNDP I Cis PARC CK-MB
RAC1
---.-..=
CD30 Ligand 10F13P-2 PTN RAC1 SCFsR Kallikrein7 KPCT
Renin
71
0.887 0.861 1.748 (1919
Cls CK-MB PARC BTK Midkine Protluombin B
LC
CD3OLigand Kallikrein7 KPCI pm; IG FRP-2 SCFsR C9
CDIC5-p35
72
0.901 0.855 1.757 0.91
CSI( Produombin Rcnin Cis Ubiquitin+1
FGE-17 LRIG3
'Kallikrein7 SCFsR HSP90a PIN LRIG3 IGFBP-2
Prothrombin PARC
73
0.883 0.878 176 0 919
BTK CDK5-935 Cis CO RAC I Contactin-
5 CNDP1
Kallikrein7 SCFsR HSP90u PTN ERBB1 CycluphilinA
IGFBP-2 CK-MB
74
0 883 0.884 1 766 0.924
PARC LDH-H1 LRIG3 CI s CO FYN
UBE2N
CD30L igand IGHP-2 PTN RACI LR.LG3 SCFsR LDI
1-111 Renin
75
0.906 0.866 1 773 0.918
Kallikrein7 BTK CNDP I Prothro nib in Cis
GAPDH,liver Endos Latin ,
ICIFFIP-2 SCFsR G A PDH,liver PIN Cis R AC1
PARC CO
76
0.911 0.849 1 76 0.923
Kallikrein7 LRIG3 sL-Selcctin HSP90a CDK5-p35 11.--15Ra BTK
PTN RAC I IGFB P-2 PARC SCFsR Kali
ikrein7 FGF-17 CD3OLigand
77
0.892 0.864 1 756 0.919
GAP DI LI iver Renin BTK C9 LRIG3 Ubiquitin i I
MEI('
PTN GAPDH,liver IGFBP-2 LRIG3 SCFsR
CD3OLigand Kallikrein7 RACI
0
78
.878 (1.87%I 756 0.927
PARC sL-Selectin C9 BTK Midkine Renin MIP-5
C)
La
0
I-
I-.
-.3
W LRIG3 ERBB I HSP90a SCFsR Ka Ili
Icrein7 TCTP PIN C9
0 79
LDH-HI CD30Ligand Prothrombin KPCI IGFBP-2
CDK5-0.35 BTK 0.90 I 0.844 1 745 0.905
'
.
n.) PIN SCFsR AMPM2 IGFB P-2
Kallikrein 7 CD3OLigand LRIG3 C9
0 80
0.897 0 864 1 76 0.919
BTK s 1.-Selectin PARC CDK5-n35 Cl s
LDIT-111 Pro thrombin
I-.
Oa Kallikrein7 LRIG3 HSP90a PIN IGFBP-2 CK-
MB SCFsR UBE2N
I 81
PARC Renin CD30Ligand LDH-H1 BMP-1
Prothrombin B LC 0.864 0 884 1 747 0 923
0
-.3 LRIG3 IGH3P-2 HSP90a PIN Prothrombin
SCFsR CK-MB LDH-H 1
I
0.878 0.878 1.756 0_923
82
PARC Renin Cis CSK Kallikrein7 CDK5-p35 BMP-
1
1--`
CO
83 Kallilcrein7 SCFsR HSP90a PIN LATC13 IGFRP-
2 Prothrombin PARC
0.873
0.886 1.76 0.919
FYN Cis RACI C9 CDK5-035 Contae tin-5
CD30Ligand
R4 CD30Ligand SCFsR RACI C9 PIN LR1G3
Kallikrein7 1GFBP-2
0.892
0.875 1.767 0.917
LD11-111 BTK. Endos Latin CN DP I sL-Selectin
UBE2N FGF-17
PIN RACI 1GFBP-2 PARC SCFsR
CD3OLigand GAPDH,liver sL-Seleetin
85
0.887 0.872 1 759 0.926 H
C.1 s Kallikrein7 Pmthrombin C9 BTK
IL-15Ra CDK5-n35 .
CD
CD30Ligand 1GFBP-2 PIN RACI SCFsR Ka11ikrein7 LDH-
H I LRIG3
86
0.883 0.872 1 755 0.921 0"
CK-MB PARC Renin CI s Cyclophil inA MEK1
Prothrombin -
..
CD301 inand SCFsR
" ' RACI C9 PIN LRIG3 Kallikrein7 TGFBP-2
CD
87
0.892 0.864 1.756 0.923
LDH-H1 BTK Renin Prothrombin CK-MB FGF-17
M1P-5
6...) LRIG3 ERBB1 HSP90a SCFsR Kallikrein7 TCTP PIN
C9 -NI
t..,..1 88
0.892 0.852 1.744 0.908
41. Wit-Ill CD3OLigand Prothromb in KP CI 1GFBP-2
CDK5-035 Midkine ..----..
PIN SCFsR AMPM2 IGFB P-2
Kallikrein 7 CD3OLigand LRIG3 C9 0
89
0.897 0.864 1.76 0.918 0
RTK sT.-Seleetin CNDP I Cis CK-MB
CyclophilinA Midkine
PIN RACI IGFBP-2 PARC SCFsR
KaIlikrein7 CD3OLigand BTK D
90
0.878 0.869 1.747 0.925 ro-
Renin CK-MB Midkine Cis Ubiquifin+1 LDH-H1 BLC
-----, ,
CD3OLioand EC& BP-2 PIN RACI LRIG3 SCFsR LDIT-H1
Renin .:-.
91
0.892 0.864 1.756 0.918
Ka1lilcrein7 BTK CNDP I Proth ro mb in C 1 s CK-MB
CSK
PIN RAC I IGFBP-2 PARC SCFsR Kali
ikrein7 CD3OLigand BTK
92
0.887 0.872 1.759 0.926
R.cnin C I s sL-Scleetin GAPDH,liver LDH-H
I Contactin-5 CDK.5-o35
CD30Ligand SCFsR RACI C9 PTN C Is
GAPDH,Iiver Kallikrein7
93
0.897 0.869 1.766 0 926
CNDP I BTK sf.-Selectin Endostatin LRIG3
Uhiquitin I-1 PARC
,
PIN SCFsR RAC! HS P90a LR1G3 PARC
C9 IGFBP-2
94
0.892 0 866 1.758 0.92
ProIhrombin Kal I ilcrein7 Renin BTK FGF-17 IL-15Ra FYN
PARC Kallikrein7 IISP90a PIN IGH3P-2 LRIG3 SCFsR
C9
95
0.897 0.858 I 755 0.915
URP2N RACI Cis sL-Se feet in Prothrombin
MEK I CDK5-p35 ,
CD30I ioancl SCFsR . _ . RACI C9 PIN C Is
GAPDH,liver Kalil krein7
96
0.906 0.849 1.756 0.916
Prothrombin MW-5 CNDP I UBE2N Endostatin BTK
FGF-17
97 CD3OLMand 1GFBP-2 PIN
., RAC' LRIG3 SCFsR L DH-1-11 Renin
0 892
0.832 1 744 0.919
Kai I ikrein7 BTK CNDP1 Pro diro m bin Cis CK-MB
f(fl)
98 PIN SCFsR AMPM2 IGFBP-2
Kallikrein 7 CD30Ligand Renin BTK
I
0.897 0.864 I 76 0.921
Midkine CK-MB PARC Cis LRIG3 Prothrombin FYN
a
LA)
o
1-.
1-.
...1
w PIN SCFsR A MPM2 IG FB P-2 Kal 1
i krein 7 CD3OLigand LRIG3 C9
0 99
BTK sL-Seletuin PARC C I 6 FI'14
CK-MB B LC 0.869 0.878 1.746 0.922
IQ KPCI d CD3OLioan
.,, PTN SCFsR HSP90a LRIG3
PARC 1GFBP-2
0 100
CK-MB Renin Kalli krein7 CI s Pmthrombin R
AC I CSK 0. x97 o.x5x 1 755 0.912
I-.
_
co
01 Marker Count , Marker Count
,..1 SCFsR 100 , CNDP I ' /3
1 PTN 100 Mictkine 16
i-=
03 Kal1ikrein7 100 KPCI 16
EGFBP-2 90 FGF-17 16 , ,
CD30Ligand , 85 UBE2N 14
LRIG3 , 84 FYN 14
Cis 76 CvelophilinA 14
Prothro ',Min 72 . BMP-1 13
¨I
CO
PARC 70 AMPM2 13
CT
RAC I 69 Ubiquitin+1 ,
12 ¨
-C9 64 Enclostatin 12
. CD
BTK 53 CSK 12
NJ
bõ) Renin 5/ , BLC 12
-...1
t.,..)
GAPDILliver 43 TCTP 11
un
CK-MB 40 MIP-5 11
0
31.-Selec1in 39 MEK I 11
0
LDH-1-11 39 ¨ IL-I5Ra 11
D
.--p.
HSP90a , 38 ERBB1 11
=
- ........-
C.DK 5-n35 31 Contactin-5 11 .
Table 28. Aptamer Concentrations
Target Final Aptamer Target Final
Aptamer
____________________ Cone (nM) Cone (nM)
AMPM2 0.5 IMB I 1
App. A-I ______________ 0.25 Kallikrein 7 0.5
b-ECGF 2 KPCI 0.25
BLC ___________________ 0.25 LDH-H 1 0.5
BMP-1 1 LGMN 0.5
BTK . 0.25 LRIG3 0.25
Cls 0.25 Macrophage 2
_______________________________ mannose receptor
C9 1 MEK1 0.5
Cadherin E 0.25 METAP1 0.25
Cadherin-6 0.5 Midkine 0.5
Calpn I 0.5 MT-5 1
Catalase 0.5 MK13 1
CATC 0.5 MMP-7 0.25
,
Cathepsin H 0.5 NACA 0.5
CD30 Lie.and 0.5 NAGK 0.5
CDK5/1335 0.5 PARC 0.5
CK-MB 1 Proteinase-3 _____ 1 __
CNDP I 0.5 Prothrombin 0.5
Contactin-5 1 PTN 0.25
CSK ____________________________ RAC I 0.5 __
Cyclophilin A 0.5 Renin 0.25
Endostatin 1 RGM-C 0.5 ____________
ERBB1 0.5 - -SCE sR 1
FYN 0.25 sL-Selectin ____ 0.5
GAPDH,liver 0.25 TCTP 0.5
HMG-1 0.5 UBE2N 0.5
HSP 90a 0.5 Ubi9uitin+1 0.5
HSP 90b 0.5 VEGF 1
IGFBP-2 1 YES 0.5
IL-15 Ra 0.5
IL-17B 0.5
236
,
CA 3011730 2018-07-18
Table 29
Benign Asymptomatic
Site NSCLC Nodule Smokers
1 32 0 47
2 63 176 128
3 70 195 94
4 54 49 83
Sum 213 420 352
Males 51% 46% 49%
Females 49% 54% 51%
Median 68 60 57
Age
Median 40 42 34
Pack Years
Median 1.94 2.43 2.58
FEW]
Median 74 88 90
FE V 1%
Median
FEV1/17VC 70 72 73
Table 30. Biomarkers Identified in Benil;mNodule-NSCLC in Aggrc $zated Data
Stress-induced-
SCF SR CNDP1 phosphoprotein 1 __
RGM-C MEK1 LRIG3
ERBB1 MDHC ERK-1
Cadherin E Catelase Cyclophilin A
CK-MB BMP-1 Caspase-3 _______
METAP1 ART UFM1
HSP90a C9 RAC1
IGFBP-2 TCPTP Peroxiredoxin-1
Calpain I RPS6KA3 PAFAHbeta subunit
KPCI IMB1 MK01
aMMP-7 UBC9 Integrina1b1
I3-ECGF Ubiquitin+1 IDE
HSP9Ob Cathepsin H _______ CAMK2A
-NAGK CSK21 BLC
FGF-17 BTK BARK1
Macrophage mannose
receptor Thrombin elF-5
MK13 LYN UFC1
NACA HSP70 RS7
GAPDH UBE2N PRKACA
csk' TCTP ¨AWITA2
RabGDPdissociation inhibitor Stress-induced-
Activin A beta phosphoprotein 1
Prothrombin MAPKAPK3
237
CA 3011730 2018-07-18
Table 31. Biomarkers Identified in Smoker-NSCLC in Agegated Data __
SCE? sR Renin oispase-3
PTN ______________________ CSK AMPM2 ___
1-ISP90a Contactin-5 RS7
Kallikrein 7 1JBE2N OCAD1 ___________
LRIG3 MPIF-1 I-ISP70
IGF13P-2 PRKACA GSK-3a1pha __
PARC granzymeA FSTL3
CD30 Ligand 1Thiquitin+1 ____ PAFAH beta subunit
Prothrombin NAGK Integrin al bl
ERBB1 Cathepsin S ERK-1
KPCI _____________________ TCTP CSK21
BTK ______________________ LIBC9 CATC
GAPDH.liver MK13 ____________ MK01
CK-MB Cystatin C OEN
LD11411 RPS6KA3 b2-Microglobulin
CNDP1 IL-15Ra UFM1
RAC 1 Calpain I 1 JFC1
C9 MAPKAPK3 Peroxiredoxin-1
FGF-17 IMB I PKB
Endostatin BARK] IDE
Cyclophilin A CathepsinFi 1-1SP9Ob
Macrophage mannose
Cis _____________________ receptor BGI-13 __
CD30 Dtk BLC
BMP-1 NACA XPNPEP1
RabGDPdissociation
SBDS inhibitor beta TNFsR-1 _________
M1P-5 LYN DUS3
CCL28 ____________________ METAP1
MMP-7 MK12
Table 32. Biomarkers Identified in Benign Nodule-NSCLC by Site
FR13B1 FGF-17
LRIG3 CD3OLigand
HMG-1 LGMN
YES Proteinase-3
MEK1
MK13 BLC
Macrophage mannose receptor 1L-17B
ApoA-I CATC
CNDP1 Cadherin-6
õ
BMP-1
238
CA 3011730 2018-07-18
Table 33. Biomarkers Identified in Smoker-NSCLC by Site
Kallikrein 7 CSK Azurocidin
.. . ......
SCF sR FYN b2-Microglobulin
,
ERBB I BLC OCAD I
C9 TCTP , LGMN
LRIG3 Midkine PKB
AMPM2 FGF-17 XPNPEPI
HSP90a MEKI Cadherin-6
_ ___________________________________________
' sL-Selectin BMP-1 _PTEN .
BTK LYN LYNB
_
CNDP1 Integrin alb I DIJS3
_
CDK5-05 PKB gamma Carbonic anhydrase XIII
Table 34. Biomarkers Identified in Benign Nodule-NSCLC in Blended Data Set
PAFAH beta
YES Catalase subunit el14-5
MK13 Prothrombin AMPM2 TNEsR-I
LRIG3 BTK TCPTP BLC
HMG-1 DRG-1 BGH3 , MAPKAPK3
ERBB1 UBE2N Ubiquitin+1 b2-Microglobulin
Cadherin E Activin A BARKI SOD
CK-MB TCTP LYN GSK-3 alpha
C9 UBC9 ______ PRKACA Fibrinogen
SCFsR NAGK LGMN ERK-1
CNDPI Calpain I Integrin al bl Cadherin-6
RGM-C GAPDII IISP70 IDE
METAP1 UFM1 XPNPEP1 LIFC1
Macrophage Stress-induced-
mannose receptor Caspase-3 phosphoproteinl __ PSA-ACT
BMP-1 b-ECGF RPS6KA3 CATC
KPCI RACI SHP-2 pTEN
IGFBP-2 MDHC ________ CEA PSA _____
CSK Proteinase-3 OCAD1 CATE ______
NACA MKOI Cyclopyilin A Peroxiredoxin-1
RabGDP
dissociation
IMB1 MEK1 inhibitor beta SBDS
Cathepsin 1-1 JISP90a DUS3 RS7
Carbonic anhydrase
MMP-7 Thrombin CAMK2A XIII
VEGF FGF-17 CaMKKalpha
HSP9Oh ART CSK21
239
CA 3011730 2018-07-18
Table 35. Biomarkers Identified in Smoker-NSCLC in Blended Data Set
SCEsi? UBE2N CystatinC GSK-3alpha
LR1G3 MIP-5 LYN CATC
HSP90a Contactin-5 MPIF-1 SBDS
['AFAR beta
ERBB I 1Thiquitin+1 GCP-2 subunit
Macrophage mannose
C9 receptor KPCI IMBI
AMPM2 ¨PRKACA MK12 CSK21
Kallikrein 7 Cathepsin S MAPKAPK3 PKB
Pm BMP-1 Integrin al bl Dtk
PARC Cyclophilin A IISP70 DUS3
CD30 Ligand , CCL28 , RPS6KA3 Calpain I
Prothrombin Endostatin NACA TNBR-I
CSK Cathepsin II RS7 PTP-1B .
¨CK-MB Granzyme A _____________________ Peroxiredoxin-1 IDE
BTK GAPDH,liver MMP-7 ¨HSP90b ¨
Cis _ EGF-17 TEN
P Fibrinogen
IGFBP-2 BARK1 I.IFM I Caspase-3
¨
LDH-H1 13LC UBC9 PSA-ACT
_.
RabGDP dissociation
RAC1 inhibitor beta FSTL3 OCAD1
__....,
Renin CD30 BGI-13 SOD
CNDP I _____________ MKI3 IIFC1 METAPI
TCTP NAGK MK01 PSA
I IL-15Ra b2-Miertglobulin ERK-1 _______________
Table 36
Biomarkers for Lung Cancer i Benign Nodule Smokers
AMPM2 YES SCFsR
BMP-1 MK13 LRIG3
BTK LRIG3 HSP90a
Cis HMG-1 ERBB I
C9 UMBI1111111.111.0
Cadherin E CadherinE AMPM2
Catalase CK-MB Kallikrein7
Cathepsin H I C9 _______ PTN
CD3OLigand I SCFsR PARC
CK-MB _______________________ I CNDP1 CD3OLigand
CNDP1 I RGM-C Prothrombin
Contactin-5 1 META P1 CSK
1 Macrophage
CSK _________________________ ;1 mannose receptor CK-MB
ERBB1 1 BMP-1 , BTK
HMG-1 , KPCI Cis
240
CA 3011730 2018-07-18
Table 36 (cont.)
IISP90a ICiFBP-2 IGFBP-2
IISP9Ob CSK LDH-111
IGFBP-2 ______________________ NACA RAC'
IL-15Ra 1MB ] Renin
IMB1 Cathcpsinli CNDP1
Kallikrein7 MMP-7 _______ TCTP
KPCI VEGF IL-15Ra
LDI-I-H1 IISP90b IIBE2N
LRIG3 Catalase MIP-5
Macrophage mannose receptor Prothmmbin Contactin-5
METAP1 ApoA-I ___________________________ Ubiquitin+1
MIP-5 ________________________ b-ECGF BLC
MK13 BLC BMP-1
MMP-7 Cadherin-6 CDK5-235
Cyclophilin
NACA Calpain I A
PARC CATC Endostatin
Pro thrombin CD3OLigand FGF-17
PIN FGF-17 FYN
RAC1 GAPDH GAPDH
Renin IISP90a KPCI
RGM-C 1L-1711 MEK1
SCF sR LGMN Midkine
TCTP MEK1 sL-Selectin
UBE2N NAGK
Ubiquitin+1 Protcinasc-3
VEGF
YES
ApoA-I
b-ECGF
BLC
Cadherin-6
Calpain I
CATC
CDK5-p35
CyclophilinA
Endostatin
FYN
FGF-17
GAPDH
IL-17B
LGMN
MEKI
Midkinc
NAGK
241
CA 3011730 2018-07-18
Table 36 (cont.)
Proteinase-3
I
sl.-Selectin 1
'rabic 37
Aptarner Solution K11 Assay Up or
To (M) 1.1,OQ Down
Designated (M) Regulated
Biomarker
----,-
AMPM2 3x10-1 NM Up ,
9x10-In 2x10"" Down
Apo A-1 .
lx10-") NM
Up
13-ECGF _ (pool) .
¨5x10-1u 7x10-14
Up
BLC (pool)
BMP-1 2x le 9x1 (I" - Down
BTK 8x10."
2x10-13 Up
_1E94_ ___________________________________
Cis ________________ 8x10' ,x1012 Up
,
--C9 1x10" fx1414 Down
Cadherin E 3x10:m . 2x 10-11' Down '
2x10 2x10-11 ' up -
Cadherin-6 _______________________________ _
2x10-11 7x1(114
Calpain I Up
Catalase 7x10-i
8x10-'4 Up
(pool)
8x10 9 NM
CATC Up
Cathepsin 1-1 I xle
(pool) _ 8x10-I3 Up
CD30 1.igand 2x10-w
7x10-I3 Up
(pool)
'
CDK5/p35 2x10-'' NM Up
CK-MB 1 x10-"' NM Down
(pool) -
CNDP1 3x10-us NM Down
Contactin-5 3x10-" NM Down
CSK 3x10-1' 5x la" Up 4
Cyclophilin I xle RIP
A (pool) up
.,_
Endostatin 5x10"'" _., 1x10-13 Lip
ERBB1 1 x 1 e 4x ler- Down
5x10-15¨
FGF-17 (pool) NM lip
3x I 0-n9 NM
FYN (pool) Up
242
CA 3011730 2018-07-18
Table 37 (cont.)
Aptamer Solution Kd Assay Up or
To (M) LLOQ Down
Designated (M) Regulated
Biornarker
8x10-14 4x10-I3
GAPDH Up
HMG- I 2x10-Ttr __ ]I0_ __ Up
HSP 90a, 1 x10-1" 1x10-12 Up _
HSP9013 2x1041) 4x j0:1-2- Up
ICiFBP-2 6x10-1u 9X10-13 Up_
IL-15 Rot 4x10Tr
1x10'3
Up
(pool)
¨ Ai
3x10 4x10-13
IL-17B (pool) Ups
IMB1 8x10-
NM Up
(pool) ___________________________________
Kallikrein 7 6x10 2x10-12 Down
KPCI , 9x I er NM Up
LDI1-111 1 x10-Isi 8x10-'' Up
7x10-u9 NM
LC;MN Up
LRIG3 3x10-" , 8x1014 Down
Macrophage
mannose 1x1(- 9 1x10" Up
receptor
_ _
6x10:TIT ' MEK1 NM Up
METAP1 7x10-11 - 9x102I3 Up
..,._
Midkine
2x10 4x10-11
Up
MIP-5 9x10-''9
2x 10-13
Up
(pool)
MK13 2x10-u9 NM Up
MMP-7 7x10-il 3 x 16 Up
NACA 2x10-11 NM Up
2x104)4 NM
NAGK , (pool) Up
PARC 9x10-11 1x10-13 Up
4x10-11
5x109
Ll
Proteinase-3 (pool) p
Prothrombin 5x10-'7 '-' 1x10-1 Down ,
PTN 4x10-1E -1, '
5x10 - _ Up_
7x10-11 RAC1 NM Up
Renin _ 3x HI" __ 3x1013 Up _
RGM-C 3x 1 6-41 - NM Down
SCI- sR 5x10-11 3x1042 Down
2x1(ru 2x10-'3
Down
sL-Selectin (pool)
243
CA 3011730 2018-07-18
Table 37 (cont.)
Aptamer Solution Kd Assay Up or
To (M) LLOQ Down
Designated (M) Regulated
Biomarker
TCTP 2x10-11
NM Up
(pool)
UBE2N 6x10-11
NM Up
(pool)
Ubiquitin+l 2x10 -1u 1x10-12
Up
VEGF 4x10-1 - 9x le Up
YES 2x1e9 NM Up
244
CA 3011730 2018-07-18
Table 38. Parameters for Smoker Control Group
Biomarker # ,
from Table 1
Biomarker ii,. 07: //,, 0- KS p-value AUC
d
. -
1 AMPM2 3.05 1.07E-02 3.20 3.62E-02 0.45 5.55E-24 0.75
4 BLC 2.58 1.23E-02 2.72 3.97E-02 0.37 8.72E-17 0.74
, BMP-1 4.13 1.32E-02 4.00 _ 2.01E-02 0.38 1.21E-17 0.75
6 BTK 3.12 2.44E-01 3.51 2.45E-01 0.35 3.25E-15 0.72
7 Cis ______ 4.01 3.47E-03 4.06 4.23E-03 0.31 4.68E-12 0.69
8 C9 5.31 3.54E-03 5.38 5.37E-03 0.43 3.49E-22 0.75
CD30 Ligand 3.21 2.86E-03 3.26 4.42E-03 0.31 1.08E-11 0.70
16 CDK5-p35 2.98 3.48E-03 õ 3.02 4.75E-03 0.25 1.63E-07 0.67
17 CK-MB 3.25 5.18E-02 3.07 4.89E-02 0.33 1.42E-13 0.71
-
18 CNDP1 3.65 1.97E-02 3.52 3.07E-02 0.36 4.14E-16 0.73
19 Contactin-5 3.66 9.35E-03 3.59 1.33E-02 0.31 1.67E-11 0.68
CSK 3.25 6.59E-02 , 3.54 1.10E-01 0.41 1.33E-20 0.76
21 Cyclophilin A 4.42 6.04E-02 4.65 6.80E-02 0.38 2.17E-17 0.73
22 Endostatin 4.61 4.29E-03 4.67 1.07E-02 0.32 1.42E-12 0.69
,
23 ERBB1 4.17 2.25E-03 4.10 5.18E-03 0.47 9.39E-27--08-
24 FGF-17 3.08 1.12E-03 3.11 _ 1.31E-03 032 1.07E-12 0.71
FYN ______ 3.18 6.88E-02 _ 3.24 7.99E-02 0.13 1.53E-02 0.58
26 GAPDH 3.26 7.32E-02 3.51 1.62E-01 0.40 2.02E-19 0.68
28 HSP90a 4.45 1.86E-02 4.61 1.86E-02 0.50 3.09E-30 0.80
IGFBP-2 4.30 3.42E-02 4.48 4.17E-02 0.37 5.40E-17 - 0.74 _
31 IL-15 Ra 3.03 9.74E-03 3.12 2.10E-02 0.31 7.31E-12 0.69
34 Kallikrein 7 3.52 8.67E-03 3.44 1.21E-02 0.36 2.47E-15 0.70
_
KPCI 2.58 2.92E-03 2.66 1.01E-02 0.40 2.30E-19 0.74
36 LDH-H1 3.60 8.03E-03 3.67 1.45E-02 0.32 3.70E-12 0.68
38 LRIG3 3.55 3.10E-03 3.50 3.60E-03 0.36 1.39E-15 0.72 .
MEK1 _
2.81 1.54E-03 2.84 2.75E-03 0.28 1.96E-09 0.67
_
42 Midkine 3.21 3.13E-02 3.24 5.58E-02 0.13 1.90E-02 0.56
43 MIP-5 3.60 3.65E-02 3.77 , 5.88E-02 0.34 8.40E-14 0.70
48 PARC 4.90 1.94E-02 5.01 2.13E-02 0.34 7.01E-14 0.71
Prothrombin 4.68 5.37E-02 4.53 4.31E-02 0.32 1.09E-12 0.68
..
' 51 PTN 3.73 7.08E-03 3.80 7.36E-03 0.34 3.97E-14 0.72
52 RAC1 ____ 3.85 6.13E-02 4.09 7.31E-02 0.40 4.60E-19 0.72
53 Renin 3.25 2.52E-02 3.39 6.36E-02 0.30 4.23E-11 0.68
_
SCF sR 3.79 1.11E-02 _3.68 , 1.48E-02 037 9.90E-17 0.75
56 -6-L-Selectin , 4.46 5.63E-03 , 4.40
9.30E-03 0.30 6.24E-11 0.69
57 TCTP 4.19 4.69E-02 4.44 7.43E-02 0.43 9.69E-22 0.76
________ 58 __ UBE2N 4.42 9.30E-02 4.67 9.53E-02 0.34 6.56E-14 0.72
59 Ubiquitin+1 4.25 1.75E-02 4.34 1.43E-02 0.31 1.55E-11 0.68
245
CA 3011 7 30 2 01 8-0 7-1 8
Table 39. Parameters for benign nodules control grou )
, BiomaTrkableer #
Biomarker /1, 07 Pa Crr-/ KS p-value AUC
from 1 .
2 ApoA-I 3.83 1.04E-02 3.77 1.56E-02 0.24 1.67E-07 0.65
3 b-ECGF 3.03 1.27E-03 3.06 1.53E-03 0.30 7.50E-12 0.68
4 BLC 2.60 1.50E-02 2.72 3.97E-02 0.31 1.77E-12 0.70
BMP-1 4.11 1.39E-02 4.00 2.01E-02 0.32 2.00E-13 0.72
8 C9 5.31 4.84E-03 5.38 5.37E-03 0.39 , 9.42E-
20 0.75
9 Cadherin E 4.51 5.91E-03 4.43
9.86E-03 0.37 1.93E-17 0.74 -
Cadherin-6 2.91 3.79E-03 2.98 1.12E-02 0.36 1.42E-16 0.72
11 Calpain I 4.37 1.33E-02 4.50 2,32E-02 0.40
7.63E-21 0.75
12 Catalase 4.27 2.09E-02 4.37 1.30E-02 0.34 4.30E-15 0.72
13 CATC 2.80 5.83E-03 2.86 7.63E-03 0.31 8.55E-13 0.69
________ 14 Cathepsin H 4.59 3.24E-03 4.63 7,54E-
03 0.30 4.29E-12 0.66
CD30 Ligand 3.21 4.19E-03 3.26 4.42E-03 0.26
4.70E-09 0.68
17 CK-MB 3.23 4.47E-02 3.07 4.89E-02 0.32 2.76E-13 0.70
18 CNDP1 3.65 2.03E-02 3.52 3.07E-02 0.35 2.04E-15 0.72
CSK 3.25 7.98E-02 3.54 1.10E-01 0.41 2.35E-21 0.76
23 ERBB1 4.17 2.76E-03 4.10 5.18E-03 0.46 1.22E-26 0.77
24 FGF-17 3.08 1.26E-03 3.11 1.31E-03 0.31 9.59E-13 0.71
26 GAPDH 3.22 7.96E-02 3.51 1.62E-01 0.40 7.88E-21 0.69
27 HMG-1 4.01 4.57E-02 4.19 7.55E-02 0.30 1.99E-11 0.70
28 HSP90a 4.43 2.23E-02 4.61 1.86E-02 0.51 1.26E-33 0.81
29 HSP90b 3.06 3.70E-03 3.14 9.67E-03 0.42 2.73E-22 0.75
IGFBP-2 4.32 3.57E-02 4.48 4.17E-02 0.35 2.30E-15 0.73
32 IL-17B 2.19 3.73E-03 2.23 4.16E-03 0.28 3.65E-10 0.68
33 IMB1 3.47 2.21E-02 3.67 5,45E-02 0.42 2.04E-22 0.75
KPCI 2.57 3.26E-03 2.66 1.01E-02 0.43 3.57E-23 0.75
37 LGMN 3.13 2.03E-03 3.17 4.15E-03 0.30
1.15E-11 0.69 ]
38 LRIG3 3.55 3.59E-03 3.50 3.60E-03 0.33 9.00E-14 0.71
Macrophage
mannose
39 receptor 4.10 1.51E-02 4.22 2.48E-02 0.36 7.24E-17 0.72
____________ MEK1 2.81 1.77E-03 2.84 2.75E-03 0.31 3.79E-12 0.69
41 METAP1 2.67 2.45E-02 2.89 5.83E-02 0.44 2.99E-24 0.75
44 MK13 2.79 3.38E-03 2.85 4.88E-03 0.36 6.16E-17 0.74
MMP-7 3.64 3.24E-02 3.82 4.85E-02 0.371 1.89E-17 0.73
46 NAGA 3.11 8.28E-03 3.21 2.63E-02 0.34 4.91E-15 0.70
47 NAGK 3.71 2.04E-02 3.84 2.63E-02 0.38 7.50E-19 0.73
49 Proteinase-3 3.95 9.09E-02 4.18 1.23E-01 0.30 2.22E-11 0.69
Prothro mbin 4.67 4.19E-02 4.53 4.31E-02 0.32 2.17E-13
0.68
54 RGM-C 4.44 4.85E-03 4.38 6.13E-03 0.30 1.00E-11 0.69
SCF sR 3.77 9.71E-03 3.68 1.48E-02 0.35 1.96E-15 0.72
VEGF 3.55 8.80E-03 3.62 1.14E-02 0.30 1.27E-11 0.69
61 YES 2.97 9.54E-04 3.00 1.73E-03 0.29 7.59E-11 0.67
246
CA 3011730 2018-07-18
0
la
io
H.
1-.
-.3
La
0
Table 40. Sensitivity + Specificity for Exemplary Combinations of Biomarkers
n.)
o
Sensitivity
I-. #
Sensitivity Specificity -I- A UC
03
Specificity .
O
SCF
--.1 1 . sR " 0.629
0.727 . 1.356 I 0.75 .
1 I SCF
I-.
co 2 1 sR HSP90a 0.761
0.753 1.514 I 0.84 ,
SCF
3 - sR HSP90a ERBB1 0.775
0.827 1.602 I 0.87 1
SCF
4 sR HSP90a ERBB1 PTN I ,
0.784 0.861 1.645 0.89 1
SCF
sR HSP90a ERBB1 PTN BTK , 0.84 0.844 , 1.684
0.9 1
,
-
SCF [ CD30 i
6 sR HSP90a i ERBB1 PTN BTK Ligand 0.822
. 0.869 1.691 0.9 1
SCF I. C030 Kallikrein
I
7 sR HSP90a i ERBB1 PTN BTK Ligand 7 0.845
0.875 1.72 0.91
t'.)SCF i CD30 Kallikrein
-P 8 sR HSP90a ERBB1 PTN BTK Ligand 7 LRIG3 0.859
0.864 1.723 0.91
---. SCF CD30 Kallikrein LDH-
9 sR HSP90a 1 ERBB1 PTN BTK Ligand 7 LRIG3
H1 0.869 0.872 1.741 0.91
SCF CD30 ' Kallikrein LOH- PARC
sR HSP90a 1 ERBB1 PTN BTK Ligand 7 LRIG3 H1
0.873 0.878 1.751 0.91
Table 41. Parameters derived from training set for naive Bayes classifier.
Biomarker pe i __________________
Cc ild ,
a-
d
1-ISP90b 3.06 , 3.70E-03 3.14 9.67E-03
ERBB1 , 4.17 2.76E-03 4.10 5.18E-03
RGM-C 4.44 4.85E-03 4.38 6.13E-03
CaclherinE 4.51 5.91E-03 4.43 9.86E-03
- , _____________________ ,
S CFsR 3.77 9.71E-03 3.68 1.48E-02
METAP1 2.67 2.45E-02 2.89 5.83E-02
b-ECGF 3.03 1.27E-03 3.06 1.53E-03
CK -MB 3.23 4.47E-02 3.07 4.89E-02
A RT 2.93 1.92E-03 2.97 2.98E-03
I IS P90a 4.43 2.23E-02 4.61 1.86E-02
248
CA 3011730 2018-07-18
Table 42. Calculation details for naïve Bayes classifier
= 2 1 ( X,da 1
,
cr
I .v - ,t, ,
1. Ln
Biomarker Log(RFU) ---- I ' '' 1 /1- ln LI
likelihood
- -oo {
2 (Tr.; ace, (likelihood)
HSP90b 3.133 -0.797 -0.002 ____ 0.480 -0.315 .. 0.730
ERBB I 4.127 -0.374 -0.050 0.315 -0.009 0.991
RGM-C 4.476 -0.175 -0.727 0.117 0.669 ,
1.952
Cadheriii E 4.575 -0.358 -1.071 0.256 0.969 2.636
SCFsR 3.783 -0.007 -0.362 0.209 0.565 1.759
METAPI 2.548 -0.318 -0.975 0.434 1.091 2.977
_-
b-ECGF 3.022 -0.037 -0.389 0.096 0.448 1.565
CK-MB 3.494 -0.754 -1.823 0.044 1.113 3.044
, ART 2.918 -0.041 -0.401 __ . ,
0.218 0.578 1.783 _
1-ISP90a . 4.444 -0.004 -0.757 -0.090 = 0.664
1.942
249
CA 3011730 2018-07-18
